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Summary 
Zinc is an essential trace metal involved in diverse cellular processes. 
Cellular zinc levels are controlled by three families of proteins, including ZIP 
channels, which facilitate zinc influx into the cytosol. Aberrant function of many 
ZIP channels has been associated with human diseases. However, their cellular 
mechanisms are relatively unclear. Importantly, our group have reported that 
ZIP7 function is triggered by CK2−mediated phosphorylation on residues S275 
and S276, and have created a pZIP7 antibody that recognises this 
phosphorylated form of ZIP7. This project therefore aimed to decipher 
post−translational mechanisms of three ZIP channels: ZIP7, ZIP6, and ZIP10. 
Computational analysis of ZIP sequences revealed salient characteristics of ZIP 
channels, especially those belonging to the LIV−1 subfamily, and detected 
multiple potential phosphorylation sites in the cytosolic loop between TM3 and 
TM4 of ZIP3, ZIP4, ZIP6, ZIP7 and ZIP10. Characterisation of the pZIP7 
antibody revealed that it specifically recognised ZIP7 when phosphorylated on 
S275 and S276 and accurately indicated increased or impaired function of the 
protein. Employing different antibody arrays, phosphorylation of multiple kinases 
by ZIP7 overexpression or zinc was demonstrated, introducing multiple 
signalling pathways as downstream cascades of ZIP7−mediated zinc release 
from intracellular stores. An investigation on ZIP6 detected that it was 
phosphorylated by CK2, CK1, GSK−3, and PLK1 exclusively in mitotic cells. 
This led to a deeper discovery of the cellular mechanism of ZIP6 in mitosis 
involving its heteromer formation with ZIP10 and its binding to pS727 STAT3, 
which also bound to pStathmin, a protein required for microtubule 
reorganisation. Importantly, ZIP6 and ZIP10 antibody treatment successfully 
inhibited mitosis in multiple breast cancer cell lines, either nocodazole−induced 
or endogenous. Collectively, this project has provided a deeper insight into 
ZIP7, ZIP6 and ZIP10 cellular mechanisms, introduced pZIP7 antibody as a 
potential biomarker, and proposed ZIP6 and ZIP10 antibodies as promising 
mitosis−blocking agents. 
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1. Introduction 
 
 
2 
1.1 Zinc in human health and diseases  
Zinc is nutritionally categorised as an essential trace element, which is 
the second most abundant in the human body, with iron being the most plentiful 
trace element in the body (McCall et al. 2000). The human body contains 2 g or 
30 mmol of zinc, which is distributed throughout all tissues and fluids in the 
body with 60% of total body zinc in the skeletal muscle (King et al. 2000), and 
the highest concentration of zinc in the choroid region of the eye and the 
prostatic secretion (FAO/WHO 2002). In contrast to other metals, zinc is 
uniquely found associated with all classes of enzymes (Vallee and Galdes 
1984). Using a bioinformatics approach, 2,800−3,200 human proteins, 
accounting for approximately 10% of the human proteome, are indicated as zinc 
proteins (Andreini et al. 2006; Passerini et al. 2007).  
The necessity of zinc in human health had not been recognised until the 
profound description of a clinical syndrome attributed to zinc deficiency in a 
case series of 10 malnourished Iranian villagers (Prasad et al. 1961). In this 
report, these patients shared a common clinical history of geophagia, a form of 
pica characterised by craving for eating earth, soil, or clay. Upon physical 
examination, these patients were seen to have short stature, iron−deficiency 
anaemia, hepatosplenomegaly, and hypogonadism. The link of this clinical 
syndrome to zinc deficiency later became clearer a few years later when 
extensive biochemical studies in 16 stunted male Egyptian villagers with this 
clinical syndrome associated the condition with low plasma zinc levels (Prasad 
et al. 1963). Since the discoveries of cases with zinc deficiency, the importance 
of zinc in human health has been increasingly acknowledged and the 
knowledge of cause and pathogenesis of zinc deficiency syndrome has been 
increasingly understood (Roohani et al. 2013).  
Zinc is involved in a vast variety of physiological processes (Kambe et al. 
2015). It is therefore not surprising that the clinical syndrome of zinc deficiency 
in its severe form can be clinically characterised by abnormalities of virtually all 
the human organ systems (Hambidge 2000). The typical clinical manifestations 
of full−blown zinc deficiency include anorexia, pica, growth retardation, 
dermatopathy, hair loss, gonad dysfunction, delayed wound healing, 
compromised immune system, neuropsychiatric symptoms, glucose intolerance, 
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abnormal pregnancy, and increased risk of cardiovascular diseases and cancer 
(Yanagisawa 2008). The severest end of the spectrum of zinc deficiency is 
called acrodermatitis enteropathica, which has been described as a rare lethal 
autosomal recessive disorder characterised by intestinal malabsorption of zinc 
(Moynahan 1974). This condition of severe zinc deficiency manifests itself as a 
clinical syndrome of dermatitis (particularly in the acral, perioral, and periocular 
areas), alopecia, and diarrhoea, hence the proposal of the name acrodermatitis 
enteropathica by Danbolt and Closs (Danbolt and Closs 1942). The gene 
mutated in this condition has been mapped to chromosome 8q24.3, which 
encodes ZIP4 (SLC39A4), a member of the LIV−1 subfamily of ZIP channels 
responsible for intestinal absorption of zinc (Küry et al. 2002). Consequently, 
the ZIP4 gene has now been recognised as the gene defect responsible for the 
manifestation of acrodermatitis enteropathica (Andrews 2008).  
It is noteworthy that regardless of the typical recognition of this condition 
as an inherited disease, an acquired form of acrodermatitis enteropathica has 
also been documented in adults. These patients have been reported to have the 
typical dermatologic presentation of the disease with a history of inadequate 
zinc intake in combination with chronic use of common anti−hypertensive drugs, 
which potentially enhances urinary loss of zinc (Macdonald et al. 2012), chronic 
alcoholism (Chaudhry et al. 2008), and surgical gastric bypass (Cunha et al. 
2012). Additionally, transient neonatal zinc deficiency, an autosomal dominant 
disorder, has been known as a cause of hypozincaemia in infancy and 
classified as type 2 hypozincaemia in children (with the classical acrodermatitis 
enteropathica being classified as type 1) (Kumar et al. 2012). Pathogenetically, 
type 2 hypozincaemia has been attributed to a missense mutation of the gene 
of ZnT2 (SLC30A2), a zinc transporter responsible for zinc secretion from the 
mammary glands, resulting in impaired zinc secretion into the breast milk 
(Chowanadisai et al. 2006). 
Regardless of the advancement of the insight into pathogenesis of zinc 
deficiency, this condition remains highly prevalent worldwide even today, with 
17.3% of the population estimated to be at risk of inadequate zinc intake, based 
upon the bioavailability of absorbable zinc content in the national food supplies 
(Wessells and Brown 2012). Furthermore, both diagnosis of zinc deficiency and 
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determination of its prevalence are considered difficult particularly for cases with 
marginal or mild zinc deficiency, because of the non−specificity of clinical 
manifestations and the lack of a clinically−useful biomarker with undisprovable 
reliability for determining total body zinc status (Wieringa et al. 2015). A 
systematic review demonstrated that, out of 32 biomarkers investigated, only 
zinc levels in plasma, hair and urine successfully responded to a short−termed 
experimental manipulation of dietary zinc intake in a dose−dependent manner 
(Lowe et al. 2009). Nonetheless, accuracy of these three markers in 
determining body zinc status is yet to be proved, since the test results analysed 
in this systematic review could be interfered with by many factors. Moreover, 
the authors of this systemic review also suggested that body zinc homeostasis 
might be able to control the plasma zinc levels within the physiological range, 
thus limiting the use of this biomarker in cases with a long−termed change in 
dietary zinc intake. Additionally, metabolic redistribution of zinc from plasma to 
tissues, which may be triggered by various influences such as meals, infection, 
and other forms of stresses, can reduce plasma zinc levels, thereby 
confounding the interpretation of hypozincaemia (King 2011). Nowadays, 
diagnosis of individual cases solely depends on clinical evaluation and plasma 
zinc levels, the only test currently used in routine clinical practice (BMJ Best 
Practice). In contrast, for assessing a population−level zinc status, a combined 
use of three indicators was suggested, including the prevalence of inadequate 
zinc intakes according to the estimated average requirement, the prevalence of 
hypozincaemia, and the prevalence of children up to 5 years old who have low 
height−for−age (de Benoist et al. 2007). In as much as either subclinical or 
clinical zinc deficiency affects numerous people worldwide, both in developed 
and developing countries, and the detection is still a real challenge due to the 
lack of a reliable diagnostic test, zinc is inevitably considered as a micronutrient 
of remarkable significance both biologically and epidemiologically (Hambidge 
and Krebs 2007). 
Beneficial effects of zinc in human health are widely−known nowadays. 
Zinc has positive effects on the immune system (Haase and Rink 2014b), the 
free radical scavenging mechanism (Oteiza 2012) and the wound healing 
process (Lansdown et al. 2007) as well as the intrinsic anti−microbial action of 
zinc against bacteria (David 2012) and fungi (Reeder et al. 2011). As a result, 
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zinc in its different forms is often included in various dietary supplements 
(Schwingshackl et al. 2015), topical therapeutic agents (Sadeghian et al. 2011), 
and even common everyday products such as anti−dandruff shampoos 
(Schwartz et al. 2013). A meta−analysis of 33 randomized clinical trials reported 
a significant positive effect of supplemental zinc in growth of prepubertal 
children, suggesting zinc supplementation as a means to improve the bodily 
zinc condition, and to prevent underweight and stunting in children who are at 
risk of zinc deficiency (Brown et al. 2002). Furthermore, zinc supplementation 
has also been approved to be used as a chemo−therapeutic means for acute 
diarrhoea (Walker et al. 2015) and common cold (Fashner et al. 2012) and 
proposed to benefit patients with early stages of age−related macular 
degeneration (Lawrenson and Grzybowski 2015). 
1.2 Biological functions of zinc in the human body 
Zinc plays indispensable roles in diverse biological processes. It plays 
important roles in different cellular mechanisms including, but not limited to, 
transcription, signal transduction, growth, proliferation, differentiation, apoptosis, 
and metabolism of carbohydrates, lipids, proteins, nucleic acids, and other 
micronutrients (FAO/WHO 2002; Hambidge and Krebs 2007). Not only does 
zinc help the body fight against infectious microorganisms by enhancing both 
the innate and the adaptive immune systems (Haase and Rink 2014b), but zinc 
also prevents cellular oxidative damage by exercising its properties as an 
antioxidant (Oteiza 2012), albeit it is more appropriately counted as a 
pro−antioxidant (Maret 2008). Furthermore, there has been increasing 
evidential support for zinc acting in the brain as a neuromodulator released by 
zincergic neurons, which are glutamatergic neurons that also secrete zinc (Kay 
and Tóth 2008; Takeda et al. 2013). Additionally, zinc is required for formation 
of water−insoluble crystals in pancreatic beta cell granules, which constitute 
hexamers of two zinc ions and four insulin molecules (Lemaire et al. 2009).  
Intracellularly, zinc has been shown to indispensably function as a 
second messenger (Yamasaki et al. 2007), participating in various cellular 
signalling pathways, including those involved in carcinogenesis (Taylor et al. 
2011). This notable role of zinc was experimentally demonstrated in mast cells 
after activation by an extracellular stimulus (Yamasaki et al. 2007). In this study, 
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mast cells were stimulated by cross−linking of the high affinity immunoglobulin 
E receptor, resulting in zinc release from the perinuclear region where the 
endoplasmic reticulum (ER) is located. This zinc release required both 
preceding calcium influx and MAPK activation, and the resulting increase in 
cytosolic zinc is known as a “zinc wave”. Furthermore, this zinc wave production 
was shown in the same study to mediate cellular signalling events at least partly 
through a direct inhibitory action of zinc on tyrosine phosphatase activity.  
According to this study in mast cells (Yamasaki et al. 2007), zinc satisfies 
four out of five criteria for a second messenger that were proposed by 
Sutherland (Sutherland et al. 1968; Aley et al. 2013). These criteria consist of 
(1) inhibition of the extracellular messenger action by a second messenger 
antagonist; (2) demonstration of the extracellular messenger effect by 
application of the second messenger; (3) ability of the second messenger to be 
synthesised and metabolised; (4) changes of the second messenger level in 
response to the stimulus; and (5) presence of specific intracellular binding sites. 
In relation to these criteria, the study in mast cells demonstrated that TPEN, a 
zinc chelator, inhibited the extracellular messenger action in mast cells; 
application of zinc produced the effects the extracellular stimulus; the zinc level 
changed in response to the extracellular stimulus; and tyrosine phosphatases 
were identified as a target of zinc (Yamasaki et al. 2007). Even though the third 
criterion was not fully shown, because zinc was not synthesised in the cells, 
zinc was shown to be released from cellular stores. Altogether, these data have 
established the role of zinc as a second messenger. Noteworthy, evidence of 
zinc as a key signalling molecule has also been provided in T cells (Yu et al. 
2011). However, the increase in cytosolic zinc levels following the activation of 
the T cell receptor was shown in this study to result from zinc influx mediated by 
zinc channel ZIP6, rather than zinc release from cellular stores. 
Following the discovery of zinc acting as a second messenger, this 
similar role of zinc has also been detected in other non−immune cells. In 
Chinese hamster ovary cells, activation of the insulin−like growth factor 1 
receptor (IGF−1R) was demonstrated to trigger zinc−mediated phosphorylation 
of extracellular−signal−regulated kinases 1 and 2 (ERK1/2) and protein kinase 
B (PKB or AKT) (Pandey et al. 2010). In addition to IGF−1R, activation of the 
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epidermal growth factor receptor (EGFR) was also shown in the same study to 
initiate the same zinc−mediated responses in vascular smooth muscle cells. 
Similarly, our group have revealed zinc−mediated phosphorylation of ERK1/2 
and AKT in breast cancer cells following an extracellular stimulus of either zinc 
plus zinc ionophore pyrithione or the epidermal growth factor (EGF) plus 
calcium ionophore ionomycin (Taylor et al. 2012). Consistent with the proposed 
mechanism of the zinc−induced signalling events reported in mast cells 
(Yamasaki et al. 2007), the zinc−mediated responses seen in these 
non−immune cells were attributed to the zinc−induced inhibition of protein 
tyrosine phosphatases (Wilson et al. 2012). 
In order for zinc to be classified as a second messenger, it is crucial that 
in response to cellular exposure to a first messenger, the zinc ions that produce 
a zinc wave and thereby modulate cellular signalling molecules originate from 
an intracellular compartment rather than an extracellular source (Bornfeldt 
2006). Importantly, zinc has been shown to fulfil this criterion for a second 
messenger by inability of diethylenetriaminepentaacetic acid (DTPA), a 
membrane−impermeable zinc chelator, to inhibit zinc wave production in mast 
cells (Yamasaki et al. 2007). Furthermore, stimulation with EGF plus ionomycin 
was shown to produce a zinc wave in a similar manner to stimulation with zinc 
plus pyrithone in breast cancer cells (Taylor et al. 2012), proving an intracellular 
origin of the zinc ions that elicit the zinc wave. The role of zinc as a second 
messenger now provides an opportunity for zinc−mediated cellular effects to be 
observed within minutes independently of the transcriptional roles of zinc, which 
require hours or days to accomplish (Hirano et al. 2008). Furthermore, this also 
raises the importance of cellular zinc signalling to the level comparable to 
calcium signalling (Taylor et al. 2011). However, precise mechanistic details of 
zinc release control and relevance of zinc signalling to pathogenesis of human 
diseases are yet to be elucidated. 
1.3 ZIP channels 
Either too much or too little zinc adversely affects cellular homeostasis. 
Zinc excess causes cell death, either apoptosis (programmed cell death) or 
necrosis (Kim et al. 1999), whilst cellular zinc deprivation causes growth arrest 
(MacDonald 2000) and induces the apoptotic pathways (Fraker 2005). It is 
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therefore extremely crucial that a cell judiciously controls the concentration of 
free zinc in the cytosol where zinc ions are capable of efficiently activating 
numerous signalling molecules. Three families of proteins have been 
discovered to participate in this stringent regulation: ZIP channels (SLC39A, 
zinc importers), ZnT transporters (SLC30A, zinc exporters), and zinc−binding 
proteins such as the cysteine−rich metallothioneins (Lichten and Cousins 2009), 
which are also known to serve as an intracellular resource of zinc for redox 
signalling (Ruttkay-Nedecky et al. 2013). ZIP channels mobilise zinc into the 
cytosol either from extracellular space or from intracellular stores, thereby 
increasing cytosolic zinc bioavailability, whereas ZnT transporters reduce 
cytosolic zinc by transporting zinc in the opposite direction (Kambe et al. 2015). 
Noteworthy, in contrast to ZnT transporters, which are discovered to function as 
Zn2+/H+ exchangers (Ohana et al. 2009), the underlying mechanistic detail of 
zinc transport by ZIP channels is relatively obscure.  
ZIP channels are generally regarded in the literature as transporters; yet 
there are pieces of evidence supporting that they in fact transport zinc in a 
channel−like manner (Kambe et al. 2015). Firstly, ZIP proteins, like other ion 
channels, mobilise zinc down a transmembrane concentration gradient, given 
that the amount of free zinc ions in the cytosol is so small that it has been 
considered negligible by some authors (Alam and Kelleher 2012). Noteworthy, 
in spite of this negligible amount of free zinc ions the cytosol, it is by no means 
negligible in terms of the impact of zinc ions on cell physiology (Maret 2013). 
Secondly, a molecular characterisation of ZIPB, a ZIP homolog from Bordetella 
bronchiseptica, demonstrated that this primitive ZIP protein works as a 
non−saturable ion−selective electro−diffusional channel that facilitates passive 
uptake of zinc into the cell (Lin et al. 2010). These characteristics of ZIP7B are 
compatible with the salient biochemical properties of an ion channel, which 
include non−saturability with the ion substrate and passive transport of the ion 
that is dependent on the electrochemical properties of the ion (Nelson and Cox 
2013). Nevertheless, the exact zinc transport mechanism of human ZIP 
channels is still largely unknown, and no investigation using electrophysiological 
methods, such as a patch clamp technique (Kornreich 2007), has been 
reported. Given these pieces of evidence suggesting that ZIP channels 
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potentially function as ion channels, zinc transport proteins in the ZIP family are 
referred to as ZIP channels throughout this thesis.  
ZIP channels are classified according to the phylogenetic tree into four 
subfamilies, consisting of gufA, subfamily I, subfamily II, and the LIV−1 
subfamily (Taylor et al. 2007) (Fig. 1.1). All ZIP channels are predicted to have 
eight transmembrane domains (TM) between a long N−terminus and a short 
C−terminus, which are both extracytosolically located (Guerinot 2000) (Fig. 1.2). 
A long variable region, which contains multiple histidine residues, is present in 
the cytosolic loop between TM3 and TM4 and thereby proposed to be a 
zinc−binding region (Guerinot 2000) (Fig. 1.2). Interestingly, many members of 
the LIV−1 subfamily have two additional regions that contain multiple histidine 
residues: The N−terminus and the extracytosolic loop between TM2 and TM3 
(Taylor and Nicholson 2003) (Fig. 1.2). Importantly, in TM5 of the LIV−1 
subfamily, there is a unique consensus motif HEXPHEXGD (H, histidine; E, 
glutamate; P, proline; D, aspartate; G, glycine; X, any amino acid), which is not 
seen in any other subfamilies of ZIP channels (Taylor and Nicholson 2003). 
Interestingly, this HEXPHEXGD consensus motif matches the region in zinc 
metallopeptidases (zincins) that binds zinc (Hooper 1994), suggesting that this 
HEXPHEXGD motif is a catalytic zinc−binding site for ZIP channels. Indeed, this 
region, which contains highly−conserved histidine residues, has been thought to 
be responsible for selective zinc transport (Guerinot 2000). This speculation has 
been further confirmed by the findings that ZIP8 and ZIP14, which have the 
initial histidine residue of the HEXPHEXGD motif replaced with a glutamate 
residue (Taylor et al. 2007), are capable of transporting metal ions other than 
zinc ions, such as cadmium, manganese (Girijashanker et al. 2008) and iron 
(Wang et al. 2012).  
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Figure 1.1 Classification of the ZIP family of zinc transport proteins 
 
This diagram shows the classification of ZIP channels according to the phylogenetic tree 
(Nimmanon and Taylor 2015). ZIP channels can be grouped into four subfamilies: GufA 
(ZIP11), subfamily I (ZIP9), subfamily II (ZIP1, ZIP2 and ZIP3), and the most−recently 
characterised LIV−1 subfamily (ZIP4, ZIP5, ZIP6, ZIP7, ZIP8, ZIP10, ZIP12, ZIP13 and ZIP14). 
 
 
Figure 1.2 Predicted structure of the LIV−1 subfamily members 
 
This figure illustrates the predicted structure of the LIV−1 subfamily according to a ZIP 
sequence computational analysis (Taylor and Nicholson 2003). Like other subfamilies of ZIP 
channels, the LIV−1 subfamily members are predicted to have eight transmembrane domains 
(TM), with extracytosolic N− and C−termini and a long histidine−rich intracytosolic loop between 
TM3 and TM4. Uniquely for the LIV−1 subfamily, they have additional histidine−rich regions at 
the amino−terminus and the region between TM2 and TM3. 
ECS, the extracellular space; ER, the endoplasmic reticulum; H, the histidine−rich region.  
1. Introduction 
 
 
11 
The majority of the LIV−1 subfamily members of ZIP channels are 
located on the plasma membrane, and their function is therefore to import zinc 
into the cell (Hogstrand et al. 2009). Importantly, at least two members of this 
subfamily, namely ZIP7 and ZIP13, have been shown to be on intracellular 
membranes. Immunofluorescence imaging revealed co−localisation of 
recombinant ZIP7 with calreticulin, an ER marker (Taylor et al. 2004; Valentine 
et al. 2007) and recombinant ZIP13 with GM130, a Golgi marker (Bin et al. 
2011). Instead of mediating cellular zinc influx from the extracellular space, 
ZIP7 and ZIP13 are therefore regulating zinc release from cellular stores. 
Besides the special cellular localisation of ZIP7, this ZIP channel is ubiquitously 
expressed throughout the human body (Taylor et al. 2004). Furthermore, ZIP7 
activation by CK2−mediated phosphorylation on residues S275 and S276 
(Taylor et al. 2012) results in activating phosphorylation of downstream 
effectors of zinc release from cellular stores, including tyrosine kinases that are 
involved in breast cancer progression (Taylor et al. 2008b). Hence ZIP7 is 
reasonably designated as “a gatekeeper for intracellular zinc release” and “a 
hub for tyrosine kinase activation” (Hogstrand et al. 2009). 
Interestingly, chicken B cells (DT40) lack endogenous ZIP7 (Kambe et al. 
2006), but have Golgi membrane−located ZIP9 functioning as a gatekeeper of 
zinc release from the stores instead of ZIP7 (Matsuura et al. 2009). Activation of 
ZIP9 in chicken B cells was shown to result in inhibition of protein tyrosine 
phosphatases and consequential activation of downstream activators of zinc 
release from cellular stores (Taniguchi et al. 2013), suggesting potential 
functional interchangeability of the intracellularly−located ZIP channels. 
Furthermore, these data also suggest that a prolonged ZIP7 functional defect in 
mammalian cells might be successfully compensated for by an increase in 
protein expression of other ZIP channels such as ZIP9.  
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1.4 The muffler model 
Participating with zinc transport proteins in regulating free zinc levels in 
the cytosol, the metallothioneins facilitate the zinc−buffering reaction when cells 
are in a steady state, and the zinc−muffling reaction when zinc ions transiently 
flux into the cytosol (Colvin et al. 2010). Thanks to this highly effective cellular 
zinc−buffering system, the cytosolic free zinc levels are strictly maintained 
within the high picomolar to low nanomolar range, and only a small alteration 
can be observed following loading of micromolar levels of zinc (Krezel and 
Maret 2006).  
To decipher this robust zinc−buffering system, a computational modelling 
study in correlation with experimental data was performed in cortical neuronal 
cells (Colvin et al. 2008). Among the three models investigated in this study, 
only the muffler model was able to predict the cellular free zinc and total zinc 
content in different conditions, including cellular exposure to exogenous zinc 
with or without pyrithione, and cellular exposure to ethylenediaminetetraacetic 
acid (EDTA), a metal chelator. This model incorporated a protein with high 
affinity for zinc ions, which was called the “muffler”, as well as sequestration and 
release of zinc into and from deep cellular stores into the equations. Notably, 
this “muffler” model is consistent with the role of zinc as a second messenger, 
which necessitates zinc being released from cellular stores in order to exert its 
action via activation of downstream effectors, as previously mentioned. 
Furthermore, this model highlights the importance of the cellular store−located 
ZIP channels through which zinc is released into the cytosol. 
According to the muffler model (Colvin et al. 2010), when zinc ions flux 
into a cell from the extracellular space, the increase in free zinc levels is 
immediately modulated by the metallothionein−driven muffling reaction. The 
metallothioneins then shuttle the excess zinc ions to cellular stores such as the 
ER. Upon activation by an extracellular stimulus, zinc ions within the stores are 
released into the cytosol via a ZIP channel, leading to zinc−mediated cellular 
responses. A simplified schematic of the muffler model is shown in Fig. 1.3.  
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Figure 1.3 The muffler model 
 
This schematic demonstrates intracellular zinc homeostasis with regard to the muffler model 
(Colvin et al. 2010). When zinc ions enter a cell via a ZIP channel, they are immediately bound 
to the muffler such as the cysteine−rich metallothioneins (MT) and shuttled to a cellular store 
such as the ER (Colvin et al. 2010). Upon activation, zinc ions are released from the store via a 
ZIP channel, leading to zinc−mediated cellular responses. 
 
1.5 Zinc and cancer  
According to the well−recognised action of zinc in promoting immunity 
and fighting against oxidative injuries, zinc is generally believed to be a 
promising dietary compound that prevents cancer (Dhawan and Chadha 2010). 
Regardless of lack of strong evidence from a clinical trial, many studies have 
supported the cancer−preventative effect of zinc. Epidemiologically, zinc 
deficiency, as judged by low serum zinc levels, is highly prevalent in patients 
with breast cancer (Arinola and Charles-Davies 2008; Gumulec et al. 2014) as 
well as cancers of the head and neck (Buntzel et al. 2007; Gumulec et al. 
2014), the lungs (Gumulec et al. 2014), the digestive tract (Boz et al. 2005; 
Gumulec et al. 2014), the liver (Gumulec et al. 2014), the gallbladder (Gupta et 
al. 2005), the female reproductive organs (Martin-Lagos et al. 1997; Naidu et al. 
2007), and the prostate (Gumulec et al. 2014). The high prevalence of zinc 
deficiency in breast cancer patients has also been confirmed by a decrease in 
hair zinc levels (Memon et al. 2007), which is another indicator of body zinc 
status with reliability comparable to serum zinc levels (Lowe et al. 2009). 
Noteworthy, there are still conflicting data regarding the correlation between 
serum zinc levels and cancer. A meta−analysis, which included 8,584 cases 
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and 14,153 controls from 114 various clinical observational studies, reported 
decreased serum zinc levels in patients with most types of cancer (Gumulec et 
al. 2014). In contrast, a more recent, but smaller, meta−analysis, which included 
926 cases and 1324 controls from 21 studies, observed the association of 
breast cancer with low zinc levels only in the hair, but not in the serum (Wu et 
al. 2015). This discrepancy may be partly explained by the presence of many 
physiological or pathological factors that can confound serum zinc 
measurements (King 2011) 
Experimentally, zinc deficiency in primary human lung fibroblasts, 
induced either by limitation of zinc supply or application of zinc chelator TPEN, 
was shown using DNA microarrays to upregulate genes that are involved in 
oxidative stress response, DNA damage and DNA repair, but downregulate 
expression of different DNA repair genes (Ho et al. 2003). An increase in 
oxidative DNA damage as a result of zinc deficiency was demonstrated using 
comet assays (single−cell gel electrophoresis) in both human lung fibroblasts 
(Ho et al. 2003) and rat glioma C6 cells (Ho and Ames 2002). Interestingly, 
although protein expression of P53 was significantly increased as a result of 
zinc deficiency (Ho et al. 2003), function of this DNA repair protein, which 
contains zinc and requires zinc for its site−specific DNA binding (Loh 2010), 
was shown to be markedly impaired without an adequate zinc supply (Bruinsma 
et al. 2002). These data have mechanistically indicated zinc deficiency as a 
cause of oxidative DNA damage, which cannot be effectively repaired, thereby 
predisposing cells to cancer development. 
In addition, in vivo studies in mice and rats have provided evidence that 
zinc supplementation is able to prevent chemically induced cancers of the lungs 
(Satoh et al. 1993), the colon (Dani et al. 2007) and the oesophagus (Fong et 
al. 2001). Notwithstanding, clinical studies have been unable to provide 
agreeable data concerning the usefulness of zinc in cancer prevention, showing 
that zinc intake may either decrease (Kristal et al. 1999), have no association 
with (Leitzmann et al. 2003; Chang et al. 2004; Gonzalez et al. 2009) or 
increase (Kolonel et al. 1988) the risk of prostate cancer. Importantly, a 
randomised clinical trial in 5,141 men demonstrated a beneficial effect of zinc 
supplementation on prostate cancer prevention, even though the effect was not 
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distinguishable from effects of other vitamins and minerals that were taken 
together with zinc (Meyer et al. 2005). Noteworthy, the correlation between risk 
of cancer and body zinc status is to be interpreted with caution, given that there 
is no highly reliable indicator of the body zinc status available to date (Wieringa 
et al. 2015). Collectively, regardless of pieces of scientific evidence suggesting 
a potential role of zinc as a cancer chemo−preventive agent, further clinical 
studies are still needed to confirm this suggestion. 
1.6 Zinc and ZIP channels in breast cancer  
In so far as zinc is hypothesised to be an important element that prevents 
cancer, a tumour mass is expected to have zinc levels lower than its 
non−cancerous tissue counterpart. As expected, cancers of the prostate, the 
liver, the lungs and the thyroids have been shown to have low tissue levels of 
zinc (Huang et al. 2006). Surprisingly, in contrast to these cancers, breast 
cancer has been reported to have higher zinc concentrations in the tumour 
mass than in the normal breast tissue counterparts (Taylor et al. 2011). 
Emission spectrography, which is a sensitive chemical method for determining 
the amount of elements, was performed in eight breast cancer cases, revealing 
a 7−fold increase in mean zinc levels in breast cancerous tissues when 
compared to corresponding non−cancerous breast tissues (Mulay et al. 1971). 
This increase in zinc levels was further confirmed by two other studies using 
atomic absorption spectrophotometry, which, however, showed that the 
increase only ranged from 1.7− to 2−fold (Margalioth et al. 1983; Jin et al. 
1999). Moreover, a recent investigation determined zinc levels in breast cancer 
tissues in a series of 59 cases, using synchrotron radiation micro probe x−ray 
fluorescence, which allows discrimination between zinc levels in cancerous and 
surrounding non−cancerous areas in the same specimens (Farquharson et al. 
2009). Importantly, this investigation revealed that the tissue zinc levels were 
significantly increased only in oestrogen receptor−positive breast cancer cases 
(with a 1.5−fold increase), but not in oestrogen receptor−negative cases (with 
no increase), when compared to the adjacent non−cancerous breast tissue. 
Noteworthy, not only does the amount of zinc change, but the isotopic 
composition of zinc has also been reported to be lighter in breast cancer 
tumours compared to blood and normal breast tissue, introducing another 
potential biomarker for early detection of breast cancer (Larner et al. 2015). 
1. Introduction 
 
 
16 
Collectively, these data suggest that zinc levels in cancer tissues may not 
necessarily reflect body zinc status of the patients, and an abnormal increase in 
cellular zinc levels due to aberrant expression of a ZIP channel might in fact be 
contributory, rather than inhibitory, to breast carcinogenesis. 
There has been increasing evidence of abnormal functioning of some 
ZIP channels in breast cancer cells (Taylor et al. 2011). Gene expression of 
ZIP6, the first ZIP channel to be associated with breast cancer, is positively 
correlated with oestrogen receptor positivity (Manning et al. 1993) and regional 
lymph node involvement (Manning et al. 1994). Interestingly, recent studies 
using a larger scale analysis in breast cancer specimens have proved that ZIP6 
is a reliable marker of oestrogen receptor−positive breast cancer (Schneider et 
al. 2006; Tozlu et al. 2006). Another ZIP channel that has been implicated in 
breast carcinogenesis is ZIP10, which has also been shown using gene 
expression analyses in breast cancer samples to be associated with oestrogen 
receptor status (Taylor et al. 2007) and regional lymph node metastasis (Kagara 
et al. 2007). Importantly, our group have also reported apparently increased 
zinc levels in tamoxifen−resistant breast cancer cells when compared to 
tamoxifen−sensitive breast cancer cells, which is attributed to increased gene 
and protein expression of ZIP7 (Taylor et al. 2007). Furthermore, this increase 
in ZIP7 expression in tamoxifen−resistant breast cancer cells has been shown 
to contribute to aggressive behaviours in these cells (Taylor et al. 2008b). Given 
the links of ZIP6, ZIP10 and ZIP7 to breast cancer, mechanistic roles of these 
three ZIP channels in breast carcinogenesis will be discussed in more detail in 
the following sections. 
1.6.1 ZIP7 in breast cancer 
ZIP7, a member of the LIV1−subfamily of ZIP channels, is ubiquitously 
expressed throughout the human body (Taylor et al. 2004). ZIP7 has been 
proposed to play a crucial role in control of zinc release from cellular stores and 
thereby in regulation of cellular tyrosine kinase activation (Hogstrand et al. 
2009). Interestingly, the ZIP7 gene, also recognised as SLC39A7 or HKE4, has 
been mapped to the human major histocompatibility complex II region on 
chromosome 6p21.3 (Ando et al. 1996), raising a possibility that this ZIP 
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channel might participate in zinc signalling involved in immunological 
responses, although no thorough investigation has been reported.  
ZIP7 is uniquely localised to the ER, as confirmed by co−localisation of 
ZIP7 with calreticulin, an ER marker, in MCF−7 cells using the 
immunofluorescence technique (Taylor et al. 2004). This localisation has been 
further confirmed in Hela cervical cancer cells using the same method, 
demonstrating co−localisation of ZIP7 with ZnT5 variant B, a ZnT5 splice variant 
known to be specifically located in the ER (Thornton et al. 2011). However, it is 
noteworthy that one study proposed a subcellular location contrary to this, 
showing in human lung fibroblasts, prostate epithelial cells, erythroleukemia 
cells and breast cancer cells that ZIP7 was located in the Golgi (Huang et al. 
2005). This proposal was based on a staining pattern of ZIP7 in these cells that 
resembled a cis−Golgi matrix protein according to a previous description 
(Nakamura et al. 1995). Moreover, in the same study, treatment with Brefeldin 
A, a reversible dissembler of the Golgi (Sciaky et al. 1997), was able to induce a 
reversible change in the staining pattern of ZIP7 in MCF−7 cells, consistent with 
ZIP7 being localised in the Golgi (Huang et al. 2005). However, this study did 
not directly demonstrate co−localisation of ZIP7 with a Golgi marker. Despite 
these conflicting pieces of evidence, it is indisputable that ZIP7 is located on 
intracellular membranes, the ER and/or the Golgi, and responsible for zinc 
release from cellular stores. 
In breast cancer cells that have acquired resistance to tamoxifen (TAMR 
cells) (Knowlden et al. 2003), ZIP7 is overexpressed, resulting in a twofold 
increase in cellular zinc levels when compared to the parental 
tamoxifen−responsive MCF−7 cells (Taylor et al. 2008b). Noteworthy, TAMR 
cells not only grow in the presence of tamoxifen, but also manifest a more 
aggressive behaviour than the drug−sensitive progenitor (Hiscox et al. 2004). 
Given the strong inhibitory effect of zinc on protein tyrosine phosphatase 1B 
(Haase and Maret 2005; Bellomo et al. 2014), the increased zinc levels in 
TAMR cells explain the activation of signalling pathways that contribute to the 
aggressiveness of the cells. These signalling pathways involve the known 
substrates of protein tyrosine phosphatase 1B (Bourdeau et al. 2005), including 
EGFR (Knowlden et al. 2003), IGF−1R (Jones et al. 2004), and Src (Hiscox et 
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al. 2006). Consistent with these experimental findings, the Oncomine cancer 
microarray database (Rhodes et al. 2004) has revealed ZIP7 as an independent 
indicator of poor clinical outcome in breast cancer (Taylor et al. 2007). Our 
group have deciphered mechanistic involvement of ZIP7−mediated zinc 
signalling in TAMR cells, confirming that ZIP7−mediated zinc release from 
intracellular stores induces the activating phosphorylation of EGFR, IGF−1R, 
and Src (Taylor et al. 2008b), plausibly through the inhibition effect of zinc on 
protein tyrosine phosphatases (Haase and Maret 2005; Bellomo et al. 2014) 
(Fig. 1.4). The activation of these tyrosine kinases results in phosphorylation of 
their downstream effectors such as ERK1/2 and AKT, which in turn cause cell 
proliferation and migration (Taylor et al. 2008b) (Fig. 1.4). These findings have 
highlighted ZIP7−mediated zinc signalling as a potential target for control of 
breast cancer progression and for prevention of drug−resistance development. 
Following the discovery of a role for ZIP7 in breast carcinogenesis, our 
group further investigated the functional control mechanism of ZIP7 in breast 
cancer cells and discovered a post−translational modification by 
phosphorylation on residues S275 and S276 as a ZIP7−triggering mechanism 
(Taylor et al. 2012). Both these residues of ZIP7, which are located in the 
cytosolic loop between TM3 and TM4, were shown in this investigation to be 
phosphorylated by protein kinase CK2, resulting in zinc release from 
intracellular stores, activation of ERK1/2 and AKT, and promotion of breast 
cancer cell migration. Given that CK2 is a key oncoprotein involved in 
carcinogenesis of various neoplasms with innumerable predicted substrates 
(Tawfic et al. 2001), ZIP7 might serve as a CK2 substrate that is responsible for 
the CK2−driven carcinogenic effects. Based upon this discovery, our group 
have developed a monoclonal antibody that recognises ZIP7 only when 
phosphorylated on residues S275 and S276, which is the activated form of ZIP7 
(Taylor et al. 2012). Given the role of ZIP7 in breast carcinogenesis, particularly 
in the development of endocrine resistance (Taylor et al. 2008b), this antibody 
might be used as a biomarker predictive of tamoxifen treatment outcome. 
Furthermore, because there is no efficient biomarker of body zinc status 
(Wieringa et al. 2015), ZIP7 activity in blood cells as determined using this 
pZIP7 antibody might also become a useful indicator of body zinc status.   
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Figure 1.4 ZIP7−mediated zinc signalling 
 
This schematic demonstrates a simplified ZIP7−mediated zinc−signalling pathway. ZIP7, which 
is located in the ER, is functionally activated by CK2−mediated phosphorylation on residues 
S275 and S276, which are located in the cytosolic loop between TM3 and TM4 (Taylor et al. 
2012). This ZIP7 activation results in zinc release from cellular stores, with consequential 
inhibition of protein tyrosine phosphatases and activation of tyrosine kinases that contribute to a 
cancer phenotype such as cell proliferation and migration. 
 
1.6.2 ZIP6 in breast cancer 
ZIP6 (SLC39A6), another member of the LIV−1 subfamily of ZIP 
channels, was formerly known as LIV−1 (Taylor et al. 2003) or a 4.4 kb mRNA 
(Manning et al. 1988). An incomplete form of ZIP6 in mice, which lacks 245 
residues in the N−terminus, was named “ermelin” (Suzuki and Endo 2002). The 
ZIP6 gene has been mapped to chromosome 18q12.2 according to the National 
Center for Biotechnology Information (NCBI) database. In contrast to ZIP7, 
which is ubiquitously expressed, a multiple−tissue expression array 
demonstrated that among 68 normal human tissues, the ZIP6 gene is 
preferentially expressed in brain tissue and tissues that are hormonally 
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regulated, such as the placenta, the breast and the prostate (Taylor et al. 2003). 
The ZIP6 gene is regulated by oestrogen, as supported by differential 
hybridisation identifying 4−fold and 8−fold increased ZIP6 expression in MCF−7 
and ZR−75 breast cancer cells, respectively, as a result of oestrogen treatment 
(Manning et al. 1988). Furthermore, a Northern blot analysis in 118 primary 
breast cancer tumours revealed that the ZIP6 mRNA level was positively 
correlated with oestrogen−receptor positivity (Manning et al. 1993). This was 
also confirmed by another study in clinical breast cancer populations, which 
showed that ZIP6 expression was present in 50% of oestrogen 
receptor−positive cases, compared to 8% of oestrogen receptor−negative 
cases, with a positive correlation with oestradiol−inducible oestrogen 
receptor−positive cell lines (Manning et al. 1995).  
The direct correlation between ZIP6 expression and oestrogen receptor 
status has been established by a large−scale real−time reverse 
transcription−PCR (Tozlu et al. 2006) and a microarray analysis (Schneider et 
al. 2006), which were performed in 36 and 56 clinical breast cancer specimens, 
respectively. Furthermore, our group investigated gene expression of multiple 
ZIP channels in a series of 74 breast cancer specimens using the reverse 
transcription PCR technique (Taylor et al. 2007). This investigation 
demonstrated a unique gene expression profile for ZIP6 with a significant 
positive correlation with the oestrogen receptor, erbB3, erbB4, and IGF−1R, 
and an inverse correlation with EGFR. Importantly, gene expression of ZIP6 is 
positively correlated not only with oestrogen receptor status in breast cancer 
specimens, but also with regional lymph node involvement. Using a Northern 
blotting analysis, ZIP6 gene expression was demonstrated to be significantly 
associated with regional lymph node involvement in oestrogen 
receptor−positive breast cancer (Manning et al. 1994). In this study, ZIP6 was 
expressed in 63% of the cases with lymph node metastasis, whereas only 13% 
of the cases without ZIP6 expression had lymph node involvement. Collectively, 
these data have identified ZIP6 as a potential biomarker for the 
hormone−responsive breast cancer that has now been molecularly classified as 
the luminal A subtype according to molecular classification of breast cancer 
(Schnitt 2010), with presence of regional lymph node metastasis. This luminal A 
molecular subtype is associated with good prognosis, having been shown to 
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have cumulative disease−free survival at 100 months of 95% in a series of 99 
luminal A breast cancer patients (Kim et al. 2012). It is therefore not surprising 
that ZIP6 has been associated with a favourable outcome, including longer 
relapse−free and overall survival (Kasper et al. 2005). 
Function of ZIP6 became known when the protein sequence was shown 
to match the LIV−1 subfamily of ZIP channels (Taylor and Nicholson 2003). The 
role of ZIP6 as a cellular zinc importer was further supported by increased 
cellular zinc uptake in CHO cells overexpressing recombinant ZIP6 using 
Newport Green diacetate, a zinc−sensitive dye, with FACS analysis (Taylor et 
al. 2003). This ZIP6−mediated zinc uptake was shown in the same study to be 
time− and temperature−dependent, suggesting a carrier−mediated process of 
zinc transport. Furthermore, the recombinant ZIP6 was shown using 
immunofluorescence to be located on the plasma membrane and the 
lamellipodia, which are membrane protrusions at the front of motile or migrating 
cells powered by actin polymerisation (Krause and Gautreau 2014), consistent 
with the role of ZIP6 as a zinc importer. Noteworthy, this intriguing localisation 
at the lamellipodia is reminiscent of the membrane−type 1 matrix 
metalloproteinase, which also contains an HEXXH motif and moves to the 
migration front where the protein promotes migration (Mori et al. 2002).  
Currently, there is no available data directly indicating an increase in 
ZIP6 expression in breast cancer cells in general compared to normal 
mammary glandular cells. However, this assumption is supported by the fact 
that 73% of 3,030 breast cancer samples investigated in a study were classified 
as oestrogen receptor−positive using immunohistochemistry, which showed 
high concordance with Affymetrix U133A microarray data with the area under 
the receiver operating characteristics (ROC) curve of 0.949 (Karn et al. 2010). 
This fact implies that the majority of breast cancer cases are ZIP6−expressing, 
corresponding to the oestrogen receptor status, and therefore indirectly 
suggests that ZIP6 is a zinc channel responsible for the increased zinc levels in 
cancerous breast tissue (Mulay et al. 1971; Margalioth et al. 1983). Importantly, 
tissue zinc levels were shown to be exclusively increased in oestrogen 
receptor−positive cases, but not in oestrogen receptor−negative cases 
(Farquharson et al. 2009). This relationship between tissue zinc levels and 
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oestrogen receptor positivity is reminiscent of the aforementioned direct 
relationship between ZIP6 expression and oestrogen receptor status. 
Collectively, these data have attributed the increased zinc levels in breast 
cancer tissues, particularly the oestrogen receptor−positive cases, to the 
increased gene and protein expression of ZIP6.  
The mechanism of ZIP6 in breast carcinogenesis had not become 
evident until it was firstly shown in embryonic development to be essential for 
the epithelial−mesenchymal transition (EMT) (Yamashita et al. 2004), which is a 
process whereby epithelial cells lose their epithelial phenotype and acquire a 
mesenchymal phenotype that enables them to migrate (Thiery et al. 2009). In 
this study, ZIP6 was shown to be a downstream target of the signal transducer 
and activator of transcription 3 (STAT3) during zebrafish gastrulation, leading to 
ZIP6−mediated nuclear retention of transcriptional repressor Snail, 
down−regulation of E−cadherin and cell migration (Yamashita et al. 2004). 
Importantly, the link between ZIP6 and STAT3 was also observed in breast 
cancer (Taylor et al. 2007), suggesting potential involvement of ZIP6 in breast 
cancer migration and metastasis, which also require EMT (Thiery et al. 2009). 
Our group recently demonstrated in MCF−7 cells that STAT3 induces 
transcription of ZIP6, and ZIP6 is produced as a pro−protein and stored in the 
ER (Hogstrand et al. 2013). In this study, Western blotting using antibodies that 
recognise ZIP6 at different regions suggested that the ZIP6 pro−protein 
undergoes an N−terminal cleavage before its relocation to the plasma 
membrane where it imports zinc into the cell. The imported zinc then induces 
inhibitory phosphorylation of GSK−3, either directly (Ilouz et al. 2002) or 
indirectly via zinc−activated AKT (Lee et al. 2009; Ohashi et al. 2015), which in 
turn phosphorylates GSK−3 (Moore et al. 2013). Alternatively, given that 
GSK−3 is positively controlled by protein phosphatase 2A−mediated 
dephosphorylation on residue S9 (Zhou et al. 2009b), zinc may also induces 
this inhibitory of GSK−3 through its inhibitory action on this phosphatase 
(Xiong et al. 2015). Under normal circumstances, GSK−3 mediates 
phosphorylation of Snail (Zhou et al. 2004), resulting in cytoplasmic relocation 
and proteasomal degradation of Snail (Bauer et al. 2009). The inhibition of 
GSK−3 following ZIP6−mediated zinc influx therefore results in nuclear 
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retention of Snail and down−regulation of E−cadherin, enabling the cell to 
detach, migrate and metastasise (Hogstrand et al. 2013). The simplified 
schematic of this ZIP6 mechanism in EMT is shown in Figure 1.5. This 
mechanism of ZIP6 in breast cancer EMT clearly explains the direct relationship 
between ZIP6 and lymph node involvement in breast cancer. 
 
Figure 1.5 The ZIP6 mechanism in the epithelial−mesenchymal transition  
 
This schematic demonstrates a simplified mechanism of ZIP6 in the epithelial−mesenchymal 
transition (EMT) according to a previous study in our group (Hogstrand et al. 2013). When 
transcriptionally activated by STAT3, ZIP6 is produced as a pro−protein and stored in the ER. 
ZIP6 is activated by N−terminal proteolytic cleavage, and relocated to the plasma membrane, 
where it imports zinc ions into the cytosol, resulting in inhibitory phosphorylation on GSK−3, 
nuclear accumulation of transcriptional repressor Snail, down−regulation of E−cadherin and cell 
migration and metastasis.  
 
ZIP6 is involved in EMT not only in breast cancer, but also in other types 
of cancer. In Panc−1 pancreatic cancer cells, ZIP6 knockdown by siRNA 
transfection resulted in reduced nuclear localisation of Snail and increased gene 
and protein expression of E−cadherin when compared to an empty vector 
control (Unno et al. 2009), suggesting that ZIP6 enhances EMT in both breast 
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cancer and pancreatic cancer in a similar fashion. Interestingly, ZIP6 has also 
been shown to drive EMT even in prostatic cancer (Lue et al. 2011), tissue of 
which is known to be zinc−depleted (Huang et al. 2006). An investigation of the 
ZIP6 mechanism in prostate cancer EMT was performed in ARCaPE cells, 
which are a derivative of androgen−refractory prostate cancer cells with an 
epithelial phenotype (Lue et al. 2011). Interestingly, ZIP6 overexpression in 
these cells was shown to activate EMT via activation of matrix 
metalloproteinases 2 and 9, shedding of heparin binding−epidermal growth 
factor, phosphorylation of EGFR, and consequential triggering of the ERK 
signalling pathway, a pathway known to contribute to the EMT process. These 
data suggest that ZIP6 is mechanistically involved in EMT in a cancer 
type−specific manner. 
1.6.3 ZIP10 in breast cancer 
ZIP10, the closest paralogue of ZIP6, is another ZIP channel known to 
be involved in breast carcinogenesis. Its purified protein from brush border 
membrane of rat’s kidneys was originally described as a zinc−binding protein 
that had high affinity and specificity for zinc binding (Kumar and Prasad 1999). 
This protein was confirmed shortly thereafter to be a zinc transport protein 
(Kumar and Prasad 2000). Using immunofluorescence, a later investigation 
demonstrated that this protein was localised to the plasma membrane (Kaler 
and Prasad 2007). Furthermore, the same investigation also showed using a 
65Zn uptake assay that this protein mediated zinc influx in a time−, 
temperature−, and concentration−dependent manner. 
According to the NCBI database, the ZIP10 gene is mapped to 
chromosome 2q32.3. According to the Functional Annotation of the Mammalian 
Genome (FANTOM5) database (Lizio et al. 2015), the ZIP10 gene is seen to be 
widely expressed in human tissues, with preference for some organs, such as 
the brain, the spinal cord, the lungs, the kidneys, the intestines and the 
reproductive organs. Like ZIP6, a gene expression analysis using reverse 
transcription PCR demonstrated a positive correlation of ZIP10 gene expression 
with oestrogen receptor status in a series of 75 primary breast cancer samples 
(Taylor et al. 2007) and also with regional lymph node metastasis in a series of 
177 primary breast cancer samples (Kagara et al. 2007).  
1. Introduction 
 
 
25 
Confirming the involvement of ZIP10 in breast cancer EMT, ZIP10 gene 
expression was significantly higher in cell lines with high capability to invade 
and metastasise, such as MDA−MB−231 and MDA−MB−435S, when compared 
to less aggressive cell lines, such as MCF−7, T47D, ZR75−1 and ZR75−30 
(Kagara et al. 2007). Furthermore, the same study demonstrated using 
migration assays in the two highly invasive cell lines, MDA−MB−231 and 
MDA−MB−435S, that ZIP10 knockdown and zinc chelation resulted in 
decreased capability of the cells to migrate, proving essentiality of both ZIP10 
and cellular zinc in breast cancer invasiveness. These data have introduced 
ZIP10 as another potential biomarker for prediction of breast cancer metastasis. 
Nevertheless, mechanistic details of ZIP10 involvement in EMT are still unclear 
and yet to be further investigated. 
1.7 Post−translational modifications of ZIP channels 
Regulation at the transcriptional level in various circumstances has been 
described for ZIP channels (Cousins et al. 2006). However, there is emerging 
evidence that ZIP channel proteins are also regulated by post−translational 
modifications. Given that ZIP channels have crucial roles in carcinogenesis, 
understanding of their post−translational modifications will provide opportunities 
to develop a chemo−therapeutic strategy for cancer treatment by modulating 
the modifications on these proteins that affect their function or cellular 
localisation. Two post−translational processes that have been implicated in the 
functional control of ZIP channels are phosphorylation and proteolytic cleavage, 
which will be further detailed in the following sections.  
1.7.1 Phosphorylation of ZIP channels 
Phosphorylation is the most extensively−studied reversible 
post−translational process in which a phosphoryl group is transferred from 
adenosine triphosphate (ATP) and covalently attached to a molecule, 
preferentially a serine (84%), threonine (15%) or tyrosine residue (less than 1%) 
(Humphrey et al. 2015). This process is mediated by a group of enzymes called 
kinases and reversed by phosphatase−mediated dephosphorylation (Cheng et 
al. 2011). It is undeniable that phosphorylation is mechanistically involved in 
almost all cellular aspects (Cohen 2002). Phosphorylation exerts its function as 
a modulator that controls enzyme activity and protein degradation, binding, 
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conformation, and translocation, and has biological crosstalk with other 
post−translational modifications, such as ubiquitination, acetylation, and 
methylation (Humphrey et al. 2015). Given that activity of a protein does not 
always reflect gene or protein expression levels of the protein, post−translation 
modifications, especially phosphorylation, constitute a key mechanism that 
causes this discrepancy (Lim 2005). It is therefore not surprising that disruption 
of phosphorylation control has been known as a key mechanism involved in 
pathogenesis of human diseases, including cancer. 
The importance of phosphorylation in oncogenesis has been supported 
by identification of disruption of either phosphorylation sites or kinase functions 
in cancer. A high−throughput bioinformatics approach demonstrated that 
prevalence of the mutations that cause gain and loss of phosphorylatable 
residues was approximately 1.9% and 3.2%, respectively, which were both 
twice as high as control datasets (Radivojac et al. 2008). Furthermore, 164 out 
of 478 known eukaryotic protein kinases in human have been mapped to the 
amplicons that are commonly affected by cancer mutations (Manning et al. 
2002). Importantly, some kinase inhibitors have been invented and successfully 
used for cancer treatment. Imatinib mesylate (Gleevec), a Bcr−Abl tyrosine 
kinase inhibitor, is one of the most successful targeted therapies, having 
become the first−line treatment for chronic myeloid leukaemia (Henkes et al. 
2008). Trastuzumab (Herceptin), a monoclonal antibody against receptor 
tyrosine kinase erbB2 or HER2/neu, has also greatly benefitted patients with 
HER2−positive breast cancer (Pinto et al. 2013). These data highlight 
phosphorylation as a key cellular process that is essential for functional control 
of proteins, and when this mechanism is disrupted, dysregulated proteins may 
greatly contribute to pathogenesis of diseases. Additionally, given the crucial 
role of phosphorylation in regulation of protein functions, it is reasonable to raise 
the question whether ZIP channels may also be controlled by this mechanism. 
Zinc is released from intracellular stores on the time scale of minutes in 
response to an extracellular stimulus, which has been observed in mast cells 
(Yamasaki et al. 2007) and breast cancer cells (Taylor et al. 2008b). This early 
response suggests that the process of zinc release might involve a 
post−translational mechanism that triggers ZIP channels in the cellular stores, 
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such as ZIP7, independently of transcriptional activation of the channels, which 
requires several hours to finish the process. Consistent with this suggestion, our 
group have proved the role of phosphorylation in functional control of ZIP7 
(Taylor et al. 2012). In this study, ZIP7 was demonstrated to be phosphorylated 
by CK2 on residues S275 and S276, as previously mentioned in Section 1.6.1. 
This finding has specifically indicated residues S275 and S276 as potential sites 
for modulating the function of ZIP7. Furthermore, the association of ZIP7 with 
CK2 has introduced ZIP7 as a key substrate of this kinase that is responsible 
for the CK2−related cancer aggressiveness and poor clinical outcome (Ortega 
et al. 2014). Additionally, the discovery of ZIP7 control by phosphorylation also 
suggests a possibility that other ZIP channels, particularly those belonging to 
the LIV−1 subfamily, may also be post−translationally controlled in the same 
fashion. A number of phosphorylation sites, both serine/threonine and tyrosine 
residues, have been detected in online phosphorylation site databases for ZIP3, 
ZIP6, ZIP8 and ZIP10 (Hogstrand et al. 2009). However, these sites have not 
been confirmed by site−specific experiments other than mass spectrometry, 
and their roles as well as their responsible kinases are yet to be investigated. 
1.7.2 Proteolytic cleavage of ZIP channels 
In contrast to phosphorylation, proteolytic cleavage is an irreversible 
process in which protease−mediated hydrolysis breaks a protein into smaller 
pieces (Walsh et al. 2005). As a result, the proteolytic cleavage products have 
new termini, which are termed neo−N terminus and neo−C terminus (Marino et 
al. 2015). Proteolytic cleavage has been widely overlooked, despite its 
ubiquitous involvement not only in protein degradation, but also in protein 
activation or inactivation, localisation, maturation, and secretion (Rogers and 
Overall 2013). Some viruses have also been demonstrated to require this 
post−translational process for their infectivity, such as the 1918 influenza virus 
(Chaipan et al. 2009).  
Proteases have been increasingly identified, with the MEROPS online 
peptidase database annotating 990 genes as human proteases, which account 
for 4−5% of the human genome (Rawlings et al. 2014). Based upon their 
catalysis mechanism, they can be classified into 5 classes: cysteine, serine, 
threonine, aspartic, and metalloproteases (Puente et al. 2003). The first 3 
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classes mediate covalent catalysis, employing an amino acid as the nucleophile 
of the catalytic site, whereas the last 2 classes mediate non−covalent catalysis, 
employing an activated water molecule as the nucleophile of the catalytic site 
(Turk 2006). Alternatively, these proteases can be divided based upon their 
modes of substrate cleavage into endopeptidases and exopeptidases (Barrett 
and McDonald 1986). Endopeptidases cleave their substrates in the middle of 
the molecules, whereas exopeptidases cleave their substrates at either the 
N−terminus (aminopeptidases) or the C−terminus (carboxypeptidases) (López-
Otín and Bond 2008). 
ZIP4 was the first ZIP channel to be established as post−translationally 
processed by proteolytic cleavage. Triggered by zinc deficiency, ZIP4 was 
shown to be proteolytically cleaved at the extracellular N−terminus immediately 
proximal to TM1 (Kambe and Andrews 2009). After this cleavage, an active 
37−kDa fragment of ZIP4 on the apical plasma membrane of intestinal cells 
absorbs zinc from the intestinal lumen. This study therefore revealed that 
proteolytic cleavage is an important post−translational mechanism required for 
zinc−transport function of ZIP4. Intriguingly, quantitative interactome and 
bioinformatic analyses revealed in vivo spatial proximity of ZIP6 and ZIP10 to 
the cellular prion protein (PrPC) (Watts et al. 2009). Furthermore, the PrP−like 
peptide sequence was detected in the extracellular N−terminus of ZIP6 and 
ZIP10, and ZIP5, which are grouped in the same sub−branch in the 
phylogenetic tree of ZIP channels (Schmitt-Ulms et al. 2009). These 
observations suggest mechanistic similarities of ZIP6, ZIP10, and ZIP5 to PrPC, 
which has ecto−domain shedding as a crucial post−translational mechanism 
(Altmeppen et al. 2012). Importantly, the process of ecto−domain shedding has 
also been reported for both ZIP10 (Ehsani et al. 2012) and ZIP6 (Hogstrand et 
al. 2013). Triggered by deprivation of zinc or manganese, ZIP10 is cleaved at 
the N−terminus, shedding its PrP−like ecto−domain and the remained segment 
of ZIP10 is then enabled to transport zinc and manganese to maintain 
homeostasis of these metals (Ehsani et al. 2012). In a different context, 
N−terminal cleavage of the ER−located ZIP6 pro−protein enables the 
processed ZIP6 to relocate to the plasma membrane where ZIP6 imports zinc 
into the cytosol (Hogstrand et al. 2013), as described in Section 1.6.2 (Fig. 1.5). 
Collectively, these findings have established that proteolytic cleavage is a 
1. Introduction 
 
 
29 
crucial functional control mechanism and a requirement for zinc−transport 
capability for ZIP channels, particularly ZIP4, ZIP10, and ZIP6. 
1.8 Zinc in the cell cycle 
Zinc has been known for over 50 years to play a key role in cell 
proliferation, since EDTA, a chelating agent of divalent cations, was shown in a 
study to suppress DNA synthesis and this suppression was reversed by zinc 
(Fujioka and Lieberman 1964). Employing Fluozin−3, a zinc−sensitive 
fluorescent dye, the pivotal role of zinc in the cell cycle was further supported by 
a discovery of intracellular zinc fluctuations in a specific pattern during different 
cell cycle stages (Li and Maret 2009). Additionally, it was recently demonstrated 
in human hepatoblastoma cells that zinc deficiency caused transcriptional 
down−regulation of p21 (Wong et al. 2007), a potent cyclin−dependent kinase 
(CDK) inhibitor. Noteworthy, p21 is now known to promote cyclin D1 function by 
enhancing cyclin D1/CDK4/CDK6 complex formation (LaBaer et al. 1997). 
Repression of p21 transcription by different causes has been proved to reduce 
this complex formation, resulting in a block at the G1/S transition in vascular 
smooth muscle cells (Kavurma and Khachigian 2003) and endothelial cells 
(Noseda et al. 2004). These findings suggest that zinc deficiency might also 
inhibit cell cycle progression through this mechanism. However, the 
mitosis−inhibitory effect of zinc deficiency was shown to be independent of the 
reduction in p21 protein levels in human hepatoblastoma cells (Wong et al. 
2007). Additionally, chronic zinc deprivation induced by exposure of neuronal 
precursor cells to TPEN was shown to induce the p53 pathway, resulting in 
impaired cell proliferation and eventually apoptosis (Corniola et al. 2008). 
Altogether, these data endorse the importance of zinc in normal cellular cell 
cycle machinery. 
Confirming the pivotal role of zinc in DNA synthesis, thymidine 
incorporation, which is indicative of DNA synthesis, was shown to be markedly 
reduced by 90% after exposure of 3T3 fibroblast cells to diethylenetriamine 
pentaacetate, a divalent metal ion chelator, and this inhibition was specifically 
reversed by supplementation of zinc (Chesters et al. 1989). The need for zinc in 
proper DNA synthesis was shown in the same study to start from the mid−G1 
phase when the proteins that are essential for initiation of DNA synthesis such 
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as thymidine kinase were produced. This finding was consistent with an 
observation that zinc deprivation by EDTA significantly suppressed enzyme 
activity of thymidine kinase (Lieberman et al. 1963). The requirement of zinc in 
the G1 phase was later supported by the prominent peaks of zinc 
concentrations observed in the early G1 phase and the late G1/S phase (Li and 
Maret 2009). Interestingly, even though DNA synthesis is known to be a 
zinc−dependent process, zinc is not required to be readily available during the 
process for its accomplishment (Chesters et al. 1989). However, it was shown 
in myoblasts that zinc was still needed during the S phase and also the G2 
phase for subsequent cell passage through the G2/M phase and cell entry into 
the G1 phase (Chesters and Petrie 1999). The requirements of zinc during the 
pre−mitotic phases, which include the G1, S, and G2 phases, were shown to 
coincide with zinc−dependent increases in mRNA concentrations of the cyclins 
that are specifically required at different cell cycle stages (Chesters and Petrie 
1999). Collectively, these findings suggest the pivotal role of zinc throughout the 
mitotic process. Nevertheless, the exact mechanism of zinc in the mitotic phase 
is still unknown. 
1.9 STAT3 
It has already been shown that ZIP6 is transcriptionally activated by 
STAT3 in zebrafish gastrula organizer cells (Yamashita et al. 2004) and breast 
cancer cells (Hogstrand et al. 2013), whereas ZIP10 expression is regulated by 
STAT3/STAT5 in B−cell lymphoma cells (Miyai et al. 2014). STATs, or signal 
transducers and activators of transcription, are known as a family of latent 
cytoplasmic transcription factors, which have a major role in defining destiny of 
a cell. They were originally recognised as a DNA−binding protein complex 
called interferon−stimulated gene factor 3, which was reported to be involved in 
interferon alpha−induced transcriptional activation (Schindler et al. 1992). This 
protein complex is now known to comprise STAT1, STAT2, and interferon 
regulatory factor 9 and becomes activated by Janus kinases (JAK), which is a 
family of receptor−bound non−receptor tyrosine kinases (Fink and Grandvaux 
2013). Further investigations have indicated essential roles of this JAK/STAT 
pathway in diverse cellular processes, leading to identification of other members 
of the STAT family, namely STAT3 to STAT6, with STAT5 being divided into 
STAT5a and STAT5b (Schindler and Darnell 1995). Participation of this 
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JAK/STAT pathway in cell proliferation, cell differentiation, apoptotic cell death, 
inflammation and embryonic/foetal development has now been well established 
(Abroun et al. 2015). 
The human STAT genes have been mapped to 3 clusters on 
chromosomes 2 (STAT1 and STAT4), 12 (STAT3, STAT5a and STAT5b), and 
17 (STAT2 and STAT6) (Darnell 1997). Importantly, each STAT gene contains 
a conserved single tyrosine residue on the C−terminal tail around residue 700 
(Schindler and Darnell 1995). Phosphorylation on this C−terminal tyrosine 
residue results in formation of either a homodimer or a heterodimer, which is a 
highly competent DNA−binding form of STATs that translocates to the nucleus 
and modulates STAT−dependent gene transcription (Rawlings et al. 2004). For 
example, STAT3 has been reported to form a dimer either with another 
molecule of STAT3 or with STAT1, STAT4, STAT5, and STAT6 in different 
contexts (Delgoffe and Vignali 2013). The formation of a STAT dimer is 
dependent upon intermolecular interaction of the phosphotyrosine of one STAT 
molecule with the Src Homology 2 domain of the other STAT molecule (Heim et 
al. 1995). Outstandingly, STAT3 and STAT5 are two major STATs that 
participate in promotion of tumour cell proliferation and prevention of tumour cell 
death (Walker et al. 2014). Furthermore, STAT3 is the only STAT that is 
involved in regulation of cancer immunity, thereby being appreciated as a 
potential target for cancer treatment (Yu et al. 2014). Additionally, the unique 
indispensable function of STAT3 is highlighted by early embryonic lethality that 
is exclusively found in mice deficient of STAT3, but not in mice deficient of any 
other STATs (Akira 1999). 
Notably, a link between STAT3 and a ZIP channel became known for the 
first time when ZIP6 was demonstrated to be a gene that was transcriptionally 
activated by STAT3 during zebrafish gastrulation (Yamashita et al. 2004). Using 
morpholino injection as a means to modify gene expression in zebrafish 
embryos, this study showed that depletion of STAT3 abolished ZIP6 gene 
expression, and depletion of STAT3, ZIP6, or Snail1 prevented the organiser 
cells from undergoing a normal EMT process. These results have indicated 
ZIP6 as a STAT3 downstream target that is essential for EMT in zebrafish 
gastrulation, with Snail1 also involved in this pathway. Noteworthy, these 
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findings are consistent with the embryonic lethality in STAT3−deficient mice, 
which occurs in a stage requiring nutrient influx for cell migration (Akira 1999).  
Importantly, all the three proteins that are associated with EMT in 
gastrulation, consisting of STAT3 (Devarajan and Huang 2009), ZIP6 (Manning 
et al. 1994), and Snail (Blanco et al. 2002), have also been associated with 
breast cancer metastasis. The role of this STAT3−ZIP6−Snail pathway in breast 
cancer EMT has been described in Section 1.6.2. Noteworthy, as a step in the 
EMT process, our group observed cell rounding and detachment as a result of 
the E−cadherin transcriptional repression by Snail (Hogstrand et al. 2013). This 
adoption of a spherical shape of cells is a prominent feature of the mitotic 
process (Thery and Bornens 2008). Given that both STAT3 (Abroun et al. 2015) 
and zinc (MacDonald 2000) are actively involved in mitosis, it is plausible that 
ZIP6 might be an intermediary between these two signalling molecules during 
the mitotic process. Furthermore, our group have also observed that cells 
expressing ZIP6 had decreased pY705 STAT3 and increased pS727 STAT3 
(Hogstrand et al. 2013). This inverse relationship between pY705 STAT3 and 
pS727 STAT3 has also been observed in nocodazole−induced mitotic cells (Shi 
et al. 2006), and is consistent with direct binding of zinc to STAT3, which results 
in a structural change of STAT3 that disrupts its activation by JAK1−mediated 
tyrosine phosphorylation (Kitabayashi et al. 2010). In so far as ZIP6 plays a role 
in the cell rounding prior to mitosis, it is interesting to investigate whether 
ZIP6−mediated zinc influx is also responsible for the conversion of 
pY705 STAT3 to pS727 STAT3 during mitosis. 
1.10 Aims of this project  
The general aim of this project was to decipher post−translational 
mechanisms of ZIP7, ZIP6, and ZIP10, which play important roles in breast 
carcinogenesis. To attain this goal, the following objectives were pursued:  
1. To define downstream pathways of ZIP7−mediated zinc release from 
intracellular stores 
2. To explore potential phosphorylation sites in all ZIP channels 
3. To investigate ZIP6 phosphorylation sites in mitosis  
4. To determine a role for ZIP6 and ZIP10 in mitosis 
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2.1 Cell preparation and treatments 
2.1.1 Cell culture and cell seeding for experiments 
MCF−7 (human breast carcinoma) cells were cultured in Roswell Park 
Memorial Institute (RPMI) medium (Gibco) supplemented with 5% foetal bovine 
serum (FBS) and antibiotics (10 IU/mL Penicillin, 10 µg/mL Streptomycin, and 
2.5 µg/mL Amphotericin B). Tamoxifen−resistant MCF−7 (TAMR) cells 
(Knowlden et al. 2003), MDA−MB−231 (MDA−231) cells, and MDA−MB−436 
(MDA−436) cells were cultured in phenol−red−free RPMI medium (Gibco) 
supplemented with 5% charcoal−stripped steroid−depleted FBS, and 200 mM 
L−glutamine, antibiotics (10 IU/mL Penicillin, 10 µg/mL Streptomycin, and 
2.5 µg/mL Amphotericin B). Additionally, 10−7 M 4−hydroxytamoxifen was 
added to the medium for TAMR cells. NMuMg (mouse breast glandular) cells, 
either wild−type or ZIP6−knockout, were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) with 4.5 g/L glucose supplemented with 10% FBS, 
10 µg/mL bovine insulin, 200 mM L−glutamine, and antibiotics (10 IU/mL 
Penicillin, 10 µg/mL Streptomycin, and 2.5 µg/mL Amphotericin B). 
For experiments, cells were trypsinised using 10 mL of 0.05% trypsin and 
0.02% EDTA in PBS for up to 5 minutes at 37oC, which was neutralised using 
an equal amount of medium with serum. After resuspending the cell pellet in 
medium with serum, 100 µL of the cell suspension was added to 10 mL Isoton II 
balanced electrolyte solution (Beckman Coulter). The number of cells present 
was determined using a Coulter counter (Beckman Coulter), and 1.5x105 cells 
were seeded onto 35 mm dishes, either with 22x22 mm ultra−thin glass 
coverslips (0.17 mm thick) for immunofluorescence or without coverslips for 
Western blotting. For proximity ligation assay, 0.5x105 cells were seeded into 
each well of an 8−well chamber slide (Lab−Tek, Fisher), which has a removable 
chamber with a gasket on a standard microscope slide. For growth assays, 
0.2x105 cells were seeded into each well of a 24−well plate. MCF−7 cells were 
nourished with phenol−red−free RPMI medium (Gibco) that was supplemented 
with 5% FBS, 200 mM L−glutamine and antibiotics (10 IU/mL Penicillin, 
10 µg/mL Streptomycin, and 2.5µg/mL Amphotericin B). Other cell lines were 
grown in regular medium with supplements as mentioned earlier. The medium 
was refreshed every 3−4 days. 
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2.1.2 Transfections 
When MCF−7 cells were 60−90% confluent, they were transfected with 
plasmid DNAs using Lipofectamine−2000 transfection reagent (Invitrogen). The 
plasmid DNAs contained a CMV promoter and a carboxyl−terminal V5 tag in 
vector pcDNA3.1/V5−His−TOPO (Fig. 2.1). 
 
Figure 2.1 Schematic of ZIP7 or ZIP6 gene inserted in a plasmid vector  
 
This schematic demonstrates a simplified structure of the pcDNA3.1/V5−His−TOPO plasmid. It 
contains a carboxyl−terminal V5 epitope with a T7 priming site and a BGH reverse priming site, 
which were used for verification of a DNA insert. This vector also contains a CMV promoter 
(PCMV), an ampicillin−resistant gene (Amp), and a polyhistidine tag (His6). 
 
Either 3.5 µg ZIP7 plasmid DNA or 3.75 µg ZIP6 plasmid DNA, and 
7.5 µL Lipofectamine 2000 reagent were separately diluted in 188 µL 
phenol−red−free RPMI medium (Gibco) without serum and antibiotics (either 
antibacterial or antifungal drugs). Within 5 minutes of dilution at room 
temperature, diluted DNA and diluted Lipofectamine 2000 were mixed together 
and incubated at room temperature for 20 minutes. The transfection reaction 
was added into a dish that contains cells in phenol−red−free RPMI medium 
(Gibco) with FBS and L−glutamine, making a final volume of 1.5 mL. For 
transfection a ZIP6 construct, 3 mM sodium butyrate was added for 16 hours to 
upregulate the CMV promoter and thereby enhance expression of the 
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recombinant proteins (de Poorter et al. 2007). The cells were incubated in the 
transfection mixture at 37°C for 16−24 hours for ZIP7 and 16 hours for ZIP6.  
2.1.3 Treatments 
For short−term zinc treatment (up to 20 minutes), cells were incubated in 
either 20 μM zinc plus 10 μM sodium pyrithione in phenol−red−free RPMI 
medium with glutamine, but without serum and antibiotics (either antibacterial or 
antifungal drugs), at 37°C. For short−term zinc treatment (up to 30 minutes) in 
live cell experiments, 100 μM zinc plus 10 μM sodium pyrithione in 
phenol−red−free RPMI medium with serum and glutamine, but without 
antibiotics (either antibacterial or antifungal drugs), at 37°C. For nocodazole 
treatment, cells were incubated with 100 nM nocodazole in RPMI medium with 
serum, glutamine, and antibiotics (antibacterial and antifungal drugs) at 37°C for 
20 hours. For antibody treatment, a ZIP6 or ZIP10 antibody (Table 2.1) was 
added to RPMI medium with serum, glutamine, and antibiotics (antibacterial and 
antifungal drugs). For zinc chelation, 50 µM TPEN, a membrane−permeable 
zinc chelator, was added to the medium.  
For ZIP6 experiments that require separation of the adherent and the 
non−adherent cells, cells were collected using the mitotic shake−off technique 
(Izawa and Pines 2015). Briefly, the medium, which contained some 
non−adherent cells, was transferred to a collection tube, and 1 mL of 
phenol−red−free RPMI medium with FBS and L−glutamine, but without 
antibiotics (either antibacterial or antifungal drugs), was gently added to the 
dish. The cells were agitated by gently tapping on the side of the dish 3 times. 
The loosely−attached non−adherent cells that had been detached were directly 
collected and transferred to the corresponding collection tube. The monolayer 
adherent cells in the bottom was trypsinised using 1 mL of 0.05% trypsin and 
0.02% EDTA in PBS for up to 5 minutes at 37oC, which was then neutralised 
with 1 mL of the medium with serum before being collected.  
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Table 2.1 ZIP antibodies  
Antibody Sp Type Company 
Catalogue 
number 
 Dilutions Ab 
Rx  IF WB PLA FACS 
pZIP7 a m mAb Biogenes −  1:100 1:1000 − − − 
Total ZIP7 b  r pAb Biogenes −  1:200 1:1000 − − − 
ZIP6 E−20 c r pAb SCBT SC84875  − 1:1000 1:100 1:25 − 
ZIP6 M d m mAb Biogenes −  − − − −  
ZIP6 Y e m mAb Biogenes −  1:20 1:1000 − 1:25  
ZIP10 f r pAb Sigma SAB2102209  − − − −  
ZIP10 g m mAb Sigma SAB1401780  − 1:1000 1:100 − − 
ZIP10 h r pAb Abcam Ab83947  − 1:1000 1:100 − − 
ZIP10 R i r pAb Biogenes −  − − 1:100 −  
 
a pZIP7 (S275/S276) mAb. The epitope is TKEKQ pS pS EEEEK (residues 270−281, the 
cytosolic loop between TM3 and TM4).  
b Total ZIP7 pAb. The epitope is GRQERSTKEKQSSE (residues 264−277, the cytosolic loop 
between TM3 and TM4). 
c ZIP6 E−20 pAb. The epitope is in the cytosolic loop between TM3 and TM4.  
d ZIP6 M7 mAb. The epitope is HHDHDHHSDHEHHSD (residues 93–107, the N−terminus).  
e ZIP6 Y3 mAb. The epitope is VSEPRKGFMYSRNTNEN (residues 238–254, the N−terminus).  
f ZIP10 (SAB2102209) pAb. The epitope is LHRQHRGMTELEPSKFSKQAAENEKKYYIEKLFE 
RYGENGRLSFFGLEKL (residues 36−85, the N−terminus). 
g ZIP10 (SAB1401780) pAb. The epitope is 
CIRMFKHYKQQRGKQKWFMKQNTEESTIGRKLSDHK LNNTPDSDWLQLKPLAGTDDSVVSE 
DRLNETELTDLEGQQESPPKNYLCIEEEKIIDHSHSDGLHTIHEHDL (residues 514−621, from 
TM3 to the cytosolic loop between TM3 and TM4). 
h ZIP10 (Ab83947) pAb. The epitope is in the cytosolic loop between TM3 and TM4.  
i ZIP10 R (animal 25) pAb. The epitope is LEPSKFSKQAAENE (residues 46−59, the 
N−terminus). 
Sp, species; IF, immunofluorescence; WB, Western blot; PLA, proximity ligation assay; FACS, 
fluorescence−activated cell sorting; Ab Rx, antibody treatment experiments; m, mouse; r, rabbit;  
Biogenes, Biogenes GmbH; CST, Cell Signaling Technology; SCBT, Santa Cruz Biotechnology; 
Sigma, Sigma−Aldrich; mAb, monoclonal antibody; pAb, polyclonal antibody. 
 
2.2 Bacterial transformation and plasmid preparation 
The process of bacterial transformation, plasmid preparation, 
transfection, and characterisation of DNA constructs is illustrated in Fig. 2.2 and 
2.3. Each process will be further explained in individual sections. Briefly, 
competent bacteria were transformed with a pcDNA3.1/V5−His−TOPO plasmid 
that contained a ZIP7 or ZIP6 construct. Presence and orientation of the insert 
was confirmed by PCR using a specific ZIP7 or ZIP6 primer and a BGH reverse 
primer (Fig. 2.2). A clone that contained the correctly−orientated DNA insert 
was purified using a HiSpeed or EndoFree Plasmid Maxi Kit (Fig. 2.2).  
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Figure 2.2 An experimental strategy for plasmid preparation 
 
1. Competent bacteria are transformed with a pcDNA3.1/V5−His−TOPO plasmid that 
contains a ZIP7 or ZIP6 construct.  
2. Presence and orientation of the insert are confirmed by PCR using a specific ZIP7 or 
ZIP6 primer and a BGH reverse primer.  
3. A clone that contains the correctly−orientated DNA insert is selected for plasmid 
preparation, using either a HiSpeed or EndoFree Plasmid Maxi Kit.  
 
For characterisation of a DNA construct, a transfection was performed 
using Lipofectamine 2000 (Fig. 2.3). Cells were then treated with zinc plus zinc 
ionophore sodium pyrithione or nocodazole (Fig. 2.3). Immunofluorescence, 
Western blotting, flow cytometry or proteome profiler antibody array procedure 
was performed for determination of protein expression or modification such as 
phosphorylation (Fig. 2.3). Furthermore, cellular zinc levels were determined by 
fluorescence microscopy or flow cytometry using zinc−sensitive dyes, consisting 
of Fluozin−3, Newport Green and Zinquin, whereas protein binding was 
determined by immunoprecipitation or proximity ligation assay (Fig. 2.3). All the 
antibodies that were used in these experiments are listed in Tables 2.1−2.3. 
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Figure 2.3 An experimental strategy for investigations in this project 
 
1. For experiments in transfected cells, purified plasmids are transfected into MCF−7 cells 
using Lipofectamine 2000. 
2. Cells are treated with zinc plus zinc ionophore sodium pyrithione. For experiments on 
mitosis, cells are treated with nocodazole to increase the number of mitotic cells. 
3. Cellular effects are determined using various techniques. Protein expression or 
modification (phosphorylation) is determined using immunofluorescence, Western 
blotting, flow cytometry and proteome profiler antibody arrays. Zinc levels are 
determined using a zinc−sensitive fluorescence dye (Fluozin−3, Newport Green, or 
Zinquin) with either fluorescence microscopy or flow cytometry. Protein interaction or 
binding is determined using immunoprecipitation or proximity ligation assay. 
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Table 2.2 Primary antibodies other than ZIP antibodies 
Antibody Sp Type Company 
Catalogue 
number 
Dilutions 
IF WB PLA FACS 
β−actin−peroxidase m mAb Sigma A3854 − 1:50000 − − 
β−catenin m mAb Sigma C7082 1:100 1:1000 − − 
CK1a m mAb SCBT SC74582 − 1:1000 1:100 − 
CK2a m mAb SCBT SC12738 − 1:1000 1:100 − 
GAPDH−peroxidase m mAb CST SC32233 − 1:50000  − 
GSK−3 m mAb Abcam Ab93926 − 1:1000 1:100 − 
pAKT (S473) r pAb CST 9271 − 1:1000 − − 
pCREB (S133) r pAb CST 9198 − 1:1000 − − 
pGSK−3 (S9) r pAb CST 9336 − 1:1000 − − 
pHistone H3 (S10) m mAb CST 9706S − − − 1:10 
pHistone H3 (S10) r pAb CST 3377S 1:500 1:1000 − 1:10 
pP70 S6  
(T421/S424) 
r pAb CST 9204 − 1:1000 − − 
pSer m mAb SCBT SC81514 − 1:1000 − − 
pStathmin (S38) r pAb CST 4191S − − 1:200 − 
pSTAT3 (S727.49) m mAb SCBT SC136193 − 1:1000 1:200 − 
pSTAT5a/b (S726) r pAb SCBT SC12893R − 1:1000 − − 
V5 r pAb Abcam Ab15828 1:1000 1:1000 − − 
V5 r pAb SCBT SC83849R 1:1000 − − − 
 
Sp, species; IF, immunofluorescence; WB, Western blot; PLA, proximity ligation assay; FACS, 
fluorescence−activated cell sorting; 
m, mouse; r, rabbit;  
CST, Cell Signaling Technology; SCBT, Santa Cruz Biotechnology; Sigma, Sigma−Aldrich; 
mAb, monoclonal antibody; pAb, polyclonal antibody. 
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Table 2.3 Secondary antibodies  
Antibody Sp Company 
Catalogue 
number 
 Dilutions 
 IF WB FACS 
Alexa Fluor−488 GAM MP A11029  1:1000 − 1:100 
Alexa Fluor−488 GAR MP A11034  1:1000 − 1:100 
Alexa Fluor−594 GAM MP A11032  1:1000 − 1:100 
Alexa Fluor−594 GAR MP A11037  1:1000 − 1:100 
Alexa Fluor−647 GAM MP A21237  1:1000 − 1:100 
Alexa Fluor−647 GAR MP A21246  1:1000 − 1:100 
HRP−linked IgG GAM Fisher 10094724  − 1:10000 − 
HRP−linked IgG GAR CST 7074  − 1:10000 − 
 
Sp, species; IF, immunofluorescence; WB, Western blot; FACS, fluorescence−activated cell 
sorting; 
GAM, goat anti−mouse; GAR, goat anti−rabbit; HRP, horseradish−peroxidase; 
Fisher, Fisher Scientific; MP, Molecular Probe; CST, Cell Signaling Technology 
 
2.2.1 Site−directed mutagenesis 
Site−directed mutagenesis was performed by Mutagenex Inc, and the 
mutations were confirmed by DNA sequencing. Individual serine, threonine, or 
tyrosine residues were mutated to alanine (codon GCA, GCT or GCC) for a 
phosphoablative (null) mutant or aspartate (codon GAC) for a phosphomimetic 
mutant (Table 2.4).  
 
Table 2.4 DNA sequences of ZIP7 and ZIP6 mutants  
Construct Wild−type DNA sequence Mutant DNA sequence 
 
ZIP7 S275A S276A CAGAGCTCAGAG CAGgcCgCAGAG  
ZIP7 S275D S276D CAGAGCTCAGAG CAGgaCgacGAG  
ZIP6 S471A CAGTTGTCCAAGTAT CAGTTGgCCAAGTAT  
ZIP6 Y473A TCCAAGTATGAATCT TCCAAGgctGAATCT  
ZIP6 S475A TATGAATCTCAACTT TATGAAgCTCAACTT  
ZIP6 S478A CAACTTTCAACAAAT CAACTTgCAACAAAT  
ZIP6 T479A CTTTCAACAAATGAG CTTTCAgCAAATGAG  
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2.2.2 Bacterial transformation 
DNA constructs were inserted into an ampicillin−resistant 
pcDNA3.1/V5−His−TOPO plasmid vector and were amplified by transformation 
of single−use JM109 E. coli competent cells (Promega) according to the 
manufacturer’s instructions. Briefly, 1 µL plasmid solution in Tris−EDTA (TE) 
buffer, which contained 3.0−3.3 µg plasmid DNA, and 50 μL competent cells 
were mixed and incubated on ice for 30 minutes. The bacteria were then 
heat−shocked at 40 ºC for 20 seconds, replaced on ice for 2 minutes, 
supplemented with 450 µL super optimal broth with catabolite repression (SOC) 
medium, and incubated at 37ºC with shaking for 60 minutes. Eventually, 100 µL 
of the transformation reaction was plated on a Luria−Bertani (LB) agar plate 
with 100 µg/mL ampicillin at 37ºC for 18 hours. The transformed bacteria on an 
agar plate were kept at 4 ºC for less than one month. 
Presence and orientation of DNA inserts in the plasmid vector were 
verified by PCR using a forward primer specific to either ZIP7 (MWG Biotech 
AG, sequence: 5’−TTGTTGCCTTTCTTGTCGTG−3’) or ZIP6 (MWG Biotech 
AG, sequence: 5’−GTCTAACAGCTCTAGGAGGC−3’) and a BGH reverse 
primer (MWG Biotech AG, sequence: 5’−TAATACGACTCACTATAGGG−3’). 
Noteworthy, the BGH reverse primer was complementary to the BGH reverse 
priming site of the pcDNA3.1/V5−His−TOPO vector (Fig. 2.1). Each 25 µL PCR 
mixture contained 1x NH4 reaction buffer [16 mM (NH4)2SO4, 67 mM Tris−HCl 
(pH 8.8)] (Bioline), 1.5 mM of MgCl2 (Bioline), 200 µM of dNTP mix, 0.2 µM of 
each primer, and 1 U of BIOTAQ DNA polymerase (Bioline), and a bacterial 
colony from the LB agar plate. Twenty cycles of PCR were programmed to 
perform the following thermal cycling conditions: the denaturation step at 94 ºC 
for 10 seconds, the annealing step at 55 ºC for 30 seconds, and the extension 
step at 72 ºC for 2 minutes. An initial denaturation at 94 ºC for 10 minutes and a 
final extension at 72 ºC for 10 minutes were also added to the PCR settings. 
Five µL of each PCR product was separated by 1% agarose gel 
electrophoresis, along with 0.6 µg/lane 1 kb DNA Step Ladder (Promega) at 
100 V for 45 minutes, and visualised with a UV transilluminator. 
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2.2.3 Plasmid preparation 
The correctly−orientated plasmids obtained within the competent cells 
were purified using the HiSpeed Plasmid Maxi Kit (Qiagen) for ZIP7 constructs 
or the EndoFree Plasmid Maxi Kit (Qiagen) for ZIP6 constructs according to the 
manufacturer’s instructions. Briefly, a colony of the transformed competent cells 
was inoculated in 5 mL LB medium with 100 µg/mL ampicillin at 37ºC with 
vigorous shaking for 8 hours. The starter culture was diluted 1/500 into 250 mL 
LB medium with 100 µg/mL ampicillin, and further grown at 37ºC with vigorous 
shaking for 16 hours. After centrifugation at 6,500 rpm at 4 °C for 15 minutes 
and resuspension of the pellet with 10 mL buffer P1 with 100 µg/mL RNAse and 
1x LyseBlue added, the competent cells were lysed with 10 mL buffer P2 for 5 
minutes. The bacterial lysate was then neutralised with 10 mL buffer P3 and 
cleared by filtration using a QIAfilter Cartridge.  
For the HiSpeed Plasmid Maxi Kit, the plasmid DNA was purified using a 
HiSpeed Maxi Tip, from which the DNA was eluted with 15 mL buffer QF. The 
DNA obtained was further purified by precipitations with isopropanol and 70% 
ethanol, employing the QIAprecipitator Module provided in the kit. The purified 
DNA was finally dissolved in 500 L endotoxin−free Buffer TE.  
For the EndoFree Plasmid Maxi Kit, endotoxin was removed from the 
filtrate by incubation in 2.5 mL buffer ER on ice for 30 minutes. The plasmid 
DNA was purified using a QIAGEN−tip 20 anion−exchange tip, from which the 
DNA was eluted with 15 mL buffer QN. The DNA obtained was further purified 
by precipitations with isopropanol and 70% ethanol. Finally, the purified DNA 
was re−dissolved in 200 µL endotoxin−free Buffer TE. 
The plasmid DNA solution was analysed with a UV spectrophotometer 
for concentration and purity, which were determined by the absorbance at 
260 nm (OD260) and the ratio of the absorbance at 260 nm to the absorbance 
at 280 nm (OD260/OD280 ratio), respectively. Additionally, the plasmid DNA 
was also analysed with 1% agarose gel electrophoresis along with 0.6 µg of 
1 kb DNA Step Ladder (Promega) at 100 V for 45 minutes and visualised with a 
UV transilluminator. Eventually, the plasmid was verified using 
immunofluorescence stained with the anti−V5 antibody, which will be shown in 
the corresponding chapters. 
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2.3 Immunofluorescence 
Cells on a 22x22 mm 0.17 mm thick glass coverslip or an 8−well 
chamber slide (Lab−Tek, Fisher) were fixed with 4% formaldehyde in PBS for 
15 minutes and washed with PBS twice. For the 8−well chamber slide, the 
chamber was removed after fixing, leaving a gasket on the slide. The cells 
either on the coverslip or on the slide were blocked and permeabilised with 1% 
bovine serum albumin (Sigma−Aldrich) and 0.4% saponin (Sigma−Aldrich) in 
PBS for 15 minutes, with additional blocking with 10% normal goat serum 
(DAKO) in the blocking/permeabilisation solution for 15 minutes. The cells were 
then probed with primary antibodies (Tables 2.1 and 2.2) for 60 minutes. After 
washing, the cells were incubated with either a mixture of 2 µg/mL Alexa Fluor 
goat anti−mouse 594 and goat anti−rabbit 488 antibodies (Molecular Probes) or 
a mixture of 2 µg/mL Alexa Fluor goat anti−mouse 488 and goat anti−rabbit 594 
antibodies (Molecular Probes) (Table 2.3) for 30 minutes, with light protection. 
The coverslip was mounted on a slide with VECTASHIELD Mounting Media 
(Vector Laboratories) containing 1.5 µg/mL 4,6−diamidino−2−phenylindole 
(DAPI) and sealed with nail varnish. For the 8−well chamber slide, the gasket 
was removed, and a 22x50 mm 0.17 mm thick glass coverslip was mounted on 
the slide with the mounting media with DAPI and sealed with nail varnish. The 
stained slides were stored at 4ºC in the dark until they were visualised on a 
Leica RPE automatic microscope using a 63x oil immersion lens with a multiple 
bandpass filter for DAPI, Texas Red and fluorescein. Images were acquired 
using Openlab modular imaging software for Macintosh operating system with 
one−level deconvolution. Brightness and contrast adjustments were performed 
using GIMP 2.8.4 (GNU Image Manipulation Program) open−source software. 
2.4 Western blotting and co−immunoprecipitation 
2.4.1 Cell harvesting and sample preparation 
Cells in a 35 mm dish were lysed with 100 µL lysis buffer pH 7.6 (50 mM 
Tris, 150 mM NaCl, 5 mM EGTA, and 1% Triton X−100) with 10% (v/v) protease 
inhibitor cocktail for mammalian cells (Sigma−Aldrich) and additional 
phosphatase inhibitors (2 mM sodium orthovanadate and 50 mM sodium 
fluoride). The lysate was incubated on ice with occasional mixing for 60 minutes 
to allow maximal separation of the plasma membrane proteins from the 
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membrane and centrifuged at 12,000 rpm for 12 minutes at 4ºC. Concentration 
of the supernatant was analysed with a UV spectrophotometer, using a 
Bio−Rad/Bradford dye−binding protein microassay. The sample was diluted in 
Laemmli sample buffer (Laemmli 1970), to make a final concentration of 
1 µg/µL, boiled at 100 ºC for 5 minutes and stored at −20oC.  
2.4.2 Co−immunoprecipitation 
Four−hundred μg cell lysate was incubated with either 0.4 g rabbit 
LIV−1 E−20 antibody (Santa Cruz Biotechnology, SC−84875) or 4.0 g rabbit 
V5 polyclonal antibody (Abcam, Ab9116) at 4ºC overnight. On the following day, 
the sample was mixed with 20 μl of EZview Red Protein A Affinity Gel beads 
(Sigma−Aldrich, P6486) at 4 ºC for 4 hours. The beads were washed with lysis 
buffer containing protease inhibitors 4 times and eventually resuspended in 
20 μL lysis buffer with 20 μL Laemmli sample buffer (Laemmli 1970). The 
precipitated proteins were separated from the beads by boiling at 100 ºC for 
5 minutes and centrifuging at 9600 rpm for 30 seconds. The supernatant was 
collected for analysis by Western blotting. 
2.4.3 Polyacrylamide gel electrophoresis−sodium dodecyl sulphate 
(SDS−PAGE) and immunodetection 
Proteins were separated by 7.5−12% SDS−PAGE at 120 V for 90 
minutes and transferred onto a nitrocellulose membrane at 100 V for 60 
minutes. Proteins on the membrane were reversibly stained with 0.1% (w/v) 
Ponceau S in 5% acetic acid to image bands, before washing off with Tris 
Buffered Saline with Tween−20 (TBST). Non−specific proteins were blocked 
with 5% non−fat dried milk (Marvel) in TBST for 60 minutes. The blot was then 
incubated with a primary antibody at 4 ºC overnight. The primary antibodies 
used are shown in Tables 2.1 and 2.2. After incubation with the primary 
antibody, the membrane was incubated with either horseradish−peroxidase 
(HRP)−labelled goat anti−mouse or anti−rabbit antibodies (1:10,000) 
(Table 2.3) at room temperature for 60 minutes. Either a β−actin 
peroxidase−conjugated antibody or a GAPDH peroxidase−conjugated antibody 
(Table 2.2) was used as a standard, with which the membrane was incubated at 
room temperature for 15 minutes. Combinations of Pierce ECL Western blotting 
detection reagents (Thermo Scientific), Clarity Western ECL substrate 
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(Bio−Rad), SuperSignal West Dura Substrate (Thermo Scientific), and 
SuperSignal West Femto Substrate (Thermo Scientific) were used for the 
chemiluminescence−based immunodetection. To visualise the protein bands, 
the blot was exposed to a high−resolution blue sensitive X−ray film (Photon 
Imaging Systems) in a dark room. Densitrometric data were acquired using 
Alpha DigiDoc version 4.10, and the results were analysed with Microsoft Excel 
2010 or 2013 program, using β−actin, GAPDH, or V5 for normalisation. 
2.5 Flow cytometry 
2.5.1 Immunostaining 
Cells in a 35 mm dish were trypsinised using 1 mL of 0.05% trypsin and 
0.02% EDTA in PBS for up to 5 minutes at 37oC and centrifuged at 1000 rpm 
for 5 minutes. The cells were washed in 1 mL ice−cold PBS, and incubated with 
50 µL of primary antibodies (Tables 2.1 and 2.2) in blocking/permeabilisation 
solution (1% BSA and 0.4% saponin in KRH buffer) on ice for 60 minutes. The 
cells were washed again in 1 mL ice−cold PBS and then incubated with 50 µL 
of 20 µg/mL Alexa Fluor goat anti−mouse 647 plus 20 µg/mL Alexa Fluor goat 
anti−rabbit 488 antibodies (Molecular Probes) (Table 2.3) in the 
blocking/permeabilisation solution on ice for 30 min. The cells were then fixed 
with 500 µL 4% formaldehyde at room temperature for 15 min, centrifuged at 
1000 rpm for 10 min and resuspended in 500 µL PBS. Fluorescence intensity 
was measured with BD FACSVerse Flow Cytometer. Data were analysed using 
Flowing Software version 2.50 (Turku Centre for Biotechnology). 
2.5.2 Cell cycle analysis 
Cells in a 35 mm dish were trypsinised using 1 mL of 0.05% trypsin and 
0.02% EDTA in PBS for up to 5 minutes at 37oC, washed in PBS and fixed in 
70% ethanol at −20 ºC overnight or longer. After centrifuging at 2000 rpm for 10 
minutes, the fixed cells were washed in ice−cold PBS twice and incubated with 
the staining solution (20 µg/mL propidium iodide, 0.2 µg/mL DNase−free RNase 
A, and 0.1% Triton X−100 in PBS) at 37ºC for 20 minutes. The cell suspension 
was filtered through a cell strainer (12x75 mm; mesh size: 35 µm) to collect the 
single cells. Fluorescence intensity was measured with BD FACSVerse Flow 
Cytometer. Cell cycle analysis was performed with FlowJo Software version 10, 
using the Watson pragmatic algorithm (Watson et al. 1987). 
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2.6 Zinc assays 
Cells were loaded with 5 µM Fluozin−3 (Invitrogen), 25 µM Zinquin 
(Santa Cruz Biotechnology) or 5 µM Newport Green diacetate DCF (Invitrogen) 
in phenol−red−free RPMI medium with glutamine and serum, but without 
antibiotics (either antibacterial or antifungal drugs), at 37ºC for 30 minutes in the 
dark. The cells were washed and incubated in the same medium without dye for 
at least 30 minutes to allow complete de−esterification of intracellular AM 
esters. For determination of cellular zinc using fluorescence microscopy, the 
cells were fixed after treatment. The coverslip was mounted on a glass slide, 
and the cells were visualised as described for immunofluorescence. At least 6 
images were taken from each coverslip using the same exposure time for each 
experiment. Fluorescence intensity was determined using ImageJ Software 
version 1.49 (Schneider et al. 2012), and the total corrected cellular 
fluorescence was calculated by subtracting integrated density with background 
intensity, which equals area of selected cell multiplied by mean fluorescence of 
average background readings (McCloy et al. 2014). For determination of cellular 
zinc using flow cytometry, fluorescence intensity was measured with BD 
FACSVerse Flow Cytometer. Mean fluorescence was calculated using Flowing 
Software version 2.50 (Turku Centre for Biotechnology). 
2.7 Proximity ligation assays (PLA) 
The process of PLA is illustrated in Fig 2.4. Treated and/or transfected 
cells on an 8−well chamber slide (Lab−Tek, Fisher) were fixed with 4% 
formaldehyde in PBS for 15 minutes. After washing with PBS twice, the 
chamber was removed, leaving the hydrophobic well borders on the slide to 
accommodate 100 mL volumes. The cells were blocked and permeabilised with 
a 50/50 mixture of the blocking/permeabilisation solution and the Duolink 
blocking solution (Sigma−Aldrich) for 15 minutes. The blocking/permeabilisation 
solution contains 1% bovine serum albumin (Sigma−Aldrich) and 0.4% saponin 
(Sigma−Aldrich) in PBS. The cells were then incubated with primary antibodies 
(Tables 2.1 and 2.2) in the blocking/permeabilisation solution at room 
temperature for 60 minutes. The slide was placed in a water chamber to prevent 
drying, and the cells were then probed with a mixture of Duolink II anti−rabbit 
MINUS and anti−mouse PLUS probes (Sigma−Aldrich), which contain 
oligonucleotides, in the blocking/permeabilisation solution at 37ºC for 60 
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minutes. Utilising Duolink In Situ Detection Reagents Red (Sigma−Aldrich), 
signals were produced by further incubating the cells with ligase in the ligation 
buffer at 37ºC for 30 minutes to hybridise the PLA probes and generate a 
closed circle and polymerase in the amplification buffer at 37ºC for 100 minutes 
to enhance rolling circle amplification in the water chamber.  
 
Figure 2.4 Proximity ligation assays (PLA) 
 
This schematic shows the process of PLA. Cells are incubated with two antibodies against the 
proteins of interest. These antibodies are raised from two different animal species. PLA probes, 
plus and minus, bind to the primary antibodies corresponding to the animal species from which 
they are raised. Enzymes ligase and polymerase are applied to enhance ligation and 
amplification of the oligonucleotide attached to the probes, resulting in ring DNA circle formation 
and rolling circle amplification. A red fluorescent probe that is added during the amplification 
step hybridises with the amplified DNA. Provided the two target proteins are in close proximity, 
the binding is detected as red fluorescent dots. 
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After the gasket was completely removed, a 22x50 mm 0.17 mm thick 
glass coverslip was mounted on the slide using VECTASHIELD Mounting 
Media (Vector Laboratories) containing DAPI and sealed with nail varnish. The 
slide was visualized on a Leica RPE automatic microscope using a 63x oil 
immersion lens with a multiple bandpass filter for DAPI and Texas Red. The 
images were acquired and presented as maximal projections of 25 stacks taken 
0.3 μm apart using Openlab modular imaging software for Macintosh operating 
system. The numbers of dots per cell were determined using Duolink ImageTool 
software (Olink Bioscience). Brightness and contrast adjustments were 
performed using GIMP 2.8.4 software. 
2.8 Growth assays 
Cells were grown in a 24−well plate and treated with either a ZIP6 or a 
ZIP10 antibody (Table 2.1) at 24 hours. The cells were collected every day until 
day 4. The medium was refreshed on day 3. To collect the cells, they were 
trypsinised using 1 mL of 0.05% trypsin and 0.02% EDTA in PBS for 5 minutes 
at 37oC, and 3 mL Isoton II balanced electrolyte solution (Beckham Coulter) 
was added to each well. To prepare single cells, the cell suspension was drawn 
up into a 5 mL syringe through a 25G needle and transferred to a Coulter 
Counter counting cups containing 6 mL Isoton II balanced electrolyte solution 
(Beckham Coulter). The amount of the single cells was determined using a 
Beckham Coulter counter (Beckham Coulter). 
2.9 Proteome profiler antibody array procedures  
The human phospho−receptor tyrosine kinase (RTK) (R&D Systems, 
ARY001B), phospho−mitogen−activated protein kinase (MAPK) (R&D Systems, 
ARY002B), phospho−kinase (R&D Systems, ARY003B), and protease (R&D 
Systems, ARY021B) antibody arrays were used. The strategies of array signal 
detection are illustrated in Fig. 2.5 and 2.6.  
After transfection and zinc treatment, cells in a 35 mm dish with 90% 
confluence were lysed in either 100 L Lysis Buffer 17 with 10 g/mL Aprotinin, 
10 g/mL Leupeptin, and 10 g/mL Pepstatin (for the phosphor−RTK and the 
protease arrays) or 100 L Lysis Buffer 6 (for the phospho−kinase and the 
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phospho−MAPK arrays). The rest of the procedures were performed according 
to the manufacturer’s instruction utilising the reagents supplied with the arrays.  
For the phospho−RTK array, each membrane was blocked in Array 
Buffer 1 at room temperature for 60 minutes and incubated in 300 µg lysate 
diluted in the blocking buffer at 4 ºC overnight. On the following day, the array 
was incubated with the Anti−Phospho−Tyrosine−HRP Detection Antibody in 
Array Buffer 2 at room temperature for 2 hours.  
 
Figure 2.5 Human phospho−receptor tyrosine kinase (RTK) arrays 
 
This schematic illustrates the signal detection strategy for phospho−RTK arrays. Three pairs of 
reference spots are present on the left upper, right upper, and left lower corners of each array. 
Capture antibodies are blotted on the membrane in duplicate and bind to RTKs that are present 
in cell lysates. Tyrosine phosphorylation of particular RTKs is determined by application of an 
HRP−conjugated anti−phospho−tyrosine antibody. Signals are detected using a standard 
chemiluminescence procedure.  
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For the phospho−kinase array, each of Part A and Part B of the 
membrane was blocked in Array Buffer 1 at room temperature for 60 minutes 
and incubated in 300 µg lysate diluted in the blocking buffer at 4 ºC overnight. 
On the following day, the array was incubated with either Detection Antibody 
Cocktail A (for Part A) or B (for Part B) in Array Buffer 2/3 (Array Buffer 2 diluted 
in Array Buffer 3) at room temperature for 2 hours and with Streptavidin−HRP 
(1:2,000) in Array Buffer 2/3 at room temperature for 30 minutes.  
 
Figure 2.6 Human phospho−kinase, phospho−mitogen−activated protein 
kinase (MAPK), and protease arrays 
 
This schematic illustrates the signal detection strategy for phospho−kinase, phospho−MAPK, 
and protease arrays. Three pairs of reference spots are present on the left upper, right upper 
and left lower corners of each array. Capture antibodies are blotted on the membrane in 
duplicate and bind to kinases or proteases that are present in the cell lysates. Phosphorylation 
of particular kinases on specific sites or presence of particular proteases is determined by 
application of biotin−conjugated detection antibodies and HRP−conjugated streptavidin. Signals 
are detected using a standard chemiluminescence procedure.  
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For the phospho−MAPK and the protease arrays, each membrane was 
blocked in either Array Buffer 5 (the phospho−MAPK array) or Array Buffer 6 
(the protease array) at room temperature for 60 minutes. The membrane was 
then incubated in 300 µg (the phospho−MAPK array) or 200 µg (the protease 
array) of the lysate that had been pre−incubated with Detection Antibody 
Cocktail at room temperature for 60 minutes. On the following day, the array 
was incubated with Streptavidin−HRP (1:2,000) in the blocking buffer at room 
temperature for 30 minutes.  
All the arrays were applied with Chemi Reagent Mix and exposed to film 
for 10 minutes. Signal intensities were determined by densitometric analysis 
using Alpha DigiDoc version 4.10. Heat maps were generated using a GENE-E 
matrix visualization and analysis platform (The Board Institute). 
2.10 Statistical analysis 
Statistical analysis was performed using either independent t−test or 
analysis of variance (ANOVA) with Dunnett’s test. The change was considered 
significant when p<0.05. Statistical significance was assumed with ∗ = p<0.05, 
∗∗ = p<0.01, ∗∗∗ = p<0.001. Error bars shown represent standard errors.  
2.11 Materials  
All the materials that were used in this project are shown in Table 2.5. 
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Table 2.5 Materials  
Reagent Company 
Catalogue 
number 
 
 
Acrylamide/bis−acrylamide  
(30% solution (v/v), 29:1 ratio) 
Sigma−Aldrich,  
Poole, Dorset, UK 
A3699  
Agarose Bioline Ltd,  
London, UK 
BIO−41025  
Alpha Digidoc RT Densitometry software Alpha Innotech Corp,  
California, USA 
  
Amersham Protran 0.45µm nitrocellulose Fisher Scientific UK Ltd, 
Loughborough, UK 
10087970  
Ammonium persulphate (APS) Sigma−Aldrich,  
Poole, Dorset, UK 
A3678   
Amphotericin B (Fungizone) Invitrogen,  
Paisley, UK 
15290  
Amplification red (5x) Olink Bioscience,  
Uppsala, Sweden 
82011  
Aprotinin Sigma−Aldrich,  
Poole, Dorset, UK 
10820  
BD FACSVerse Becton, Dickinson UK Ltd, 
Oxford, UK 
  
Bio−Rad protein assay dye reagent 
concentrate 
BioRad Laboratories Ltd,  
Hertfordshire, UK 
500−0006  
Blue sensitive X-ray film  
(18x24 cm) 
Photon Imaging Systems, 
Swindon, UK 
FM024  
Bovine serum albumin (BSA) Sigma−Aldrich,  
Poole, Dorset, UK 
A2153   
Bovine trypsin Lorne Laboratories Ltd,  
Reading, UK 
  
Bromophenol blue BDH Chemicals Ltd,  
Poole, Dorset, UK 
  
Cecil CE 2041 spectrophotometer CECIL,  
Cambridge, UK 
  
Cell scrapers Greiner Bio−One Ltd,  
Gloucestershire, UK 
  
Class II biological safety cabinet MDH Intermed Airflow from 
Bioquell,  
Andover, UK 
  
Coulter Counter counting cups and lids Sarstedt AG and Co.,  
Nümbrecht, Germany 
  
DAPI dilactate Invitrogen,  
Paisley, UK 
D3571  
Denly BA852 autoclave Thermoquest Ltd,  
Basingstoke, UK 
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Reagent Company 
Catalogue 
number 
 
 
Dimethyl sulphoxide (DMSO) Sigma−Aldrich,  
Poole, Dorset, UK 
D8418   
Disposable cuvettes Fisher Scientific UK Ltd,  
Loughborough, UK 
FB55143  
Di−thiothreitol (DTT) Sigma−Aldrich,  
Poole, Dorset, UK 
43815  
DNase−free RNase A (Ribonuclease A 
from bovine pancreas) 
Sigma−Aldrich,  
Poole, Dorset, UK 
R5503  
dNTPs  
(dGTP, dCTP, dATP, dTTP; 100 mM) 
Amersham,  
Little Chalfont, UK 
28−4065−52  
Dulbecco's Modified Eagle Medium 
(DMEM) with 4.5 g/L glucose 
Fisher Scientific UK Ltd, 
Loughborough, UK 
11960044  
Duolink ImageTool software Olink Bioscience,  
Uppsala, Sweden 
  
Duolink II PLA probe 
(Anti−mouse, plus) 
Olink Bioscience,  
Uppsala, Sweden 
82001  
Duolink II PLA probe 
(Anti−rabbit, minus) 
Olink Bioscience,  
Uppsala, Sweden 
82005  
Eppendorf tubes Eppendorf,  
Hamburg, Germany 
  
Ethanol Fisher Scientific UK Ltd,  
Loughborough, UK 
10428671  
Ethidium bromide (EtBr) Sigma−Aldrich,  
Poole, Dorset, UK 
E8751   
Ethylene diamine tetraacetic acid (EDTA) Sigma−Aldrich,  
Poole, Dorset, UK 
59815  
EZview Red Protein A Affinity Gel  Sigma−Aldrich,  
Poole, Dorset, UK 
P6486  
Falcon tube with cell strainer cap  
(12x75 mm; mesh size: 35 µm) 
Fisher Scientific UK Ltd,  
Loughborough, UK 
10585801  
FlowJo data analysis 10 software  FlowJo LLC, 
Oregon, USA 
  
Fluozin−3 Invitrogen,  
Paisley, UK 
F24195  
Foetal bovine serum (FBS) Invitrogen,  
Paisley, UK 
26140  
Formaldehyde Fisher Scientific UK Ltd,  
Loughborough, UK 
10041040  
Glass coverslips  
(thickness no. 1, 22x22 mm and 22x50 
mm) 
BDH Chemicals Ltd,  
Poole, Dorset, UK 
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Reagent Company 
Catalogue 
number 
 
 
Glass slides Fisher Scientific UK Ltd,  
Loughborough, UK 
  
Glycerol Fisher Scientific UK Ltd,  
Loughborough, UK 
10152970  
Glycine Fisher Scientific UK Ltd,  
Loughborough, UK 
G/P460/53  
Hoechst 33342 Fisher Scientific UK Ltd,  
Loughborough, UK 
62249  
Improvision OpenLab 4.04 software Improvision,  
Coventry, UK 
  
Insulin solution from bovine pancreas  
(10 mg/mL) 
Sigma−Aldrich,  
Poole, Dorset, UK 
I0516  
Isopropanol Fisher Scientific UK Ltd,  
Loughborough, UK 
10723124  
Isoton II azide−free balanced electrolyte 
solution 
Beckman,  
High Wycombe, UK 
  
Lab−Tek chamber slide system, 8−well 
glass slide 
Sigma−Aldrich,  
Poole, Dorset, UK 
177402  
Leica DM−IRE2 inverted microscope Leica Microsystems 
Imaging, Solutions Ltd,  
Cambridge, UK 
  
Leupeptin Sigma−Aldrich,  
Poole, Dorset, UK 
L0649  
L−glutamine Invitrogen,  
Paisley, UK 
25030  
Ligase Olink Bioscience,  
Uppsala, Sweden 
82027  
Ligation (5x) Olink Bioscience,  
Uppsala, Sweden 
82009  
Lipofectamine 2000 transfection reagent Invitrogen,  
Paisley, UK 
11668019  
Lower buffer for SDS−PAGE gels 
(Tris 1.5 M, pH 8.8) 
BioRad Laboratories Ltd,  
Hertfordshire, UK 
161−0798  
Magnesium chloride (MgCl2) Sigma−Aldrich,  
Poole, Dorset, UK 
M8787   
Magnetic stirrer Fisher Scientific UK Ltd,  
Loughborough, UK 
  
Methanol Fisher Scientific UK Ltd,  
Loughborough, UK 
10499560  
Micro−centrifuge tubes  
(0.5 mL and 1.5 mL) 
Elkay Laboratory Products,  
Basingstoke, UK 
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Reagent Company 
Catalogue 
number 
 
 
Mini−Protean 3 electrophoresis 
apparatus 
BioRad Laboratories Ltd,  
Hertfordshire, UK 
  
N,N,N’,N’−tetramethylene−diamine 
(TEMED) 
Fisher Scientific UK Ltd,  
Loughborough, UK 
BPE150−20  
N,N,N′,N′−Tetrakis(2−pyridylmethyl) 
ethylenediamine (TPEN) 
Sigma−Aldrich,  
Poole, Dorset, UK 
P4413  
Newport Green DCF Invitrogen,  
Paisley, UK 
N7991  
Nikon Eclipse TE200 phase contrast 
microscope 
Nikon,  
Kingston−upon Thames, UK 
  
Olympus 8 MP digital camera Olympus,  
Oxford, UK 
  
Penicillin/Streptomycin Invitrogen,  
Paisley, UK 
15140  
Pepstatin A Sigma−Aldrich,  
Poole, Dorset, UK 
P5318  
Pierce ECL Western Blotting Substrate Pierce and Warriner Ltd,  
Cheshire, UK 
32106  
Pipette Tips Greiner Bio−One Ltd,  
Gloucestershire, UK 
  
Platform rocker STR6 Stuart Scientific, Bibby 
Sterilin Ltd,  
Stone, UK 
  
Polymerase Olink Bioscience,  
Uppsala, Sweden 
82028  
Polyoxyethylene−sorbitan monolaurate 
(Tween 20) 
Sigma−Aldrich,  
Poole, Dorset, UK 
93774  
Precision Plus protein blue standards BioRad Laboratories Ltd,  
Hertfordshire, UK 
161−0393SP  
Propidium iodide solution Sigma−Aldrich,  
Poole, Dorset, UK 
P4864  
Protease inhibitor cocktail (in DMSO) Sigma−Aldrich,  
Poole, Dorset, UK 
P8340  
Proteome Profiler Human 
Phospho−Kinase Array Kit 
Bio-Techne EMEA, 
Abingdon, UK 
ARY003B  
Proteome Profiler Human 
Phospho−Mitogen−activated Protein 
Kinase (MAPK) Antibody Array Kit 
Bio-Techne EMEA, 
Abingdon, UK 
ARY002B  
Proteome Profiler Human 
Phospho−Receptor Tyrosine Kinase 
(RTK) Array Kit 
Bio-Techne EMEA, 
Abingdon, UK 
ARY001B  
Proteome Profiler Human Protease Array 
Kit 
Bio-Techne EMEA, 
Abingdon, UK 
ARY021B  
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Reagent Company 
Catalogue 
number 
 
 
PTC−100 Thermocycler MJ Research Ltd,  
Massachusetts, USA 
  
Roller platform Stuart Scientific,  
Bibby Sterilin Ltd,  
Stone, UK 
  
Roswell Park Memorial Institute (RPMI) 
medium 1640 
Fisher Scientific UK Ltd, 
Loughborough, UK 
11875093  
Roswell Park Memorial Institute (RPMI) 
medium, phenol−red−free 1640 
Fisher Scientific UK Ltd, 
Loughborough, UK 
32404014  
Sanyo 950 W microwave Sanyo Europe,  
Loughborough, UK 
  
Sanyo MCO−17AIC incubator Sanyo E&E Europe BV,  
Loughborough, UK 
  
Sodium butyrate Sigma−Aldrich,  
Poole, Dorset, UK 
B5887  
Sodium chloride (NaCl) Sigma−Aldrich,  
Poole, Dorset, UK 
S3014   
Sodium dodecyl sulphate (SDS) Sigma−Aldrich,  
Poole, Dorset, UK 
L3771   
Sodium fluoride (NaF) Sigma−Aldrich,  
Poole, Dorset, UK 
919  
Sodium molybdate (Na2MoO4) Sigma−Aldrich,  
Poole, Dorset, UK 
243655  
Sodium orthovanadate (Na3VO4) Sigma−Aldrich,  
Poole, Dorset, UK 
S6508  
Sterile disposable pipettes  
(5 mL, 10 mL and 25 mL) 
Sarstedt AG and Co.,  
Nümbrecht, Germany 
  
Sterile Falcon tubes  
(15 mL and 50 mL) 
Sarstedt AG and Co.,  
Nümbrecht, Germany 
  
Sterile phosphate buffered saline 
(PBS) 
Invitrogen,  
Paisley, UK 
  
Sterile universal containers  
(30 mL) 
Greiner Bio−One Ltd,  
Gloucestershire, UK 
  
Sub−cell agarose electrophoresis system BioRad Laboratories Ltd,  
Hertfordshire, UK 
  
SuperSignal West Dura Extended 
Duration Substrate 
Pierce and Warriner Ltd,  
Cheshire, UK 
34075  
SuperSignal West Femto Maximum 
Sensitivity Substrate 
Pierce and Warriner Ltd,  
Cheshire, UK 
34095  
Syringes  
(5 mL and 10 mL) 
Sherwood Medical Davis 
and Geck,  
Gosport, UK 
  
2. Materials and methods 
 
 
58 
Reagent Company 
Catalogue 
number 
 
 
Tissue culture plasticware  
(24−well plates, filter flasks,  
35 mm, 60 mm and 100 mm dishes) 
Nunc Int.,  
Roskilde, Denmark 
  
Triton X−100 Sigma−Aldrich,  
Poole, Dorset, UK 
93443  
Trizma (Tris) base Sigma−Aldrich,  
Poole, Dorset, UK 
T1503  
Upper buffer for SDS−PAGE gels (Tris 
0.5M, pH 6.8) 
BioRad Laboratories Ltd,  
Hertfordshire, UK 
161−0799  
UV transilluminator Alpha Innotech Corp,  
California, USA 
  
VectorShield mounting medium with 
DAPI 
Vector Laboratories Inc,  
Peterborough, UK 
H−1200  
Western blocking reagent Roche Diagnostics,  
Mannheim, Germany 
11921673001  
Zinquin Santa Cruz Biotechnology,  
Heidelberg, Germany 
SC 222427  
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3.1 Introduction 
The link between increases in function of many ZIP channels, particularly 
those belonging to the LIV−1 subfamily (Taylor and Nicholson 2003), and 
human diseases including cancer, has been well established (Taylor et al. 
2011). For example, ZIP7, a gatekeeper of zinc release from cellular stores and 
a hub for tyrosine kinase activation (Hogstrand et al. 2009), has been implicated 
in development of tamoxifen resistance and aggressive phenotypes of breast 
cancer cells (Taylor et al. 2008b). However, functional control of ZIP channels is 
still unclear. Importantly, our group have proposed a post−translational control 
mechanism for ZIP7, showing that ZIP7 function is triggered by phosphorylation 
on residues S275 and S276, which are located in the histidine−rich 
intracytosolic loop between TM3 and TM4 (Taylor et al. 2012). Knowing that 
ZIP7 is functionally controlled by phosphorylation, it was hypothesised that 
there could also be other phosphorylation sites in ZIP7 as well as in other ZIP 
channels. The aims of this chapter were therefore to analyse peptide 
sequences of ZIP channels and to explore potential phosphorylation sites as 
well as discover candidate kinases. To achieve these aims, a computational 
analysis of the amino acid sequences of all the ZIP channels was performed. 
Furthermore, employing different online databases, we focused the search for 
the potential phosphorylation sites on the intra cytosolic loop between TM3 and 
TM4 in which the phosphorylation sites in ZIP7 are located.  
3.2 Materials and methods 
Online databases and platforms that were used are shown in Table 3.1. 
Amino acid sequences of ZIP channels in a text−based FASTA format were 
retrieved from the gene database of the National Center for Biotechnology 
Information (NCBI) and aligned into a ClustalW format using the TCoffee 
multiple sequence alignment program (Swiss Institute of Bioinformatics) 
(Notredame et al. 2000). The multiple aligned sequences were then shaded for 
identical or similar residues using the BoxShade 3.21 online program (Swiss 
Institute of Bioinformatics) (Hofmann and Baron 1996) and a phylogenetic tree 
was generated using the Phylogeny.fr web service (Dereeper et al. 2008). 
Potential proteolytically−cleaved PEST motifs were identified using the Emboss 
Pestfind platform (Rogers et al. 1986).  
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Table 3.1 Online databases and platforms used for the sequence analysis  
Data Database or platform Reference 
 
 
Peptide sequences  NCBI a −  
Sequence alignment TCoffee b (Notredame et al. 2000)  
Alignment formatting BoxShade c  (Hofmann and Baron 1996)  
Phylogenetic tree 
generation 
Phylogeny.fr d (Dereeper et al. 2008)  
PEST motif analysis EMBOSS: Pestfind e (Rogers et al. 1986)  
Phosphorylation sites HPRD f (Keshava Prasad et al. 2009)  
 PHOSIDA g (Gnad et al. 2011)  
 Phospho.ELM h (Dinkel et al. 2011)  
 PhosphoNET i −  
 PhosphoSitePlus j (Hornbeck et al. 2015)  
Protein functions UniprotKB k (The UniProt Consortium 2015)  
 
a NCBI, National Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/gene  
b TCoffee. http://www.tcoffee.org  
c Boxshade. http://www.ch.embnet.org/software/BOX_form.html  
d Phylogeny.fr. http://www.phylogeny.fr  
e EMBOSS: Pestfind. http://emboss.bioinformatics.nl/cgi-bin/emboss/epestfind  
f HPRD, Human Protein Reference Database. http://www.hprd.org 
g PHOSIDA. http://www.phosida.com 
h Phospho.ELM, Phospho Eukaryotic Linear Motif. http://phospho.elm.eu.org  
i PhosphoNET. http://www.phosphonet.ca  
j PhosphoSitePlus. http://www.phosphosite.org 
k UniProtKB, UniProt Knowledgebase. http://www.uniprot.org/help/uniprotkb  
 
Potential phosphorylation sites were searched for using gene names of 
human ZIP channels (SLC39A1−14) in 3 different online phosphorylation site 
databases: PhosphoNET (Kinexus Bioinformatics Corporation), PHOSIDA (Max 
Planck Institute of Biochemistry) (Gnad et al. 2011) and PhosphoSitePlus (PSP) 
(Hornbeck et al. 2015). The peptide sequences and residue numbers reported 
for the phosphorylation sites and their locations were confirmed with those 
retrieved from the UniProtKB/Swiss−Prot database (The European 
Bioinformatics Institute) (The UniProt Consortium 2015). Only the sites that had 
been experimentally confirmed in mammalian cells by mass spectrometry and 
that resided in the cytosolic loop between TM3 and TM4 were selected. Data 
from all these databases were combined together. Predicted kinases with the 
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highest prediction scores were selected, and their functions were searched for 
in the UniProt Knowledgebase (UniProtKB) (The UniProt Consortium 2015). 
Additionally, predicted phosphorylation sites and kinases according to amino 
acid sequences were searched for in the Human Protein Reference Database 
(Keshava Prasad et al. 2009).  
3.3 Results and discussion 
3.3.1 Analysis of amino acid sequences of ZIP channels 
To demonstrate evolutionary relationships and molecular similarities 
among different human ZIP channels, a phylogram was created from their 
peptide sequences. Supporting the established classification of ZIP channels 
(Taylor and Nicholson 2003), the phylogenetic tree showed that ZIP channels 
could be grouped into four subfamilies: subfamily II (ZIP1−ZIP3), subfamily I 
(ZIP9), GufA (ZIP11), and the LIV−1 subfamily (ZIP4−ZIP8, ZIP10, and 
ZIP12−ZIP14) (Fig. 3.1).  
 
Figure 3.1 A phylogenetic tree of human ZIP channels 
 
This phylogram was generated using Phylogeny.fr web service (Dereeper et al. 2008). The bar 
at the bottom provides a scale for the degree of genetic changes as represented by the 
horizontal dimension of the phylogram. The numbers next to each node indicate a measure of 
support for the nodes. According to this phylogram, human ZIP channels can be grouped into 
four subfamilies: subfamily II, subfamily I, GufA subfamily, and the LIV−1 subfamily.  
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According to the phylogenetic tree (Fig. 3.1), three pairs of the ZIP 
channels in the LIV−1 subfamily were grouped together, and each pair has 
been shown to have some prominent characteristics in common. ZIP7 and 
ZIP13, which were grouped separately from the rest of the LIV−1 subfamily with 
the statistical support for the node of 0.89 (Fig. 3.1), have been reported to be 
intracellularly located. ZIP7 has been reported to be located in the ER (Taylor et 
al. 2004) and/or the Golgi (Huang et al. 2005), whereas ZIP13 has been 
reported to be located in the Golgi (Bin et al. 2011). ZIP6 and ZIP10 are also 
grouped together with the statistical support for the node of 0.86 (Fig. 3.1). Both 
ZIP6 and ZIP10 contain peptide sequences in the N−terminus that indicate their 
evolutionary link to prion genes (Schmitt-Ulms et al. 2009), undergo an 
N−terminal cleavage upon activation (Ehsani et al. 2012; Hogstrand et al. 
2013), and play important roles in carcinogenesis, particularly the EMT process 
(Kagara et al. 2007; Hogstrand et al. 2013). Additionally, ZIP8 and ZIP14 are 
grouped together in the same sub−branch with the statistical support for the 
node of 0.85 (Fig. 3.1). Interestingly, even though ZIP8 and ZIP14 are 
recognised as zinc channels, they are capable of transporting other metals such 
as cadmium and manganese (Girijashanker et al. 2008) as well as iron (Zhao et 
al. 2014). The ability of ZIP8 and ZIP14 to transport metal ions other than zinc 
might be at least partially attributed to the lack of the initial histidine residue, a 
known zinc−binding amino acid, in the consensus motif of the LIV−1 subfamily 
in TM5, HEXPHEXGD, which will be discussed further in Section 3.3.2.3.  
The peptide sequences of all the human ZIP channels were then aligned 
according to their similarities (Fig. 3.2 and 3.3). All the TM regions were 
identified according to a previous computational sequence analysis (Taylor and 
Nicholson 2003) (Fig. 3.3). General features that were observed in all the ZIP 
channels included the presence of eight TMs, a very short C−terminus and a 
long intracytosolic loop between TM3 and TM4 (Fig. 3.3). This particular 
intracytosolic loop was shown to be a histidine−rich region, which is defined as 
a region containing consecutive HX repeats (H, histidine; X, any amino acid) 
(Guerinot 2000). The TM regions were highly conserved across different types 
of the ZIP channels, whereas the N−terminus (Fig. 3.2) and the loops between 
the TM regions (Fig. 3.3) were highly variable. 
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Figure 3.2 Alignment of all human ZIP channels (N-terminus) 
 
hZIP4     1 MASLVSLEL-----G--LLLAVLVVTATAS---------P-------------PAGLLSLLTSGQGALDQEALGGLLNTLADRVHCANGPCGKCLSVEDALGLG------EP----------------EGSGLPPGPVLEARYVARLSAAAVLYLSNPEG 
hZIP5     1 MMGSPVSHLL--AGF--CVWVVLGWVGGS----------------------------------------------------------------------------------------------------------------------------------- 
hZIP6     1 MARKLSVI---------LILTF-AL-SVTN---------P-------------L---------------------------------------------------------H----------------ELK----------------------------- 
hZIP7     1 MARGLGAPHW--VAV--GLLTWA--------------------------------------T--------------------------------------------------LGL-LVA----------------------------------------- 
hZIP8     1 MAPGRAVA-----GL--LLLAA------------------------------------------------------------------------------------------AGL--------------------------------------------- 
hZIP10    1 MKVHMHTK-F--CLI--CLLTFIF--HHCNHCHEEHDHGPEAL-------HRQHR------G--------------------------------------------------MTE-LEP----------------------------------------- 
hZIP12    1 MCFRTKLSVS-WVPLF-LLLSRVFSTETDK---------PSAQDSRSRGSSGQPADLLQVLSAGDHPPHNHS-RSLIKTLLEKTGCP---RRRNGM------QGDCNLCFEPDALLLIAGGNFEDQLRE------------EVVQRVSLLLLYYIIHQEE 
hZIP13    1 MPGCPC-PGCGMAGPRLLFLTALAL----------------------------------------------------------------------------------------E-LLERAGGSQ------------------------------------ 
hZIP14    1 MKLLLLHPAF--QSC--LLLTLLGL-WRTT---------P----------------------------------------------------------------------------------------EAH----------------------------- 
hZIP9     1 MD-------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP1     1 MGPWGE--------PELLVWRPEA---------------------------------------------------------------------------------------------------------------------------------------- 
hZIP2     1 MEQL------------------------------------------------------------------------------------------------------------------------------------------------------------ 
hZIP3     1 MVK------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP11    1 MLQG------------------------------------------------------------------------------------------------------------------------------------------------------------ 
 
 
hZIP4   110 TCEDARAGLWASHA----DHLLALLESPKALTPGLSW---------------LLQRM------QARAAGQTPKTACVDIP QLLEEAV---GAGAPGSAGGVLAALLD-HVRSG-S-CF-HALPSPQYFVDFVFQQHSSEVPMTLAELSALMQRLGVGREA 
hZIP5    26 ----------------------------------------------------------------------------------------------------------------VPN-LG-PAEQEQNHYLAQLFGLYGENGTLTAGGLARLLHSLGLGRVQ 
hZIP6    26 --------AAAFPQ----TTEK---ISPNW--------------------------------------------------------------------------------ESGIN-VD-LAISTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIK 
hZIP7    27 ----------------------------------------------------------------------------------------------------------------G---LG-GHDDLHDD-LQEDFHGHS--HRHSHEDF------------- 
hZIP8    19 ---------GGVAEGPG------------------------------------------------------------------------------------------------------------LAFSEDVLSVFGANLSLSAAQLQHLLEQMGAASRV 
hZIP10   49 ---------------------------------------------------------------------------------------------------------------SKFS-KQ-AAENEKKYYIEKLFERYGENGRLSFFGLEKLLTNLGLGERK 
hZIP12  128 ICSSK----LNMSNKEYKF-----------------YLHSLLSLRQDEDSSFLSQNETEDILAFTRQYFDTSQSQCMETK TLQKKSGIVSSEGANESTLPQLAAMIITLSLQG-VCLGQGNLPSPDYFTEYIFSSLNRTNTLRLSELDQLLNTLWTRSTC 
hZIP13   35 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP14   30 ----------------------------------------------------------------------------------------------------------------ASS-LG-APAISAASFLQDLIHRYGEGDSLTLQQLKALLNHLDVGVGR 
hZIP9     3 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP1    17 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP2     5 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP3     4 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP11    5 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
 
hZIP4   238 -----------------HSD-HS---------------------------------------------------------------------------HR----H----------------------R-------------------------------- 
hZIP5    72 --------------GLRLGQ-HGP---------------------------------------------------------------------------------------------------------------------------------------- 
hZIP6    89 --------------RIHIHHDHDHHSDHEHHS------------DHERHSD---------------------------------------------HEHHSEHEH----------HSDHDHHSHHNHAAS------------------------------ 
hZIP7    55 ----------------------------------------HHGHSHAHGHG------------------------------------HTHESIWHGHTHDHDHGHS---HEDLHHG-------------------------------------------- 
hZIP8    62 --------------G--VPE-------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP10   96 --------------VVEINHE-DLGHDHVSHLDILAVQEGKHFHSHNHQHSHNHLNSENQTVTSVSTKRNHKCDPEKETVEVSVKSDD---------KHMHDHNHRLRHHHRLHHHLDHNN-THHFHNDSITPSERGEPSNEPSTETNKTQEQSDVKLPK 
hZIP12  266 IKNEKIHQFQRKQNN--IIT-HD---------------------------------------------------------------------------QD----Y----------------------S-------------------------------- 
hZIP13   35 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP14   76 --------------GN-VTQ-HV----------------------------------------------------------------------------------------------------------------------------------------- 
hZIP9     3 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP1    17 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP2     5 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP3     4 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP11    5 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
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Figure 3.2 Alignment of all human ZIP channels (N-terminus) (continued) 
 
hZIP4   247 -------------------------------------------------------------------GASSRD-------------------------------PVP----------------------------------------LISSSNSSS-VWD 
hZIP5    81 --L--TGRAASPAAD------------------NSTHRPQ------NPELSVDVWAG-------MPLGPSGWGDLEESKA PH------------------LPRGPAPSGL----------------DLLHR---------------LLLLDHSLADH-LN 
hZIP6   138 GKN--KRKALCPDH-------------------DSDSSGK------DPRNSQGKGAH-------RPEHASGRRNVKDSVS ASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRVSRLAGRKTNESVSEPRKGFMYSRNT--NENP 
hZIP7    92 ------------------------------------------HSHGYSHESLYHR-------------------------------------------------------------------------------------------GHGHDHEH--S-H- 
hZIP8    66 --------------------------------------------------------------------------------------------------------------------------------------------------------PGQL--HF 
hZIP10  231 GKRKKKGRKSNENSEVITPGFPPNHDQGEQYEHNRVHKPDRVHNPGHSHVHLPERNGHDPGRGHQDLDPDNEGELRHTRK--------------------------------------------------REAPHVKNNAII----SLRKDLNE--DDHH 
hZIP12  290 ------------------------------------------------NFSSSMEKE---------------------------------------------------------------------------------------------SEDGPV-SWD 
hZIP13   35 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP14   83 ----------------------------------------------------------------------------------------------------------------------------------------------------------QGHRNL 
hZIP9     3 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP1    17 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP2     5 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP3     4 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
hZIP11    5 ---------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
 
hZIP4   268 TVCLSARDVMAAYGLSEQAGVTPEAWAQLSPALLQQQLSGACTSQSRP-------------PVQDQLSQSERYL 
hZIP5   156 EDCLNGSQLLVNFGLSPAAPLTPRQFALLCPALLYQIDSRVCIGAPA---------------PAPPGDLLSALL 
hZIP6   262 QECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHTSE-------KKA--EIPPKTYSLQIAWV 
hZIP7   115 ----------GGYGE------------SGAPGIKQD------------------------------LDAVTLWA 
hZIP8    72 NQCLTAEEIFSLHGFSNATQITSSKFSVICPAVLQQLNFHPCEDRPK---------------HKTRPSHSEVWG 
hZIP10  335 HECLNVTQLLKYYGHGANSPISTDLFTYLCPALLYQIDSRLCIEHFDKLLVEDINKDKNLVPEDEANIGASAWI 
hZIP12  308 QTCFSARQLVEIFLQKGLSLISKEDFKQMSPGIIQQLLSCSCHLPKDQ-------Q------AKLPPTTLEKYG 
hZIP13   35 ------------------------------PALRSRGTATACRLDNKE-------SES--WGALLSGERLDTWI 
hZIP14   89 STCFSSGDLFTAHNFSEQSRIGSSELQEFCPTILQQLDSRACTSENQE-------NEENEQTEEGRPSAVEVWG 
hZIP9     3 ----------------------------------------------------------------------DFIS 
hZIP1    17 --------------------------------------------------------VA--S-EPPVPVGLEVKL 
hZIP2     5 ---------------------------------------------------------------------LGIKL 
hZIP3     4 --------------------------------------------------------------------LLVAKI 
hZIP11    5 ---------------------------------------------------------------------HSSVF 
 
Amino acid sequences in the N−terminus of all human ZIP channels were aligned using the TCoffee multiple sequence alignment program. Residues that were at 
least 50% identical (black) and complementary (grey) were shaded using the BoxShade 3.21 online program. The CPALLY motif, which contains three conserved 
cysteine residues, is indicated in a box with a black border. This motif is uniquely seen in the N−terminus of the LIV−1 subfamily, except ZIP7 and ZIP13. 
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Figure 3.3 Alignment of all human ZIP channels (from TM1 to C−terminus) 
 
hZIP4   329 YGSLATLLICLC-AVFGLLLLTCTGC----RGVTHYILQTFLSLAVGALTGDAVLHLTPKVLGLHTHSEEGL------------SP------------------------------------------------QPTWRLLAMLAGLYAFFLFENLFNLL 
hZIP5   215 QSALAVLLLSLP-SPLSLLLLRLLG-----PRLLRPLLGFLGALAVGTLCGDALLHLLPHAQEGRHAGPG---------------G----------------------------------------LPE---K--DLGPGLSVLGGLFLLFVLENMLGLL 
hZIP6   327 GGFIAISIISFL-SLLGVILVPLMN-----RVFFKFLLSFLVALAVGTLSGDAFLHLLPHSHASHHHSHSHE------------EP-----------------------AMEMKRGPLFSHLSSQNIEESAYF-DSTWKGLTALGGLYFMFLVEHVLTLI 
hZIP7   137 YALGATVLISAA-PFFVLFLIPVESN----SPRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHTLEQ------------PG-----------------------HGHS-------------HSG---QGPILSVGLWVLSGIVAFLVVEKFVRHV 
hZIP8   131 YGFLSVTIINLA-SLLGLILTPLIK-----KSYFPKILTFFVGLAIGTLFSNAIFQLIPEAFGFDPKVD-----------------------------------------------------------------SYVEKAVAVFGGFYLLFFFERMLKML 
hZIP10  409 CGIISITVISLL-SLLGVILVPIIN-----QGCFKFLLTFLVALAVGTMSGDALLHLLPHSQGGHDHSHQHA------------HG-----------------------HGHS-----HGHESNKFLEE---Y-DAVLKGLVALGGIYLLFIIEHCIRMF 
hZIP12  369 YSTVAVTLLTLG-SMLGTALVLFHSC----EENYRLILQLFVGLAVGTLSGDALLHLIPQVLGLHKQEAPEF-------------G-----------------------HF---------------HES---K-GHIWKLMGLIGGIHGFFLIEKCFILL 
hZIP13   70 CSLLGSLMVGLS-GVFPLLVIPLEMGTMLRSEAGAWRLKQLLSFALGGLLGNVFLHLLPEAWAYTCSASPG--------------G-----------------------EGQS-------------LQ------QQQQLGLWVIAGILTFLALEKMFLDS 
hZIP14   96 YGLLCVTVISLC-SLLGASVVPFMK-----KTFYKRLLLYFIALAIGTLYSNALFQLIPEAFGFNPLED-----------------------------------------------------------------YYVSKSAVVFGGFYLFFFTEKILKIL 
hZIP9     7 ISLLSLAMLVGC-YVAGI--IPLAV------NFSEERLKLVTVLGAGLLCGTALAVIVPEGVHALYEDILEG------------KHHQASETHNVIASDKAAEKSVVHEHEHS-------------HDH---TQLHAYIGVSLVLGFVFMLLVDQIGN-- 
hZIP1    32 GALVLLLVLTLLCSLVPICVLRRPGANHEGSASRQKALSLVSCFAGGVFLATCLLDLLPDYLAAIDEALA----------------------------------------AL--------------HVT---L-QFPLQEFILAMGFFLVLVMEQITLAY 
hZIP2    10 GCLFALLALTLGCGLTPICFKWFQI--DAARGHHRLVLRLLGCISAGVFLGAGFMHMTAEALEEIESQIQKFMVQNRSASERNSSG-----------------------DAD--------------SAH---M-EYPYGELIISLGFFFVFFLESLALQC 
hZIP3    10 LCMVGVFFFMLLGSLLPVKIIETDF---EKAHRSKKILSLCNTFGGGVFLATCFNALLPAVREKLQKVLS----------------------------------------LG--------------HIS---T-DYPLAETILLLGFFMTVFLEQLILTF 
hZIP11   10 QALLGTFFTWGM-TAAGAALVFV-----FSSG-QRRILDGSLGFAAGVMLAASYWSLLAPAVEMATSSG----------------G-----------------------F----------------GAF---A-FFPVAVGFT-LGAAFVYL-ADLLMPH 
 
 
hZIP4   424 LPRDPE---------------------DL------------EDGP--CG--------HSSH----SHG-GHSH----GV-------SLQLA-P----SELRQPKPPH----EGSRADLVAEES--------PE--------------------------- 
hZIP5   309 RHRGLR--------------------PRCCRR-KRRNLETRN-----------LDPENGSGMALQP-L-QAAP-----E-------------PG---AQGQREK-------------------------------------------------------- 
hZIP6   445 KQFKDK--------------------KKKNQK-KPENDDDVEIKKQLSK--------YESQLSTNEEK-VDTDDRTEGY-----LRADSQE-P----SHFDSQQPAV----LEEEEVMIAHAH--------PQEVYNEYVPRGCKNKCHSHFHDTLGQSD 
hZIP7   241 KGGH-----------------------GHSHGH----------G-------------HAHSHTRGSH----GH----GR-------Q--ER-S----TKEKQSSEEE----EKETRGVQK-RR--------G---------------------------- 
hZIP8   220 LKTYGQ--------------------NGHTHFG-NDN----------------FGPQEKTH---QP-KALPA-I--NGVT-------CYAN-PA--VTEANGHIH------FD----NVSVVS--------L---------------------------- 
hZIP10  519 KHYKQQ--------------------RGKQKWFMKQNTEESTIGRKLSDHKLNNTPD-SDWLQLKP-L-AGTD-----DSVVSEDRLNETELTD---LEGQQESPPKNYLCIEEEK-IIDHSHSDGLHTIHEHDLHAA---------AHNH--------- 
hZIP12  469 VSPNDK--------------------QGLSLVNG-------HVG-------------HSHHLALNSEL-SDQAG--RGK-------------SA---STIQLKSP------------------------------------------------------- 
hZIP13  173 KEE------------------------GTSQ--------------------------------------------------------------------------AP----NKDPTAAAAALN--------G---------------------------- 
hZIP14  185 LKQKNE------------------HHHGHSHYA-SES----------------LP-SKKDQ---EE-GVMEKLQ--NGDL-------DHMI-PQHCSSELDGKAP------MVDEKVIVGSLS--------V---------------------------- 
hZIP9   128 -----------------------------S------------------------------------H----------V---------------------------------------------------------------------------------- 
hZIP1   134 K-EQS----------------------GP----------------------------------------------------------------------------SP----LEETRALLGTVN--------G---------------------------- 
hZIP2   127 CPGAA----------------------GG----------------------------------------------------------------------------ST----VQDEEWGG--AH--------I---------------------------- 
hZIP3   109 RKEKPSFIDLETFNA------------GS--------------------------------------------D--VG---------------------------SD----SEYESPFMGGAR--------G---------------------------- 
hZIP11  102 LGAAEDPQTTLALNFGSTLMKKKSDPEGPALL-FPESELSIRIGR--AG--------L---L-------SDKSE--NG---------------------------EA----YQRKKAA---AT--------G----------------------------  
 
 
hZIP4   481 -------------------------------L-----LNPEPR---RLSPELRLLPYMITLGDAVHNFADGLAVGAAFASSW-------KTGLATSLAVFCHELPHELGDFAALLHAGLSVRQALLLNLASAL-TAFAGLYVALAV--G------V-SEE 
hZIP5   358 ----------------NS----QH-PPAL-APPG---HQGHSH----GHQGGTDITWMVLLGDGLHNLTDGLAIGAAFSDGF-------SSGLSTTLAVFCHELPHELGDFAMLLQSGLSFRRLLLLSLVSGA-LGLGGAVLGVGL--S------LGPVP 
hZIP6   553 DLIHHHHDYHHILHHHHHQNHH----PHS-HSQR---YSREEL----KDAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGL-------SSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAM-LAYLGMATGIFI--G------HYAEN 
hZIP7   292 ----------------------GS-TVPK-DGPVRPQNAEEEK----RGLDLRVSGYLNLAADLAHNFTDGLAIGASFRGGR-------GLGILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAV-GALAGTACALLTE-GGAVGSEIAGGA 
hZIP8   280 ----------------------QD-GKKE---PSS-CTCLKGP----KLSEIGTIAWMITLCDALHNFIDGLAIGASCTLSL-------LQGLSTSIAILCEEFPHELGDFVILLNAGMSTRQALLFNFLSAC-SCYVGLAFGILV--G------N--NF 
hZIP10  629 -----HGENKTVLRKHNHQWHHKH-SHHS-HGPC---HSGSDL----KETGIANIAWMVIMGDGIHNFSDGLAIGAAFSAGL-------TGGISTSIAVFCHELPHELGDFAVLLKAGMTVKQAIVYNLLSAM-MAYIGMLIGTAV--G------QYANN 
hZIP12  515 ----------------------ED-SQAA-EMPIG-SMTASNR----KCKAISLLAIMILVGDSLHNFADGLAIGAAFSSSS-------ESGVTTTIAILCHEIPHEMGDFAVLLSSGLSMKTAILMNFISSL-TAFMGLYIGLSV--S------A-DPC 
hZIP13  195 -------------------------------GHCLAQPAAEPGLG-AVVRSIKVSGYLNLLANTIDNFTHGLAVAASFLVSK-------KIGLLTTMAILLHEIPHEVGDFAILLRAGFDRWSAAKLQLSTAL-GGLLGAGFAICTb-G----CSPAAEE 
hZIP14  253 ----------------------QD-LQAS---QSA-CYWLKGV----RYSDIGTLAWMITLSDGLHNFIDGLAIGASFTVSV-------FQGISTSVAILCEEFPHELGDFVILLNAGMSIQQALFFNFLSAC-CCYLGLAFGILA--G------S--HF 
hZIP9   131 ------------------------------H-------STDD----PEAARSSNSKITTTLGLVVHAAADGVALGAAASTSQT------SVQLIVFVAIMLHKAPAAFGLVSFLMHAGLERNRIRKHLLVFALaVTYLGLSKSSKE--A------LSEVN 
hZIP1   155 ----------------------GP--QHWHDGPGVPQAS-GAP---ATPSALR--ACVLVFSLALHSVFEGLAVGLQRDR---------ARAMELCLALLLHKGILAVSLSLRLLQSHLRAQVVAGCGILFSC-MTPLGIGLGAAL-—A-E-SAGPLHQL 
hZIP2   147 ----------------------FE--LHSH-G-HLPSP---------SKGPLR--ALVLLLSLSFHSVFEGLAVGLQPTV---------AATVQLCLAVLAHKGLVVFGVGMRLVHLGTSSRWAVFSILLLAL-MSPLGLAVGLAVT-GGD-SEGG-RGL 
hZIP3   144 ----------------------HALYVEPH-G-HGPSLSVQGL---SRASPVR--LLSLAFALSAHSVFEGLALGLQEEG---------EKVVSLFVGVAVHETLVAVALGISMARSAMPLRDAAKLAVTVSA-MIPLGIGLGLGIESA----QGVPGSV 
hZIP11  169 ----------------------------LPEGPAVPVPSRGNL-AQPGGSSWRR-IALLILAITIHNVPEGLAVGVGFGAIEKTASATFESARNLAIGIGIQNFPEGLAVSLPLRGAGFSTWRAFWYGQLSGM-VEPLAGVFGAFAVVL--------AEP  
TM1 
TM4 
TM2 TM3 
TM5 TM6 
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Figure 3.3 Alignment of all human ZIP channels (from TM1 to C−terminus) (continued) 
 
hZIP4   577 SEAWILAVATGLFLYVALCDMLPAMLKVRDPR------PWLLFLLHNVGLLGGWTVLLLLSLYEDDITF 
hZIP5   463 LTPWVFGVTAGVFLYVALVDMLPALLRPPEPL------PTPHVLLQGLGLLLGGGLMLAITLLEERLLPVTTEG 
hZIP6   675 VSMWIFALTAGLFMYVALVDMVPEMLHNDASDHG--CSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
hZIP7   401 GPGWVLPFTAGGFIYVATVSVLPELLREASPLQ---------SLLEVLGLLGGVIMMVLIAHLE 
hZIP8   385 APNIIFALAGGMFLYISLADMFPEMNDMLREKVTGRKTDFTFFMIQNAGMLTGFTAILLITLYAGEIELE 
hZIP10  749 ITLWIFAVTAGMFLYVALVDMLPEMLHGDGDNEEHGFCPVGQFILQNLGLLFGFAIMLVIALYEDKIVFDIQF 
hZIP12  621 VQDWIFTVTAGMFLYLSLVEMLPEMTHVQTQR------PWMMFLLQNFGLILGWLSLLLLAIYEQNIKI 
hZIP13  302 TAAWVLPFTSGGFLYIALVNVLPDLLEEEDPWR---------SLQQLLLLCAGIVVMVLFSLFVD 
hZIP14  358 SANWIFALAGGMFLYISLADMFPEMNEVCQEDER-KGSILIPFIIQNLGLLTGFTIMVVLTMYSGQIQIG 
hZIP9   232 ATGVAMLFSAGTFLYVATVHVLPEVGGIGHSHKPDATGGRGLSRLEVAALVLGCLIPLILSVGHQH 
hZIP1   257 AQSVLEGMAAGTFLYITFLEILPQELASSEQR-----------ILKVILLLAGFALLTGLLFIQI 
hZIP2   242 AQAVLEGVAAGTFLYVTFLEILPRELASPEAP-----------LAKWSCVAAGFAFMAFIALWA 
hZIP3   247 ASVLLQGLAGGTFLFITFLEILAKELEEKSDR-----------LLKVLFLVLGYTVLAGMVFLKW 
hZIP11  284 ILPYALAFAAGAMVYVVMDDIIPEAQISGNGK-----------L-ASWASILGFVVMMSLDVGLG 
 
Amino acid sequences between TM1 and the C−terminus of all human ZIP channels were aligned using the TCoffee multiple sequence alignment program. 
Residues that were at least 50% identical (black) and complementary (grey) were shaded using the BoxShade 3.21 online program. The predicted TM regions 
(Taylor and Nicholson 2003) are indicated in boxes with black borders. 
a (ZIP9, TM6), AAPVMSM; b (ZIP13, TM6), QSPKGVV 
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3.3.2 Identification of unique characteristics of the LIV−1 subfamily 
When comparing the LIV−1 subfamily with all the other ZIP channels, the 
LIV−1 subfamily demonstrated some unique characteristics. These included a 
longer N−terminus (Fig. 3.4 and 3.5); a CPALLY motif (Fig. 3.6); PEST motifs in 
ZIP6 and ZIP10 (Fig. 3.7); additional histidine−rich regions in the N−terminus 
(Fig. 3.4 and 3.8) and the extracytosolic loop between TM2 and TM3 (Fig. 3.4 
and 3.9); and a HEXPHEXPHGD motif within TM5 (Fig. 3.9). These salient 
features were individually analysed.  
3.3.2.1 A long N−terminus containing a CPALLY motif 
Amino acid residues in the N−terminus of each ZIP channel were 
counted (Fig. 3.5). The LIV−1 subfamily members had a long N−terminus, with 
an average of 230 amino acids, ranging from 68 amino acids in ZIP13 to 408 
amino acids in ZIP10 (Fig. 3.5). In contrast, the N−terminus of the other ZIP 
channels was 18 times shorter than the LIV−1 subfamily, having an average of 
13 amino acids and ranging from 6 amino acids in ZIP9 to 31 amino acids in 
ZIP1 (Fig. 3.5). These data confirmed that a long N−terminus is a prominent 
characteristic of the LIV−1 subfamily. Furthermore, this characteristic also 
suggested a more complex post−translational mechanism of the LIV−1 
subfamily than the other subfamilies, since signal sequences are contained in 
the N−terminus (Coleman et al. 1985), and post−translational modifications in 
the N−terminus have been shown to participate in functional control of proteins 
(Lai et al. 2015). Noteworthy, a signal sequence is a 20−25 amino acid 
sequence that plays an important role in targeting a protein into a secretory 
pathway or integrating a protein into cellular membranes. A potential 
ER−retention signal peptide ARGL (residues 2−5) has been detected in the 
N−terminus of ZIP7, consistent with the unique localisation of ZIP7 in the ER 
(Taylor et al. 2004). Another potential ER−retention signal peptide with 
sequence RKLS (residues 3−6) is present in the N−terminus of ZIP6 (Taylor et 
al. 2003) and might explain the ER localisation of the pro−protein form of ZIP6 
prior to its plasma membrane relocation (Hogstrand et al. 2013). Additionally, a 
potential cleavage site was seen in the N−terminus of ZIP6 and ZIP10, and this 
will be discussed in Section 3.3.3. 
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Figure 3.4 Structure of the LIV−1 subfamily of ZIP channels 
 
This schematic illustrates a simplified structure of the LIV−1 subfamily members (A), compared 
to other ZIP channels (B). Distinctive features of this subfamily include a longer N−terminus and 
additional histidine−rich regions in the N−terminus and the extracytosolic loop between TM2 
and TM3. Numbers of the HX repeats detected in particular regions are indicated in brackets. 
These numbers represent combined numbers of consecutive HX motifs, where H stands for 
histidine and X stands for any amino acid. 
N, the amino−terminus; C, the carboxyl−terminus; H, the histidine−rich region. 
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Figure 3.5 Numbers of residues in the N−terminus of ZIP channels 
 
This bar chart reveals sizes of all human ZIP channels. Numbers inside the bars indicate 
amounts of amino acid residues in the N−terminus and in the rest of the molecules (from the 
TM1 to the C−terminus). Numbers outside the bars indicate full lengths of the proteins. 
LIV−1, the LIV−1 subfamily; I, subfamily I; II, subfamily II 
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Another unique characteristic of the LIV−1 subfamily is the CPALLY 
motif, which is located in the N−terminus immediately proximal to TM1 (Taylor 
and Nicholson 2003). This motif consisted of three highly conserved cysteine 
residues and a proline residue, which was 100% identical across this subfamily 
(Fig. 3.2 and 3.6). This motif was present in the majority of the LIV−1 subfamily 
members (Fig. 3.2 and 3.6), but absent in all the other subfamilies (Fig. 3.2). 
Importantly, ZIP7 and ZIP13 were the only two ZIP channels in the LIV−1 
subfamily that did not have this motif (Fig. 3.6). ZIP7 did not have any cysteine 
residue in this region, whereas ZIP13 had only one cysteine residue at the distal 
end of this region (Fig. 3.6). Even though this motif was present in ZIP4 and 
ZIP12, the second cysteine residue in the middle of this region was replaced 
with a serine residue (Fig. 3.6), which is structurally similar to cysteine but have 
a sulphur atom in the thiol group replaced with an oxygen atom. 
 
Figure 3.6 The CPALLY motif in the LIV−1 subfamily of ZIP channels 
 
hZIP4  270 CLSARDVMAAYGLSEQAGVTPEAWAQLSPALLQQQLSGAC 
hZIP5  158 CLNGSQLLVNFGLSPAAPLTPRQFALLCPALLYQIDSRVC 
hZIP6  264 CFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSC 
hZIP8   74 CLTAEEIFSLHGFSNATQITSSKFSVICPAVLQQLNFHPC 
hZIP10 337 CLNVTQLLKYYGHGANSPISTDLFTYLCPALLYQIDSRLC 
hZIP12 341 CFSARQLVEIFLQKGLSLISKEDFKQMSPGIIQQLLSCSC 
hZIP14  91 CFSSGDLFTAHNFSEQSRIGSSELQEFCPTILQQLDSRAC 
 
hZIP7   96 -YSHESLYHRGHGHDHEHSHGGYGESGAPGIKQDLDA--- 
hZIP13  33 --------------------------SQPALRSRGTATAC 
 
The CPALLY motif of ZIP4, ZIP5, ZIP6, ZIP8, ZIP10, ZIP12, and ZIP14 were aligned using the 
TCoffee multiple sequence alignment program, with the equivalent region in ZIP7 and ZIP13 
shown separately. Residues that were at least 70% identical (black) and complementary (grey) 
were shaded using the BoxShade 3.21 online program. This CPALLY motif is a region in the 
N−terminus upstream of TM1 that contains three consensus cysteine residues (Taylor and 
Nicholson 2003). This motif is absent in ZIP7 and ZIP13.  
 
The CPALLY motif has been proposed to provide substantial structural 
support for the LIV−1 subfamily members, given that cysteine residues in the 
CPALLY motif contain thiol groups needed for formation of disulphide bonds 
(Taylor and Nicholson 2003), which normally stabilise the tertiary structure of 
proteins (Lodish et al. 2000). Furthermore, there was a highly conserved 
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cysteine residue in TM5 immediately proximal to the HEXPHEXGD motif 
(Fig. 3.10). This cysteine residue was present in all the LIV−1 subfamily 
members, but it was exceptionally replaced with a leucine residue in ZIP7 and 
ZIP13 (Fig. 3.10). The binding of the cysteine residues in the CPALLY motif to 
this additional cysteine residue in TM5 might provide a control mechanism for 
zinc movement through the pores of the ZIP channels (Taylor et al. 2007). The 
absence of these cysteine residues both in the CPALLY motif and in TM5 of 
ZIP7 and ZIP13 therefore suggested that these zinc channels might employ a 
different mechanism for controlling the pores without a need for these cysteine 
residues. 
A Hispanic American, who presented with a phenotype of acrodermatitis 
enteropathica, has been reported to have two homozygous mutations of the 
ZIP4 gene, C309T and P84L (Wang et al. 2002). Interestingly, residue C309 is 
the third cysteine residue in the CPALLY motif of human ZIP4 (Wang et al. 
2002). This report therefore further highlights the importance of this motif in the 
function of ZIP channels. Plausibly, the functional impairment of ZIP4 in this 
patient might be partly attributed to the disruption of the tertiary structure of 
ZIP4 caused by the lack of the cysteine residue in this motif. Nevertheless, the 
effect of the lack of the second cysteine in this motif in normal human ZIP4 and 
ZIP12 (Fig. 3.6) on their function was not evident. This might be due to the 
presence of multiple additional cysteine residues in the N−terminus far proximal 
to the CPALLY motif (Fig. 3.2), which might provide sufficient thiol groups for 
structural support and pore control for ZIP4 and ZIP12.  
3.3.2.2 A PEST site in the N−terminus of ZIP6 and ZIP10  
A PEST motif is a hydrophilic region comprising a 12 amino-acid cluster 
that is rich in proline (P), glutamate (E), serine (S), and threonine (T), in the 
absence of positively−charged residues such as arginine, histidine, and lysine 
(Rogers et al. 1986; Rechsteiner and Rogers 1996). The PEST motif has been 
recognised as a potential target for ubiquitination−mediated proteolytic cleavage 
(Meyer et al. 2011; Ramakrishna et al. 2011). The PEST motif was searched for 
in all human ZIP channels. Strong PEST motifs with PEST scores above the 
threshold score of +5 were uniquely detected in ZIP6 and ZIP10 (Fig. 3.7), 
which were not present in any other ZIP channels in the LIV−1 subfamily. ZIP6 
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had only one strong PEST motif in its N−terminus upstream of the CPALLY 
motif, with a PEST score of +5.07 (Fig. 3.7, the sequence underneath a green 
solid line). ZIP10 had two PEST motifs: one in the N−terminus proximal to the 
CPALLY motif and the other in the cytosolic loop between TM3 and TM4, with 
PEST scores of +16.60 and +7.97, respectively (Fig. 3.7, the sequences above 
green dashed lines). Noteworthy, there were also many other PEST motifs 
present that were reported as poor PEST motifs, with PEST scores ranging 
from −5.77 to −23.57 in ZIP6 and from +2.38 to −25.86 in ZIP10, which were 
assumed to be negative.  
Generally, a PEST motif is linked to a shortened half−life of a protein 
since it predestines the protein to be proteolytically degraded through a 
ubiquitination−mediated mechanism (Meyer et al. 2011; Ramakrishna et al. 
2011). However, in contrast to this general role in negatively regulating a protein 
by enhancing proteolytic degradation, a PEST motif in the CaVβ3 subunit of 
voltage−gated calcium channels is required for calcium/calpain−mediated 
cleavage that leads to activation of the channels (Sandoval et al. 2006). 
Consistent with this finding, both ZIP6 (Hogstrand et al. 2013) and ZIP10 
(Ehsani et al. 2012) undergo N−terminal cleavage or ectodomain shedding, 
which triggers zinc transport function of these zinc channels. For ZIP6, this 
N−terminal proteolytic cleavage in breast cancer cells results in relocation of 
ZIP6 to the plasma membrane, ZIP6−mediated zinc influx, inhibitory 
phosphorylation of GSK−3β, nuclear retention of Snail, and down−regulation of 
E−cadherin, triggering the epithelial-mesenchymal transition (EMT), a process 
necessary for migration and metastasis (Hogstrand et al. 2013). This 
N−terminal cleavage or ecto−domain shedding mechanism is also required for 
activation of ZIP10 in zinc− or cadmium−deprived condition (Ehsani et al. 2012), 
even though the involvement of this mechanism in EMT has not been reported. 
Given the fact that both ZIP6 and ZIP10 are associated with breast cancer 
metastasis (Kagara et al. 2007; Hogstrand et al. 2013) and are activated by 
proteolytic cleavage (Ehsani et al. 2012; Hogstrand et al. 2013), inhibition of this 
post−translational event in these ZIP channels might become a new strategy for 
breast cancer treatment. 
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Figure 3.7 Alignment of ZIP6 and ZIP10 with analysis of the PEST motifs 
hZIP6     1 ----MARKLSVILILTFALSVTNPLHELKA---AAFPQTTEKISPNWESGINVDLAISTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIH 
hZIP10    1 MKVHMHTKFCLICLLTFIFHHCNHCHEEHDHGPEALHRQHRGMTELEPSKFSKQAAENEKKYYIEKLFERYGENGRLSFFGLEKLLTNLGLGERKVVEIN 
 
hZIP6    94 HDHDHHSDHEHHSDHERHSDHEHHSEHEHHSDHDHHSHHNHAA-SGKNKRKALCP-DHD-------SDSSGKDPRNSQGKGAHRPEHASGRR----NVKD 
hZIP10  101 HED-LGHDHVSHLDILAVQEGKHFHSHNHQHSHNHLNSENQTVTSVSTKRNHKCDPEKETVEVSVKSDDKHMHDHNHRLRHHHRLHHHLDHNNTHHFHND 
 
hZIP6   181 SVSASEVTST--------------------------------------------------------------VYNTVSEGTHFLETIETPRPGKLFPKDV 
hZIP10  200 SITPSERGEPSNEPSTETNKTQEQSDVKLPKGKRKKKGRKSNENSEVITPGFPPNHDQGEQYEHNRVHKPDRVHNPGHSHVHLPER-NGHDPGRG-HQDL 
 
hZIP6   219 SSSTPPSVTSKSR--VSRLAGRKTNESVSEPRKGFMYSRNTNENPQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHTSEKKAE--- 
hZIP10  298 D----PDNEGELRHTRKREAPHVKNNAIISLRK----DLNEDDHHHECLNVTQLLKYYGHGANSPISTDLFTYLCPALLYQIDSRLCIEHFDKLLVEDIN 
 
hZIP6   314 -----IPPKTYSL-QIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALAVGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHL 
hZIP10  390 KDKNLVPEDEANIGASAWICGIISITVISLLSLLGVILVPIINQGCFKFLLTFLVALAVGTMSGDALLHLLPHSQGGHDHSHQHAHG-----HGHSHGHE 
 
hZIP6   408 SSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQ-KKPENDDDVEIKKQLSKYESQLSTNEE------KVDTDDRTEGYLRADSQE 
hZIP10  485 SNKFLEE---YDAVLKGLVALGGIYLLFIIEHCIRMFKHYKQQRGKQKWFMKQNTEESTIGRKLSDHKLNNTPDSDWLQLKPLAGTDDSVVSEDRLNETE 
 
hZIP6   501 PSHFDSQQPA-----VLEEEEVMIAHAHPQEVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSH---SQRYSREELKDAGV 
hZIP10  582 LTDLEGQQESPPKNYLCIEEEKIIDHSHSDGLHTIH------------EHDLHAAAH---NHHGENKTVLRKHNHQWHHKHSHHSHGPCHSGSDLKETGI 
 
hZIP6   593 ATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHYAENVSMWIFAL 
hZIP10  667 ANIAWMVIMGDGIHNFSDGLAIGAAFSAGLTGGISTSIAVFCHELPHELGDFAVLLKAGMTVKQAIVYNLLSAMMAYIGMLIGTAVGQYANNITLWIFAV 
 
hZIP6   693 TAGLFMYVALVDMVPEMLHNDAS--DHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
hZIP10  767 TAGMFLYVALVDMLPEMLHGDGDNEEHGFCPVGQFILQNLGLLFGFAIMLVIALYEDKIVFDIQF 
Amino acid sequences of ZIP6 and ZIP10 were aligned using the TCoffee multiple sequence alignment program. Residues that were at least 70% identical (black) 
and complementary (grey) across all the LIV−1 subfamily members were shaded using the BoxShade 3.21 online program. The predicted TM regions (Taylor and 
Nicholson 2003) (orange boxes), the CPALLY motif (a blue box), and the PEST motifs (the ZIP6 motif beneath a green continuous line, and the ZIP10 motifs above 
green dashed lines) are indicated. The PEST motifs were analysed using Emboss Pestfind platform (Rogers et al. 1986).  
TM1 TM2 
TM3 
TM4 TM5 TM6 
TM7 TM8 
CPALLY 
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It is also noteworthy that ZIP4, another member of the LIV−1 subfamily, 
has been reported to be activated by an N−terminal cleavage during zinc 
deficiency (Kambe and Andrews 2009), regardless of the absence of a strong 
PEST motif in this ZIP channel. Additionally, ZIP1 was the only ZIP channel in 
all the other subfamilies that also had a PEST motif, with sequence 
KEQSGPSPLEETR (positions 134 to 146, PEST score +11.14), which was 
located in the cytosolic loop between TM3 and TM4. A PEST motif in the human 
calcium receptor predestines the protein to lysosomal degradation (Zhuang et 
al. 2012). Furthermore, a PEST motif is present in a cytosolic loop of a 
pathological protein in Tangier disease called ABCS1 with a high PEST 
prediction score, and this motif was shown to be responsible for 
Calpain−mediated degradation of this pathological protein (Wang et al. 2003). 
These findings therefore implied that the presence of a PEST site in the 
cytosolic loop between TM3 and TM4 of ZIP1 and ZIP10 might be responsible 
for the lysosomal degradation of these ZIP channels, consistent with a report of 
ZIP1 being degraded through lysosomal degradation (Huang and Kirschke 
2007). However, the exact contribution of this site to the degradation of either 
ZIP1 or ZIP10 has not been investigated. 
3.3.2.3 Histidine−rich regions in the N−terminus and cytosolic loops 
The presence of a histidine−rich region in the long variable cytosolic loop 
between TM3 and TM4 has been recognised as a common characteristic of the 
ZIP family (Taylor and Nicholson 2003). This region has been proposed to be a 
potential zinc−binding domain of the ZIP channels (Guerinot 2000). 
Interestingly, histidine−rich areas were also detected in the N−terminus and the 
extracytosolic loop between TM2 and TM3 of many members of the ZIP family, 
particularly those belonging to the LIV−1 subfamily (Fig. 3.2 and 3.3). We 
therefore investigated the numbers of histidine residues as well as the HX 
repeats, with the generic formula of (HX)n (H, histidine; X, any amino acid; n, 
number of consecutive HX motifs) in the whole sequences of the ZIP channels. 
The numbers of both histidine residues and the HX repeats were also 
individually determined in the N−terminus, the extracytosolic loop between TM2 
and TM3, and the intracytosolic loop between TM3 and TM4.  
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Overall, the LIV−1 subfamily members had an average of 35 histidine 
residues and 9 HX repeats, which was 3.5 times and 5 times higher than other 
ZIP channels, respectively (Fig. 3.8A), suggesting a higher zinc−binding 
capacity of the LIV−1 subfamily than other subfamilies. In the N−terminus of the 
LIV−1 subfamily members, there were up to 52 histidine residues (in ZIP10) and 
up to 30 HX repeats (in ZIP10), with an average of 17 histidine residues and 8 
HX repeats (Fig. 3.8B). However, no histidine residue was present in the 
N−terminus of ZIP13, and no HX repeat was present in the N−terminus of ZIP5, 
ZIP8, ZIP13 and ZIP14 (Fig. 3.8B). There was neither histidine residue nor HX 
repeat present in the N−terminus of all the other ZIP channels, except ZIP11, 
which had a histidine residue with no HX repeat (Fig. 3.8B). 
 
Figure 3.8 Histidine residues and the HX repeats in the N−terminus 
 
These bar charts reveal numbers of histidine residues and the HX repeats in the whole 
sequence (A) and in the N−terminus (A) for each ZIP channel. The numbers of the HX repeats 
represent combined numbers of consecutive HX motifs, where H stands for histidine and X 
stands for any amino acid. LIV−1, the LIV−1 subfamily; I, subfamily I; II, subfamily II  
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In the region between TM2 and TM3, an average of 3 histidine residues 
and 2 HX repeats were present in the LIV−1 subfamily, yet many members of 
this subfamily, including ZIP5, ZIP8, ZIP13 and ZIP14, did not have an HX 
repeat (Fig. 3.9A). Among the other ZIP channels, the HX repeats were present 
only in ZIP9, which had 5 HX repeats in this region (Fig. 3.9A). Provided that 
ZIP9 is a gatekeeper of zinc release from cellular stores in chicken cells, which 
lacked endogenous ZIP7 (Taniguchi et al. 2013), the presence of the HX 
repeats in this extracytosolic loop of ZIP9 suggested that this region might be 
used for sensing zinc in cellular stores and thereby controlling zinc release from 
the stores. To confirm the histidine−rich cytosolic loop as a shared feature of 
the ZIP family, the LIV−1 subfamily members were demonstrated to contain an 
average of 6 HX repeats in the intracytosolic loop between TM3 and TM4, 
whereas the other ZIP channels had an average of 2 HX repeats in this 
cytosolic loop (Fig. 3.9B). The 2 exceptions in which no HX repeat was present 
in this region were ZIP13 and ZIP11 (Fig. 3.9B).  
Even though the additional presence of the HX repeats in the 
N−terminus and the extracytosolic loop between TM2 and TM3 was shown to 
be a prominent characteristic of the LIV−1 subfamily, many exceptions were 
observed. This particular characteristic was therefore considered to be highly 
variable and rather non−specific to this subfamily. Nevertheless, the presence 
of the HX repeats could by no means be overstated. Investigations of the role of 
the histidine−rich repeats have been extensively performed in metal tolerance 
proteins of Arabidopsis thaliana (AtMTP), which, like ZnT transporters, belong 
to the cation diffusion facilitator family. The histidine−rich loop in AtMTP1 has 
been shown to function as a cytosolic zinc sensor (Kawachi et al. 2008; Tanaka 
et al. 2013; Tanaka et al. 2015), a regulator of zinc transport (Tanaka et al. 
2013), and a determinant of metal selectivity (Podar et al. 2012), supporting the 
role of histidine residues in zinc selectivity (Hoch et al. 2012).  
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Figure 3.9 Histidine residues and the HX repeats in the cytosolic loops 
between TM2 and TM3, and between TM3 and TM4 
 
These bar charts reveal numbers of histidine residues and the HX repeats in the region 
between TM2 and TM3 (A) and the region between TM3 and TM4 (B) for each ZIP channel. 
The numbers of the HX repeats represent combined number of consecutive HX motifs, where H 
stands for histidine and X stands for any amino acid. 
LIV−1, the LIV−1 subfamily; I, subfamily I; II, subfamily II 
 
In ZnT5, a mammalian ZnT transporter, the histidine−rich loop has also 
been shown to play a major role in zinc binding (Suzuki et al. 2005). 
Importantly, ZnT5 contains histidine−rich regions on both sides of the plasma 
membrane (Kambe et al. 2015) and has been reported to bi−directionally 
transport zinc (Valentine et al. 2007). The unprecedented presence of 
histidine−rich regions on both sides of the membrane in the majority of the 
LIV−1 subfamily therefore suggested a possibility that these ZIP channels might 
also be capable of facilitating zinc transport bi−directionally. Supporting this 
suggestion, yeast KE4, an ER−located ZIP7 ortholog, was shown to be capable 
3. Computational sequence analysis of ZIP channels  
 
 
79 
of facilitating bidirectional zinc transport in Saccharomyces cerevisiae 
(Kumánovics et al. 2006). Nevertheless, this notable bidirectional zinc transport 
has yet to be proved for human ZIP channels. 
Additionally, the absence of the HX repeats in ZIP11 and ZIP13 was a 
remarkable finding, making the role of these two channels as zinc transport 
proteins questionable. Nevertheless, there are pieces of evidence proving the 
role for both ZIP11 (Yu et al. 2013) and ZIP13 (Jeong et al. 2012) in zinc 
transport. These observations suggested that the presence of individual 
histidine residues anywhere in the protein might be sufficient for zinc transport 
function of these ZIP channels, thereby making the role of the HX repeats in 
zinc transport, rather than the function of these ZIP channels, questionable. 
3.3.2.4 A HEXPHEXGD consensus motif in TM5 
In TM5, the motif HEXPHEXGD was prominently conserved across the 
LIV−1 subfamily members, with apparently low similarity in all the other ZIP 
channels (Fig. 3.3), consistent with a proposal of this motif as a consensus motif 
for this subfamily (Taylor and Nicholson 2003). This consensus motif matches 
the region that is reported to be zinc−binding in zinc metallopeptidases (zincins) 
(Hooper 1994), suggesting that this region could be a catalytic zinc−binding site 
of the ZIP channels. In the LIV−1 subfamily, the two glutamate residues (E), the 
proline residue (P), the second histidine residue (H), the glutamine residue (G), 
and the aspartate residue (D) in this motif showed 100% identity (Fig. 3.10). 
The two X residues (any amino acids) also showed a relatively high degree of 
identity and similarity across the LIV−1 subfamily (Fig. 3.10). Collectively, these 
observations supported the HEXPHEXGD motif as a consensus motif for the 
LIV−1 subfamily. 
Notably, the initial histidine residue (H) of the HEXPHEXGD motif was 
replaced with a glutamate residue (E) in ZIP8 and ZIP14 (Fig. 3.10), the two ZIP 
channels which were grouped together in the same sub−branch of the 
phylogenetic tree (Fig. 3.1). Furthermore, these two ZIP channels did not have 
the additional HX repeats either in the N−terminus (Fig. 3.8B) or in the 
extracellular loop between TM2 and TM3 (Fig. 3.9A). Both the histidine residues 
(Hoch et al. 2012) and the HX repeats (Podar et al. 2012) are needed for zinc 
selectivity of the ZIP channels over other metals. The lack of these components 
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in ZIP8 and ZIP14 might therefore explain their ability to also facilitate the 
cellular uptake of bivalent metals other than zinc, such as cadmium (Dalton et 
al. 2005; Girijashanker et al. 2008), manganese (He et al. 2006; Girijashanker 
et al. 2008), and iron (Liuzzi et al. 2006; Wang et al. 2012; Zhao et al. 2014). 
Interestingly, ZIP14 has been shown to participate in pathogenesis of iron 
overload in hepatocytes of hemochromatotic mice (Jenkitkasemwong et al. 
2015). Ironically, according to a metal cation competition assay in 
ZIP8−retrovirally−transfected cells, cadmium uptake via ZIP8 is most effectively 
inhibited by manganese, followed by mercury, lead, copper, zinc and then 
caesium, suggesting exceptionally high affinity of ZIP8 for manganese even in 
preference to zinc (He et al. 2006). Not surprisingly, these two zinc channels 
have now become known as canonical manganese importers in the nervous 
system (Chen et al. 2015).  
 
Figure 3.10 TM5 of ZIP channels in the LIV−1 subfamily 
 
 
hZIP4   527 LATSLAVFCHELPHELGDFAALLH 
hZIP5   414 LSTTLAVFCHELPHELGDFAMLLQ 
hZIP6   626 LSTSVAVFCHELPHELGDFAVLLK 
hZIP7   349 ILTTMTVLLHEVPHEVGDFAILVQ 
hZIP8   334 LSTSIAILCEEFPHELGDFVILLN 
hZIP10  700 ISTSIAVFCHELPHELGDFAVLLK 
hZIP12  571 VTTTIAILCHEIPHEMGDFAVLLS 
hZIP13  248 LLTTMAILLHEIPHEVGDFAILLR 
hZIP14  367 ISTSVAILCEEFPHELGDFVILLN 
 
Amino acid sequences of TM5 of all the LIV−1 subfamily members were aligned using the 
TCoffee multiple sequence alignment program. Residues that were at least 70% identical 
(black) and complementary (grey) were shaded using the BoxShade 3.21 online program. The 
consensus motif of the LIV−1 subfamily with sequence HEXPHEXGD is indicated. 
 
3.3.3 ZIP channel phosphorylation site discovery with kinase prediction 
Since ZIP7 was discovered to be activated by CK2−mediated 
phosphorylation on residues S275 and S276 (Taylor et al. 2012), it was 
hypothesised that other phosphorylation sites either in ZIP7 or in other ZIP 
channels might also be involved in post−translational regulation of ZIP 
channels. We therefore comprehensively explored the phosphorylation sites in 
HEXPHEXGD 
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all the ZIP channels using multiple online databases, including PhosphoNET 
(Kinexus Bioinformatics Corporation), PHOSIDA (Gnad et al. 2011) and 
PhosphoSitePlus (Hornbeck et al. 2015). To reduce the huge number of the 
phosphorylation sites to a manageable level and to exclude the less likely sites, 
only the sites that had been experimentally confirmed in mammalian cells by 
mass spectrometry were selected and listed along with their kinase prediction 
(Table 3.2; Fig. 3.11). Only the residues located in the cytosolic loop between 
TM3 and TM4 were included, given the presence of a conserved 
mixed−charged area in this cytosolic loop immediately proximal to TM4 (Taylor 
and Nicholson 2003), which indicated this cytosolic loop as a reactive region 
likely to interact with other proteins (Zhu and Karlin 1996). Furthermore, the two 
experimentally−confirmed phosphorylated residues in ZIP7, S275 and S276, 
are also located in this particular cytosolic loop (Taylor et al. 2012). 
A total of 29 such phosphorylation sites were detected in the cytosolic 
loop between TM3 and TM4 of ZIP3, ZIP4, ZIP6, ZIP7, and ZIP10 (Table 3.2; 
Fig. 3.11). Residues S275 and S276 of ZIP7 (Sharma et al. 2014) were the only 
sites that had already been confirmed by site−specific methods (Taylor et al. 
2012), whereas all the other residues have been detected only by mass 
spectrometry−based proteomics. In ZIP3, 7 sites were detected, including 
residues S125, S129, S131, Y133, Y147, S156, and S163 (Table 3.2; 
Fig. 3.11). In ZIP4, only one residue, S490, was reported by a study to be 
phosphorylated (Table 3.2; Fig. 3.11). In ZIP6, residues S471, Y473, S478, 
T479, Y493, Y528, and Y531 were detected (Table 3.2; Fig. 3.11). In ZIP7, 
besides S275 and S276, phosphorylation on residues S293 and T294 had also 
been reported (Table 3.2; Fig. 3.11). In ZIP10, as many as 10 residues were 
detected to be phosphorylated, including residues T536, S539, T540, S546, 
T553, S570, S573, T583, S591, and Y596 (Table 3.2; Fig. 3.11). Interestingly, 
the sites that were predicted to be phosphorylated by CK2 with the highest 
prediction scores for the individual sites were present not only in ZIP7, but also 
in ZIP3 (S129), ZIP6 (S478), and ZIP10 (S583 and T583) (Table 3.2; Fig. 3.11). 
It is therefore plausible that CK2 might also phosphorylate ZIP3, ZIP6, and 
ZIP10 on these potential sites, thereby triggering cellular zinc influx and 
replenishing zinc into the stores.  
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Table 3.2 Phosphorylation sites in the cytosolic loop between TM3 and TM4 of ZIP channels with predicted kinases 
(updated 10th August 2015) 
ZIP Site Sequence 
Reference 
(mass spectrometry) a 
No. of 
rec. b 
Predicted kinase 
(gene symbol) 
Function of the  
predicted kinase c 
ZIP3 S125 LETFNAGSDVGSDSE (Franz-Wachtel et al. 2012) 15 Rho-associated protein 
kinase 1 (ROCK) 
N/A 
 S129 NAGSDVGSDSEYESP (Weber et al. 2012) 13 Protein kinase CK2 
(CSNK2) 
Cell cycle progression, apoptosis, 
transcription, viral infection 
 S131 GSDVGSDSEYESPFM (Phanstiel et al. 2011) 3 Inhibitor of nuclear factor 
kappa-B kinase epsilon 
(IKBKE) 
Protection against DNA damage-
induced cell death. 
 Y133 DVGSDSEYESPFMGG (Phanstiel et al. 2011) 1 Mast/stem cell growth 
factor receptor Kit (KIT) 
Cell survival and proliferation, 
haematopoiesis, stem cell 
maintenance, gametogenesis, mast 
cell development, migration and 
function 
 Y147 GARGHALYVEPHGHG (Palacios-Moreno et al. 2015) 184 Tyrosine-protein kinase 
FRK (FRK) 
Negative regulation of cell 
proliferation 
 S156 EPHGHGPSLSVQGLS  (2010) CST Curation Set 10170 d 5 Serine/threonine-protein 
kinase mTOR (MTOR) 
Cellular metabolism, growth and 
survival. 
 S163 SLSVQGLSRASPVRL (2009) CST Curation Set 6183 d 1 None  
ZIP4 S490 NPEPRRLSPELRLLP (Brill et al. 2009) 1 Mitogen-activated protein 
kinase 13 (MAPK13) 
Cell proliferation, differentiation, 
transcription and development 
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ZIP Site Sequence 
Reference 
(mass spectrometry) a 
No. of 
rec. b 
Predicted kinase 
(gene symbol) 
Function of the  
predicted kinase c 
ZIP6 S471 VEIKKQLSKYESQLS (Zhou et al. 2013) 2 Calcium/calmodulin-
dependent protein kinase 
type II gamma (CAMK2G) 
N/A 
 Y473 IKKQLSKYESQLSTN (Wu et al. 2010) 1 N/A N/A 
 S478 SKYESQLSTNEEKVD (Sharma et al. 2014) 15 Protein kinase CK2 
(CSNK2) 
Cell cycle progression, apoptosis, 
transcription, viral infection 
 T479 KYESQLSTNEEKVDT (Wu et al. 2010) 4 DNA-dependent protein 
kinase (PRKDC) 
Molecular sensor for DNA damage 
 Y493 TDDRTEGYLRADSQE (Palacios-Moreno et al. 2015) 10 DNA-dependent protein 
kinase (PRKDC) 
Molecular sensor for DNA damage 
 Y528 HAHPQEVYNEYVPRG (Palacios-Moreno et al. 2015) 122 Tyrosine-protein kinase 
Lck (LCK) 
Host-virus interaction 
 Y531 PQEVYNEYVPRGCKN (Palacios-Moreno et al. 2015) 61 N/A N/A 
ZIP7 S275 RSTKEKQSSEEEEKE (Sharma et al. 2014) 13 Protein kinase CK2 
(CSNK2) 
Cell cycle progression, apoptosis, 
transcription, viral infection 
 S276 STKEKQSSEEEEKET (Sharma et al. 2014) 14 Protein kinase CK2 
(CSNK2) 
Cell cycle progression, apoptosis, 
transcription, viral infection 
 S293 VQKRRGGSTVPKDGP (Olsen et al. 2010) 1 MAP kinase-activated 
protein kinase-2-3 
(MAPKAPK2-3) 
Cytokines production, endocytosis, 
cell migration, chromatin 
remodelling and transcriptional 
 T294 QKRRGGSTVPKDGPV (2008) CST Curation Set 4745 d 1 Serine/threonine-protein 
kinase pim-1-3 (PIM1-3) 
Cell survival, cell proliferation 
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ZIP Site Sequence 
Reference 
(mass spectrometry) a 
No. of 
rec. b 
Predicted kinase 
(gene symbol) 
Function of the  
predicted kinase c 
ZIP10 T536 KWFMKQNTEESTIGR (Shiromizu et al. 2013) 4 Serine/threonine-protein 
kinase ATR (ATR) 
DNA damage response  
 S539 MKQNTEESTIGRKLS (Kettenbach et al. 2011) 7 Serine/threonine-protein 
kinase pim-1 (PIM1) 
Cell survival, Cell proliferation 
 T540 KQNTEESTIGRKLSD (Sharma et al. 2014) 3 Leucine-rich repeat 
serine/threonine-protein 
kinase 2 (LRRK2) 
Regulation of dardarin production 
(mutation involved in pathogenesis 
of Parkinson’s disease)  
ZIP10 S546 STIGRKLSDHKLNNT (Sharma et al. 2014) 5 Serine/threonine-protein 
kinase pim-1-3 (PIM1-3) 
Cell survival, Cell proliferation 
 T553 SDHKLNNTPDSDWLQ (Sharma et al. 2014) 5 Mitogen-activated protein 
kinase 8-10 (MAPK8-10) 
Cell proliferation, differentiation, 
migration, transformation and 
programmed cell death. 
 S570 PLAGTDDSVVSEDRL (Sharma et al. 2014) 2 Serine/threonine-protein 
kinase pim-1-2 (PIM1-2) 
Cell survival, Cell proliferation 
 S573 GTDDSVVSEDRLNET (Sharma et al. 2014) 1 Protein kinase CK2 
(CSNK2) 
Cell cycle progression, apoptosis, 
transcription, viral infection 
 T583 RLNETELTDLEGQQE (Sharma et al. 2014) 1 Protein kinase CK2 
(CSNK2) 
Cell cycle progression, apoptosis, 
transcription, viral infection 
 S591 DLEGQQESPPKNYLC (Sharma et al. 2014) 13 Cyclin-dependent kinase 
1-2 (CDK1-2) 
Cell cycle 
 Y596 QESPPKNYLCIEEEK (Sharma et al. 2014) 9 Tyrosine-protein kinase 
SYK (SYK) 
Immunity 
a For the sites where there is more than one reference, only the latest one is shown as a representative for each site. 
b No. of rec., number of records, representing the number of proteomic studies that detected phosphorylation at the individual residues using mass spectrometry. 
c Functions of the kinases were retrieved from the UniProt Knowledgebase (UniProtKB, The UniProt Consortium) (The UniProt Consortium 2015) 
d CST curation set, curation sets from Cell Signaling Technology, Inc.  
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Figure 3.11 Potential phosphorylation sites and kinases for ZIP channels 
 
Phosphorylation sites with kinase prediction of all ZIP channels were searched for in the 
PhosphoNET (Kinexus Bioinformatics Corporation), the PHOSIDA (Gnad et al. 2011), and the 
PhosphoSitePlus (Hornbeck et al. 2015) databases. The sites that had been experimentally 
confirmed by mass spectrometry in mammalian cells and that located in the cytosolic loop 
between TM3 and TM4 were selected. Predicted kinases with the highest prediction scores are 
shown. The potential phosphorylation sites are found in ZIP3, ZIP4, ZIP6, ZIP7, and ZIP10. 
ZIP7 S275 and S276 are the only two sites that have been confirmed using site−specific 
methods (Taylor et al. 2012). 
 
The hallmarks of cancer comprise six biological features that cancer cells 
need to acquire during carcinogenesis: sustained proliferation, growth 
suppressor evasion, cell death resistance, immortality, angiogenesis, and 
invasion/metastasis (Hanahan and Weinberg 2011). Considering the predicted 
kinases for ZIP3, ZIP4, ZIP6, ZIP7, and ZIP10 (Table 3.2; Fig. 3.11), in 
correlation with the hallmarks of cancer, all these ZIP channels had at least one 
predicted kinase whose function was contributory to some of these hallmarks. 
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The kinases predicted for ZIP3 included CK2, which promotes proliferation; KIT, 
which promotes proliferation and migration; and MTOR, which promotes 
proliferation and survival (Table 3.2 and 3.3; Fig. 3.11). The kinase predicted for 
ZIP4 included MAPK13, which promotes proliferation (Table 3.2 and 3.3; 
Fig. 3.11). Besides CK2, ZIP7 was predicted to be phosphorylated by 
MAPKAPK2−3, which promote cell migration, and PIM1−3, which promote cell 
proliferation and migration, whereas ZIP10 was predicted to be phosphorylated 
by PIM1−3, as well as MAPK8−10, which promote cell proliferation and 
migration, and CDK1−2, which promote cell proliferation (Table 3.2 and 3.3; 
Fig. 3.11). It is noteworthy that the functions of these kinases were obtained 
from UniProt Knowledgebase (The UniProt Consortium 2015), which might not 
have included all their functions in the literature. Moreover, because none of the 
potential phosphorylation sites, except residues S275 and S276 of ZIP7, had 
been confirmed using site−specific methods, the roles of these ZIP channels in 
carcinogenesis still need further investigations.  
 
Table 3.3 Association of the kinases predicted for the phosphorylation 
sites in ZIP channels with carcinogenesis  
ZIP channels 
Hallmarks of cancer  
associated with predicted kinases 
Proliferation Survival Migration 
ZIP3    
ZIP4    
ZIP6    
ZIP7    
ZIP10    
 
Phosphorylation sites with kinase prediction for all the ZIP channels were searched for in the 
PhosphoNET (Kinexus Bioinformatics Corporation), the PHOSIDA (Gnad et al. 2011), and the 
PhosphoSitePlus (Hornbeck et al. 2015) databases. Functions of the predicted kinases with the 
highest prediction scores for all the phosphorylation sites in each ZIP channel were looked for in 
the UniProt Knowledgebase (The UniProt Consortium 2015). In correlation with the proposed 
hallmarks of cancers (Hanahan and Weinberg 2011), every ZIP channel has at least one 
predicted kinase that contributes to some of these hallmarks of cancer. 
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3.3.4 Analysis of potential phosphorylation sites in ZIP7 
To determine evolutionary conservation of residues S275 and S276 in 
ZIP7, which might imply potential importance of these residues in ZIP7 
post−translational control, ZIP7 amino acid sequences in different animal 
species were aligned. ZIP7 sequences had been reported in mammals (human, 
Sumatran orang-utan, chimpanzee, gorilla, rhesus monkey, dog, cat, rabbit, 
bovine, horse, pig, sheep, panda, mouse, and rat), an amphibian (African 
clawed frog), fishes (zebrafish, Atlantic salmon, and trout), and a plant (maize) 
(Fig. 3.12). Evolutionary conservation of the protein sequences was clearly 
seen across the eukaryotic species (Fig. 3.12). Importantly, the two consecutive 
serine residues equivalent to S275 and S276 in human ZIP7 were highly 
conserved across the mammalian species (Fig. 3.12 and 13, the red box). 
Furthermore, these two residues were located in a region that had a sequence 
consistent with the consensus motif for CK2−binding site, S/T−X−X−E (S, 
serine; T, threonine; E, glutamine; X, any amino acid) (Fig. 3.12 and 13, the red 
box). Additionally, multiple acidic amino acids were present distal to these sites 
(Fig. 3.12 and 13, the red box). These features collectively increased the 
possibility for CK2−mediated phosphorylation (Pinna 1990; Meggio and Pinna 
2003), which has already been confirmed using site−specific methods (Taylor et 
al. 2012). 
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Figure 3.12 Alignment of ZIP7 in various animal species 
 
Human              1 MA-RG-----LGAPHWVAVGLLTWATLGLLVAGLGGHDDLHDDLQEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHDH--DHGHS--HEDL----------------HHGHS--HGY-SHES 
Orang-utan         1 MA-RG-----LGAPHWVAVGLLTWATLGLLVAELGGHDDLHDDLQEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHGH--DHGHS--HGDL----------------HHGHS--HGH-SHES 
Chimpanzee         1 MA-RG-----LGAPHWVAVGLLTWATLGLLVAGLGGHNDLHDDLQEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHDH--DHGHS--HEDL----------------HHGHS--HGH-SHES 
Gorilla            1 MA-RG-----LGASHWVAVGLLTWATLGLLVAGLGGHDDLHDDLQEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHGH--DHGHS--HEDL----------------HHSHS--HGH-SRES 
Rhesus             1 MA-RG-----LGAPHWVAVGLLTWAALGLLVAGLAGHDDLHDDLQEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHGH--DHGHS--HEDL----------------HHGHS--HGH-SHES 
Dog                1 MA-RG-----LGAPHWVAVGLLTWAALGLLVAGHGGHGDLHEDLHEDF-HGH-SHRRSHEDFHHGHSYA-------HG----HGHTHES-IWHG-----------------HTHGH--EHGHA--HEDL----------------HHGHS--HGQ-SHES 
Cat                1 MA-RG-----LGAPHWVAMGLLTWAALGLLVAGHGGHGDLHQDLHEDF-HGH-SHRRSQEDFHHGHSHA-------RG----HGHTHES-IWHG-----------------HTHGH--EHGHS--HEDL----------------HHGHS--HGQ-SHET 
Rabbit             1 MA-RG-----LGAPHWVAMGLLTWAALGLLVAGHGGHGDQHEDLQEDF-HGH-SHRHSHEDFHHGHSHA-------HGHGHGHGHTHES-IWHG-----------------HTHGH--DHGHS--HEDL----------------HHGHSHSHGH-SHES 
Bovine             1 MA-RG-----LGAPRWVAVGLLTWAALGLLVAGHGGHGDLYEDLHEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHGH--DHGHL--HEDL----------------HHGHS--HGH-SHES 
Horse              1 MA-RG-----LGAPHWVAVGLLTWAALGLLVAGHGGHGDLHEDLHEDF-HGH-SHRHSHEDFHHGHSHA-------H------GHTHES-IWHG-----------------HTHGH--DHGHS--HEDL----------------HHGHS--HGH-SHEN 
Pig                1 MA-RG-----LGAPHRVAVGLLTWAALGLLVAGHGGHGDLYEDLQEDL-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHGH--DHGHS--HEDL----------------HHGHI--HGD-SHES 
Sheep              1 MA-RG-----LGAPRWVAVGLLTWAALGLLVAGHGGHGDLYEDLHEDF-HGH-SHRHSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHAH--DHGHA--HEDL----------------HHGHS--HGH-SHES 
Panda              1 MA-RG-----LGAPHWVAMGLLTWAALGLLVAGHGGHGDLHEDLHEDF-HGH-SHRRSHEDFHHGHSHA-------HG----HGHTHES-IWHG-----------------HTHGH--EHGHS--HEDL----------------HHGHS--HGQ-SHEN 
Mouse              1 MT-MG-----LRAPHWVAVGLLTWAALGLLVAGHEGHGDLHKDVEEDF-HGH-SHGHSHEDFHHGHSHGHSHEDFHHG----HGHTHES-IWHG-----------------HAHSH--DHGHS--REEL----------------HHGHS--HGH-SHDS 
Rat                1 MA-RV-----LRDPHWVAVGLLTWAALGLLVAGHEGHGDLHRDVEEDF-HGH-SHGHSHEDFHHGHSH---------G----HGHTHES-IWHG-----------------HAHSH--DHGHS--REDV----------------HHGHS--HGH-SHDS 
Frog               1 MG-RLWLKSGVGCALLVAIFMFCCL----------VHTALS-QAHEDFHHGH-SH------AHHGHSHGH------HG----HGHSHHGHDCHG-----------------HGHSH---HGHS--HEDL----------------NHGHS--HVHHGHSH 
Zebrafish          1 MR-VF-----SKSLLLIAVGILMSQQTLAHSHHHHGHGDG------GC-HGH-SHG--GAKMHHGASKW-------SA----EAN--LP-HAEE-----------------EHHVH--DHGHT--HDHA-----------------HDHG--HAH-SHGD 
Salmon             1 MA-HG---------RLLALTLFSGAVLLLATQLTV------------A-HSH-SHDHGHAHS-HGGGGC-------DG----HSHGSQK-LHHGASKWSAEANLPPAESSHHGHAH--DHGHK--HEES----------------GHGHT--HGG-ERE- 
Trout              1 MMAHG---------RLLALTLFSGAVLLLVAQLTV------------A-HSH-SHDHGHAHDHHGHAHD-------H-----HGHAHDH-HGHA-----------------HSHGGSGSDGHSHGSQKL----------------HHGAS--KWS-AEAN 
Maize              1 MR-RQ-----SLAT--VLLLLVAAAALAAPAAG---HFESSC----PF-YDHGGHGEPHERHDHGHSCG-------G------GADHEH-H-HH-----------------HHHGH--GHGEI--QRLLPEEMAEEADLELESFGYEDHD--HGH-HHHH 
 
 
Human            101 L-----YHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDAVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHT-----LE----Q----------PGHGHS 
Orang-utan       101 L-----YHRGHGHD---N-EHSR---------G-----------GYG-ESGAPGI-KQDLDAVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHT-----LE----Q----------PGHGHS 
Chimpanzee       101 L-----YHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDAVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHT-----LE----Q----------PGHGHS 
Gorilla          101 L-----YHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDAVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHT-----LE----Q----------PGHGHS 
Rhesus           101 L-----FHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDAVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHT-----LE----Q----------HGHGHS 
Dog              101 L-----YHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----LE----Q----------PGHGHS 
Cat              101 L-----YHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----LE----Q----------PGHGHS 
Rabbit           107 L-----YHRGHGHD---H-EHSR---------G-----------GYG-ESGAPGI-KQDLDTVTLWAYALGATVLISAAPFFFLFLIPVESNS-PRHSSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHT-----VE----Q----------RGHGHS 
Bovine           101 L-----HHRGHGHD---H-EHSH---------G-----------GSG-ESGAPGV-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----PE----Q----------PGHGHS 
Horse             99 L-----YHRGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----QE----H----------PGHGHS 
Pig              101 L-----YHPGHGHD---H-EHSH---------G-----------GYG-ESGAPGI-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----LE----Q----------PGHGHS 
Sheep            101 L-----HHRGHGHD---H-EHSH---------G-----------GYG-ESGALGV-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-ARHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----LE----Q----------PGHGHS 
Panda            101 L-----YHRGHGHD---H-EHSH---------G-----------GFG-ESGAPGI-KQDLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHP-----LE----Q----------PGHGHS 
Mouse            108 L-----HHGGHGHA---HREHSH---------G-----------TSR-EAGAPGI-KHHLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHHA-----PE----Q----------PGHGHS 
Rat               99 L-----HHRGHGH--------SH---------G-----------ASR-EAGAPGI-KHHLDTVTLWAYALGATVLISAAPFFVLFLIPVESNS-PRHRSLLQILLSFASGGLLGDAFLHLIPHALEPHSHDT-----PA----Q----------PGHGHS 
Frog              92 Q-----DHHGHSHEEIQH-EHSPD--HKEQSHVVEERTKREAPTGDN-LIHNHGS-KEKMEPVQLWTYAICATLLISAAPFFILFLIPVQSNS-SQHQSLLKLLLSFASGGLLGDAFLHLIPHALEPHSVHEAVAEPEE----T----------HGHGHS 
Zebrafish         90 I-----HDHGHAHK---H-GHAH---------D-----------HGA-EKSKKVVEAGKRNMVELWMQAIGATLLISAAPFLILFLIPVQSNT-DQHQNLLKVLLSFASGGLLGDAFLHLIPHALEPHSHHS-----QPHSEESHGQSH---GEESHGHS 
Salmon           100 --------------------------------------------------------GEKRDIVELWMQAIGATLLISAAPFFILFLIPVQSNT-DQNKNLLKVLLSFASGGLLGDAFLHLIPHALVPHSHHG-----DE----GHGHSHDSEESQDHGHS 
Trout             89 LPPAEESHHGHAHD---H-GHKHEESGHGH--T-----------HGGERMIREA-EGEKRDIVELWMQAIGATLLISAAPFFILFLIPVQSNT-DQHKNLLKVLLSFASGGLLGDAFLHLIPHALVPHSHHG-----DE----GHGHSHDSEESQDHGHS 
Maize            106 H-----H------------HHSHG--------------------D------------METSPMGVWLSAMGCSLLVSMASLVCLVLLPVIFFKGKPSKAIVDSLAVFGAGAMLGDSFLHQLPHAFGGGHSHS-----HD--------------HEGHDHA 
 
 
  
TM2 TM1 
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Figure 3.12 Alignment of ZIP7 in various animal species (continued) 
 
Human            210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHSHT--R--G-SHGHG-RQERSTKEKQSSEE---------------------------EEKET--RGVQKRRGGSTVPKDGPV--R--PQN--AEEEKR---G-L 
Orang-utan       210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHSHT--H--G-SHGHG-RQECSTKEKQSSEE---------------------------EEKET--RGVQKRRGGSTVPKDGPV--R--PQN--AEEEKR---G-L 
Chimpanzee       210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHSHT--R--G-SHGHG-RQERSTKEKQSSEE---------------------------EEKET--RGVEKRRGGSTVPKDGPV--R--PQN--AEEEKR---G-L 
Gorilla          210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGRG--HAHSHT--R--G-SHGHG-RQERSTKEKQSSEE---------------------------EEKET--RGVQKRRGGSTIPKDGPV--R--PQN--AEEEKR---GLE 
Rhesus           210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHSHT--H--G-SHGHG-RQERSNKEKQSSEE---------------------------EEKET--GGVQKRRGGSTVPKDGPV--R--PQN--AEEEKR---G-L 
Dog              210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HTHGHT--Q--G-SHGHG-TQKYPSKEKQSSEE---------------------------EEKEA--NGSRKRKGGSTRLKDGPL--R--PQN--SEEEKT---G-S 
Cat              210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHGPT--Q--G-GHGHG-RQERSSKEKQSSEE---------------------------EEKEA--GGSRKRRGGSTGLKDGPV--R--PQN--SEEEKK---V-Q 
Rabbit           216 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HTHGHG--H--G-SHGRA-RQECPPKEKQSSEE---------------------------EEKEG--GVLRKRKGGSTGPKDGSV--G--AQN--PEEEKT---G-S 
Bovine           210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHGHT--H--G-SHEHG-RQERSSKEKQSSEE---------------------------EEKEA--GALRKRRGGSTRPKDGPV--R--PQN--AEEEKA---G-S 
Horse            208 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HTHGHT--H--G-SHRHG-RQERHSKEKQSSEE---------------------------EEKEA--GGLRKRKGGNMGPKDGPV--R--PEN--SEEGKT---G-S 
Pig              210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---EHSHGHG--HAHGHT--H--G-GHGHG-RQECPSKEKQSSEE---------------------------EEKEA--GASRKRRGGSTRPKDGPV--R--PQH--SGEEKA---G-S 
Sheep            210 H------SGQGPILSVGLRVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--HAHGHT--H--E-SHEHG-RQERSSKEKQSSEE---------------------------EEKEA--GALRKRRGGSTRPKDGPV--R--PQN--AEQEKA---G-S 
Panda            210 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHGHGHAHGHT--R--G-SHGHG-KQERPSKEKQSSEE---------------------------EEKEG--GGPRKRKGGSTELKDGPV--R--PQN--SEEEKT---G-S 
Mouse            218 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHSHGHG--DRHAHG--D----SHTHGDRHECSSKEKPSTE----------------------------EEKEV--GGLRKRRGGNTGPRDGPV--K--PQS--PEEEKA---G-S 
Rat              204 H------SGQGPILSVGLWVLSGIVAFLVVEKFVRHVKGGH---GHAHAHG--HGHSHGDSHAHGHSHAHGDRHECPSKGKPSSE----------------------------DEKEA--GGLRKRRGGDTGPRDGPL--K--PQN--PEEEKT---G-S 
Frog             227 HG-----QSHSQMMLVGLWVLAGIIAFLVVEKFVRHLKGEH---GHGHGHS--HAA-----------------KEKIVDD-ATEKE---------------------------EEKDPGKDGVRQRKKGSSTVQKG--------KN--GNKEPL---Q-S 
Zebrafish        211 HG-----AAHGHMMSVGLWVLGGIVAFLVVEKFVRLLKGGH---SHSHSHS--PS---------------------APKSKDSDEE---------------------------DDK----------KGQKKGEKDKVV--S--QQKPTKKTVET---S-S 
Salmon           194 HG-----AAHGHMMSVGLWVLGGIVAFLVVEKFVRLLKEGH---GHGHSHA--AP-----------------------KAKESDGE---------------------------EKN----------KG----EKDG----------KES-KDEK---T-T 
Trout            221 HG-----AAHGHMMSVGLWVLGGIVAFLVVEKFVRFLKEGN---GHGHSHA--AP-----------------------KAKESDGE------------E--------------ENK----------EG----EKDGKE--SKDEKTPKG-VEEK---T-T 
Maize            198 HAHEHAHAHSLQDLSVGLSVLFGIVLFFIVEKIVRYVEDNSQNGAHSMGHG--HHH-----------HNHK-RHDSSDKAKLNYQKSDTDGKDIDHAEEEPSVNDTTGKISDGHESE---ATIRKRSS--SKATDGEATNS--GRD--PAPEKAPSIS-N 
 
 
Human            314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEIAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVIMMVLIAHLE 
Orang-utan       314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEIAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Chimpanzee       314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEIAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVIMMVLIAHLE 
Gorilla          315 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEIAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Rhesus           314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEVAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Dog              314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAIGALAGTACALLTEGGAVGSEVAGGTGSGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Cat              314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAIGALAGTACALLTEGGAVGSEVASGTGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Rabbit           320 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGQGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSDGAGGAGPGWILPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Bovine           314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEVAGGAGPGWILPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Horse            312 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAIGALAGTACALLTEGGAVGSEVAGGTGPGWILPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Pig              314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTAFALLTEGGAAGSEVAGGTGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Sheep            314 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAVGALAGTACALLTEGGAVGSEVAGGAGPGWILPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLQ 
Panda            316 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAIGALAGTACALLTEGGAVGSEVAGGTGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVVMMVLIAHLE 
Mouse            321 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLVTAIGALAGTACALLTEGGAVDSDVAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVAMMVLIAHLE 
Rat              313 DLRVSGYLNLAADLAHNFTDGLAIGASFRGGRGL-GILTTMTVLLHEVPHEVGDFAILVQSGCSKKQAMRLQLLTAIGALAGTACALLTEGGAVGSEVAGGAGPGWVLPFTAGGFIYVATVSVLPELLREASP-LQ-SLLEVLGLLGGVAMMVLIAHLE 
Frog             318 EMTVSGYLNLAADFTHNFTDGLAIGASFLVSSSV-GIVTTITILLHEVPHEIGDFAILVQSGCTKRKAMMLQLSTALGALAGTICSLLAEG-------IGEAATLWILPFTAGGFIYIATVSVIPELLKDSRP-LQ-SILETFGLLLGVAMMVLIAQFE 
Zebrafish        295 DIKVSGYLNLAADFTHNFTDGLAIGASFLVGPAV-GAVTTITILLHEVPHEIGDFAILVQSGCTKRKAMCLQLLTAVGALAGTACSLLAEG-------VGDATTAWILPFTAGGFVYIAAVTVLPELLAGHSSFWQ-SLLEILALLFGVGMMVLIAEYE 
Salmon           265 DIKVSGYLNLAADFTHNFTDGLAIGASFLVGPAV-GTVTTLTILLHEVPHEIGDFAILVQSGCTKKKAMCLQLLTALGALAGTACSLLAEG-------VGAAATAWILPFTAGGFVYIATVTVLPELLVGRSSLGQ-SVMEILAMLVGIYMMVLIAEYE 
Trout            301 DIKVSGYLNLAADFTHNFTDGLAIGASFLVGPAV-GTVTTLTILLHEVPHEIGDFAILVQSGCTKKKAMCLQLLTALGALAGTACSLLAEG-------VGAAATAWILPFTAGGFVYIATVTVLPELLVGRSSLGQ-SVMEILAMLVGIYMMVLIAEYE 
Maize            334 SNLVFGYLNLFSDGVHNFTDGMALGSAFLLHGSVGGWSRTLFLLAHELPQEVGDFGILVRSGFTVSKALFFNFLSALVALAGTALALSL-G-------KDPGHSSLIEGFTAGGFIYIAVAGVLPQMNDQKTT-IKSSVAQLISLAMGMLVALGISLVE 
Amino acid sequences of ZIP7 from mammals (human, Sumatran orang-utan, chimpanzee, gorilla, rhesus monkey, dog, cat, rabbit, bovine, horse, pig, sheep, 
panda, mouse and rat), an amphibian (African clawed frog), fishes (zebrafish, Atlantic salmon and trout), and a plant (maize) were aligned using the TCoffee multiple 
sequence alignment program. Residues that were at least 70% identical (black) and complementary (grey) were shaded using the BoxShade 3.21 online program. 
The regions equivalent to the TM regions (orange box) and the serine residues S275 and S276 (red box) in hZIP7 are indicated. 
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TM3 CK2-phosphorylated serine residues 
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Figure 3.13 The CK2−phosphorylated sites in ZIP7  
 
Human       270 TKEKQSSEEEEKETRGVQKRRGGSTVP 
Orang-utan  270 TKEKQSSEEEEKETRGVQKRRGGSTVP 
Chimpanzee  270 TKEKQSSEEEEKETRGVEKRRGGSTVP 
Gorilla     270 TKEKQSSEEEEKETRGVQKRRGGSTIP 
Rhesus      270 NKEKQSSEEEEKETGGVQKRRGGSTVP 
Dog         270 SKEKQSSEEEEKEANGSRKRKGGSTRL 
Cat         270 SKEKQSSEEEEKEAGGSRKRRGGSTGL 
Rabbit      270 PKEKQSSEEEEKEGGVLRKRKGGSTGP 
Bovine      270 SKEKQSSEEEEKEAGALRKRRGGSTRP 
Horse       268 SKEKQSSEEEEKEAGGLRKRKGGNMGP 
Pig         270 SKEKQSSEEEEKEAGASRKRRGGSTRP 
Sheep       270 SKEKQSSEEEEKEAGALRKRRGGSTRP 
Panda       272 SKEKQSSEEEEKEGGGPRKRKGGSTEL 
Mouse       270 SKEKPSTEEEKEV GGLRKRRGGNTGP 
Rat         270 SKGKPSSEDEKEA GGLRKRRGGDTGP 
Frog        277 DDATEKEEEKDPGKDGVRQRKKGSSTV  
Zebrafish   255 SAPKSKDSDEEDDKKGQKKGEKDKVVS 
Salmon      238 PK--------AKESDGEEKNKG----- 
Trout       265 PK--------AKESDGEEENKEGEKDG 
 
Amino acid sequences of ZIP7 from mammals (human, Sumatran orang−utan, chimpanzee, 
gorilla, rhesus monkey, dog, cat, bovine, horse, pig, sheep, panda, mouse, and rat), an 
amphibian (African clawed frog), and fishes (zebrafish, Atlantic salmon and trout) were aligned 
using the TCoffee multiple sequence alignment program. The region equivalent to residues 
270−296 of human ZIP7 is shown. Residues that were at least 70% identical (black) and 
complementary (grey) were shaded using the BoxShade 3.21 online program. The serine 
residues equivalent to S275 and S276 of ZIP7 are indicated in a red box. 
 
3.3.5 Analysis of potential phosphorylation sites in ZIP6 
To explore the possibility that ZIP6 was post−translationally regulated by 
phosphorylation like ZIP7, all available ZIP6 sequences in different animal 
species were aligned. ZIP6 sequences were found in mammals (human, 
chimpanzee, Sumatran orang−utan, marmoset, gibbon, Tasmanian Devil, cat, 
dog, mouse, and rat) and zebrafish (Fig. 3.14). The sites that had been reported 
to be phosphorylated by mass spectrometry were investigated for their 
evolutionary conservation, focusing on residue S478, which was predicted to be 
phosphorylated by CK2, and the sites in the vicinity, including residues S471 
and T479 (Fig. 3.14 and 3.15). Additionally, even though phosphorylation on 
residue S475 had not been experimentally confirmed, the sequence in this 
region matched established consensus motifs for multiple kinases. The residue 
S475 was therefore listed as a predicted phosphorylation site, according to the 
Human Protein Reference Database (Keshava Prasad et al. 2009). 
S275 S276 
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Figure 3.14 Alignment of ZIP6 in various animal species 
 
Human              1 ------MARKLSV-----------------------------------------ILILTFALSVTNPLHELKA-AAFPQTTEKISPNWESGINVDLAISTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSDHEHHSDHERHS 
Chimpanzee         1 ------MARKLSV-----------------------------------------ILILTFALSVTNPLHELKA-AAFPQTTEKISPNWESGINVDLAITTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSDHEHHSDHEHHS 
Gorilla            1 ------MARKLSV-----------------------------------------ILILTFALSVTNPLHELKA-AAFPQTTEKISPNWESGINVDLAITTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSDHEHHSDHEHHS 
Orang-utan         1 ------MARKLSV-----------------------------------------ILILTFALSVTNPLHELKA-AAFPQTTEKISPNWESGINVDLAITTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHEHHSDHEHHSDH---- 
Marmoset           1 ------MARKLSI-----------------------------------------ILILTFVLSVTNPLHELKSTAAFPQTTEKINPNWESGINVDLAVTTRQYHLQQLFYRYGENNTLSVEGFRKLLQNIGLDKIKRIHIHHDHEHHSDHEHHSDHDHH- 
Gibbon             1 ------MARKLSV-----------------------------------------ILILTFALSVTNPFHELKA-AAFPQTTEKISPNWESGINVDLAITTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHNHDHHSDHEHHSDHEHH- 
Tasmanian Devil    1 MLQETTMEKTFPV-----------------------------------------ALLFTLVISVLGNHHGIE--------PEKSVPNWATSINIDLAIVTQRQHLQELFHRYGENDSLTVEGFRKLLQNIGIDKTKRIHINHDHDHH------------- 
Cat                1 ------MARNLSV-----------------------------------------ILILTLTLSVTNPLHELEPATAFPQTTEKIITNWESGINVDLAVTTRRHHLQQLFHRYGENNSLSVEGFRKLLQNIGIDKIKKIHIHHDHDHHSD----------- 
Dog                1 ------MARNLSV-----------------------------------------ILILTFTLSVTNPLHELEPATAFPQTTEKIITNWESGINVDLAVTTRRHHLQQLFHRYGENNSLSVEGFRKLLQNIGIDKVKKIHIHHDHDHHSD----------- 
Mouse              1 ------MATDLSV-----------------------------------------IMILTFALWVTSPLHELQSTAAFSQTTEKINSNWEPGVNVDLAVTMQRHHLQQLFYRYGENDSLSVEGFRKLLQNIGIDKIKRVHIHHDHEHHADHEHHSDHEHHS 
Rat                1 ------MATNLSV-----------------------------------------IMILTFALWVTNPLHELQSTAAFSQTTEKINSNWESGINVDVAVTMQRHHLQQLFYRYGENDSLSVEGFRKLLQNIGIDKIKRVHIHHDHERHSDHER-------- 
Zebrafish          1 ------MMTFLCTRSGRRASGVECRIAAERAYFRVRGLPVANMIGWWPRLCPVMSLALLWACSVGA-GSDCKS-VAI-E------------TDSRIAEQTQQRHLQALFDKYGQNGSISLEGLFNLLKGVGLDRIRKVMVHHPGNAHN-HTHTHDHTH-- 
 
 
Human            113 ------DHEHHSEHEHHSDHDHHSHHNHAASGKNKRKALCPDHDSDSSGKDPR----NSQGKGAHRPEHASGRRNV--KDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRV---SRLAGR---KTNESV-SEPRKG--F 
Chimpanzee       113 ------DHEHHSDHEHHSDHDHHSHRNHAASGKNKRKALCPDHDSDNSGKDPR----NSQGKGAHRPEHASGRRNV--KDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTEKSRV---SRLAGR---KTNESV-SEPRKG--F 
Gorilla          113 ------DHEHHSDHEHHSDRDHHSHRNHAASGKNKRKALCPDHDSDSSGKDPR----NSQGKGAHRPEHASGRRNV--KDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTEKSRV---SRLAGR---KTNESV-SEPRKG--F 
Orang-utan       109 --------------EHHSDHEHHSHRNHAASGKNKRKALCPDHDSDSSGKDPR----NSQGKGAHRSEHASGRRNV--KDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTEKSRG---SRLAGR---KTNESV-SEPRKG--F 
Marmoset         113 -----------SDHEHHSDHEHHSHHNHAASGKNNRKALCPDHDSDSSSKEPR----NTQGKGAHQLEHASGRRNV--KDSVSASEATSTMYNTVSEGTHFLETIETPKPGKLFPKDVSGSTPPSVTEKSRV---SQLAGR---KTNESM-SEPRKG--F 
Gibbon           112 -----------SDHEHHSDHEHHSHRNHAASGKNKRKALCPDHDSDSSGKDPR----NSQGKGAHRPEHPNGRRNV--KDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTEKSRV---SRLAGR---KTNESV-SEPRKG--F 
Tasmanian Devil   99 ------------------------HHHHATINKNIKKTLCPEHESGGISKDTR----NSQIKGLHKSENIGSQPSV--LVKDSVSEMTTVIYSTAIEGNRLLKTTK-----QLLPKDSNSSSSSNTTEGSNV---SLLASE---KANESVVNEPDRGGSS 
Cat              103 -------------------HDHHSHRNHAPSNKNNRKALCPDHEPDSSGKDPR----NSQGKGSHRSEHANSRRNVLIKDGVTASEVTSTMYNTVSEGTHFLETIDTPKPGKLFPKDVSSSTPPSITEKGRM---SQLASR---KTNESV-SEPRKG--F 
Dog              103 -------------------HDHHSHRNHAASNKNNRKALCPDHESDSLGKDPR----NSQGKGSHRSEHANGKRNVLIKDGVTASEVTSTVYNAVSEGTHFLETIDTPKPGKLFPKDVSSSTPPSITEKSRV---SRLTSK---KTNESV-SEPRKG--F 
Mouse            114 DHEHHSDHEHHSDHEHHSDHEHHSHRSHTVAGKNNRKAFCPDLDSDNSGKNPR----TSLGKGSRPAEHMNGRRNI--KESASSSEVTSAVYNAVSEGTRFVETIETPKPGRR-TKDVNPSTPPSITEKSRVGRLSRLARK---KSNESV-SEPRKS--F 
Rat              106 ----------------HSDHERHSHRGHAAAGKNSRKAFCPDLDSDNSGKNPN----TSQGKGSRPAEHVNGRRNG--KESASSSEVTSAVYNTVSEGTHFLETIETPKPGRR-TKDINPSTPPSITEKSRVGRLSRLARR---KGNDSV-SEPRKS--F 
Zebrafish        137 --------------THV---DKLTAHTHPVTTK----KGDMDHSVEKSDPVPKAQPDPASGKKSQSDAHHNLYMK--MN-QESTTAL---------------------------------TTPSYVTRSRRT---NRSADYDFTQDHAS-FSPSQPN--V 
 
 
Human            252 MYSRNTNEN-------------------PQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHT-SEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Chimpanzee       252 MYSRNTNEN-------------------PQECFNASKLLTSHGMGIQIPLNATEFNYLCPAIINQIDARSCLIHT-SEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Gorilla          252 MYSTNTNEN-------------------PQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHT-SEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Orang-utan       240 MYSRNTNEN-------------------PQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHT-SEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Marmoset         247 MYSRNMNEN-------------------PQECLNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHT-SEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Gibbon           246 MYSRNTNEN-------------------PQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHT-SEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Tasmanian Devil  218 IYSKHSNQN-------------------VQECFNASKLLQSHGMGIHVLLNATEFNYLCPAIINQIDVKSCIVHVTSEKKTEI--------------------------PPKAYSLQIAWIGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Cat              231 MYSRNTNEN-------------------TQECFNASKLLTSHGMGIQVLLNATEFNYLCPAIINQIDARSCLIHTTSEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Dog              231 MYSRNTNEN-------------------TQECFNASKLLTSHGMGIQTMLNATEFNYLCPAIINQIDARSCLIHTTSEKKAEI--------------------------PPKTYSLQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Mouse            261 MYSRNTNDN-------------------IQECFNTTKLLTSHGMSIQALLNATEFNYLCPAIINQIDARACLIHTASEKKAEI--------------------------PPKTYSLQIAWLGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Rat              237 MYSRTSNDN-------------------IQECFNATKLLTSHGMSVQALLNATEFNYLCPAIINQIDARSCLIHTASEKKAEI--------------------------PPKTYSLQIAWLGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALA 
Zebrafish        234 THSNHTHHDEDTPTHQHDDHDEHEHARASLGCQNASTILQTHGMRKEASLSVKDFSFLCPALLMQIDSKSCIVHEDEDEHSDHSHHHKHHHHHHDHQHLQHPHNHTNGRGQRNTPVYIAWLGGFLSITLISLLALVGVVLIPLMNRVCFNFLLSFLVALA 
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Figure 3.14 Alignment of ZIP6 in various animal species (continued) 
 
Human            366 VGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAVLEEEEVMIAHAHPQ 
Chimpanzee       366 VGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAVLEEEEVMIAHAHPQ 
Gorilla          366 VGTLSGDAFLHLLPHSHASHHHSHNHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAVLEEEEVMIAHAHPQ 
Orang-utan       354 VGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAILEEEEVMIAHAHPQ 
Marmoset         361 VGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEENAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDMDIKKQLSKYESQLSANEEKVDTDDRTEGYLRADSQEPSHCDSQQPAVLEEEEVMIAHAHPQ 
Gibbon           360 VGTLSGDAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDTDDRTEGYLQADSQEPSHFDSQQPAILEEEEVMIAHAHPQ 
Tasmanian Devil  333 VGTLSGDAFLHLLPHSHASHHHSHNHEDQPLQASRGPLFSHLSSQNIEESTYFDSTWKGLTALGGLYFMFLAEHLITLIKQFKDKKKKTQKKPESDDEMEIKKQLSKYESQLSTNEEKLDTDERPEGYIGAESQDPAHFDSQQPAVLEEEEVMIAHSHPQ 
Cat              346 VGTLSGDAFLHLLPHSHASHQHSHSHEEPAMEAKRGPLFSHLSSENIEESTYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKYESQLSTNEEKVDADDRPEGYLRADSQEPSHFDSQQPAILEEEEVMIAHAHPQ 
Dog              346 VGTLSGDAFLHLLPHSHASHHHSHSHEESAMEMKRGPLFSHLSSQNIEESTYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPETDDDVEIKKQLSKYESQLSTNEEKVDAEDRPEGYLRADSQEPSHFDSQQPAILEEEEVMIAHAHPQ 
Mouse            376 VGTLSGDALLHLLPHSHASHQHSHSHEEPAMEMKRGPLFSHLSAQNIEESSYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDEDVESKKQLSKYDSQLSSNEEKVDPGERPESYLRADSQEPSPFDSQQPTMLEEEEVMIAHAHPQ 
Rat              352 VGTLSGDALLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSAQNLEESSYFDSTWKGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDEDVESKKQLSKYESQLSTNEEKVDTGERPESYLQADSQEPSPFDSQQPTLLEEEEVMIAHAHPQ 
Zebrafish        394 VGTLSGDALLHLIPHSQGHHHHGHSEEH------------------AEEEDSLRPVWTGLTALSGVYIMFLIEHFLTLGKMYKDKNQKVQKRVDLTTEVLESEKLP----SLEENDVKIEAAETNGG----------------RALAEEEEVMLG----A 
 
 
Human            526 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Chimpanzee       526 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Gorilla          526 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Orang-utan       514 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Marmoset         521 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Gibbon           520 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Tasmanian Devil  493 EVYNEYVSRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Cat              506 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Dog              506 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Mouse            536 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Rat              512 EVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHPHSHSQR----YSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIFIGHY 
Zebrafish        512 ELYNDI---DCENKCHSHFHDTVGQSDEQHHHHHDYHHILHHHHSQNHHPHTHTHRHTHSYSQQHFEQAGVATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGLSTSVAVFCHELPHELGDFAVLLKAGMSVRQAMLYNLLSALMGYLGMIIGILIGHY 
 
 
Human            682 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
Chimpanzee       682 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
Gorilla          682 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
Orang-utan       670 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
Marmoset         677 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFLLQNAGMLLGFGIMLLISIFEHKIVFRINF 
Gibbon           676 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGMLLGFGIMLLISIFEHKIVFRINF 
Tasmanian Devil  649 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFLLQNAGILLGFGIMLLISVFEHKIVFSINF 
Cat              662 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGILLGFGIMLLISIFEHKIVFRINF 
Dog              662 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGILLGFGIMLLISIFEHKIVFRINF 
Mouse            692 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGILLGFGIMLLISIFEHKIVFRINF 
Rat              668 AENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQNAGILLGFGIMLLISIFEHKIVFRINF 
Zebrafish        669 AENVATWIFALTAGLFMYVALVDMVPEMLHNDASEAGFSHYGFFLLQNAGILLGFGIMLIIAVFEDRIQLDLGY 
 
Amino acid sequences of ZIP6 from mammals (human, chimpanzee, Sumatran orang−utan, marmoset, gibbon, Tasmanian Devil, cat, dog, mouse, and rat) and 
zebrafish were aligned using the TCoffee multiple sequence alignment program. Residues that were at least 70% identical (black) and complementary (grey) were 
shaded using the BoxShade 3.21 online program. The regions equivalent to the PEST site (the motifs underneath a green continuous line), the CPALLY motif (a 
blue box), the predicted TM regions (orange boxes), and the potential phosphorylation sites (red boxes with red arrows) in human ZIP6 are indicated. The PEST 
motifs were analysed using Emboss Pestfind platform (Rogers et al. 1986). 
TM2 TM3 
TM4 TM5 TM6 
TM8 TM7 
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Figure 3.15 The potential phosphorylation sites in ZIP6  
 
 
Human            465 EIKKQLSKYESQLSTNEEKV 
Chimpanzee       465 EIKKQLSKYESQLSTNEEKV 
Gorilla          465 EIKKQLSKYESQLSTNEEKV 
Orang-utan       453 EIKKQLSKYESQLSTNEEKV 
Marmoset         460 DIKKQLSKYESQLSANEEKV 
Gibbon           459 EIKKQLSKYESQLSTNEEKV 
Tasmanian Devil  432 EIKKQLSKYESQLSTNEEKL 
Cat              445 EIKKQLSKYESQLSTNEEKV 
Dog              445 EIKKQLSKYESQLSTNEEKV 
Mouse            475 ESKKQLSKYDSQLSSNEEKV 
Rat              451 ESKKQLSKYESQLSTNEEKV 
 
Amino acid sequences of ZIP6 from mammals (human, chimpanzee, Sumatran orang−utan, 
marmoset, gibbon, Tasmanian Devil, cat, dog, mouse, and rat) were aligned using the TCoffee 
multiple sequence alignment program. The region equivalent to residues 465−484 of human 
ZIP6 is shown. Residues that were at least 70% identical (black) and complementary (grey) 
were shaded using the BoxShade 3.21 online program. The serine and threonine residues 
equivalent to S471, S475, S478 and T479 of human ZIP6, which are potential phosphorylation 
sites in this region, are indicated in red boxes.  
 
Like ZIP7, a high degree of evolutionary conservation was observed in 
ZIP6 across different mammal species (Fig. 3.14). Residues S471, S475, and 
S478 were 100% identical, whereas residue T479 was 83.33% identical 
(Fig. 3.14 and 3.15). The high conservation of these potential phosphorylation 
sites identified these sites as important residues for ZIP6 functional control. 
  
S471 
T 
S475 
T 
S478 
T479 
3. Computational sequence analysis of ZIP channels  
 
 
94 
3.4 Chapter summary 
The computational sequence analysis of ZIP channels confirmed the 
unique characteristics of the LIV−1 subfamily among all the ZIP channels, as 
proposed in a previous study (Taylor and Nicholson 2003). The LIV−1 subfamily 
members had an apparently longer N−terminus than the other subfamilies 
(Fig. 3.5), suggesting a more complex post−translational control for these ZIP 
channels. Furthermore, the N−terminus of the LIV−1 subfamily members, 
except ZIP7 and ZIP13, contained a CPALLY motif, a sequence upstream of 
TM1 containing 3 consensus cysteine residues (Fig. 3.6). The presence of the 
cysteine residues in the CPALLY motif as well as another cysteine residue in 
TM5 might explain a mechanism whereby these ZIP channels control zinc 
movement through their pores (Taylor et al. 2007). Uniquely for the N−terminus 
of ZIP6 and ZIP10, there is a PEST motif (Rogers et al. 1986; Rechsteiner and 
Rogers 1996) (Fig. 3.7), consistent with the previous reports that highlight 
proteolytic cleavage as a key post−translational mechanism for ZIP6 and ZIP10 
(Ehsani et al. 2012; Hogstrand et al. 2013). Moreover, the HX repeats, which 
are generally detected in the cytosolic loop between TM3 and TM4, were 
notably present in the N−terminus and the extracytosolic loop between TM2 and 
TM3 of the majority of the LIV−1 subfamily (Fig. 3.8 and 3.9). Importantly, a 
HEXPHEXPHGD motif in TM5 was uniformly present in the LIV−1 subfamily 
and totally absent in all the other subfamilies, confirming its uniqueness for this 
subfamily (Taylor and Nicholson 2003) (Fig. 3.10). 
Furthermore, the exploration of phosphorylation sites revealed multiple 
sites in the cytosolic loop between TM3 and TM4 of ZIP3, ZIP4, ZIP6, ZIP7, and 
ZIP10, which had been confirmed by mass spectrometry in mammalian cells 
(Table 3.2; Fig. 3.11). The two adjacent serine residues in ZIP7, S275 and 
S276, were shown to be highly likely sites for CK2−mediated phosphorylation, 
and this has recently been confirmed using site−specific experiments (Taylor et 
al. 2012). Importantly, residue S478 on ZIP6 was predicted to be a 
CK2−phosphorylated site (Table 3.2; Fig. 3.11). This serine residue on ZIP6 
and the nearby residues, including S471, S475 and T479, were proved to be 
highly conserved across different mammal species (Fig. 3.14 and 3.15), 
implying that these residues might be important for the ZIP6 functional control. 
These potential sites on ZIP6 will be further investigated in Chapter 6 
4. Characterisation of pZIP7 antibody 
 
 
95 
 
 
 
 
 
 
 
 
 
 
Chapter 4:  
Characterisation of pZIP7 antibody 
  
4. Characterisation of pZIP7 antibody 
 
 
96 
4.1 Introduction 
In the previous chapter, the computational analysis demonstrated a 
number of different potential phosphorylation sites in ZIP3, ZIP4, ZIP6, ZIP7, 
and ZIP10. Among these sites, only the two residues in ZIP7, S275 and S276, 
have been experimentally confirmed by site−specific procedures to be 
phosphorylated by CK2, resulting in activation of ZIP7−mediated zinc release 
from the stores (Taylor et al. 2012). ZIP7 has been proposed to be involved in 
development of tamoxifen resistance in breast cancer cells and contributory to 
aggressive behaviours in the tamoxifen−resistant cells (Taylor et al. 2008b). 
Furthermore, ZIP7 gene expression is independently predictive of poor clinical 
outcome of breast cancer (Taylor et al. 2007; Nimmanon and Taylor 2015). An 
indicator of ZIP7 activity could therefore become clinically useful. Our group 
have developed a monoclonal antibody that recognises ZIP7 only when 
phosphorylated on residues S275 and S276. This chapter therefore aims to 
characterise this antibody by investigating the specificity of this antibody to this 
phosphorylated form of ZIP7 and its potential usefulness in determining ZIP7 
function. 
Firstly, to determine the specificity of this antibody, immunofluorescence 
was performed in the cells that were transfected with wild−type ZIP7, a ZIP7 
phosphomimetic mutant (S275D/S276D), and a ZIP7 phosphoablative mutant 
(S275A/S276A). Secondly, using immunofluorescence and Western blotting, 
the ability of this antibody to detect a ZIP7−mediated zinc wave following zinc 
treatment was investigated. Thirdly, its potential usefulness in recognising the 
increase in ZIP7 function in tamoxifen−resistant MCF−7 cells, or TAMR cells 
(Knowlden et al. 2003), was examined. Finally, the antibody was used to 
investigate two ZIP7 mutants, ZIP7 P190A and E363K, which have been 
reported in two patients suffering from an immunodeficiency disease.  
4.2 Materials and methods 
DNA constructs of ZIP7 S275A/S276A, P190A, and E363K had been 
inserted into an ampicillin−resistant pcDNA3.1/V5−His−TOPO plasmid vector, 
and were amplified by transformation of the single−use JM109 E. coli 
competent cells (Promega). Polymerase chain reaction (PCR) using a forward 
primer specific to ZIP7 and a BGH reverse primer confirmed the presence of the 
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correctly−orientated ZIP7 DNA in 1 out of 10 clone for ZIP7 S275A/S276A 
(Fig. 4.1A) and all clones for P190A and E363K (Fig. 4.1B). The plasmids of 
ZIP7 WT, S275A/S275A, S275D/S275D, P190A, and E363K were purified 
using the HiSpeed Plasmid Maxi Kit (Qiagen). The plasmid DNA solution was 
analysed with a UV spectrophotometer, showing OD260/OD280 ratios within a 
desirable range of 1.8−2.0, signifying the purity of the DNAs, and 
concentrations ranging from 0.74−3.50 µg/µL (Table 4.1). Additionally, the 
plasmid DNA was analysed with 1% agarose gel electrophoresis, showing a 
strong band between 5000-7000 bp (expected size = 6283 bp) (Fig 4.2).  
 
Figure 4.1 Bacterial transformation for ZIP7 mutants 
 
The JM109 E. coli competent cells were transformed with the pcDNA3.1/V5-His-TOPO that 
contains the DNA of ZIP7 S275A/S276A (A), and ZIP7 clinical mutants, P190A and E363K (B). 
Presence of the DNA inserts and their orientation in the plasmid vector were verified by PCR 
using a specific ZIP7 forward primer and a BGH reverse primer. The PCR products were 
separated by 1% agarose gel electrophoresis, revealing a band of approximately 900 bp 
(expected size = 903 bp), which was approximately the same size as the positive control. Clone 
10 of the S275A/S276A mutant, clone 1 of the P190A mutant, and clone 1 of the E363K mutant 
were selected for plasmid preparation.  
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Table 4.1 Concentrations and OD260/280 ratios of prepared plasmids 
Plasmid 
Concentration 
(µg/µL)  
OD260/280 
Ratio 
ZIP7 WT 1.12 1.931 
ZIP7 S275A S276A 3.50 2.000 
ZIP7 S275D S276D 0.74 1.900 
ZIP7 P190A 1.22 1.937 
ZIP7 E363K 1.16 1.966 
 
Figure 4.2 Plasmid preparation for wild−type and mutant ZIP7 constructs 
 
Plasmids of ZIP7 S275A/S276A and S275D/S276D mutants (A), as well as wild−type ZIP7 (WT) 
and the clinical mutants, P190A and E363K (B), were purified using the HiSpeed Plasmid Maxi 
Kit (Qiagen). The purified plasmid DNAs were analysed with 1% agarose gel electrophoresis, 
showing a strong band of between 5000-7000 bp (expected size = 6283 bp). 
 
Please refer to Chapter 2 for the methods of transfection and treatments 
(Section 2.1), immunofluorescence (Section 2.3), Western blotting (Section 2.4), 
flow cytometry (Section 2.5), and zinc assays (Section 2.6). 
4.3 Results and discussion 
4.3.1 Wild−type and mutant ZIP7 constructs are robustly transfected 
To verify the purified plasmids of ZIP7 constructs, immunofluorescence 
using a V5 antibody was performed. The V5 antibody targets the C−terminal V5 
tag of the plasmid constructs. Immunofluorescence images revealed that 
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20−30% of cells transfected with the ZIP7 S275A/S275A, S275D/S275D 
(Fig. 4.3A), P190A, and E363K (Fig. 4.4A) mutants expressed V5, suggesting a 
transfection rate of 20−30%. This transfection rate was comparable to that of 
wild−type ZIP7 (Fig. 4.3A and 4.4A). An ER−like localisation pattern of the 
recombinant proteins was observed in enlarged images of the transfected cells 
(Fig. 4.3B and 4.4B). This staining pattern was consistent with two previous 
studies in which wild−type ZIP7 recombinant protein was demonstrated to 
co−localise with Calreticulin, an ER marker, in CHO cells (Taylor et al. 2004) 
and the ER−located variant B of ZnT5 in HeLa cells (Thornton et al. 2011), 
confirming the ER localisation of ZIP7. 
 
Figure 4.3 A robust transfection of ZIP7 S275A/S276A and S275D/S276D  
 
MCF−7 cells were transfected with wild−type ZIP7 (WT) and ZIP7 mutants, S275A/S276A (AA) 
and S275D/S276D (DD). Immunofluorescence was performed using a V5 antibody, which was 
conjugated to Alexa Fluor 488 (green), with DAPI nuclear staining (blue). Representative 
microscopic views were captured using a 63x magnification lens. The images reveal that 
20%−30% of the cells are transfected with the ZIP7 mutants, as judged by positive V5 staining, 
which is comparable to the transfection with wild−type ZIP7 (A). Closer views of the transfected 
cells (B) reveal a robust expression of the recombinant proteins, with a typical ER−like 
localisation of ZIP7. 
Scale bar, 25 μm. 
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Figure 4.4 A robust transfection of ZIP7 P190A and E363K  
 
MCF−7 cells were transfected with wild−type ZIP7 (WT) and the ZIP7 clinical mutants, P190A 
and E363K. Immunofluorescence was performed using a V5 antibody, which was conjugated to 
Alexa Fluor 488 (green), with DAPI nuclear staining (blue). Representative microscopic views 
were captured using a 63x magnification lens. The images reveal that 20%−30% of the cells are 
transfected with the ZIP7 mutants, as judged by positive V5 staining, which is comparable to the 
transfection with wild−type ZIP7 (A). Closer views of the transfected cells (B) reveal a robust 
expression of the recombinant proteins, with a typical ER−like localisation of ZIP7. 
Scale bar, 25 μm. 
 
4.3.2 pZIP7 antibody binds ZIP7 when phosphorylated on S275/S276 
The pZIP7 antibody has been generated by the Biogenes GmbH 
Company against peptide TKEKQ pS pS EEEEK (positions 270−281) (Fig. 4.5). 
To determine the specificity of the antibody to this phosphorylated form of ZIP7, 
immunofluorescence was performed in cells transfected with different ZIP7 
constructs, including wild−type ZIP7, a ZIP7 phosphoablative mutant 
(ZIP7 S275A/S276A), or a phosphomimetic mutant (ZIP7 S275D/S276D). 
Noteworthy, in the ZIP7 phosphoablative mutant, residues S275 and S276 were 
substituted for alanine to prevent phosphorylation, whereas in the 
phosphomimetic mutant, these two residues were substituted for aspartate, 
which structurally mimics phosphoserine (Nordle Gilliver et al. 2010). A V5 
antibody was used to identify the recombinant proteins.  
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Figure 4.5 The peptide epitope of the pZIP7 antibody 
 
This schematic illustrates the predicted structure of ZIP7, which is located in the ER (Taylor and 
Nicholson 2003; Taylor et al. 2004) and activated by CK2−mediated phosphorylation on 
residues S275 and S276 (Taylor et al. 2012). A monoclonal antibody that recognises ZIP7 when 
residues S275 and S276 are phosphorylated have been developed. The epitope sequence of 
the antibody is TKEKQ pS pS EEEEK (positions 270−281). 
ER, the endoplasmic reticulum.  
 
The result revealed that 40% of the cells transfected with wild−type ZIP7 
(V5−positive cells) were positive for pZIP7 (Fig. 4.6). Percentage of the 
pZIP7−positive cells increased to virtually 100% in the cells transfected with the 
ZIP7 phosphomimetic mutant, but decreased to 0% in the cells transfected with 
the ZIP7 phosphoablative mutant (Fig. 4.6). The presence of some 
non−transfected cells with strong pZIP7 staining confirmed the negative pZIP7 
staining for the phosphoablative mutant (Fig. 4.6). Additionally, overlay images 
of the cells transfected with wild−type ZIP7 and the ZIP7 phosphomimetic 
mutant that were pZIP7−positive demonstrated that pZIP7 and V5 were 
co−localised, with an ER−like staining pattern (Fig. 4.6). Altogether, these 
findings suggested that the pZIP7 antibody could bind to either the 
phosphorylated form of wild−type ZIP7 or the phosphomimetic construct, but 
could not recognise the phosphoablative construct, indicating the specificity of 
this antibody to ZIP7 when residues S275 and S276 were phosphorylated.  
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Figure 4.6 pZIP7 antibody recognition of ZIP7 when phosphorylated  
 
MCF−7 cells were transfected with wild−type ZIP7, a ZIP7 phosphomimetic mutant 
(S275D/S276D), and a ZIP7 phosphoablative mutant (S275A/S276A). Immunofluorescence 
was performed using V5 and pZIP7 antibodies, which were conjugated to Alexa Fluor 488 
(green) and Alexa Fluor 594 (red), respectively, with DAPI nuclear staining (blue). 
Representative microscopic views were captured using a 63x magnification lens.  
Scale bar, 25 μm. 
 
4.3.3 pZIP7 antibody detects zinc−induced ZIP7 activation 
To investigate the ability of the antibody to recognise a ZIP7-mediated 
zinc wave after external zinc stimulation, immunofluorescence and Western 
blotting were performed in cells transfected with wild−type ZIP7. Using 
immunofluorescence, approximately 40% of the cells transfected with wild−type 
ZIP7, probed with V5, overexpressed pZIP7 before zinc treatment (Fig. 4.7). 
Percentage of the pZIP7−positive cells significantly increased to 58% as a 
result of 10−minute external zinc stimulation (Fig. 4.7). Zinc ionophore 
pyrithione was also added to the treatment to enhance ZIP7 activation, given 
that zinc pyrithione, not zinc alone, produced effects comparable to an external 
zinc stimulation at the same treatment duration (Taniguchi et al. 2013).   
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Figure 4.7 Increased ZIP7 phosphorylation after zinc stimulation  
 
MCF−7 cells were transfected with wild−type ZIP7 (WT) and were treated with 20 μM zinc plus 
10 μM sodium pyrithione for 10 minutes. Immunofluorescence was performed using V5 and 
pZIP7 antibodies, which were conjugated to Alexa Fluor 488 (green) and Alexa Fluor 594 (red), 
respectively, with DAPI nuclear staining (blue). A representative microscopic view captured 
using a 63x magnification lens is shown (A) with percentages of the transfected cells that are 
positive for pZIP7 demonstrated in a bar graph as mean of 4 representative fields ± standard 
error (B). Statistical significance is compared between the cells with and without zinc treatment. 
Scale bar, 25 μm. * p < 0.05.  
 
 
Using Western blotting, the total ZIP7 antibody (Taylor et al. 2008b) 
recognised protein bands at 40 and 35 kDa (Fig. 4.8), which were predicted to 
represent the recombinant ZIP7 containing a 5−kDa C−terminal V5 tag and the 
endogenous ZIP7, respectively. In contrast, the pZIP7 antibody recognised a 
distinct band at 48 kDa (Fig. 4.8). A 4−kDa change in size has been reported for 
phosphorylation on two serine residues in a protein molecule (Bin et al. 2011). 
The difference in size of the pZIP7 band from the upper total ZIP7 band by 
8 kDa (Fig. 4.8) therefore supported the presence of other phosphorylation sites 
in ZIP7 in addition to residues S275 and S276. Importantly, residues S293 and 
T294 were detected as potential phosphorylation sites in ZIP7 (Table 3.2; 
Fig. 3.11). Hypothetically, simultaneous phosphorylation on these two residues 
could be responsible for this big mobility shift on the blot (Fig. 4.8).  
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Figure 4.8 pZIP7 antibody detection of a distinct band at 48 kDa 
 
MCF−7 cells were transfected with wild−type ZIP7. Immunoblotting was performed using the 
pZIP7 and the total ZIP7 antibodies. A protein band of 48 kDa was detected with the pZIP7 
antibody, whereas protein bands of 40 and 35 kDa were detected with the total ZIP7 antibody. 
 
To confirm the immunofluorescence results, which demonstrated the 
ability of the pZIP7 antibody to detect zinc−activated ZIP7 (Fig. 4.7), a course of 
zinc treatment was performed in cells transfected with wild−type ZIP7. To verify 
the samples, Western blotting of pS473 AKT was performed first. AKT is a 
direct downstream effector of zinc release from cellular stores, which has been 
shown to be phosphorylated on S473 at 5 minutes after zinc treatment in 
MCF−7 cells transfected with wild−type ZIP7 (Taylor et al. 2012). This AKT 
activation is compatible with early CK2−mediated ZIP7 phosphorylation on 
residues S275 and S276, which was detected at 2 minutes after zinc treatment 
(Taylor et al. 2012). Given the instantaneous activation of AKT after zinc 
treatment, AKT phosphorylation was considered as a good indicator of the 
ZIP7−mediated zinc release from cellular stores. Consistent with the previous 
study, AKT activation was detected at 5 minutes after zinc treatment and 
became markedly increased at 10 minutes after zinc treatment (Fig. 4.9A). 
Probing with a V5 antibody confirmed the constant transfection levels in all the 
samples, and densitometric data normalised to V5 statistically confirmed the 
AKT activation at 5 minutes after zinc treatment (Fig. 4.9A). These data verified 
ZIP7 activation in these samples of zinc−treated cells.   
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Figure 4.9 pZIP7 antibody detection of zinc−activated ZIP7 
 
A. MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 
10 μM sodium pyrithione. Immunoblotting was performed using a pS473 AKT antibody. 
Protein bands of pS473 AKT (60 kDa) and β−actin (45 kDa) are demonstrated. 
Densitometric data normalised to V5 are shown in a bar graph as mean ± standard 
error (n = 3). Statistical significance is compared to time 0.  
* p < 0.05,  *** p < 0.001. 
B. MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 
10 μM sodium pyrithione. Immunoblotting was performed using the pZIP7 and the total 
ZIP7 antibodies. Protein bands of pZIP7 (48 kDa), total ZIP7 (40 kDa) and β−actin 
(45 kDa) are demonstrated. Densitometric data are shown in a bar graph as mean of 
pZIP7/total ZIP7 ratios ± standard error (n = 2). Statistical significance is compared to 
time 0.  
* p < 0.05,  ** p < 0.01. 
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Using these verified samples, Western blotting analysis of pZIP7 and 
total ZIP7 was performed. The Western blot showed a gradual increase in 
pZIP7 levels after zinc treatment (Fig. 4.9B). In contrast to the pZIP7 levels, 
total ZIP7 levels staged the same throughout the 20−minute course of zinc 
stimulation (Fig 4.9B). Densitometric data presented as pZIP7/total ZIP7 ratios 
detected significant ZIP7 phosphorylation at 2 minutes after zinc treatment 
(Fig. 4.9B). This ZIP7 activation at 2 minutes was compatible with the AKT 
activation at 5 minutes after zinc treatment (Fig. 4.9A). Collectively, these 
results demonstrated that the pZIP7 antibody was able to recognise ZIP7 
activation by phosphorylation on residues S275 and S276 after zinc stimulation, 
and was potentially useful for determination of ZIP7 activity. 
4.3.4 pZIP7 antibody detects increased ZIP7 activation in TAMR cells 
It has already been established that TAMR (tamoxifen−resistant) breast 
cancer cells, which derive from endocrine−sensitive MCF−7 cells (Knowlden et 
al. 2003), have increased cellular zinc levels, corresponding to the increase in 
ZIP7 protein levels in TAMR cells when compared to MCF−7 cells (Taylor et al. 
2008b). Exploiting this cell model, we examined the ability of the pZIP7 antibody 
to detect the increase in ZIP7 activity. We firstly tested three different 
zinc−selective dyes that had been widely used by zinc biologists, consisting of 
Zinquin (Kd for Zn2+ = 370nM, UV light), Fluozin−3 (Kd for Zn2+ = 15nM, green 
fluorescence), and Newport Green (Kd for Zn2+ = 1µM, green fluorescence). 
MCF−7 cells were transfected with wild−type ZIP7, treated with zinc for 30 
minutes, and analysed using FACS analysis in live cells.  
Using Zinquin, the fluorescence intensity gradually increased throughout 
the 30−minute course of zinc treatment (Fig. 4.10A). However, TPEN treatment 
failed to reverse the change and the difference in fluorescence intensity was not 
apparent between the transfected and the non−transfected cells (Fig. 4.10A), 
suggesting that Zinquin was neither specific nor sensitive to zinc. On the 
contrary, the fluorescence intensity of Fluozin−3 increased at 5 minutes after 
zinc treatment in both the transfected and the non−transfected cells, and the 
levels remained constantly high after 5 minutes (Fig. 4.10B). The fluorescence 
intensity was apparently higher in the transfected cells than in the 
non−transfected cells throughout the course of zinc treatment (Fig. 4.10B). The 
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rises in the intensity were completely abolished by zinc chelation (Fig. 4.10B). 
These data suggested that Fluozin−3 was both sensitive and specific to zinc 
and was potentially useful for future investigations. On the other hand, the 
fluorescence intensity of Newport Green slightly increased at 10 minutes after 
zinc stimulation for wild−type ZIP7 (Fig. 4.10C). The Newport Green 
fluorescence intensity apparently decreased to even below the baseline levels 
after zinc chelation (Fig. 4.10C). However, no remarkable change in 
fluorescence intensity of Newport Green was detected in the non−transfected 
control (Fig. 4.10C). The findings for Newport Green therefore suggested that 
this fluorescent dye was specific, but not sensitive, to zinc, consistent with its 
relatively high dissociation constant for zinc.  
Fluozin−3 is structurally related to calcium fluorescent probes fluo-3 and 
fluo-4, having chelator structure resembling calcium chelator BAPTA (Kikuchi et 
al. 2004). It has excitation and emission peaks at 494 nm and 518 nm, which 
are not altered by addition of zinc or any other transition metals, and its 
detection of zinc is not perturbed by high amounts of calcium or magnesium 
(Zhao et al. 2008). Weak fluorescence was induced by a high amount of 
calcium at 40 M, with substantially lower sensitivity reported for other metals 
(Gee et al. 2002). Given the specificity and sensitivity of Fluozin−3, it was 
selected for further investigation. 
To confirm the increased zinc levels in TAMR cells compared to MCF−7 
cells, TAMR cells were loaded with Fluozin−3 and imaged using fluorescence 
microscopy. All the microscopy and camera settings, particularly the exposure 
time, were kept the same for all the images in each experiment, to validate the 
comparison between different samples. TAMR cells were shown to have a slight 
increase in green fluorescent intensity, which signified a mild increase in cellular 
free zinc levels in the cells, when compared to MCF−7 cells (Fig. 4.11A). To 
semi−quantitatively compare the fluorescence intensity in these images, the 
total corrected cellular fluorescence (TCCF) was calculated using the equation 
TCCF = integrated density – (area of selected cell x mean background 
fluorescence) (McCloy et al. 2014). This calculation proved statistical 
significance of the small increase in the Fluozin−3 fluorescence intensity in 
TAMR cells when compared to MCF−7 cells (Fig. 4.11B).   
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Figure 4.10 Zinc measurement using different dyes 
 
MCF−7 cells were transfected with wild−type ZIP7 and loaded with Zinquin, Fluozin−3, or 
Newport Green. The cells were treated with 100 M zinc plus 10 μM sodium pyrithione in the 
medium with full serum. Fluorescence intensity was measured in live cells using FACS analysis. 
TPEN was added after the 30−minute course of zinc treatment. Geometric mean fluorescence 
intensities of Zinquin (A), Fluozin−3 (B), and Newport Green (C) in the transfected cells are 
demonstrated and compared to the non−transfected cells.  
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Figure 4.11 Increased zinc in TAMR cells suggested by zinc imaging 
 
MCF−7 cells and tamoxifen−resistant MCF−7 cells (TAMR cells) were loaded with Fluozin−3 
(green) and fixed in 4% formaldehyde. The nuclei were stain with DAPI (blue). A representative 
microscopic view was captured with a 63x magnification lens using the same exposure time and 
other settings (A). Fluorescence intensity was determined in at least 4 representative images 
using ImageJ software (Schneider et al. 2012). The total corrected cell fluorescence was 
calculated by subtracting the integrated density with the background intensity (McCloy et al. 
2014) and presented in a bar graph as mean ± standard error (B).  
Scale bar, 25 μm. * p < 0.05.  
 
To confirm the increased zinc levels in TAMR cells as shown using 
fluorescence microscopy, the fluorescent intensity was also measured using 
FACS analysis. Live cells were treated with zinc and TPEN, and zinc levels 
were presented as Fluozin−3 saturation, which was calculated using the 
equation Fluozin−3 saturation (%) =
𝐹−𝐹0
𝐹𝑚𝑎𝑥−𝐹0
𝑥100, where F = basal 
fluorescence intensity, F0 = minimum fluorescence intensity after TPEN 
treatment, and Fmax = maximum fluorescence intensity after zinc treatment 
(Qin et al. 2013). Fluozin−3 saturation in TAMR cells was 16%, which was 3 
times as high as MCF−7 cells (Fig. 4.12A). A course of zinc treatment was then 
performed. An increase in zinc levels as a result of zinc release from cellular 
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stores by ZIP7 was detected at 5 minutes after zinc treatment in both TAMR 
and MCF−7 cells, and the increase was reversed by zinc chelation, verifying the 
specificity of the dye to zinc (Fig. 4.12B). Furthermore, the Fluozin−3 
fluorescence intensity was higher in TAMR cells than in MCF−7 cells throughout 
the 30-minute course of zinc treatment (Fig. 4.12B). The results of zinc assays, 
both using fluorescence microscopy and FACS, therefore agreeably confirmed 
the significant increase in zinc levels in TAMR cells when compared to MCF-7 
cells. Nevertheless, zinc imaging was shown to be less effective than FACS in 
detection of the increased zinc levels in TAMR cells. 
 
Figure 4.12 Increased zinc in TAMR cells confirmed by FACS analysis 
 
MCF−7 cells and tamoxifen−resistant MCF−7 cells (TAMR cells) were loaded with fluozin−3 
(green), and treated with 20 μM zinc plus 10 μM sodium pyrithione. Fluorescence intensity was 
measured using FACS analysis. The cells were treated with TPEN at the end of the 30−minute 
course of zinc treatment, and the fluorescence intensity was measured at 10 minutes after 
TPEN treatment. Zinc levels are presented as saturation percentages, calculated using the 
equation Fluozin−3 saturation (%) =
𝐹−𝐹0
𝐹𝑚𝑎𝑥−𝐹0
𝑥100 (Qin et al. 2013) (A). Mean fluorescence 
intensities throughout the course of treatment are demonstrated as mean ± standard error (n = 
3) (B). Statistical significance is compared either between cell types (A) or to time 0 (B).  
* p < 0.05, *** p < 0.001.  
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This result was confirmed by another student in the group, Silvia Ziliotto, 
who compared ZIP7 activation in different cell lines, including TAMR cells and 
MCF−7 cells, using the pZIP7 antibody. Immunofluorescence of pZIP7 
demonstrated that virtually 100% of TAMR cells were positive for pZIP7, 
whereas only 8% of MCF−7 cells were seen to be pZIP7−positive (Fig. 4.13A). 
Confirming this increase in ZIP7 activation, Western blotting was performed. 
AKT activation was used as an indicator of ZIP7 activation, given that AKT is a 
direct downstream effector of ZIP7−mediated zinc release from cellular stores 
(Taylor et al. 2012). The Western blot of pAKT demonstrated a twofold increase 
in AKT activation when compared to MCF−7 cells (Fig. 4.13B). This increased 
AKT activation was compatible with the 3−fold increased zinc levels in TAMR 
cells observed in the Fluozin−3 assays using FACS (Fig. 4.12A) and suggestive 
of an increase in ZIP7 activity in TAMR cells when compared to MCF−7 cells. 
Importantly, the Western blot of pZIP7 showed that pZIP7 levels were 
significantly increased 8−fold in TAMR cells when compared to MCF−7 cells 
(Fig. 4.13C). Collectively, these data showed that the pZIP7 antibody was able 
to detect the increase in ZIP7 activation, and reflect the high zinc levels in 
TAMR cells. 
4.3.5 pZIP7 antibody detects impaired function of ZIP7 clinical mutants 
Two siblings who suffered from a blistering skin condition in the first few 
days of life have been observed with failure to thrive, (Hambleton S., personal 
communication). Family history indicated childhood blistering conditions on both 
sides of the family, and their maternal grandmother had been diagnosed with 
zinc deficiency. The blood profile of the patients revealed a marked increase in 
T−cell population with predominance of CD4−positive cells, and absence of B 
cells. The profile was compatible with Bruton agammaglobulinemia. A genetic 
test was performed at Newcastle University, showing a compound 
heterozygous mutation of ZIP7; one allele harboured a P190A mutation, and the 
other an E363K mutation. As part of collaboration with Newcastle University, 
recombinant ZIP7 DNA with each mutation was created from our wild−type ZIP7 
plasmid construct and sent to our laboratory group for further experimentation.  
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Figure 4.13 Detection of increased ZIP7 activity in TAMR cells 
 
As a part of Silvia Ziliotto’s project, immunofluorescence of pZIP7 (A) and immunoblotting of 
pAKT (B) and pZIP7 (C) were performed in MCF−7 cells and tamoxifen−resistant MCF−7 cells 
(TAMR cells). For immunofluorescence, the cells were immunostained using the pZIP7 
antibody, which was conjugated to Alexa Fluor 593 (Red), and the nuclei were stained with 
DAPI (blue). A representative microscopic view of MCF−7 and TAMR cells was captured using 
a 63x magnification lens (A), showing that 8.3% of MCF−7 cells and virtually 100% of TAMR 
cells are positive for pZIP7. For immunoblotting, protein bands of pS473 AKT (60 kDa), pZIP7 
(48 kDa), and β−actin (45 kDa) are demonstrated (B−C). Densitometric data of pAKT and 
pZIP7, normalised to β−actin, are presented in bar graphs as mean ± standard error (n = 3). 
Statistical significance is compared between the two cell types.  
Scale bar, 25 μm. ** p < 0.01, *** p < 0.001. Courtesy of Silvia Ziliotto. 
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The mutations of P190A and E363K are located in TM2 and TM5, 
respectively (Fig. 4.14). Both of these TMs are highly conserved across the 
LIV−1 subfamily of ZIP channels (Fig. 3.3). The E363K mutation interestingly 
involves the LIV−1 subfamily consensus motif HEXPHEXGD in TM5, which is 
also a potential zinc−binding region that is essential for zinc transport (Taylor 
and Nicholson 2003) (Fig. 4.14). The potential effect of the E363K mutation on 
the zinc transport function of ZIP7 is therefore reasonable. Glutamate (E) is a 
negatively charged amino acid that has a high affinity towards zinc ions, 
whereas lysine (K) is a positively charged amino acid that cannot bind to zinc 
(Trzaskowski et al. 2008). In as much as the zinc−binding amino acid glutamate 
is located in the potential zinc−transport region (Taylor and Nicholson 2003), its 
substitution for a non−zinc−binding amino acid lysine would reasonably interfere 
with the zinc−transport function of the channel. In contrast to the E363K 
mutation, the P190 mutation does not directly affect the notable zinc−binding 
site in TM5. Nevertheless, according to an amino acid sequence analysis 
comparing the sequences of the ZIP channels to the 
haemagglutininesterase−fusion glycoprotein of influenza C virus, TM2 was 
predicted to interact with TM5 in maintaining the pore region in the tertiary 
structure of the ZIP channels in the LIV−1 subfamily (Taylor and Nicholson 
2003). Moreover, transmembrane helix kinks, which are crucial for membrane 
protein structure, typically occur at proline residues (Yohannan et al. 2004). As 
a result, a mutation affecting the residue P190 could have some negative effect 
on the conformation and the pore generation of ZIP7, thereby adversely 
influencing the function of ZIP7 in mobilising zinc across the ER membrane.  
The purified plasmids of ZIP7 P190A and E363K were verified for their 
transfection efficiency and their expression within the cells by 
immunofluorescence using a V5 antibody. The result revealed that both these 
mutant constructs were robustly transfected into cells (Fig. 4.4). Furthermore, 
an ER−like staining pattern was also observed for these mutant constructs, 
suggesting that the mutations did not affect ZIP7 in terms of its protein 
production, stability, or delivery to the ER membrane. 
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Figure 4.14 Locations of the ZIP7 P190A and E363K mutations 
 
This figure illustrates the predicted structure of ZIP7, with mutation sites and amino acid 
sequences of the ZIP7 clinical mutants, P190A and E363K, indicated. The mutations are 
located in TM2 and TM5, respectively. Importantly, both the residues P190 and E363 are 100% 
identical across the LIV−1 subfamily of ZIP channels, and the residue E363 involves the second 
glutamate residue of the LIV−1 subfamily consensus motif HEXPHEXGD.  
ER, the endoplasmic reticulum; N, the amino−terminus; C, the carboxyl−terminus. 
 
 
4.3.5.1 Both ZIP7 P190A and E363K are able to produce a zinc wave 
To investigate the effects of the ZIP7 clinical mutants on zinc 
homeostasis, free zinc levels in the cytosol after stimulation of ZIP7−mediated 
zinc release from cellular stores were determined. MCF−7 cells were 
transfected with ZIP7 P190A and E363K, and loaded with Fluozin−3. The 
fluorescence intensity was determined using FACS analysis. The Fluozin−3 
fluorescence intensity in the cells transfected with wild−type ZIP7 was 
significantly increased at 5 minutes after zinc stimulation (Fig. 4.15), consistent 
with the ZIP7−mediated zinc release from cellular stores (Taylor et al. 2012). 
The rise in fluorescence intensity was successfully abolished by zinc chelation 
(Fig. 4.15). The cells transfected with either mutant also demonstrated a 
dramatic increase in fluorescence intensity, which was comparable to wild−type 
ZIP7 and responsive to zinc chelation (Fig 4.15). However, the increase did not 
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show a statistical significance, except for ZIP7 P190A at 10 minutes after zinc 
stimulation (Fig 4.15). In contrast, the non−transfected cells showed a slight 
increase in zinc levels with no statistical significance, and zinc chelation 
resulted in an apparent decrease in zinc levels (Fig 4.15). These findings 
therefore suggested that the two ZIP7 mutants were able to transport zinc in a 
manner comparable to wild−type ZIP7. However, because of the variability of 
the zinc levels before zinc treatment, a statistically significant increase was 
seen only at 10 minutes for ZIP7 P190A, and was not detected at any time point 
for ZIP7 E363K (Fig 4.15). This might imply that regardless of the increase in 
zinc levels after zinc treatment, both these mutants had impaired zinc release 
function compared to wild−type ZIP7, and ZIP7 P190A functioned better than 
ZIP7 E363K. 
 
Figure 4.15 Zinc wave production by the ZIP7 P190A and E363K mutants 
 
MCF−7 cells were transfected with wild-type ZIP7 (WT) and the ZIP7 clinical mutants, P190A 
and E363A. The cells were loaded with Fluozin−3, and treated with 100 M zinc plus 10 μM 
sodium pyrithione in the medium with full serum. Fluorescence intensity was measured in live 
cells using FACS analysis. TPEN was added at the end of the 15−minute course of zinc 
treatment. Geometric mean fluorescence intensities are demonstrated in a bar graph as mean ± 
standard error (n = 3). Statistical significance is compared to time 0.  
* p < 0.05.  
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Additionally, immunofluorescence in cells transfected with the ZIP7 
P190A and E363K mutants and loaded with Fluozin−3 was also performed to 
image the transfected cells, expecting to visualise the difference in zinc levels 
between the transfected and the non−transfected cells in the same fields 
(Fig 4.16). Nevertheless, no change in fluorescence intensities of Zinquin and 
Fluozin−3 could be seen in either the cells transfected with wild−type ZIP7 or 
the ZIP7 mutants, when compared to the adjacent non−transfect cells in the 
same visual fields (Fig 4.16). One possible explanation was that the dyes were 
leaked out from the cells during the immunostaining steps, which required a 
permeabilising agent to allow the V5 antibody to bind the recombinant proteins.  
4.3.5.2 ZIP7 E363K shows less AKT activation than ZIP7 P190A  
AKT activation was detected in MCF−7 cells that had been transfected 
with wild−type ZIP7 at 5 minutes after zinc treatment (Taylor et al. 2012). This 
AKT activation was delayed to 10 minutes after zinc treatment in the cells 
transfected with ZIP7 S275A/S276A, a phosphoablative mutant which cannot 
be phosphorylated on residues S275 and S276 (Taylor et al. 2012). This delay 
in the AKT activation suggests that the ZIP7 phosphoablative mutant did not 
activate AKT, and that the endogenous ZIP7 did after 10 minutes. The AKT 
activation was again employed as an indicator of ZIP7 activity in the 
investigation of the effects of the Z190A and E363K mutations on 
ZIP7−mediated zinc release from cellular stores, using Western blotting. 
In the cells transfected with wild−type ZIP7, pAKT levels started to 
increase at 2 minutes after zinc treatment (Fig. 4.17A, B). The levels reached 
the peak at 10 minutes and remained constantly high until 20 minutes after zinc 
treatment (Fig. 4.17A, B). For ZIP7 S275A/S276A, which was used as a 
negative control, the transfected cells demonstrated a gradual increase in pAKT 
levels at 2 and 5 minutes after zinc stimulation (Fig. 4.17A, B). The levels were 
unexpectedly higher than that for wild−type ZIP7 (Fig. 4.17A, B). Interestingly, 
although high variability was observed, the pAKT levels for ZIP7 S275A/S276A 
slightly decreased at 10 minutes and dramatically decreased, becoming 
significantly less than wild−type ZIP7, at 15 and 20 minutes after zinc 
stimulation, (Fig. 4.17A, B).  
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Figure 4.16 Zinc imaging in cells transfected with ZIP7 P190A and E363A  
 
MCF-7 cells were transfected with wild−type ZIP7 (WT) and the ZIP7 clinical mutants, P190A 
and E363A. These ZIP7 constructs contained a C−terminal V5 tag. The cells were loaded with 
Zinquin (25µM, blue) and Fluozin-3 (5µM, green), treated with 20 μM zinc plus 10 μM sodium 
pyrithione, and fixed in 4% formaldehyde. Immunofluorescence was performed using a V5 
antibody, which was conjugated to Alexa Fluor 594 (red). Representative microscopic views 
were captured using a 63x magnification lens. The result reveals no definite alteration in zinc 
content in the transfected (V5−positive) cells. 
Scale bar, 25 μm. 
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Like wild−type ZIP7, both the clinical mutants showed marked increases 
in pAKT levels up to 10 minutes after zinc stimulation (Fig. 4.17A, B). The pAKT 
levels for the ZIP7 P190A mutant did not change after 10 minutes, whereas, like 
the ZIP7 S275A/S276A mutant, the pAKT levels for the ZIP7 E363K mutant 
dramatically decreased and became significantly lower than the levels for 
wild−type ZIP7 (Fig. 4.17A, B).  
 
Figure 4.17 Ability of the ZIP7 P190A and E363K mutants to activate AKT 
 
MCF−7 cells were transfected with wild−type ZIP7 (WT) and ZIP7 mutants S275A/S276A (AA), 
P190A, and E363K. The cells were treated with 20 μM zinc plus 10 μM sodium pyrithione. 
Immunoblotting was performed using a pS473 pAKT antibody with a β−actin antibody for 
normalisation. Protein bands of pS473 pAKT (60 kDa) and β−actin (45 kDa) are demonstrated 
as representative results of 3 independent experiments (A). Densitometric data normalised to 
β−actin are demonstrated in a bar graph as mean ± standard error (n = 3) (B). Statistical 
significance is compared to wild−type ZIP7.  
* p < 0.05.  
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In summary, this experiment demonstrated that the ZIP7 P190A mutant, 
which showed an AKT activation pattern comparable to wild−type ZIP7, could 
transport zinc more effectively than the ZIP7 E363K mutant, which showed an 
AKT activation pattern similar to the ZIP7 S275A/S276A mutant. Noteworthy, no 
bands were detected at time 0 at the exposure times used to detect the signals 
because of the tremendous AKT activation as a result of zinc treatment, and the 
very low basal levels of AKT activation at time 0 in comparison with the 
zinc−activated levels. The pAKT levels during the course of zinc treatment were 
therefore compared to wild−type ZIP7 at the same time points rather than 
comparing to time 0. Moreover, there was a discrepancy between the 
representative blot and the densitometric data shown in the figure because of 
the high variability of the results. 
4.3.5.3 pZIP7 antibody detects halted ZIP7 P190A and E363K activation 
Residues P190 and E363 are not in the same region as residues S275 
and S276. Nevertheless, a conformational change caused by the P190A and 
E363K mutations might interfere with CK2 binding and thereby prevent ZIP7 
phosphorylation on residues S275 and S276. To investigate whether the 
mutations adversely affected ZIP7 phosphorylation after zinc treatment, 
Western blotting using the pZIP7 antibody was performed in the cells 
transfected with the ZIP7 S275A/S276A, P190A, and E363K mutants. 
Confirming a previous experiment in this chapter (Fig. 4.9B), a typical activation 
pattern of ZIP7 was seen in the cells transfected with wild−type ZIP7 
(Fig. 4.18A, B). A similar pattern of ZIP7 activation was also detected for ZIP7 
P190A, but with no statistical significance (Fig. 4.18A, B). In contrast, both 
ZIP7 E363K and S275A/S276A failed to demonstrate an increase in pZIP7 
levels after zinc stimulation (Fig. 4.18A, B). These findings suggested that the 
E363K mutation interfered with the CK2−mediated phosphorylation on the 
residues S275 and S276 to an extent comparable to the S275A/S276A 
mutation, whereas the P190A mutation affected this CK2−mediated 
phosphorylation to a lesser extent. Importantly, the Western blotting of pZIP7 
was consistent with the Western blotting of pAKT, showing the impaired 
function for both of ZIP7 P190A and E363K, with the P190A mutant working 
better than the E363K mutant did, thereby further suggesting the potential 
usefulness of this antibody.  
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Figure 4.18 Activation of the ZIP7 P190A and E363K mutants by zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 (WT) and ZIP7 mutants S275A/S276A (AA), 
P190A, and E363K. The cells were treated with 20 μM zinc plus 10 μM sodium pyrithione. 
Immunoblotting was performed using the pZIP7 antibody with a β−actin antibody for 
normalisation. Protein bands of pZIP7 (48 kDa) and β−actin (45 kDa) are demonstrated as 
representative results of at least 3 independent experiments (A). Densitometric data normalised 
to β−actin are demonstrated in a bar graph as mean ± standard error (n = 3) (B). Statistical 
significance is compared to time 0.  
* p < 0.05.  
 
It is noteworthy that without zinc treatment, the pZIP7 levels for 
ZIP7 E363K and S275A/S276A were consistently higher than the levels for 
wild−type ZIP7 and ZIP7 P190A. This surprisingly high basal ZIP7 activation for 
either ZIP7 S275A/S276A or E363K was consistent with a previous study that 
showed apparently high phospho−serine levels in the cells transfected with 
ZIP7 S275A/S276A at time 0 (Taylor et al. 2012). One plausible explanation 
was that the prolonged overexpression of these non−functioning ZIP7 mutants 
during the overnight transfection might have resulted in an increase in 
transcription of the endogenous ZIP7 as a compensatory mechanism.  
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To confirm the Western blotting of pZIP7 in the cells expressing 
wild−type ZIP7 and the ZIP7 clinical mutants, immunofluorescence using the 
anti−pZIP7 antibody was performed in the transfected cells with 10−minute zinc 
treatment. A V5 antibody was also applied for identification of the transfected 
cells. For wild−type ZIP7, percentage of the transfected cells that were positive 
for pZIP7 increased from 40% before zinc treatment to 58% after zinc treatment 
(Fig. 4.19A). In contrast, only 8% and 3% of the cells transfected with 
ZIP7 S275A/S276A were pZIP7−positive before and after zinc stimulation 
respectively (Fig. 4.19B). Noteworthy, the ZIP7 positivity in the cells 
overexpressing ZIP7 S275A/S276A was comparable to the basal ZIP7 
activation in the non−transfected non−treated MCF−7 cells (Fig. 4.13A).  
For the clinical mutants, 38% of the cells overexpressing ZIP7 P190A 
(Fig. 4.19C) and 37% of the cells overexpressing ZIP7 E363K were positive for 
pZIP7 (Fig. 4.19D). The positivity rates in the clinical mutants were comparable 
to the cells transfected with wild−type ZIP7, which had 40% positivity 
(Fig. 4.19C). However, neither of the mutants showed an increase in pZIP7 
positivity after zinc stimulation (Fig. 4.19C, D). These data suggested that the 
clinical mutants could be recognised by the pZIP7 antibody. However, the 
mutations significantly interfered with the zinc−induced CK2−mediated 
phosphorylation on residues S275 and S276 of ZIP7. Importantly, given that the 
antibody did not detect the ZIP7 activation in these mutants, it might be implied 
that this antibody was able to indicate the impairment of ZIP7 function, even 
though it was not able to detect the difference between the two clinical mutants. 
The discrepancy between the results from the immunofluorescence and the 
Western blotting might be due to the less sensitivity and the non−quantitative 
nature of the immunofluorescence technique. 
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Figure 4.19 Impaired activation for the ZIP7 P190A and E363K mutants 
 
MCF−7 cells were transfected with wild−type ZIP7 (WT) and ZIP7 mutants ZIP7 S275A/S276A 
(AA), P190A, and E363K. The cells were treated with 20 μM zinc plus 10 μM sodium pyrithione. 
Immunofluorescence was performed using V5 (green) and pZIP7 (red) antibodies, which was 
conjugated to Alexa Fluor 488 (green) and Alexa Fluor 594 (red), respectively, with DAPI 
nuclear staining (blue). A representative microscopic view of wild−type ZIP7 (A), ZIP7 AA (B), 
ZIP7 P190A (C), and ZIP7 E363K (D) captured using a 63x magnification lens is presented. The 
percentages of the transfected cells that are positive for pZIP7 are shown in bar graphs as 
mean of 4 representative fields ± standard error. Statistical significance is compared to time 0.  
Scale bar, 25 μm. * p < 0.05.   
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All the results for the ZIP7 clinical mutants, P190A and E363K, are 
summarised in Table 4.2. Both of the clinical mutants were able to mobilise zinc 
ions from the stores and able to produce a zinc wave, although the increase in 
zinc levels was not significant. However, the ZIP7 E363K mutant showed 
impaired ZIP7 activation by phosphorylation on residues S275 and S276. This 
impaired ZIP7 activation by the E363K mutation was consistent with a 
significant decrease in AKT activation when compared to wild−type ZIP7 at 15 
minutes after zinc treatment. In contrast, the ZIP7 P190A mutant could be 
phosphorylated on residues S275 and S276 after zinc stimulation, although no 
statistical significance was observed. Moreover, the P190A mutant could 
activate AKT after zinc stimulation to the extent comparable to wild−type ZIP7. 
These results collectively suggested that the ZIP7 P190A mutant had less 
functional impairment than the ZIP7 E363K mutant, further supporting the 
crucial involvement of the HEXPHEXGD motif in TM5 in the zinc transport 
(Taylor and Nicholson 2003). Importantly, the pZIP7 antibody was able to reflect 
the functional impairment of these two mutants, and when using the Western 
blotting technique, this antibody could even demonstrate the superior 
functionality of ZIP7 P190A over E363K. These data therefore further supported 
the potential usefulness of this antibody in determining ZIP7 function. 
 
Table 4.2 Result summary for ZIP7 P190A and E363K 
Changes after zinc stimulation 
ZIP7 constructs 
WT P190A E363K AA 
Increase in zinc level    – 
AKT activation     
ZIP7 activation (by Western blotting)    
ZIP7 activation (by immunofluorescence)    
 
The changes for wild−type ZIP7 as reference. 
 The changes comparable to wild−type ZIP7. 
 The changes significantly less than wild−type ZIP7. 
 No change detected. 
– Not investigated 
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4.4 Chapter summary 
This chapter has provided pieces of evidence supporting that our pZIP7 
antibody is both specific to the S275/S276−phosphorylated form of ZIP7 and 
potentially useful for determining ZIP7 function. Using an immunofluorescence 
technique, the specificity of the antibody was confirmed by its ability to 
recognise ZIP7 when residues S275 and S276 were mutated to aspartate, 
which structurally mimics phosphoserine (Fig. 4.6). In contrast, the mutation of 
these residues to alanine, a non−phosphorylatable amino acid, could prevent 
the binding of the antibody (Fig. 4.6). Using the same technique, there was a 
significant increase in the percentage of cells transfected with wild−type ZIP7 
that were pZIP7−positive, suggesting the ability of the antibody to detect ZIP7 
activation upon 10−minute zinc treatment (Fig. 4.7).  
Employing the Western blotting technique, an 8 kDa mobility shift of the 
pZIP7 band (at 48 kDa) when compared to the total ZIP7 band (at 40 kDa) was 
observed (Fig. 4.8). Furthermore, the pZIP7 levels were significantly increased 
at 2 minutes after zinc treatment when normalised to the total ZIP7 levels 
(Fig. 4.9), confirming that the antibody could detect a zinc wave. The ZIP7 
activation at 2 minutes after zinc treatment was consistent with a previous 
report (Taylor et al. 2012) and compatible with the AKT activation at 5 minutes 
after zinc treatment both in this project (Fig. 4.9) and in the previous report 
(Taylor et al. 2012). The ability of the antibody to determine ZIP7 activity was 
further highlighted by the finding that the pZIP7 levels were significantly 
increased in TAMR cells when compared to the parental MCF−7 cells (Fig. 4.12 
and 4.13), consistent a previous report of an increase in pZIP7 activity in TAMR 
cells (Taylor et al. 2008b). Additionally, this antibody was also able to detect 
impaired ZIP7 function in the two ZIP7 clinical mutants, P190A and E363K 
(Fig. 4.15−4.19; Table 4.2). Collectively, the data in this chapter confirmed the 
potential usefulness of this pZIP7 antibody for determining ZIP7 activity. 
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5.1 Introduction 
ZIP7 is ubiquitously expressed, ER membrane−located, and functionally 
triggered by phosphorylation (Taylor et al. 2004; Taylor et al. 2008b; Taylor et 
al. 2012). ZIP7 has therefore been designated as a gatekeeper for zinc release 
from cellular stores and a hub of cellular tyrosine kinase activation (Hogstrand 
et al. 2009). The activation of cellular tyrosine kinases is thought to be mainly 
through the inhibitory effect of zinc ions that have been released from cellular 
stores on protein tyrosine phosphatases, such as protein tyrosine phosphatase 
1B (Haase and Maret 2005; Bellomo et al. 2014). Notably, protein tyrosine 
phosphatases are strongly inhibited even by the physiologically−relevant 
nanomolar levels of zinc ions (Wilson et al. 2012).  
Our group have previously revealed that 20−min zinc treatment in 
tamoxifen−resistant MCF−7 breast cancer cells resulted in activating 
phosphorylation of both receptor tyrosine kinases (RTKs), namely EGFR 
(ErbB1), ErbB2, ErbB3, ErbB4, and IGF−1R, and a non−receptor tyrosine 
kinase, namely Src (Taylor et al. 2008b). Importantly, ZIP7 knockdown by 
transfection with ZIP7 siRNA was shown in the same study to prevent the 
phosphorylation of EGFR, IGF−1R, and Src, proving the ZIP7 dependency of 
the activation of these signalling molecules. All of these downstream effectors of 
ZIP7−mediated zinc release from cellular stores are among the known 
substrates of protein tyrosine phosphatase 1B (Bourdeau et al. 2005), and 
responsible for the aggressive behaviours of breast cancer cells that have 
acquired tamoxifen resistance (Taylor et al. 2008b). The activation of these 
tyrosine kinases in turn results in activation of ERK1/2 and AKT, which have 
been shown to be phosphorylated when ZIP7 is triggered by CK2−mediated 
ZIP7 phosphorylation on residues S275 and S276 (Taylor et al. 2012).  
To gain a deeper understanding of the role of ZIP7−mediated zinc 
signalling, this chapter aimed to explore other cellular kinases that are potential 
downstream effectors of ZIP7−mediated zinc release from cellular stores, 
employing antibody arrays for tyrosine phosphorylation of human receptor 
tyrosine kinases and site−specific phosphorylation of multiple cellular kinases. 
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5.2 Materials and methods 
The antibody arrays that were used consisted of the human 
phospho−receptor tyrosine kinase (RTK) (R&D Systems, ARY001B), 
phospho−mitogen−activated protein kinase (MAPK) (R&D Systems, ARY002B) 
and phospho−kinase (R&D Systems, ARY003B) antibody arrays. Increases in 
phosphorylation of some kinases according to the array signals were confirmed 
using Western blotting. Please refer to Chapter 2 for the methods of transfection 
and treatments (Section 2.1), antibody array procedures (Section 2.9) and 
Western blotting (Section 2.4). The antibodies used for Western blotting are 
listed in Tables 2.1 and 2.2.  
5.3 Results and discussion 
To explore potential target molecules of ZIP7−mediated zinc release 
from cellular stores, ZIP7 was overexpressed in MCF−cells by wild−type ZIP7 
transfection. Furthermore, ZIP7 was also activated by treating the cells with 
exogenous zinc. This zinc treatment has been shown to trigger ZIP7−mediated 
zinc release from cellular stores, resulting in activation of cellular kinases 
(Taylor et al. 2012). According to this previous study, CK2 binds to ZIP7 and 
induces ZIP7 activation by phosphorylation on residues S275 and S276 at 2 
minutes after zinc treatment, resulting in AKT activation at 5 minutes in cells 
transfected with wild−type ZIP7 and at 10 minutes in cells transfected with ZIP7 
S275A/S276A, which is a ZIP7 null mutant. The same study also showed that 
the activation at 10 minutes in the cells transfected with the ZIP7 null mutant is 
attributed to the action of endogenous ZIP7 in the cells. To allow adequate time 
for zinc release from cellular stores and phosphorylation of kinases with limited 
activation of downstream pathways triggered by zinc−activated kinases, the 
treatment was performed for 10 minutes. 
Three different types of antibody arrays were utilised: the phospho−RTK 
arrays, the phospho−kinase arrays, and the phospho−MAPK arrays. Using 
these arrays, phosphorylation of as many as 49 RTKs (the phospho−RTK 
arrays), 43 cellular kinases with 2 related total proteins (the phospho−kinase 
arrays), and 26 MAPKs with related kinases (the phospho−MAPK arrays) could 
be simultaneously investigated. For each type of array, the data are presented 
in four figures and a table. These four figures include (1) images of the signals 
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on the arrays (Fig. 5.1, 5.5 and 5.9), (2) a bar graph showing densitometric 
values of the pairs of corresponding duplicate dots for all the kinases detected 
(Fig. 5.2, 5.6 and 5.10), (3) a heat map generated from the densitometric data 
(Fig. 5.3, 5.7 and 5.11), and (4) a bar graph showing densitometric values for 
the kinases that were classified as “marked increase” (see definition below) 
(Fig. 5.4, 5.8 and 5.12). Noteworthy, a heat map graphically presents relative 
values of different types of samples for individual kinases as colours, where 
blue colour represents the lowest value in the row and red colour represents the 
highest value in the row according to the indicated scale (Fig. 5.3, 5.7 and 
5.11). However, the values in the rows do not give any representation of 
abundance.  
In addition, the table for each type of the arrays indicates the kinases that 
are phosphorylated as a result of either wild−type ZIP7 transfection or zinc 
treatment (Table 5.1−5.3). In each table, the kinases were arbitrarily divided into 
2 groups, based on the differences in signal density: marked increase (> 10,000 
density units) and mild increase (2,000−10,000 density units). To reduce false 
positive results due to the variability of background intensity, the differences by 
less than 2,000 units were considered negative. 
5.3.1 Multiple RTKs are phosphorylated by ZIP7 overexpression or zinc 
The phospho−RTK arrays detected only the presence of tyrosine 
phosphorylation of different RTKs, with no specific phosphorylated residues 
identified. In MCF−7 cells without treatment or transfection, the arrays detected 
tyrosine phosphorylation of ErbB3 (Fig. 5.1−5.3). ZIP7 overexpression was 
shown to decrease tyrosine phosphorylation of ErbB3, but caused a 18−fold 
increase in tyrosine phosphorylation of EGFR (Fig. 5.1−5.4, Table 5.1). 
Confirming a previous study in our group (Taylor et al. 2008b), 10−minute zinc 
treatment induced tyrosine phosphorylation of EGFR, ErbB2, ErbB3, and ErbB4 
(Fig. 5.1−5.4, Table 5.1). Furthermore, the treatment also caused marked 
increases (>10,000 density units) in ALK, EphA1, and RYK tyrosine 
phosphorylation (Fig. 5.1−5.4, Table 5.1), whereas only mild increases 
(2,000−10,000 density units) were seen for Axl, c−Ret, EphA4, EphA7, Flt−3, 
FGFR3, IGF−1R, and Tie−1 tyrosine phosphorylation (Fig. 5.1−5.4, Table 5.1).  
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Figure 5.1 Phospho−RTK arrays in MCF−7 stimulated with ZIP7 and zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Tyrosine phosphorylation of selected receptor tyrosine 
kinases (RTKs) was determined using the human phospho−RTK antibody arrays (R&D 
Systems). Signals for each tyrosine kinase are presented as a pair of duplicate spots, with three 
pairs of dark reference spots on the upper left, upper right, and lower left corners for alignment. 
The kinases that show conspicuous changes in tyrosine phosphorylation (>10,000 density units) 
in the non−transfected zinc−treated cells (MCF−7 + Zn) or the transfected non−treated cells 
(WT−ZIP7) when compared to the non−transfected non−treated cells (MCF−7) are indicated. In 
addition, the kinases that show increases in tyrosine phosphorylation in the transfected 
zinc−treated cells (WT−ZIP7 + Zn) when compared to the non−transfected zinc−treated cells 
(MCF−7 + Zn) are also indicated. 
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Figure 5.2 Densitometric analysis of phospho−RTK arrays in MCF−7 stimulated with ZIP7 and zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM sodium pyrithione for 10 minutes. Tyrosine phosphorylation of selected 
receptor tyrosine kinases (RTKs) was determined using the human phospho−RTK antibody arrays (R&D Systems). Densitometric data are presented as mean of the 
duplicate dots for each kinase. 
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Figure 5.3 A heat map of phospho−RTKs activated by ZIP7 or zinc 
  
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylated receptor tyrosine kinases (RTKs) were 
determined using the human phospho−RTK antibody arrays (R&D Systems). The heat map was 
generated using a GENE−E matrix visualization and analysis platform (The Board Institute). 
Densitometric values in relation to other samples for each kinase are presented as a spectrum 
of colour where blue colour represents the lowest value in the row and red colour represents the 
highest value in the row according to the indicated scale, irrespective of the absolute signal 
intensities. 
 
 
 
Wild−type ZIP7 transfection plus zinc treatment resulted in marked 
increases in tyrosine phosphorylation (>10,000 density units) of ALK, EGFR, 
ErbB2, EphA7, and FGFR3, with mild increases in tyrosine phosphorylation 
(2,000−10,000 density units) of c−Ret, IGF−1R, and Flt−3, when compared to 
the zinc−treated MCF−7 cells (Fig. 5.1−5.4, Table 5.1). These increases in 
tyrosine phosphorylation further confirmed the involvement of ZIP7 in the 
tyrosine phosphorylation of these kinases. On the contrary, the dependency 
upon ZIP7 function of tyrosine phosphorylation of Axl, ErbB3, ErbB4, EphA1, 
EphA4, RYK, and Tie−1 could not be confirmed, suggesting the possible 
presence of an alternative pathway that could activate these kinases without a 
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need for ZIP7−mediated zinc release from cellular stores. Collectively, these 
results detected activation of eight RTKs as a result of both ZIP7 
overexpression and zinc treatment. Importantly, three of these RTKs, namely 
EGFR, ErbB2, and IGF−1R, had been experimentally demonstrated to be 
downstream effectors of ZIP7−mediate zinc release from cellular stores (Taylor 
et al. 2008b). 
 
Figure 5.4 RTKs activated by ZIP7 or zinc (increases by >10,000 units) 
 
MCF−7 cells were transfected with wild−type ZIP7 (WT−ZIP7) and treated with 20 μM zinc plus 
10 μM sodium pyrithione for 10 minutes. Tyrosine phosphorylation of selected receptor tyrosine 
kinases (RTKs) was determined using the human phospho−RTK antibody arrays (R&D 
Systems). Average densities of the duplicate spots for the kinases that show conspicuous 
increases in tyrosine phosphorylation (>10,000 density units) in the non−transfected 
zinc−treated cells (MCF−7 + Zn) or the transfected non−treated cells (WT−ZIP7) when 
compared to the non−transfected non−treated cells (MCF−7) are demonstrated. In addition, the 
kinases that show increases in tyrosine phosphorylation in the transfected zinc−treated cells 
(WT−ZIP7 + Zn) when compared to the non−transfected zinc−treated cells (MCF−7 + Zn) are 
also included. 
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Table 5.1 RTKs phosphorylated by ZIP7 overexpression or zinc 
RTKs phosphorylated by ZIP7 overexpression a 
   
Marked increase: 
(> 10,000 units) 
ALK 
EGFR 
ErbB2 
EphA7 
FGFR3 
   
Mild increase: 
(2,000−10,000 units) 
c−Ret 
IGF−1R 
Flt−3 
   
 
RTKs phosphorylated by zinc b 
   
Marked increase: 
(> 10,000 units) 
ALK 
EGFR 
ErbB2 
ErbB3 
ErbB4 
EphA1 
RYK 
   
Mild increase: 
(2,000−10,000 units) 
Axl 
c-Ret 
EphA4 
EphA7 
Flt−3 
FGFR3 
IGF−1R 
Tie−1 
   
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Tyrosine phosphorylation of selected receptor tyrosine 
kinases (RTKs) was determined using the human phospho−RTK antibody arrays (R&D 
Systems). Average densities of the duplicate spots for the kinases were determined. 
 
a “Marked increase” and “mild increase” are arbitrarily judged by the increases in tyrosine 
phosphorylation in the transfected zinc−treated cells when compared to the non−transfected 
zinc−treated cells according to densitometric analysis as indicated. In addition, the kinases that 
show increases in tyrosine phosphorylation in the transfected non−treated cells when compared 
to the non−transfected non−treated cells are also included. 
b “Marked increase” and “mild increase” are arbitrarily judged by the increases in tyrosine 
phosphorylation in the non−transfected zinc−treated cells when compared to the 
non−transfected non−treated cells according to densitometric analysis as indicated. 
The kinases that are underlined are tyrosine−phosphorylated by either zinc alone.  
The kinases that are shown in regular formatting are tyrosine−phosphorylated by both zinc and 
ZIP7 overexpression. 
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5.3.2 Multiple kinases are phosphorylated by ZIP7 overexpression or zinc 
To extend the exploration to cellular kinases other than RTKs, we 
employed the phospho−kinase arrays to determine activation of up to 43 
different cellular kinases with 2 related total proteins. In contrast to the 
phospho−RTK arrays, the phospho−kinase arrays also indicated specific 
phosphorylated residues in the kinases. Many kinases were already 
phosphorylated in MCF−7 cells without zinc treatment or ZIP7 overexpression 
(Fig. 5.5). As a result of transfection with wild−type ZIP7, the arrays revealed 
apparent increases in phosphorylation (>10,000 density units) of c−Jun (S63), 
CREB (S133), p70 S6 (T421/S424), STAT2 (Y689), STAT5a (Y694), and 
WNK1 (T60), when compared to the MCF−7 cells without transfection 
(Fig. 5.5−5.8, Table 5.2). Furthermore, mild decreases in phosphorylation 
(2,000−10.000 density units) were also observed for p53 (S392), p38α MAPK 
(T180/Y182), Chk−2 (T68), HSP27 (S78/S82), STAT6 (Y641), PDGFRβ (Y751), 
Hck (Y411), JNK (T183/Y185, T221/Y223), and PRAS40 (T246), when 
compared to the MCF−7 cells without transfection (Fig. 5.5−5.8, Table 5.2). 
Among these increases, either marked or mild, statistical significance compared 
to the MCF−7 cells without transfection was detected only for the HSP27 
(S78/S82) phosphorylation (Fig. 5.8). Noteworthy, a replicate revealed an 
increase in AMPKα1 phosphorylation by 40,014 density units as a result of ZIP7 
overexpression. However, this increase was not reproducible, since the other 
batch directly contradicted this increase by instead showing a marked decrease.  
As a result of zinc treatment, phosphorylation of AKT (S473), AMPKα2 
(T172), CREB (S133), GSK−3α/β (S21/S9), HSP27 (S78/S82), JNK 
(T183/Y185, T221/Y223), p38α MAPK (T180/Y182), p70 S6 (T421/S424), 
STAT2 (Y689), STAT5a (Y694), STAT5a/b (Y694/Y699), and STAT5b (Y699) 
was markedly increased (>10,000 density units) (Fig. 5.5−5.8, Table 5.2). On 
the contrary, only mild increases in phosphorylation (2,000−10.000 density 
units) were observed for c-Jun (S63), EGFR (Y1086), ERK1/2 (T202/Y204, 
T185/Y187), FAK (Y397), Fgr (Y412), MSK1/2 (S376/S360), Lck (Y394), 
PRAS40 (T246), RSK (S380/S386/S377), STAT6 (Y641), and TOR (S2448) 
(Fig. 5.5−5.8, Table 5.2). Among these kinases, only the increases in 
GSK−3α/β, HSP27, JNK, p38α MAPK, and STAT5a phosphorylation were 
statistically significant (Fig. 5.8).   
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To investigate whether the increases following zinc treatment were 
mediated by ZIP7, cells were both transfected with wild−type ZIP7 and treated 
with zinc. Among the kinases activated by zinc, phosphorylation levels of CREB 
(S133), GSK−3α/β (S21/S9), HSP27 (S78/S82), p70 S6 (T421/S424), PRAS40 
(T246), and WNK1 (T60) were markedly increased (>10,000 density units) 
when compared to the non−transfected zinc−treated MCF−7 cells. On the 
contrary, phosphorylation levels of AKT (S473), c−Jun (S63), ERK1/2 
(T202/Y204, T185/Y187), FAK (Y397), JNK (T183/Y185, T221/Y223), and 
STAT5a (Y694) were mildly increased (2,000−15,000 density units) when 
compared to the non−transfected zinc−treated MCF−7 cells (Fig. 5.5−5.8, 
Table 5.2). These increases confirmed that the phosphorylation of these 
kinases was ZIP7−dependent. However, only the increase in STAT5a (Y694) 
phosphorylation was statistically significant (Fig. 5.8). Unexpectedly, p38α 
MAPK (T180/Y182), which showed a marked increase in phosphorylation 
following ZIP7 overexpression in the cells without zinc treatment, revealed a 
marked decrease in phosphorylation in the ZIP7−overexpressing zinc−treated 
cells when compared to the non−transfected zinc−treated cells (Fig. 5.8). 
However, due to the high variation of the data between the duplicates, this 
decrease was not statistically significant (Fig. 5.8). 
Interestingly, multiple kinases were shown to be phosphorylated as a 
result of ZIP7 overexpression in the zinc−treated cells, with no discernible 
increases in phosphorylation as a result of zinc treatment alone. Among these 
notable kinases, p53 (S46) and p53 (S392) were markedly phosphorylated 
(>10,000 density units), whilst AKT (T308), Chk−2 (T68), Hck (Y411), HSP60, 
Lyn (Y397), p70 S6 (T421/S424), and Yes (Y426) were mildly phosphorylated 
(2,000−10,000 density units) (Fig. 5.5−5.8, Table 5.2). Unexpectedly, total 
β−Catenin levels were also markedly increased (>10,000 density units) as a 
result of ZIP7 transfection plus zinc treatment, when compared to zinc treatment 
alone (Fig. 5.5−5.8, Table 5.2). These data therefore revealed not only the 
kinases that were phosphorylated through the ZIP7−mediated zinc−dependent 
mechanism, but also the kinases that might be phosphorylated through an 
alternative ZIP7−mediated pathway independently of zinc. Noteworthy, because 
of the high variability between the two batches of the phospho−kinase arrays, 
the statistical analysis was rather limited.  
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Figure 5.5 Phospho−kinase arrays in MCF−7 stimulated with ZIP7 and zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected kinases was determined using 
the human phospho−kinase antibody arrays (R&D Systems). Signals for each kinase are 
presented as a pair of duplicate spots, with three pairs of dark reference spots on the upper left, 
upper right, and lower left corners for alignment. The kinases that show conspicuous changes in 
phosphorylation (>10,000 density units) in the non−transfected zinc−treated cells (MCF−7 + Zn) 
or the transfected non−treated cells (WT−ZIP7) when compared to the non−transfected 
non−treated cells (MCF−7) are indicated. In addition, the kinases that show increases in 
phosphorylation in the transfected zinc−treated cells (WT−ZIP7 + Zn) when compared to the 
non−transfected zinc−treated cells (MCF−7 + Zn) are also indicated. 
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Figure 5.6 Densitometric analysis of phospho−kinase arrays in MCF−7 stimulated with ZIP7 and zinc (1/3) 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM sodium pyrithione for 10 minutes. Phosphorylation of selected kinases at 
the residues indicated below the names of the kinases was determined using the human phospho−kinase antibody arrays (R&D Systems). Densitometric data are 
presented as mean of the duplicate dots for each kinase ± standard error (n=2). 
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Figure 5.6 Densitometric analysis of phospho−kinase arrays in MCF−7 stimulated with ZIP7 and zinc (continued, 2/3) 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM sodium pyrithione for 10 minutes. Phosphorylation of selected kinases at 
the residues indicated below the names of the kinases was determined using the human phospho−kinase antibody arrays (R&D Systems). Densitometric data are 
presented as mean of the duplicate dots for each kinase ± standard error (n=2). 
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Figure 5.6 Densitometric analysis of phospho−kinase arrays in MCF−7 stimulated with ZIP7 and zinc (continued, 3/3) 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM sodium pyrithione for 10 minutes. Phosphorylation of selected kinases at 
the residues indicated below the names of the kinases was determined using the human phospho−kinase antibody arrays (R&D Systems). Densitometric data are 
presented as mean of the duplicate dots for each kinase ± standard error (n=2). 
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Figure 5.7 A heat map of phospho−kinases activated by ZIP7 or zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected kinases at the residues indicated 
was determined using the human phospho−kinase antibody arrays (R&D Systems). The heat 
map was generated using a GENE-E matrix visualization and analysis platform (The Board 
Institute). Densitometric values in relation to other samples for each kinase are presented as a 
spectrum of colour where blue colour represents the lowest value in the row and red colour 
represents the highest value in the row according to the indicated scale, irrespective of the 
absolute signal intensities.   
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Figure 5.8 Kinases activated by ZIP7 or zinc (increases by >10,000 units) 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected kinases at the residues indicated 
below the names of the kinases was determined using the human phospho−kinase antibody 
arrays (R&D Systems). Average densities of the duplicate spots for the kinases that show 
conspicuous increases in phosphorylation (>10,000 density units) in the non−transfected 
zinc−treated cells (MCF−7 + Zn) or the transfected non−treated cells (WT−ZIP7) when 
compared to the non−transfected non−treated cells (MCF−7) are demonstrated. In addition, the 
kinases that show increases in phosphorylation in the transfected zinc−treated cells 
(WT−ZIP7 + Zn) when compared to the non−transfected zinc−treated cells (MCF−7 + Zn) are 
also included. Densitometric data are presented as mean ± standard error (n=2). 
* p < 0.05, ** p < 0.01  
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Table 5.2 Kinases phosphorylated by ZIP7 overexpression or zinc 
Kinases phosphorylated as a result of ZIP7 overexpression a 
   
Marked increase: 
(> 10,000 units) 
c−Jun (S63) 
CREB (S133) 
GSK−3α/β (S21/S9) 
HSP27 (S78/S82) 
p53 (S15) 
p53 (S46) 
p53 (S392) 
p70 S6 (T421/S424) 
PRAS40 (T246) 
STAT2 (Y689) 
STAT5a (Y694) 
WNK1 (T60) 
β−Catenin 
Mild increase: 
(2,000−10,000 units) 
AKT (S473) 
AKT (T308) 
Chk−2 (T68) 
ERK1/2  
(T202/Y204,T185/Y187) 
FAK (Y397) 
Hck (Y411) 
HSP60 
JNK 
(T183/Y185,T221/Y223) 
Lyn (Y397) 
p38α MAPK (T180/Y182) 
p70 S6 (T389) 
PDGFRβ (Y751) 
STAT6 (Y641) 
Yes (Y426) 
   
 
Kinases phosphorylated as a result of zinc treatment b 
   
Marked increase: 
(> 10,000 units) 
AKT (S473) 
AMPKα2 (T172) 
CREB (S133) 
GSK−3α/β (S21/S9) 
HSP27 (S78/S82) 
JNK  
(T183/Y185,T221/Y223) 
p38α MAPK (T180/Y182) 
p70 S6 (T421/S424) 
STAT2 (Y689) 
STAT5a (Y694) 
STAT5a/b (Y694/Y699) 
STAT5b (Y699) 
WNK1 (T60) 
   
Mild increase: 
(2,000−10,000 units) 
c-Jun (S63) 
EGFR (Y1086) 
ERK1/2 
(T202/Y204,T185/Y187) 
FAK (Y397) 
Fgr (Y412) 
MSK1/2 (S376/S360) 
Lck (Y394) 
PRAS40 (T246) 
RSK (S380/S386/S377) 
STAT6 (Y641) 
TOR (S2448) 
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MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected kinases was determined using 
the human phospho−kinase antibody arrays (R&D Systems). Average densities of the duplicate 
spots for the kinases were determined. 
 
a “Marked increase” and “mild increase” are arbitrarily judged by the increases in 
phosphorylation in the transfected zinc−treated cells when compared to the non−transfected 
zinc−treated cells according to densitometric analysis as indicated. In addition, the kinases that 
show increases in phosphorylation in the transfected non−treated cells when compared to the 
non−transfected non−treated cells are also included. 
b “Marked increase” and “mild increase” are arbitrarily judged by the increases in 
phosphorylation in the non−transfected zinc−treated cells when compared to the 
non−transfected non−treated cells according to densitometric analysis as indicated. 
The kinases that are in bold are phosphorylated by ZIP7 overexpression alone. 
The kinases that are underlined are phosphorylated by zinc alone. 
The kinases that are shown in regular formatting are phosphorylated by both zinc and ZIP7 
overexpression. 
 
 
The phosphorylation of AKT (S473) and ERK1/2 (T202/Y204) as a result 
of ZIP7 overexpression or zinc treatment (Fig. 5.5−5.8, Table 5.2) has 
previously been shown to result from ZIP7−mediated zinc release from cellular 
stores (Taylor et al. 2008b), which is triggered by CK2−mediated 
phosphorylation of ZIP7 on residues S275 and S276 (Taylor et al. 2012). The 
zinc−induced phosphorylation or p70 S6 (T421/S424), ERK1/2 (T202/Y204), 
JNK (T183/Y185), and p38α MAPK (T180/Y182) (Fig. 5.5−5.8, Table 5.2) has 
also been reported in SH-SY5Y neuroblastoma cells using Western blotting in a 
previous study that linked this phosphorylation to the pathogenesis of 
Alzheimer’s disease (An et al. 2005). Importantly, the phospho−kinase array 
data further suggested that this phosphorylation of p70 S6, ERK1/2, JNK, and 
p38α MAPK was mediated by ZIP7. Noteworthy, the zinc−induced 
phosphorylation of AKT on T308, which was reported in the previous study (An 
et al. 2005), was not detected by the phospho−kinase arrays (Fig. 5.5−5.8, 
Table 5.2). However, this phosphorylation was shown to be induced by ZIP7 
overexpression using these arrays (Fig. 5.5−5.8, Table 5.2).  
The phosphorylation of p38 MAPK as a result of zinc treatment and 
HSP27 as a result of both zinc treatment and ZIP7 overexpression 
(Fig. 5.5−5.8, Table 5.2) needs to be considered because of the fact that these 
proteins are related to cell stress (Coulthard et al. 2009; Vidyasagar et al. 
2012). Their activation might suggest cell stress caused by the procedure of 
transfection or zinc treatment. Nevertheless, these two stress−related proteins 
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have also been reported to play important roles in other cellular processes. 
Importantly, both p38 MAPK (Hong et al. 2014) and HSP27 (Wei et al. 2011) 
have been reported to promote breast cancer migration and metastasis. Given 
that ZIP7 is a zinc channel that contributes to breast cancer aggressiveness 
particularly in endocrine−resistant cell lines (Taylor et al. 2008b), these two 
kinases might in fact be involved in the carcinogenetic pathways that were 
triggered by ZIP7−mediated zinc release from cellular stores, rather than the 
experimentally−induced cell stress. 
Interestingly, the phosphorylation of p53 on S15, S46, and S392 was 
shown to be solely ZIP7−dependent, with no any effect from zinc treatment 
(Fig. 5.5−5.8, Table 5.2). S46−phosphorylated p53 has been associated with its 
ability to bind to apoptosis−related genes (Smeenk et al. 2011) and 
S15−phosphorylated p53 has been shown to be triggered preceding the p53 
phosphorylation on S46 in the apoptotic process (Perfettini et al. 2005). This 
finding from the phospho−kinase arrays might therefore imply an ongoing 
apoptotic process induced by ZIP7 overexpression, which might or might not be 
confounded by the transfection procedure. In contrast to the phosphorylation on 
S46 and S15, the p53 phosphorylation on S392 has been controversially 
reported both to suppress and to promote tumorigenesis, and is under ongoing 
investigations (Dai and Gu 2010), supporting the involvement of ZIP7−mediated 
zinc signalling in cancer pathogenesis.  
5.3.3 Multiple MAPKs are phosphorylated by ZIP7 overexpression or zinc 
To confirm the activation of various cellular kinases and to explore the 
activation of more isoforms of MAPKs, the phospho−MAPK arrays were 
employed. Like the phospho−kinase arrays, the phospho−MAPK arrays not only 
indicated phosphorylation of kinases, but also specified the residues in the 
kinases that were phosphorylated. In the resting state, phosphorylation of 
GSK−3α/β (S21/S9), HSP27 (S78/S82), and p70 S6 (T421/S424) was detected 
(Fig. 5.9). Outstandingly, ZIP7 overexpression alone could markedly induce 
phosphorylation of GSK−3α/β (S21/S9) and p70 S6 (T421/S424) with increases 
in signal intensity by >10,000 density units. Furthermore, ZIP7 overexpression 
also mildly induced phosphorylation of HSP27 (S78/S82), CREB (S133), and 
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ERK1 (T202/Y204) with increases in signal intensity by 2,000−10,000 density 
units (Fig. 5.9−5.12, Table 5.3). 
Consistent with the phospho−kinase array data, the phospho−MAPK 
arrays revealed many kinases that were phosphorylated as a result of zinc 
treatment. AKT (S473, S474, S472), AKT1 (S473), AKT2 (S474), CREB (S133), 
ERK1 (T202/Y204), GSK−3α/β (S21/S9), HSP27 (S78/S82), JNK (T183/Y185, 
T221/Y223), and p70 S6 (T421/S424) were shown to have marked increases in 
phosphorylation (>10,000 density units) when compared to the MCF−7 cells 
without treatment or transfection (Fig. 5.9−5.12, Table 5.3). On the contrary, 
ERK2 (T185/Y187), JNK2 (T183/Y185), MSK2 (S360), and p38α (T180/Y182) 
were shown to have mild increases in phosphorylation (2,000−10,000 density 
units) when compared to the MCF−7 cells without treatment or transfection 
(Fig. 5.9−5.12, Table 5.3). Among these kinases, all the kinases that were 
markedly phosphorylated as a result of ZIP7 overexpression in the non−treated 
cells again revealed marked increases (>10,000 density units) in 
phosphorylation as a result of ZIP7 overexpression in the zinc−treated cells, 
except ERK1 (T202/Y204), which showed only a mild increase (2,000−10,000 
density units) (Fig. 5.9−5.12, Table 5.3). In addition, mild increases in 
phosphorylation (2,000−10,000 density units) of ERK2 (T185/Y187), JNK 
(T183/Y185, T221/Y223) and JNK2 (T183/Y185) were also seen in the 
ZIP7−overexpressing zinc−treated cells when compared to the non−transfected 
zinc−treated cells (Fig. 5.9−5.12, Table 5.3). Collectively, these data confirmed 
substantial ZIP7 involvement in the phosphorylation of these kinases on the 
particular sites. 
Agreeing with the phospho−kinase data, the phosphorylation of p53 
(S46) was induced specifically by wild−type ZIP7 transfection with no changes 
observed as a result of zinc treatment (Fig. 5.9−5.12, Table 5.3), again raising 
the question of whether the transfection procedure confounded the experiment. 
Moreover, the phosphorylation of the cell stress−related proteins, p38 MAPK 
and HSP27 (S78/S82), which resulted from zinc treatment or ZIP7 
overexpression, was also confirmed (Fig. 5.9−5.12, Table 5.3). Cell stress 
induced by the experiments therefore needed to be carefully considered. 
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Figure 5.9 Phospho-MAPK arrays in MCF−7 stimulated with ZIP7 and zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected mitogen−activated protein 
kinases (MAPKs) was determined using the human phospho−MAPK antibody arrays (R&D 
Systems). Signals for each kinase are presented as a pair of duplicate spots, with three pairs of 
dark reference spots on the upper left, upper right, and lower left corners for alignment. The 
kinases that show conspicuous changes in phosphorylation (>10,000 density units) in the 
non−transfected zinc−treated cells (MCF−7 + Zn) or the transfected non−treated cells 
(WT−ZIP7) when compared to the non−transfected non−treated cells (MCF−7) are indicated. In 
addition, the kinases that show increases in phosphorylation in the transfected zinc−treated 
cells (WT−ZIP7 + Zn) when compared to the non−transfected zinc−treated cells (MCF−7 + Zn) 
are also indicated. 
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Figure 5.10 Densitometric analysis of phospho−MAPK arrays in MCF−7 stimulated with ZIP7 and zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM sodium pyrithione for 10 minutes. Phosphorylation of selected 
mitogen−activated protein kinases (MAPKs) at the residues indicated below the names of the kinases was determined using the human phospho−MAPK antibody 
arrays (R&D Systems). Densitometric data are presented as mean of the duplicate dots for each kinase. 
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Figure 5.11 A heat map of phospho−MAPKs activated by ZIP7 or zinc 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected mitogen−activated protein 
kinases (MAPKs) at the residues indicated was determined using the human phospho−MAPK 
antibody arrays (R&D Systems). The heat map was generated using a GENE-E matrix 
visualization and analysis platform (The Board Institute). Densitometric values in relation to 
other samples for each kinase are presented as a spectrum of colour where blue colour 
represents the lowest value in the row and red colour represents the highest value in the row 
according to the indicated scale, irrespective of the absolute signal intensities. 
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Figure 5.12 MAPKs activated by ZIP7 or zinc (increases by >10,000 units) 
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected mitogen−activated protein 
kinases (MAPKs) at the residues indicated below the names of the kinases was determined 
using the human phospho−MAPK antibody arrays (R&D Systems). Average densities of the 
duplicate spots for the kinases that show conspicuous increases in phosphorylation (>10,000 
density units) in the non−transfected zinc−treated cells (MCF−7 + Zn) or the transfected 
non−treated cells (WT−ZIP7) when compared to the non−transfected non−treated cells 
(MCF−7) are demonstrated. In addition, the kinases that show increases in phosphorylation in 
the transfected zinc−treated cells (WT−ZIP7 + Zn) when compared to the non−transfected 
zinc−treated cells (MCF−7 + Zn) are also included.  
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Table 5.3 MAPKs phosphorylated by ZIP7 overexpression or zinc 
MAPKs phosphorylated as a result of ZIP7 overexpression a 
   
Marked increase: 
(> 10,000 units) 
AKT (S473,S474,S472) 
AKT1 (S473) 
AKT2 (S474) 
CREB (S133) 
ERK1 (T202/Y204) 
GSK−3α/β (S21/S9) 
HSP27 (S78/S82) 
p70 S6 (T421/S424) 
   
Mild increase: 
(2,000−10,000 units) 
ERK2 (T185/Y187) 
JNK 
(T183/Y185,T221/Y223) 
JNK2 (T183/Y185) 
p53 (S46) 
 
   
 
MAPKs phosphorylated as a result of zinc treatment b 
   
Marked increase: 
(> 10,000 units) 
AKT (S473,S474,S472) 
AKT1 (S473) 
AKT2 (S474) 
CREB (S133) 
ERK1 (T202/Y204) 
GSK−3α/β (S21/S9) 
HSP27 (S78/S82) 
JNK 
(T183/Y185,T221/Y223) 
p70 S6 (T421/S424) 
 
   
Mild increase: 
(2,000−10,000 units) 
ERK2 (T185/Y187) 
JNK2 (T183/Y185) 
MSK2 (S360) 
p38α MAPK (T180/Y182) 
   
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected mitogen−activated protein 
kinases (MAPKs) was determined using the human phospho−MAPK antibody arrays (R&D 
Systems). Average densities of the duplicate spots for the kinases were determined. 
 
a “Marked increase” and “mild increase” are arbitrarily judged by the increases in 
phosphorylation in the transfected zinc−treated cells when compared to the non−transfected 
zinc−treated cells according to densitometric analysis as indicated. In addition, the kinases that 
show increases in phosphorylation in the transfected non−treated cells when compared to the 
non−transfected non−treated cells are also included. 
b “Marked increase” and “mild increase” are arbitrarily judged by the increases in 
phosphorylation in the non−transfected zinc−treated cells when compared to the 
non−transfected non−treated cells according to densitometric analysis as indicated. 
The kinases that are in bold are phosphorylated by ZIP7 overexpression alone. 
The kinases that are underlined are phosphorylated by zinc alone. 
The kinases that are shown in regular formatting are phosphorylated by both zinc and ZIP7 
overexpression. 
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5.3.4 Western blotting verifies kinase activation by zinc or ZIP7 
To confirm the phosphorylation of the potential kinases as a result of zinc 
treatment or ZIP7 overexpression, Western blotting was performed. Given that 
zinc treatment more effectively induced phosphorylation of the majority of the 
kinases according to the antibody array results, the treatment was performed 
first to verify the activation using Western blotting. The kinases that could be 
confirmed to be zinc−activated would then be further investigated with wild−type 
ZIP7 transfection. This initial investigation included only the kinases that were 
shown to be apparently phosphorylated as a result of both ZIP7 overexpression 
and zinc treatment by either the phospho−kinase arrays or the phospho−MAPK 
arrays. The kinases selected for this investigation consisted of CREB (S133), 
p70 S6 (T421/S424), and WNK1 (T60). Given that the increase in STAT5 
phosphorylation was shown to be significant following both zinc treatment and 
ZIP7 overexpression regardless of the low amplitudes of the changes (Fig. 5.8), 
this kinase was also investigated. Phosphorylation of AKT and GSK−3β was 
included as positive controls, because they have previously been confirmed to 
be phosphorylated as a result of zinc treatment (An et al. 2005; Taylor et al. 
2008b), with a link to ZIP7 (Taylor et al. 2008b) and ZIP6 (Hogstrand et al. 
2013), respectively.  
Using our pZIP7 antibody, Western blotting demonstrated a significant 
increase in ZIP7 phosphorylation on residues S275 and S276 (Fig 5.13A). 
Confirming the previous studies (An et al. 2005; Taylor et al. 2008b) and the 
phospho−kinase array results, AKT (Fig 5.13B) and GSK−3β (Fig 5.13C) were 
shown to be significantly phosphorylated on residues S473 and S9, 
respectively, as a result of zinc treatment. Furthermore, a 3−fold increase in 
CREB phosphorylation (Fig 5.13D) and a 2−fold increase in p70 S6 
phosphorylation (Fig 5.13E) were also shown to be statistically significant, 
supporting the findings of the phospho−kinase arrays. On the contrary, only a 
mild increase in STAT5 phosphorylation was detected without statistical 
significance (Fig 5.13F). Noteworthy, no band was detected on the Western blot 
of WNK1, possibly due to the relatively high molecular weight of WNK1 
(250 kDa), which might have been lost during the transfer process when using 
the current Western blotting conditions.   
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Figure 5.13 Confirmation of zinc stimulation of kinase phosphorylation 
 
Representative blots are shown of the MCF−7 cells treated with 20 μM zinc plus 10 μM sodium 
pyrithione for 10 minutes, harvested, lysed, and probed for pS275/S276 ZIP7 (A), pS473 AKT 
(B), pS9 GSK−3β (C), pS133 CREB (D), pT421/S424 p70 S6 (E), and pS726 STAT5 (F). 
Densitometric data normalised to GAPDH are shown as mean ± standard error (n = 3). 
Statistical significance is compared between the zinc−treated cells (Zinc) and the non−treated 
cells (Con). 
** p < 0.01, *** p < 0.001 
 
To determine the link of ZIP7 to the phosphorylation of these kinases, 
Western blotting was performed in cells transfected with wild−type ZIP7. 
Because the increase in STAT5 phosphorylation could not be confirmed, 
STAT5 was not included in this experiment. Confirming the robustness of ZIP7 
transfection, the pZIP7 levels were significantly increased (Fig 5.14A). Mild 
increases in the levels of pAKT (Fig 5.14B) and pGSK−3β (Fig 5.14C) were also 
displayed and were also shown to be significant, proving the relationship of AKT 
phosphorylation with ZIP7 (Taylor et al. 2008b) and introducing ZIP7 to the 
pathways involved in GSK−3β phosphorylation, in addition to ZIP6 (Hogstrand 
et al. 2013). No change in phosphorylation was observed for CREB (Fig 5.14D). 
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In contrast, a significant 1.8−fold increase in phosphorylation was detected for 
P70 S6 as a result of ZIP7 overexpression (Fig 5.14E), proving the ZIP7 
dependency of the phosphorylation of P70 S6 and agreeing with the 
phospho−kinase and phospho−MAPK array data.  
 
Figure 5.14 Confirmation of ZIP7 stimulation of kinase phosphorylation 
 
Representative blots are shown of the MCF−7 cells transfected with wild−type ZIP7 for 16−24 
hours, harvested, lysed, and probed for pS275/S276 ZIP7 (A), pS473 Akt (B), pS133 CREB (C), 
pS9 GSK−3β (D), and pT421/S424 p70 S6 (E). Densitometric data normalised to GAPDH are 
shown as mean ± standard error (n = 3). Statistical significance is compared between the 
transfected cells (ZIP7) and the non−transfected cells (Con). 
* p < 0.05, ** p < 0.01 
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5.4 Chapter summary 
The antibody arrays demonstrated activation of various kinases, which 
was either dependent on or independent of ZIP7−mediated zinc mobilisation. 
Compatible with a previous investigation (Taylor et al. 2008b), the 
phospho−RTK arrays demonstrated tyrosine phosphorylation of EGFR, ErbB2, 
and IGF−1R as a result of ZIP7 overexpression or zinc treatment, with further 
discovery of tyrosine phosphorylation of ALK, EphA7, FGFR3, c−Ret, and Flt−3 
(Fig. 5.1−5.4, Table 5.1). Furthermore, using the phospho−kinase arrays 
(Fig. 5.5−5.8, Table 5.2) and the phospho−MAPK arrays (Fig. 5.9−5.12, 
Table 5.3), multiple kinases were detected to be phosphorylated on specific 
residues as a result of zinc treatment or ZIP7 overexpression. These kinases 
included AKT, c−Jun, CREB, ERK1/2, GSK−3α/β, HSP27, JNK, JNK2, p38α 
MAPK, p70 S6, PRAS40, STAT2, STAT5a, STAT6, and WNK1. Using Western 
blotting, the phosphorylation of CREB (S133) and p70 S6 (T421/S424) as a 
result of both ZIP7 overexpression and zinc treatment was verified (Fig. 5.13 
and 5.14). These data provided an insight into functional diversity of 
ZIP7−mediated zinc signalling through activation of a vast variety of 
downstream signalling pathways. 
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6.1 Introduction 
With the molecular link of ZIP6 to STAT3 and Snail, ZIP6 has been 
shown to play an indispensable role in the epithelial−mesenchymal transition 
(EMT) in physiological processes such as zebrafish gastrulation (Yamashita et 
al. 2004). Recently, ZIP6 has also been associated with EMT during invasion 
and metastasis of human malignant neoplasms, including breast cancer 
(Hogstrand et al. 2013), pancreatic cancer (Unno et al. 2009), cervical cancer 
(Zhao et al. 2007), and prostate cancer (Lue et al. 2011). Mechanistically, 
ZIP6−mediated zinc influx into the cytosol results in inhibitory phosphorylation 
of GSK−3, nuclear accumulation of Snail, down−regulation of E−cadherin, cell 
rounding, and thereby EMT (Hogstrand et al. 2013) (Section 1.6.2). Importantly, 
mitosis is another biological process that also requires cell rounding (Thery and 
Bornens 2008). ZIP6 was therefore hypothesised to cause cell rounding not 
only in EMT, but also in mitosis. 
Our group have discovered that ZIP7 is post−translationally activated by 
CK2−mediated phosphorylation on residues S275 and S276 (Taylor et al. 
2012). According to the screening for phosphorylation sites in all ZIP channels 
(Section 3.3.5), multiple potential phosphorylation sites were also detected in 
the cytosolic loop between TM3 and TM4 of ZIP6. Interestingly, CK2 was listed 
as a potential kinase that phosphorylated ZIP6 on residue S478 (Sharma et al. 
2014) with the highest prediction score according to different online 
phosphorylation site databases (Section 3.3.5; Fig. 6.1). There were also two 
other potential phosphorylation sites located in the same region, consisting of 
residues S471 (Zhou et al. 2013) and T479 (Wu et al. 2010) (Fig. 6.1). Even 
though CK2 was not ranked as the kinase most likely responsible for the 
phosphorylation on residues S471 and T146 of ZIP6, the sequences of these 
two residues also matched the consensus CK2−binding motif. Furthermore, 
residue S475 was also predicted to be phosphorylated with a sequence 
matching the consensus motifs of multiple kinases, including GSK−3β and CK1 
(Keshava Prasad et al. 2009; Horn et al. 2014), yet without mass spectrometry 
data support. Additionally, GSK−3β was also predicted to phosphorylate residue 
S471 (Fig. 6.1). Interestingly, a STAT3−binding motif with sequence YESQ 
(residues 473−476) (Fig. 6.1) was detected in the same region as these 
potential phosphorylation sites.   
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Figure 6.1 Potential phosphorylation and STAT3-binding sites in ZIP6  
 
This schematic demonstrates the amino acid sequence of human ZIP6 between residues 470 
and 480, which is located in the intra cytosolic loop between TM3 and TM4. Potential 
phosphorylation sites (S471, S475, S478, and T479) with their predicted kinases and a 
predicted STAT3−binding site with sequence YESQ (positions 473−476, grey box) are 
indicated. The phosphorylation sites have been confirmed by mass spectrometry in mammalian 
cells according to PhosphoNET (Kinexus Bioinformatics Corporation), PHOSIDA (Gnad et al. 
2007), and PhosphoSitePlus databases (Hornbeck et al. 2012), except S475, which has been 
suggested according to GSK−3β and CK1 consensus motifs (Keshava Prasad et al. 2009).  
 
 
The alignment of mammalian ZIP6 sequences demonstrated that both 
the potential phosphorylation sites and the STAT3−binding motif were virtually 
100% conserved across different species (Section 3.3.6; Fig. 6.2). The only 
non−identical residues were two residues in mouse ZIP6 equivalent to residues 
E474 (in the YESQ motif) and T479, which were replaced with the 
complementary residues aspartate (D) and serine (S), respectively, and a 
residue in marmoset ZIP6 equivalent to residue S479, which were replaced with 
alanine (A) (Fig. 6.2). This high degree of conservation implied the importance 
of these sites in ZIP6 functional control (Fig. 6.2). Plausibly, ZIP6 function might 
be regulated by phosphorylation on these sites, and STAT3 might interact with 
ZIP6 not only at the transcriptional level (Yamashita et al. 2004; Hogstrand et al. 
2013), but also post−translationally. Noteworthy, a preliminary investigation in 
our group observed an N−terminal proteolytic cleavage during early mitosis in 
addition to the processing at the PEST site that had previously been reported 
(Hogstrand et al. 2013). This second N−terminal cleavage might therefore also 
participate in ZIP6 post−translational control in mitosis.  
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Figure 6.2 Conservation of ZIP6 potential phosphorylation and 
STAT3−binding sites in mammals 
 
ZIP6 sequences from different mammals were aligned across the intracytosolic loop between 
TM3 and TM4 equivalent to residues 465 to 484 of human ZIP6. Potential phosphorylation sites 
(S471, S475, S478, and T479) are indicated in boxes with black solid borders, and a predicted 
STAT3−binding site (sequence YESQ, positions 473−476) is indicated in a grey box with a 
black dashed border. The phosphorylation sites have been confirmed by mass spectrometry in 
mammalian cells according to PhosphoNET (Kinexus Bioinformatics Corporation), PHOSIDA 
(Gnad et al. 2007), and PhosphoSitePlus (Hornbeck et al. 2012) databases, except S475, which 
has been suggested according to GSK−3β and CK1 consensus motifs (Keshava Prasad et al. 
2009). Residues with at least 70% identity are shown in black bold letters, whereas residues 
with less than 70% identity are shown in grey regular letters. 
 
 
 
This chapter aimed to decipher mechanisms of ZIP6 in mitosis. ZIP6 was 
firstly investigated for its interaction with pS727 STAT3, pStathmin and ZIP10 
during mitosis. Furthermore, the protease antibody arrays were utilised to 
explore the proteases that were activated during mitosis, which might explain 
the extra cleavage that had been observed in the preliminary experiment. 
Additionally, phosphorylation on the potential phosphorylation sites in ZIP6 with 
the binding of their relevant kinases during mitosis was investigated. 
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6.2 Materials and methods 
Site−directed mutagenesis was performed by the Mutagenex Inc in a 
wild−type ZIP6 construct that was contained in a pcDNA3.1/V5−His−TOPO 
plasmid vector to create ZIP6 mutants S471A, Y473A, S475A, S478A, and 
T479A, which were confirmed using DNA sequencing (Fig. 6.3). PCR was 
performed following bacterial transformation with the plasmid constructs to 
verify the presence and the orientation of the DNA insert (Fig. 6.4A). After 
plasmid preparation, agarose gel electrophoresis was performed to confirm the 
purity of the product (Fig. 6.4B), and UV spectrophotometry was performed to 
demonstrate the purity and concentrations of the plasmid DNA (Table 6.1). 
Please refer to chapter 2 for the methods of transfection and treatments 
(Section 2.1), bacterial transformation and plasmid preparation (Section 2.2), 
immunofluorescence (Section 2.3), immunoprecipitation with Western blotting 
(Section 2.4), flow cytometry (Section 2.5), zinc assays (Section 2.6), and 
proximity ligation assays (Section 2.7). Additionally, the antibody arrays used 
were the human protease arrays (R&D Systems, ARY021B) (Section 2.9).  
A schematic of the epitopes of different ZIP6 and ZIP10 antibodies used 
in chapters 6 and 7 is shown in Fig. 6.5. ZIP6 M, ZIP6 Y, and ZIP10 R 
antibodies bind to the N−terminus, whereas ZIP6 E−20 (Santa Cruz 
Biotechnology, SC−84875) and ZIP10 (Abcam, ab83947) antibodies bind to the 
cytosolic loop between TM3 and TM4 of the corresponding ZIP channels. 
 
 
Table 6.1 Concentrations and OD260/280 ratios of ZIP6 plasmids 
Plasmid 
Concentration 
(µg/µL) 
OD260/280 Ratio 
ZIP6 WT 4.11 1.948 
ZIP6 S471A  1.21 1.833 
ZIP6 Y473A 3.29 1.982 
ZIP6 S475A  0.99 1.904 
ZIP6 S478A 0.62 1.938 
ZIP6 T479A  1.02 1.925 
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Figure 6.3 DNA sequencing of ZIP6 mutant constructs  
 
This schematic shows the DNA sequences of ZIP6 mutants that were created by the 
Mutagenex Inc using site−directed mutagenesis, consisting of S471A, Y473A, S475A, S478A, 
and T479A. The sequences reveal that the individual serine (codon TCA, TCC, or TCT), 
threonine (codon ACA), and tyrosine (codon TAT) residues at the potential phosphorylation and 
STAT3−binding sites were correctly substituted for alanine (codon GCA, GCC, or GCT). 
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Figure 6.4 Preparation of ZIP6 plasmids 
 
A. JM109 E. coli competent cells were transformed with pcDNA3.1/V5-His-TOPO 
containing DNAs of wild−type ZIP6 and a ZIP6 Y473A mutant. The presence of DNA 
inserts and their orientation in plasmid vector were verified by PCR using a specific 
ZIP6 forward primer and a BGH reverse primer. The PCR products were separated by 
1% agarose gel electrophoresis. The result reveals a band of about 1100 bp (expected 
size = 1170 bp), approximately the same size as the positive control. A clone of each 
construct was selected for plasmid preparation. 
B. The plasmids of wild−type ZIP6 and ZIP6 mutants (Y473A, S478A, S471A, S479A, and 
T479A) were prepared using the EndoFree Plasmid Maxi Kit (Qiagen). The plasmid 
DNAs were analysed with 1% agarose gel electrophoresis, which shows a strong band 
of between 5000-7000 bp (expected size = 6283 bp). 
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Figure 6.5 Locations of ZIP6 and ZIP10 antibody epitopes 
 
This schematic demonstrates the predicted structure of ZIP6 or ZIP10, according to a 
computational analysis of their sequences (Taylor and Nicholson 2003). ZIP6 M/Y and ZIP10 R 
antibodies, which were generated by the Biogenes GmbH Company, bind to the extracytosolic 
N−terminus of ZIP6 and ZIP10, respectively. On the contrary, ZIP6 E−20 (Santa Cruz 
Biotechnology, SC−84875) and ZIP10 (Abcam, ab83947) antibodies bind to the cytosolic loop 
between TM3 and TM4 of ZIP6 and ZIP10, respectively. 
 
 
6.3 Results and discussion 
6.3.1 ZIP6 mutants are robustly transfected 
To verify the purified plasmids of ZIP6 constructs, consisting of wild−type 
ZIP6 and ZIP6 mutants (S471A, Y473A S475A, S478A, and T479A), MCF−7 
cells were transfected with these constructs for 16 hours. The transfection was 
performed in the presence of butyrate, which activates the CMV promoter (Choi 
et al. 2005) and thereby enhances expression of the ZIP6 recombinant protein. 
Immunofluorescence was performed using a V5 antibody to detect the 
recombinant protein, which all had a C−terminal V5 tag. Approximately 50 
transfected cells were seen on each coverslip (Fig. 6.6A). This notably low 
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expression of the recombinant ZIP6 protein has been constantly observed and 
attributed to the presence of a PEST site in the N−terminus and numerous pairs 
of consecutive arginine or lysine throughout the ZIP6 sequence, which 
predispose ZIP6 to proteolytic degradation (Taylor et al. 2003). Additionally, the 
V5−positive cells demonstrated an ER−like staining pattern (Fig. 6.6B), 
highlighting the pro−protein form of ZIP6 in the ER, which is much more 
commonly detected than the rare plasma membrane−located ZIP6 (Hogstrand 
et al. 2013). The similarity between the staining pattern of the wild−type and the 
mutant constructs of ZIP6 suggested that there was no change in ZIP6 
processing caused by the mutations. 
6.3.2 ZIP6 is increased and mediates zinc influx in mitosis 
ZIP6 pro−protein in the ER was shown to be N−terminally cleaved before 
its relocation to the plasma membrane (Hogstrand et al. 2013). According to this 
previous study, this cleavage was concluded from different cellular localisation 
of ZIP6 detected using immunofluorescence and appearance of different bands 
on a Western blot when using different ZIP6 antibodies, consisting of ZIP6 M, 
ZIP6 Y, and ZIP6 E−20 antibodies. The in−house made ZIP6 M and ZIP6 Y 
antibodies target the N−terminus of ZIP6 at residues 93–107 and residues 238–
254, respectively, whereas the commercially available ZIP6 E−20 antibody 
targets the cytosolic loop between TM3 and TM4 of ZIP6 at residues 500–550 
(Table 2.1, Fig. 6.5). Using immunofluorescence, the ZIP6 M antibody stained 
only the ER−located ZIP6 pro−protein, whereas the ZIP6 Y antibody also 
detected the plasma membrane−located ZIP6 (Hogstrand et al. 2013), 
suggesting the cleavage between the epitopes of these two N−terminal 
antibodies. The cleavage was confirmed by a Western blot showing ZIP6 bands 
at 103 kDa (full−length ZIP6, detected by all the three antibodies), 68 kDa 
(N−terminally cleaved ZIP6, detected by the ZIP6 Y and the ZIP6 E−20 
antibodies), and 35 kDa (an N−terminal fragment product of the cleavage, 
detected only by the ZIP6 M antibody). 
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Figure 6.6 A robust transfection of ZIP6 mutants  
 
MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 mutants (S471A, Y473A, S475A, 
S478A, and T479A) in the presence of butyrate for 16 hours. Immunofluorescence was 
performed using a rabbit V5 antibody, which was conjugated to Alexa Fluor 488 (green), with 
DAPI nuclear staining. Representative microscopic views captured with a 63x magnification lens 
(A) show one or two transfected cells per high power field, with a total of approximately 50 
V5−positive cells in a coverslip for both the ZIP6 wild−type and mutant constructs. Closer views 
of the transfected cells (B) reveal an ER−like staining pattern, signifying the inactive form of 
ZIP6 (Hogstrand et al. 2013). 
Scale bar, 25 μm. 
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To observe protein expression of ZIP6 in mitotic cells, 
immunofluorescence using the ZIP6 Y antibody was performed in MCF−7 cells 
treated with nocodazole for 20 hours. Noteworthy, nocodazole stabilises 
microtubule, inhibits microtubule polymerisation, and causes cell cycle arrest in 
early mitosis, thereby enriching the mitotic cell population (Vasquez et al. 1997; 
Rosner et al. 2013). A representative microscopic view demonstrated three 
mitotic cells, which were in prophase as judged by DAPI (blue, indicated by 
white arrows) (Fig. 6.7). ZIP6 was seen to be increased in these cells when 
compared to the adjacent non−mitotic cells in the same field (Fig. 6.7), 
suggesting that ZIP6 protein expression is enhanced during mitosis.  
 
Figure 6.7 Increased ZIP6 protein expression in mitotic cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Immunofluorescence was 
performed using the ZIP6 Y antibody, which was conjugated to Alexa Fluor 594 (red), with DAPI 
nuclear staining. Mitotic cells are indicated by white arrows. A representative microscopic view 
captured with a 63x magnification lens is shown. 
Scale bar, 25 μm. 
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Noteworthy, no classic plasma membrane staining pattern was observed 
in mitotic cells (Fig. 6.7). Given that the ZIP6 Y antibody stains both the 
processed ZIP6 on the plasma membrane and the ZIP6 pro−protein in the ER 
(Hogstrand et al. 2013), this unexpected staining pattern might be due to the 
abundance of the newly−produced ZIP6 pro−protein in the ER, which obscured 
the staining of the plasma membrane−located ZIP6. Moreover, a conventional 
epifluorescence microscope, which was employed in this experiment, was not 
capable of eliminating out−of−focus fluorescence signals from the planes above 
and below the focal planes. A confocal microscope might therefore be required 
for the detection of the plasma membrane staining pattern of the ZIP6 protein. 
To investigate ZIP6 processing in mitosis using Western blotting, 
different protein bands were firstly demonstrated and compared to the ZIP6 
bands that have been reported in the previous study on ZIP6 processing 
(Hogstrand et al. 2013). MCF−7 cells were transfected with wild−type ZIP6 for 
16 hours, and Western blotting was performed using a V5 antibody. Given that 
ZIP6 is enriched in the loosely−attached mitotic cells (Fig. 6.7), non−adherent 
cells in the medium were also collected and pooled together with adherent cells 
at the cell harvest. Unless otherwise specified, pooled samples were used in all 
the experiments for ZIP6 except immunofluorescence. Noteworthy, the 
pcDNA3.1/V5−His−TOPO plasmid vector in which the wild−type ZIP6 DNA was 
inserted contains a C−terminal V5−His tag, which is 5 kDa in size (Elomaa et al. 
2001). The size of a recombinant ZIP6 band was therefore estimated to be 
5 kDa larger than the corresponding band of endogenous ZIP6. Four bands of 
the ZIP6−V5 protein were present on the Western blot: 108 kDa, 73 kDa, 
48 kDa, and 42 kDa (Fig. 6.8A). The 108 kDa and 73 kDa bands were 
consistent with the 103 kDa and 68 kDa bands of the endogenous ZIP6, which 
represent the whole ZIP6 and the N−terminally cleaved ZIP6, respectively 
(Fig. 6.8B). In the previous study (Hogstrand et al. 2013), two bands of the 
endogenous ZIP6 corresponding to the 48 kDa and 42 kDa bands of the 
recombinant ZIP6 were also present on a Western blot when using the 
ZIP6 E−20 antibody and were considered non−specific.  
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Figure 6.8 Protein bands of ZIP6 
 
MCF−7 cells were transfected with wild−type ZIP6 in the presence of butyrate for 16 hours. 
Immunoblotting was performed in pooled samples of the adherent and the non−adherent cells 
using a V5 antibody. Protein bands of the recombinant ZIP6 are present at 108 kDa, 73 kDa, 
48 kDa, and 42 kDa (A). Compared to the schematic of ZIP6 processing (B) according to a 
previous study in our group (Hogstrand et al. 2013), the 108 kDa and 73 kDa bands of the 
recombinant ZIP6 correspond to the whole ZIP6 (103 kDa) and the processed/activated ZIP6 
(68 kDa), respectively.  
 
To confirm the increase in endogenous ZIP6 during mitosis, Western 
blotting using the ZIP6 E−20 antibody was performed in MCF−7 cells that had 
been treated with nododazole for 20 hours. In contrast to the previous study that 
showed multiple bands when using the ZIP6 E−20 antibody (Hogstrand et al. 
2013), only a clean band at 68 kDa was detected on the blot (Fig. 6.9), 
suggesting predominance of the processed ZIP6 protein in these samples. 
Importantly, density of the band at 68 kDa was much increased in the 
nocodazole−treated cells when compared to the control (Fig. 6.9). 
Densitometric data normalised to GAPDH demonstrated that the increase was 
2.5−fold and statistically significant (Fig. 6.9). These data revealed a significant 
increase in the processed ZIP6 during mitosis. 
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Figure 6.9 Increased ZIP6 band at 68 kDa in nocodazole−treated cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Immunoblotting was performed 
using the ZIP6 E−20 antibody. Protein bands of ZIP6 E−20 at 68 kDa and GAPDH at 37 kDa 
are demonstrated as a representative result of 3 independent experiments. Densitometric data 
normalised to GAPDH are demonstrated in a bar graph as mean ± standard error (n = 3). 
Statistical significance is compared between the nocodazole−treated cells and the control 
without treatment. 
** p < 0.01. 
 
 
In order to confirm this Western blotting result, FACS analysis was 
performed in MCF−7 cells that had been treated with nocodazole for 20 hours, 
using ZIP6 E−20 and pS10 histone H3 antibodies. Noteworthy, histone H3 is 
N−terminally phosphorylated on residue S10 in early prophase (Sauve et al. 
1999). This phosphorylation is maximally increased in metaphase, and 
decreased to the basal non−mitotic levels in telophase (Sauve et al. 1999). 
Therefore, pS10 histone H3 was used as a mitotic marker in this experiment. 
The cells in each sample were gated and divided into two groups: the 
pS10 histone H3−negative (non−mitotic) cells and the pS10 histone H3−positive 
(mitotic) cells. The fluorescence intensity of ZIP6 was separately determined in 
each group. The overlay histogram demonstrated a shift of the ZIP6 logarithmic 
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fluorescence intensity curve in the mitotic cells to the right, when compared to 
the non−mitotic cells (Fig. 6.10). The calculation of the mean fluorescence for 
each group demonstrated a significant 2−fold increase in ZIP6 intensity in the 
mitotic cells, compared to the non−mitotic cells in the same samples (Fig. 6.10). 
These data established the increased protein expression of ZIP6 during mitosis.  
 
 
Figure 6.10 Increased ZIP6 levels in mitotic cells detected by FACS 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours, and pooled samples of the 
adherent and the non−adherent cells were immunostained with ZIP6 E−20 and mouse 
pS10 Histone H3 antibodies, which were conjugated to Alexa Fluor 647 and 488, respectively. 
FACS analysis was performed. The cells were gated and divided into 2 groups: the cells that 
were positive for pS10 Histone H3 (mitotic cells) and the cells that were negative for 
pS10 Histone H3 (non−mitotic cells). Data are shown in an overlay histogram. The mean 
fluorescence intensity of ZIP6 E−20 for each population is presented in a bar graph as mean ± 
standard error (n = 3). Statistical significance is compared between the mitotic and the 
non−mitotic cells. 
** p < 0.01. 
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To associate the increased ZIP6 in mitosis with its zinc−importing 
function, FACS analysis was performed in live MCF−7 cells that had been 
treated with nocodazole for 20 hours, and loaded with zinc−sensitive 
fluorescent dye Fluozin−3. The curve of the logarithmic fluorescent intensity of 
Fluozin−3 in the nocodazole−treated cells was shifted to the right when 
compared to the control (Fig. 6.11). The analysis of the mean fluorescent 
intensity revealed a 15.8% increase in zinc levels in the nocodazole−treated 
cells compared to the control, which was shown to be statistically significant 
(Fig. 6.11). The discrepancy between the 100% increase in ZIP6 levels 
(Fig. 6.10) and the only 15.8% increase in zinc levels might be because the 
whole cell population in the samples, both mitotic and non−mitotic, was 
measured in the Fluozin−3 assay (Fig. 6.11), whereas the mitotic cells were 
specifically examined in the ZIP6 measurement (Fig. 6.10).  
 
Figure 6.11 Increased Fluozin−3 fluorescence in nocodazole−treated cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours, and pooled samples of the 
adherent and the non−adherent cells were loaded with Fluozin−3. FACS analysis was 
performed. Data are shown in an overlay histogram. The mean fluorescence intensity of 
Fluozin−3 for each population is presented in a bar graph as mean ± standard error (n = 3). 
Statistical significance is compared between the nocodazole−treated cells (Noc) and the control 
without treatment (Con). 
* p < 0.05.  
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To measure zinc levels precisely in the mitotic cells and contrast them to 
the non−mitotic cell population, a mitotic shake−off was performed (Izawa and 
Pines 2015) (Section 2.3). This technique allows a separate collection of the 
non−adherent or floating cells, which are predominantly mitotic, and the 
adherent cells, which are predominantly non−mitotic, from the same cell 
population, exploiting the loose adherence property of the mitotic cells. The 
abundance of mitotic cells in the non−adherent cell population was determined 
by cell cycle analysis using propidium iodide nuclear staining and FACS. The 
histogram of the adherent cells showed a high 2n peak (the left peak), which 
represented the cells in the G0/G1 phase, and a shorter 4n peak (the right 
peak), which represented the cells in the G2/M phase (Fig. 6.12A). In contrast, 
the non−adherent cells demonstrated a low 2n peak and a much taller 4n peak 
(Fig. 6.12A), suggesting predominance of the G2/M cell population. The 
analysis using the Watson Pragmatic algorithm showed that 90% of the 
non−adherent cells were in the G2/M phase, whereas only 48% of the adherent 
cells were in the G2/M phase (Fig. 6.12A). The difference in the percentages of 
the G2/M population was statistically significant (Fig. 6.12A).  
To confirm that the majority of the non−adherent cells were mitotic, the 
adherent and the non−adherent cells were separately collected and stained with 
Hoechst 33342, a nucleic acid stain. The histogram of the adherent cells 
showed a prominent 2n peak with no identifiable 4n peak, whereas the 
histogram of the non−adherent cells showed a small 2n peak with a prominent 
4n peak (Fig. 6.12B). The pattern of the histograms did not fit an algorithm for 
cell cycle analysis, and percentages of the G2/M cells could therefore not be 
determined. To compare the G2/M population between the adherent and 
non−adherent cells, the cells were gated and determined for percentages of the 
cells with high DNA content, which were in the area equivalent to the 4n peak of 
the non−adherent cells (Fig. 6.12B). It was assumed that the high DNA content 
group were equivalent to the cells in the G2/M phase and the low DNA content 
group were equivalent to the cells in the G0/G1 phase. The result revealed that 
79% of the non−adherent cells had high DNA content, compared to 19% of the 
adherent cells with high DNA content (Fig. 6.12B). These findings suggested 
that the non−adherent cells were predominantly in the G2/M phase, whereas 
the adherent cells were predominantly in the G0, G1 or S phases. 
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Figure 6.12 Increased G2/M population in non−adherent cells 
 
A. MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Adherent (Adh) and 
non−adherent (NAdh) cells were separately collected using the mitotic shake−off 
technique. The nuclei were stained with propidium iodide, and cell cycle analysis was 
performed using FACS. Data are shown in an overlay histogram. The calculated G2/M 
population (%) is demonstrated in a bar graph as mean ± standard error (n = 3). 
Statistical significance is compared between the adherent and the non−adherent cells. 
*** p < 0.001. 
B. MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Adherent (Adh) and 
non−adherent (NAdh) cells were separately collected using the mitotic shake−off 
technique. The nuclei were stained with Hoechst 33342, a nucleic acid stain. FACS 
analysis was performed. Data are shown in an overlay histogram. The cells were gated 
and divided into a high DNA content group and a low DNA content group. The 
percentage of the cells with high DNA content, which are assumed to be equivalent to 
the G2/M population, is demonstrated in a bar graph as mean ± standard error (n = 3). 
Statistical significance is compared between the adherent and the non−adherent cells. 
*** p < 0.001. 
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To compare zinc levels between non−adherent cells and adherent cells, 
the cells were separately collected and loaded with Fluozin−3. The overlay 
histogram revealed that the Fluozin−3 logarithmic fluorescence intensity curve 
of the adherent cells was dramatically shifted to the right (Fig. 6.13), suggesting 
an increase in zinc levels in the non−adherent cells. The calculation of the 
mean fluorescence intensity revealed a 3.2−fold increase in the non−adherent 
cells compared to the adherent cells, which was shown to be statistically 
significant (Fig. 6.13). These data confirmed the significant increase of zinc 
levels in mitosis. 
 
Figure 6.13 Increased Fluozin−3 fluorescence in non−adherent cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Adherent (Adh) and 
non−adherent (NAdh) cells were separately collected using mitotic shake−off technique. The 
cells were loaded with Fluozin−3. FACS analysis was performed. Data are shown in an overlay 
histogram. The mean fluorescence intensity is demonstrated in a bar graph as mean ± standard 
error (n = 3). Statistical significance is compared between the adherent and the non−adherent 
cells. 
*** p < 0.001. 
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To confirm the Fluozin−3 assay analysed by FACS and to determine the 
increase in zinc levels in different stages of mitosis, fluorescence microscopy 
was performed in cells loaded with Fluozin−3. Imaging demonstrated an 
increase in Fluozin−3 levels in mitotic cells compared to the adjacent 
non−mitotic cells in the same field (Fig. 6.14). The stages of mitosis were 
judged by morphology of the DAPI−stained nuclei. The corrected total cell 
fluorescence was individually calculated in the cells in each mitotic stage. 
Compared to the non−mitotic (interphase) cells, the zinc levels were 
significantly increased 5.1−fold, 3.9−fold, and 6.0−fold in prophase, metaphase, 
and anaphase, respectively (Fig. 6.14).  
 
Figure 6.14 Increased Fluozin−3 fluorescence in different mitotic stages 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours, loaded with Fluozin−3 (green), 
and fixed in 4% formaldehyde. The nuclei were stained with DAPI. A representative microscopic 
view captured with 63x magnification lens is shown. Mitotic cells are indicated by white arrows, 
and non−mitotic cells are indicated by yellow stars. Different cell cycle stages, including 
interphase (Inter), prophase (Pro), metaphase (Meta) and anaphase (Ana), were judged 
according to nuclear morphology. The corrected total cell fluorescence calculated from multiple 
images using ImageJ software (Schneider et al. 2012) is shown in a bar graph as mean ± 
standard error. Statistical significance is compared to the interphase (non−mitotic) cells. 
Scale bar, 25 μm. * p < 0.05, ** p < 0.01.   
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Interestingly, the increases were still detected in this fluorescence 
microscopy experiment (Fig. 6.14), regardless of the fact that the cells were 
fixed in 4% formaldehyde, which might theoretically diminish the signals due to 
the potential chemically−induced crosslinking of the fluorescent dye. 
Noteworthy, telophase was excluded from the analysis due to the difficulty in 
distinguishing between telophase cells and interphase cells. Collectively, these 
data demonstrated that zinc levels were significantly increased throughout the 
mitotic process, compatible with the significant increase in protein expression of 
ZIP6 during mitosis. 
6.3.3 pS727 STAT3 binds to ZIP6 on Y473 and to pStathmin in mitosis 
Zinc has been reported to bind to STAT3 and inhibit the transcriptional 
activity of STAT3 by reducing its tyrosine−phosphorylated form, pY705 STAT3 
(Kitabayashi et al. 2010). A preliminary work in our group using Western blotting 
demonstrated that zinc not only reduced the tyrosine−phosphorylated 
transcriptionally−active form of STAT3, but also enhanced serine 
phosphorylation of STAT3 on residue S727 (Nimmanon T et al., manuscript in 
preparation), consistent with a previous report of an inverse relationship 
between pY705 STAT3 and pS727 STAT3 (Decker and Kovarik 2000). Our 
findings of enhanced ZIP6−mediated zinc influx during mitosis therefore 
additionally explained the predominance of pS727 STAT3 in mitotic cells, which 
was also observed in all stages of mitosis in both normal and cancer cells 
(Nimmanon T et al., manuscript in preparation). Noteworthy, cyclin−dependent 
kinase 1−induced pS727 STAT3 is required for maintenance of the M phase in 
nocodazole−treated cells (Shi et al. 2006). However, the mechanism of 
pS727 STAT3 in mitosis is still unknown.  
To decipher any post−translational relationship of STAT3, specifically 
pS727 STAT3, with ZIP6, immunoprecipitation was performed using a V5 
antibody in cells transfected with wild−type ZIP6. Normal rabbit IgG 
immunoprecipitation was used as a negative control. To ensure the presence of 
loosely−attached mitotic cells in the samples, non−adherent cells were also 
collected and pooled together with adherent cells. Western blotting using V5 
and pS727 STAT3 antibodies in the V5−immunoprecipitated samples 
demonstrated 108 kDa and 73 kDa bands of the recombinant ZIP6 and a 
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88 kDa band of pS727 STAT3 (Fig. 6.15), confirming the robustness of the 
immunoprecipitation and the binding of pS727 STAT3 to the recombinant ZIP6, 
respectively. The binding was validated by the absence of either a ZIP6 or a 
pS727 STAT3 band in the IgG control (Fig. 6.15). Noteworthy, a strong band at 
50 kDa, which appeared on the blot when probed for either V5 or 
pS727 STAT3, was consistent with the immunoglobulin heavy chain. 
 
Figure 6.15 pS727 STAT3 binding to ZIP6 
 
MCF−7 cells were transfected with wild−type ZIP6 in the presence of butyrate for 16 hours. 
Pooled samples of the adherent and the non−adherent cells were immunoprecipitated with V5 
antibody and rabbit IgG (control). Immunoblotting was performed using V5 and pS727 STAT3 
antibodies. Protein bands of recombinant ZIP6 at 108 kDa and pS727 STAT3 at 88 kDa are 
shown. The images of both the samples were taken from the same blot. 
  
6. ZIP6 mechanisms in mitosis 
 
 
177 
To confirm the binding of ZIP6 to pS727 STAT3 and to demonstrate 
whether the binding was specifically in mitotic cells, an in situ proximity ligation 
assay (PLA) was performed in nocodazole−treated cells using ZIP6 E−20 and 
pS727 STAT3 antibodies. Noteworthy, using this PLA technique, a 
protein−protein physical interaction can be visualised as fluorescent signals 
when 2 target molecules are localised in close proximity of up to 40 nm 
(Gullberg and Andersson 2010). A representative image and signal 
quantification demonstrated an average of 23 red fluorescent dots/cell in the 
mitotic cells, with only an average of one dot per cell in the non−mitotic cells 
(Fig. 6.16), signifying the binding between the two proteins predominantly in 
mitosis. The chance of false positive signals was eliminated by the presence of 
only a few PLA signals in the controls when using only the ZIP6 antibody or the 
pS727 STAT3 antibody (Fig. 6.16). 
To interrogate a specific site in ZIP6 to which pS727 STAT3 bound, 
MCF−7 cells were transfected with ZIP6 constructs, consisting of wild−type 
ZIP6 and ZIP6 mutants (S478A, T479A, S471A, S475A, and Y473A). Because 
residues S478 and T479 of ZIP6 were located distant to the YESQ 
STAT3−binding motif, the S478A and T479A mutants were used as negative 
controls. Immunoprecipitation was performed using a V5 antibody. Probing for 
V5 demonstrated a 73 kDa band of the recombinant ZIP6 with a strong band of 
the immunoglobulin heavy chain at 50 kDa in all the samples (Fig. 6.17), 
proving that the immunoprecipitation was robust. However, the 73 kDa band 
was severely interfered by the immunoglobulin heavy chain band in the cells 
transfected with ZIP6 T479A, limiting the interpretation of the binding in this 
sample (Fig. 6.17). Probing for pS727 STAT3 showed a clean band of 
pS727 STAT3 at 88 kDa in the cells transfected with ZIP6 S478A with the signal 
intensity comparable to wild−type ZIP6 as expected (Fig. 6.17). An insignificant 
decrease in the pS727 STAT3 levels were observed for the T479A mutant, a 
negative control, which could be attributed to the interference of the 
immunoglobulin heavy chain band in one replicate (Fig. 6.17). Furthermore, the 
pS727 STAT3 levels were decreased in the cells transfected with ZIP6 S471A, 
the mutation of which affected a serine residue near the YESQ motif, but with 
no statistical significance (Fig. 6.17). On the contrary, the pS727 STAT3 levels 
were significantly reduced by 85% in the cells transfected with either 
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ZIP6 S475A or Y473A when compared to wild−type ZIP6 (Fig. 6.17). These 
data demonstrated the binding of pS727 STAT3 to ZIP6 on the predicted 
STAT3−binding motif. This binding might serve as a means whereby ZIP6 was 
functionally controlled during mitosis. Noteworthy, the decrease in the 
pS727 STAT3 binding to ZIP6 S475A could also suggest that residue S475 
might need to be phosphorylated prior to the binding 
Using an immunofluorescence technique, an investigation in our group 
initially observed an increase in pStathmin protein expression throughout the 
mitotic stages (Nimmanon T et al., manuscript in preparation). To determine the 
binding of pS727 STAT3 to pStathmin, PLA was performed in 
nocodazole−treated cells using pS727 STAT3 and pStathmin antibodies, 
revealing that the mitotic cells contained significantly higher PLA signals than 
the non−mitotic cells (Fig. 6.18). The signal quantitation confirmed the 
significant increase, showing 140 signals/cell in the mitotic cells, but only 10 
signals/cell in the non−mitotic cells (Fig. 6.18). The negative controls using 
either of the antibodies revealed a considerably lower number of PLA signals, 
validating that the signals in the sample using both of the antibodies were 
produced by the binding between the two proteins (Fig. 6.18). These data 
proposed a novel role of pS727 STAT3 through its binding to pStathmin in 
facilitating the process of microtubule reorganisation (Rubin and Atweh 2004). 
Noteworthy, the relatively high PLA signals in this experiment when compared 
to the PLA using the ZIP6 and pS727 STAT3 antibodies could be due to the 
higher protein expression and the higher approachability to pS727 STAT3 of 
pStathmin than ZIP6. Alternatively, this might be due to the higher compatibility 
with the PLA technique of the pStathmin antibody than the ZIP6 antibody. 
Additionally, given that both the STAT3−binding site and the epitope of the 
ZIP6 E−20 antibody are located in the same cytosolic loop, the binding of 
pS727 STAT3 to ZIP6 might partially interfere with the binding of the ZIP6 E−20 
antibody to its epitope, and as a result, the PLA signals were decreased. 
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Figure 6.16 pS727 STAT3 binding to ZIP6 in mitotic cells 
 
MCF−7 cells on 8−well chamber slides were treated with 100 nM nocodazole for 20 hours. A 
proximity ligation assay using ZIP6 E−20 and pS727 STAT3 antibodies was performed and 
compared to controls using either of the antibodies. Mitotic cells are indicated by white arrows. 
Quantitative measurements in at least 6 images of 25 stacks taken 0.3 μm apart from 3 
independent experiments are demonstrated as mean ± standard error. Statistical significance is 
compared between the signals in the mitotic and the non−mitotic cells. 
*** p < 0.001. Scale bar, 25 μm. 
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Figure 6.17 pS727 STAT3 binding to ZIP6 on the predicted binding site 
 
A. This schematic demonstrates the amino acid sequence of ZIP6 between residues 470 
and 480 with a predicted STAT3−binding site (sequence YESQ, positions 473−476).  
B. MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 mutants (S478A, T479A, 
S471A, S475A, and Y473A) in the presence of butyrate for 16 hours. Pooled samples of 
the adherent and the non−adherent cells were immunoprecipitated with a V5 antibody. 
Immunoblotting was performed using V5 and pS727 STAT3 antibodies. Representative 
protein bands are shown. Densitometric data of the pS727 STAT3 bands (88 kDa) 
normalised to V5 (73 kDa) are presented in a bar graph as mean ± standard error 
(n = 3). Statistical significance is compared to wild−type ZIP6. 
* p < 0.05. 
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Figure 6.18 pS727 STAT3 binding to pStathmin in mitotic cells 
 
MCF−7 cells on 8−well chamber slides were treated with 100 nM nocodazole for 20 hours. A 
proximity ligation assay using pS38 Stathmin and pS727 STAT3 antibodies was performed and 
compared to controls using either of the antibodies. Mitotic cells are indicated by white arrows. 
Quantitative measurements in at least 6 images of 25 stacks taken 0.3 μm apart from 3 
independent experiments are demonstrated as mean ± standard error. Statistical significance is 
compared between the signals in the mitotic and the non−mitotic cells. 
*** p < 0.001. Scale bar, 25 μm. 
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6.3.4 ZIP10 binds to ZIP6 and pS727 STAT3 in mitosis 
ZIP6 and ZIP10 are both members of the LIV−1 subfamily of zinc 
channels, which share the same sub−branch in the phylogenetic tree of ZIP 
channels (Taylor and Nicholson 2003) (Fig. 3.1). Consistent with their 
evolutionary closeness, their genes have many common characteristics, 
including their evolutionary link to prion genes (Schmitt-Ulms et al. 2009), 
presence of PEST proteolytic cleavage sites (Fig. 3.7), and presence of 
STAT3−binding motifs (Shao et al. 2004; Keshava Prasad et al. 2009). 
Biologically, both ZIP6 and ZIP10 have been associated with 
oestrogen−receptor positivity (Taylor et al. 2007) as well as an invasive 
phenotype (Kagara et al. 2007; Hogstrand et al. 2013) in breast cancer. 
Importantly, both ZIP6 and ZIP10 have been demonstrated to be enriched in the 
oocyte cortex and responsible for zinc influx during meiotic progression of 
oocytes (Kong et al. 2014), although no exact mechanism of ZIP6 and ZIP10 
was investigated in the study. In so far as ZIP6 was involved in mitosis, it was 
interesting to investigate the association of ZIP10 with ZIP6 during mitosis. 
To determine whether ZIP6 and ZIP10 form a heteromer during mitosis, 
immunoprecipitation was performed in cells transfected with wild−type ZIP6, 
using a V5 antibody and rabbit normal IgG. On the Western blot using the V5 
antibody, the band at 68 kDa could not be visualised due to the interference of a 
strong immunoglobulin band at 50 kDa and the smearing pattern of the bands 
above 50 kDa. However, the 108 kDa band of the recombinant ZIP6, which 
represented the full length of ZIP6 (Hogstrand et al. 2013), could be recognised 
(Fig. 6.19). This 108 kDa band was absent in the IgG control, proving that it 
represented the recombinant ZIP6 and confirming the robustness of the 
immunoprecipitation (Fig. 6.19). The binding of ZIP10 to ZIP6 was proved by 
the presence of a faint 38 kDa band of ZIP10 in the V5−immunoprecipitated 
sample (Fig. 6.19). This ZIP10 band was not detected in the 
IgG−immunoprecipitated sample (Fig. 6.19), validating the binding. The result 
demonstrated a complex formation of ZIP6 and ZIP10, but did not distinguish 
whether the complex was present in mitotic or non−mitotic cells. 
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Figure 6.19 ZIP6 binding to ZIP10 
 
MCF−7 cells were transfected with wild−type ZIP6 in the presence of butyrate for 16 hours. 
Pooled samples of the adherent and the non−adherent cells were immunoprecipitated with V5 
antibody and rabbit IgG (control). Immunoblotting was performed using V5 and ZIP10 Abcam 
antibodies. Protein bands of recombinant ZIP6 at 108 kDa and ZIP10 at 38 kDa are shown. The 
images of both the samples were taken from the same blot. 
 
To determine ZIP6 binding to ZIP10 during mitosis, PLA was performed 
in nocodazole−treated cells using ZIP6 Y and ZIP10 R antibodies. Noteworthy, 
these two antibodies were made in−house and targeted ZIP6 and ZIP10 at their 
N−terminus (Table 2.1, Fig. 6.5). The mitotic cells contained 21 PLA 
signals/cell, which were significantly higher than the non−mitotic cells, which 
contained 6 signals/cell (Fig. 6.20), suggesting that ZIP6 formed a complex with 
ZIP10 preferentially in mitosis. Only a few background signals were observed in 
the controls using a single antibody (Fig. 6.20), supporting the genuineness of 
the signals produced.  
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Figure 6.20 ZIP6 binding to ZIP10 in mitotic cells 
 
MCF−7 cells on 8−well chamber slides were treated with 100 nM nocodazole for 20 hours. A 
proximity ligation assay using ZIP6 Y and ZIP10 R antibodies was performed and compared to 
controls using either of the antibodies. Mitotic cells are indicated by white arrows. Quantitative 
measurements in at least 6 images of 25 stacks taken 0.3 μm apart from 3 independent 
experiments are demonstrated as mean ± standard error. Statistical significance is compared 
between the signals in the mitotic and the non−mitotic cells. 
*** p < 0.001. Scale bar, 25 μm. 
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Heterodimerisation has been reported for some members of the ZnT 
family, such as ZnT5 and ZnT6 (Fukunaka et al. 2009). ZIP channels are 
believed to form a homodimer when transporting zinc through the pore (Kambe 
et al. 2015). The homodimer formation has been specifically reported for ZIP13 
(Bin et al. 2011). However, no heterodimerisation of ZIP channels has been 
demonstrated. This ZIP6/ZIP10 complex formation (Fig. 6.19 and Fig. 6.20) 
provided evidence suggesting a possibility of heterodimerisation or heteromer 
formation for the ZIP family. 
To determine pS727 STAT3 binding to ZIP10, PLA was performed in 
nocodazole−treated cells, using ZIP10 Abcam and pS727 STAT3 antibodies. 
Noteworthy, this ZIP10 antibody targets the cytosolic loop of ZIP10 (Table 2.1, 
Fig. 6.5). The result revealed a significant increase in binding in the mitotic cells, 
which had 93 PLA signals/cell, compared to the non−mitotic cells, which 
contained only 10 PLA signals/cell (Fig. 6.21). These data suggested that 
pS727 STAT3 might also bind to ZIP10 during mitosis. The more PLA signals 
observed when using the pS727 STAT3 antibody with the ZIP10 Abcam 
antibody (Fig. 6.21) than with the ZIP6 E−20 antibody (Fig. 6.16) suggested that 
pS727 STAT3 might bind to ZIP10 to a greater extent than ZIP6. However, this 
could in fact be because of the different antibodies used, which might have 
different capability to bind to the ZIP channels that had already complexed with 
pS727 STAT3. Moreover, the higher PLA signals when the ZIP10 antibody was 
added alone than when the ZIP6 antibody was added alone suggested that the 
difference might be partly due to the difference in background signals produced 
by the antibodies. Noteworthy, the specific binding site of pS727 STAT3 in 
ZIP10 was not investigated. Additionally, pS727 STAT3 might bind to ZIP10 
directly or only bind to ZIP6 that had already formed a complex with ZIP10. If 
latter was the case, the false positive results rendered by the 
immunoprecipitation and the PLA experiments might have resulted from the 
presence of ZIP10 within the ZIP10/ZIP6/pS727 STAT3 complex and thereby 
the molecular proximity of ZIP10 and pS727 STAT3 within the complex. 
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Figure 6.21 pS727 STAT3 binding to ZIP10 in mitotic cells  
 
MCF−7 cells on 8−well chamber slides were treated with 100 nM nocodazole for 20 hours. A 
proximity ligation assay using ZIP10 Abcam and pS727 STAT3 antibodies was performed and 
compared to controls using either of the antibodies. Mitotic cells are indicated by white arrows. 
Quantitative measurements in at least 6 images of 25 stacks taken 0.3 μm apart from 3 
independent experiments are demonstrated as mean ± standard error. Statistical significance is 
compared between the signals in the mitotic and the non−mitotic cells. 
*** p < 0.001. Scale bar, 25 μm. 
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6.3.5 ZIP6 is processed in mitosis 
In nocodazole−treated cells, an initial investigation in our group 
demonstrated two additional bands of ZIP6 at 48 kDa (detected by the 
ZIP6 E−20 antibody) and 15 kDa (detected by the ZIP6 Y antibody) (Nimmanon 
T et al., manuscript in preparation). These bands were compatible with products 
of a second cleavage in the plasma membrane−located ZIP6 at the N−terminus 
downstream of the ZIP6 Y epitope during mitosis. To support this second 
cleavage of ZIP6, immunofluorescence was performed using the N−terminal 
ZIP6 Y antibody in cells transfected with wild−type ZIP6. A V5 antibody was 
also used for identification of the recombinant ZIP6 protein. Agreeing with the 
previous study (Hogstrand et al. 2013), the V5−positive (transfected) interphase 
cells consistently expressed ZIP6 with an ER−staining pattern of the ZIP6 
pro−protein (Fig 6.22A, the top row). In contrast, the V5−positive (transfected) 
cells that were mitotic did not express ZIP6, particularly those in metaphase and 
later stages (Fig 6.22A, the bottom row). Furthermore, FACS analysis was 
performed on nocodazole−treated cells using either the ZIP6 E−20 or the 
ZIP6 Y antibody with a pS10 histone H3 antibody, a mitotic marker. The cells 
were gated according to the levels of pS10 histone H3. Using the ZIP6 E−20 
antibody, the curve of the mitotic cell population on the histogram was shifted to 
the right, when compared to the non−mitotic cell population (Fig 6.22B). 
Consistent with the histogram, the calculation of the mean fluorescence 
intensities demonstrated a 2−fold significant increase in ZIP6 in the mitotic cells 
when compared to the non−mitotic cells (Fig 6.22B), compatible with the 
increased ZIP6 in mitosis, as discussed previously (Section 6.3.2). In contrast to 
the ZIP6 E−20 antibody, a dramatic left shift of the curve of the mitotic cell 
population was shown using the ZIP6 Y antibody when compared to the 
non−mitotic cell population, with a 79% significant decrease in mean 
fluorescence intensity demonstrated (Fig 6.22B). This left shift observed when 
using the ZIP6 Y antibody suggested a loss of the N−terminal segment 
containing the ZIP6 Y epitope and further supported the second cleavage in 
mitotic cells. 
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Figure 6.22 A ZIP6 N−terminal cleavage during mitosis 
 
A. MCF−7 cells were transfected with wild−type ZIP6 in the presence of butyrate for 16 
hours. Immunofluorescence was performed using ZIP6 Y and V5 antibodies, which 
were conjugated to Alexa Fluor 594 (red) and 488 (green), respectively. The nuclei 
were counterstained with DAPI. Representative images of the transfected cells (white 
arrow) that are non−mitotic (top) and mitotic (bottom), which were taken from the same 
slide, are presented.  
Scale bar, 25 μm. 
B. MCF−7 cells were immunostained with either ZIP6 (E−20) plus mouse pS10 Histone H3 
antibodies or ZIP6 Y plus rabbit pS10 Histone H3 antibodies. FACS analysis was 
performed. The cells were gated and divided into 2 groups: the cells that are positive for 
pS10 Histone H3 (mitotic cells) and the cells that are negative for pS10 Histone H3 
(non−mitotic cells). Data are presented in histograms. The mean fluorescence intensity 
of either ZIP6 Y or ZIP6 E−20 for each population is presented in a bar graph as mean 
± standard error (n = 3). Statistical significance is compared between the mitotic and the 
non−mitotic cells. 
** p < 0.01, *** p < 0.001.  
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To explore potential proteases that were activated during mitosis, the 
human protease antibody arrays were tested in cells treated with nocodazole 
with or without 1−hour or 2−hour recovery from the drug effects. Using these 
arrays, up to 34 proteases could be simultaneously detected in duplicate in a 
sample (Fig. 6.23). There are three pairs of reference dots on the left upper, 
right upper, and left lower corners (Fig. 6.23). Signal intensities were 
semi−quantitatively evaluated using densitometric analysis, and are shown in a 
bar graph (Fig. 6.24). To simplify the data, relative intensities of individual 
proteases across different samples are presented as a heat map, where blue 
colour represents the minimum value of the row and red colour represents the 
maximum value of the row, according to the indicated scale (Fig. 6.25). 
In the cells without nocodazole treatment, signals of multiple proteases 
were detected, consisting of ADAM9, cathepsins (A, B, C, D, V, and X/Z/P), 
MMP−7, MMP−8, MMP−12, presenilin, and proprotein convertase. With 
20−hour nocodazole treatment, ADAM9, MMP−7, presenilin, and proprotein 
convertase were shown to increase, whereas cathepsins B, V, and X/Z/P and 
MMP−8 were shown to decrease, and others were not changed when 
compared to the control (Fig. 6.23−6.25). With the progression of mitosis in the 
nocodazole−treated cells during the 1 hour and 2 hour recoveries, ADAM9, 
cathepsins (A, B, C, D, V, and X/Z/P), DPPIV/CD26, kallikrein 13, MMP−1, 
MMP−12, and presenilin were progressively increased when compared to the 
nocodazole−treated cells without drug recovery (Fig. 6.23−6.25). In contrast, 
MMP−7, MMP−8, and proprotein convertase were decreased during the 
recovery (Fig. 6.23−6.25). Given that the cleavage of ZIP6 occurred in early 
mitosis, the proteases that were increased in the nocodazole−treated cells were 
considered as the candidates likely to be activated during mitosis, including 
ADAM9, MMP−7, presenilin, and proprotein convertase (Fig. 6.23−6.25). 
Among these proteases, the increase in presenilin levels was shown to have 
the largest percentage change as a result of nocodazole treatment (Fig. 6.23 
and 6.24), suggesting presenilin as the protease with the highest potential. 
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Figure 6.23 Protease arrays in nocodazole−treated cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours with 1−hour and 2−hour 
recovery. The changes in levels of selected proteases were determined using the protease 
antibody arrays (R&D Systems). The signal for each type of proteases is presented as a pair of 
duplicate spots, with three pairs of dark reference spots on the upper left, upper right, and lower 
left corners for alignment (purple boxes). The proteases that show signals on the arrays are 
indicated.  
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Figure 6.24 Densitometric analysis of protease arrays in nocodazole−treated cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours with 1−hour and 2−hour recovery. The changes in levels of selected proteases were determined 
using the protease antibody arrays (R&D Systems). Densitometric data are presented as mean of the duplicate dots ± standard error. 
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Figure 6.25 A heat map of the proteases that change during mitosis 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours with 1−hour and 2−hour 
recovery. The changes in levels of selected proteases were determined using protease antibody 
arrays (R&D Systems). The heat map was generated using GENE−E matrix visualization and 
analysis platform (The Board Institute). Densitometric values in relation to other samples for 
each kinase are presented as a spectrum of colour where blue colour represents the lowest 
value in the row and red colour represents the highest value in the row according to the scale, 
irrespective of the absolute signal intensities. 
 
 
6.3.6 ZIP6 is phosphorylated on S478 at 2 minutes after zinc treatment 
Based on the finding that zinc−transport function of ZIP7 was triggered 
by CK2−mediated phosphorylation (Taylor et al. 2012), ZIP6 was hypothesised 
to be post−translationally controlled by the same mechanism. According to 
multiple phosphorylation site databases, CK2 has been predicted as a potential 
kinase that phosphorylates ZIP6 on residue S478 (Section 3.3.5; Fig. 6.1). 
Whether ZIP6 was also phosphorylated by CK2 on this potential site would now 
be investigated.  
To determine whether ZIP6 was serine−phosphorylated, Western blotting 
using a pSer antibody was performed in cells transfected with wild−type ZIP6 
for 18 hours in the presence of butyrate. The cells were treated with 20 µM zinc 
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plus 10 µM sodium pyrithione in serum free medium, the method which has 
been successfully used for inducing ZIP7 phosphorylation (Taylor et al. 2012) 
(Fig. 4.9, 4.18 and 5.13). Noteworthy, due to the process of zinc treatment, the 
non−adherent cells were not collected, and only the adherent cells remained in 
the samples. A gradual increase in intensity of the pSer bands at 73 kDa were 
observed as a result of zinc treatment (Fig. 6.26). The bands at 73 kDa were 
also observed on the blot when probed for V5 (Fig. 6.26), confirming that these 
pSer bands represented serine phosphorylation on the recombinant ZIP6. 
Noteworthy, the 73 kDa bands of the recombinant ZIP6 correspond to the active 
plasma membrane−located form of ZIP6 (Fig. 6.8). Densitometric data of the 
pSer bands normalised to the corresponding V5 bands demonstrated a 1.7−fold 
significant increase in pSer levels at 2 minutes after zinc treatment when 
compared to time 0 (Fig. 6.26). Even though the increase became 1.8−fold at 5 
minutes and 3.0−fold at 10 minutes when compared to time 0, no statistical 
significance was demonstrated due to the high variability of the data at these 
time points (Fig. 6.26). These data suggested a role for serine phosphorylation 
in ZIP6 post−translational regulation. 
To determine whether this serine phosphorylation of ZIP6 was on residue 
S478, Western blotting using the pSer antibody was also performed in cells 
transfected with the ZIP6 S478A mutant, in which residue S478 was mutated to 
alanine to prevent phosphorylation on this site. The cells were treated with zinc 
plus sodium pyrithione. The pSer and V5 bands at 73 kDa for wild−type ZIP6 
are shown again for comparison (Fig. 6.27). In contrast to wild−type ZIP6, the 
pSer levels in the cells transfected with ZIP6 S478A remained steady 
throughout the 10−minute course of zinc treatment (Fig. 6.27). The pSer levels 
for ZIP6 S478A became significantly lower than wild−type ZIP6 at 2 minutes 
after zinc treatment (Fig. 6.27). Nonetheless, due to the high variability of the 
densitometric values for wild−type ZIP6 at 5 and 10 minutes after zinc 
treatment, a statistical difference between the two constructs was not detected 
after 2 minutes (Fig. 6.27). 
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Figure 6.26 ZIP6 serine−phosphorylation after zinc treatment 
 
MCF−7 cells were transfected with wild−type ZIP6 in the presence of butyrate for 16 hours, and 
the adherent cells were treated with 20 µM zinc plus 10 µM sodium pyrithione. Immunoblotting 
was performed using pSer, V5 and −actin antibodies. Protein bands of pSer, V5 and −actin 
are shown as a representative result of 3 independent experiments. Densitometric data of the 
pSer bands (73 kDa) normalised to V5 (73 kDa) are shown in a bar graph as mean ± standard 
error (n = 3). Statistical significance is compared between different time points as indicated. 
** p < 0.01.  
 
 
The failure of the ZIP6 S478A mutant to be serine−phosphorylated 
suggested that residue S478 was an important serine residue phosphorylated 
as a result of zinc treatment. Interestingly, ZIP6 was shown to be 
serine−phosphorylated at 2 minutes after zinc treatment, which was as early as 
the serine phosphorylation of ZIP7 (Taylor et al. 2012). This finding suggested 
that both ZIP6 and ZIP7 might be simultaneously phosphorylated by CK2. 
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Whereas the phosphorylation of ZIP7 results in zinc release from cellular stores 
(Taylor et al. 2012), the phosphorylation of ZIP6 might result in cellular zinc 
import, supplying zinc to the stores and thereby synergistically working with 
ZIP7 in sustained activation of various tyrosine kinase signalling pathways. 
 
Figure 6.27 ZIP6 serine−phosphorylation on S478 after zinc treatment 
 
MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 S478A in the presence of butyrate 
for 16 hours, and the adherent cells were treated with 20 µM zinc plus 10 µM sodium pyrithione. 
Immunoblotting was performed using pSer antibody and V5 antibody. Protein bands of pSer 
and V5 are demonstrated as a representative result of 3 independent experiments. 
Densitometric data of the pSer bands (68 kDa) normalised to V5 (68 kDa) are demonstrated in 
a bar graph as mean ± standard error (n = 3). Statistical significance is compared between 
different time points or different ZIP6 constructs as indicated. 
* p < 0.05, ** p < 0.01.  
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6.3.7 ZIP6 is serine−phosphorylated by different kinases in mitosis  
To determine whether ZIP6 was serine−phosphorylated during mitosis, 
Western blotting was performed in nocodazole−treated cells. A marked 
increase in levels of pS10 histone H3, a mitotic marker, was demonstrated in 
the nocodazole−treated cells when compared to the non−treated cells 
(Fig. 6.28A), confirming the successful induction of mitosis by the nocodazole 
treatment. Supporting the increase in ZIP6 protein expression in mitosis 
(Fig. 6.7, 6.9 and 6.10), the ZIP6 band at 68 kDa was significantly increased 
2.6−fold in the nocodazole−treated cells when compared to the control 
(Fig. 6.28B). Furthermore, a significant 1.6−fold increase in intensity of the pSer 
band at 68 kDa, corresponding to the ZIP6 band, was also detected 
(Fig. 6.28B), revealing the serine phosphorylation of ZIP6 in mitosis. The higher 
percentage increase in ZIP6 levels than pSer levels in the nocodazole−treated 
cells implied that ZIP6 protein production outweighed the rate of its serine 
phosphorylation. The ZIP6 protein production might be markedly induced during 
mitosis, and the majority of ZIP6 that had been processed was 
serine−phosphorylated, leaving some ZIP6 on the plasma membrane 
non−phosphorylated. This amount of phosphorylated ZIP6 might be sufficient 
for the zinc influx required for mitotic progression. 
To investigate the contribution of CK2 to the serine phosphorylation of 
ZIP6 in mitosis, immunoprecipitation using the ZIP6 E−20 antibody was 
performed. Cells were treated with nocodazole for enhancing mitosis and 
thereby ZIP6 protein expression. The non−adherent cells were also collected 
and pooled together with the adherent cells, to prevent loss of mitotic cells 
during cell harvest. Probing for ZIP6 in the ZIP6−immunoprecipitated sample 
demonstrated ZIP6 bands at 103 kDa and 68 kDa, which were partially 
obscured because of the smearing pattern of the bands (Fig. 6.29). These ZIP6 
bands were equivalent to the full−length ZIP6 and the processed ZIP6, 
respectively (Fig. 6.8). The absence of the 103 kDa band and the presence of a 
barely−discernible smearing band at 68 kDa in the IgG control (Fig. 6.29) 
suggested that these ZIP6 bands truly represented ZIP6 and confirmed the 
robustness of the immunoprecipitation. The binding of CK2 to ZIP6 was 
demonstrated by the presence of a 42 kDa band when the sample was probed 
for CK2 (Fig. 6.29). The blot also revealed a few lower non−specific bands, and 
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a strong band at 37 kDa (Fig. 6.29), which was compatible with the 
immunoglobulin light chain present at the front line of protein migration on this 
blot. Importantly, the IgG control did not show the CK2 band at 42 kDa, but 
showed only the lower non−specific bands and the band of the immunoglobulin 
light chain (Fig. 6.29), validating the CK2 binding to ZIP6. 
 
Figure 6.28 Serine phosphorylation of ZIP6 during mitosis 
 
A. MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Immunoblotting was 
performed using pS10 Histone H3 antibody. Protein bands of pS10 Histone H3 (15 kDa) 
are demonstrated as a representative result of 3 independent experiments.  
B. MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Immunoblotting was 
performed using pSer and ZIP6 E−20 antibody. Representative protein bands of pSer 
and ZIP6 are demonstrated. Densitometric data of the pSer bands at 68 kDa and the 
ZIP6 bands at 68 kDa normalised to GAPDH are demonstrated in bar graphs as mean 
± standard error (n = 3). Statistical significance is compared between the 
nocodazole−treated cells (Noc) and the control without treatment (Con). 
* p < 0.05, ** p < 0.01.  
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Figure 6.29 CK2 binding to ZIP6  
 
Pooled samples of the adherent and the non−adherent MCF−7 cells were immunoprecipitated 
with ZIP6 E−20 antibody and rabbit IgG (control). Immunoblotting was performed using 
ZIP6 E−20 and CK2 antibodies. The bands of ZIP6 at 103 kDa and 68 kDa and CK2 at 42 kDa 
are shown. The images of both the samples were taken from the same blot. 
 
To identify a specific residue on ZIP6 that was phosphorylated by CK2, 
immunoprecitation using a V5 antibody was performed in cells that had been 
transfected with ZIP6 mutants (S471A, S475A, S478A, and T479A). Probing for 
V5 showed multiple bands of the recombinant ZIP6, including a band 
compatible with the full−length ZIP6 at 108 kDa (Fig. 6.30), which confirmed the 
robustness of the V5 immunoprecipitation. Probing for CK2 demonstrated a 
distinct band at 42 kDa, the predicted size of this protein kinase (Fig. 6.30). 
Nevertheless, the CK2 levels normalised to V5 did not show a decrease in CK2 
binding in any of the ZIP6 mutant samples (Fig. 6.30). This could be explained 
by the presence of multiple predicted CK2−binding sites in ZIP6 (Fig. 6.1), and 
mutation of all these sites might be necessary to detect any decrease in 
binding. Noteworthy, a relatively faint band was consistently obtained for the 
wild−type ZIP6 sample (Fig. 6.30).  
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Figure 6.30 CK2 binding to ZIP6 with no specific sites identified 
 
MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 mutants (S478A, T479A, S471A, 
and S475A) in the presence of butyrate for 16 hours. Pooled samples of the adherent and the 
non−adherent cells were immunoprecipitated with V5 antibody. Immunoblotting was performed 
using V5 and CK2 antibodies. Representative protein bands of V5 and CK2 are shown. 
Densitometric data of the CK2 bands (42 kDa) normalised to V5 (108 kDa) are presented in a 
bar graph as mean ± standard (n = 4). 
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GSK−3β is one of the potential kinases that may be responsible for ZIP6 
phosphorylation on residues S471 and S475 (Fig. 6.1). To investigate the 
binding of GSK−3β to ZIP6, immunoprecipitation using the ZIP6 E−20 antibody 
was performed in nocodazole−treated cells. However, a strong band appeared 
on the blot for the IgG control when probed for GSK−3β, nullifying the bands 
detected in the ZIP6−immunoprecipitated sample. Further attempts were 
therefore made using the V5 immunoprecipitation in cells transfected with 
wild−type ZIP6. The immunoprecipitated samples were probed for V5 and 
GSK−3β. A robust immunoprecipitation was shown by the presence of both the 
108 kDa and 73 kDa bands of the recombinant ZIP6 (Fig. 6.31). The binding of 
GSK−3β to ZIP6 was proved by the presence of a faint yet clear band of 
GSK−3β at 47 kDa (Fig. 6.31). The binding was validated by the absence of a 
ZIP6 or a GSK−3β band demonstrable in the sample immunoprecipitated with 
rabbit normal IgG (Fig. 6.31). 
To identify a specific residue targeted by GSK−3β, V5 
immunoprecipitation was performed in cells that had been transfected with ZIP6 
S471A, S475A, S478A, and T479A mutants for 16 hours in the presence of 
butyrate. The presence of a clear band of V5 at 108 kDa confirmed the 
robustness of the immunoprecipitation (Fig. 6.32). The presence of a 47 kDa 
band of GSK−3β was observed in both the wild−type and the mutant constructs, 
confirming the binding of this kinase to ZIP6 (Fig. 6.32). Importantly, a 
significant 44% reduction in the intensity of the GSK−3β band was detected for 
the S471A mutant when compared to wild−type ZIP6 (Fig. 6.32). These data 
strongly suggested the binding of the kinase to ZIP6 specifically on residue 
S471, a site predicted to be phosphorylated by GSK−3β (Fig. 6.32).  
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Figure 6.31 GSK−3β binding to ZIP6  
 
MCF−7 cells were transfected with wild−type ZIP6 in the presence of butyrate for 16 hours. 
Pooled samples of the adherent and the non−adherent cells were immunoprecipitated with V5 
antibody and rabbit IgG (control). Immunoblotting was performed using V5 and GSK−3β 
antibodies. Protein bands of recombinant ZIP6 at 108 kDa and GSK−3β at 47 kDa are shown. 
The images of both the samples were taken from the same blot. 
 
 
 
CK1 was predicted to phosphorylate ZIP6 on S475 (Fig. 6.1). To 
investigate the binding of CK1 to ZIP6, immunoprecipitation using the 
ZIP6 E−20 antibody was performed in cells treated with nocodazole for 20 
hours. The probing for ZIP6 revealed the ZIP6 bands at 103 kDa and 68 kDa, 
confirming that ZIP6 was pulled down during the immunoprecipitation 
(Fig. 6.33). Probing for CK1 demonstrated a CK1 band at 38 kDa, confirming 
the binding of this kinase to ZIP6 (Fig. 6.33). The absence of any specific bands 
in the IgG−immunoprecipitated control verified the binding (Fig. 6.33).  
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Figure 6.32 GSK−3β binding to ZIP6 on S471  
 
MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 mutants (S478A, T479A, S471A, 
and S475A) in the presence of butyrate for 16 hours. Pooled samples of the adherent and the 
non−adherent cells were immunoprecipitated with V5 antibody. Immunoblotting was performed 
using V5 and GSK−3β antibodies. Representative protein bands of V5 and GSK−3β are shown. 
Densitometric data of the GSK−3β bands (47 kDa) normalised to V5 (108 kDa) are presented in 
a bar graph as mean ± standard (n = 4). Statistical significance is compared to wild−type ZIP6. 
* p < 0.05. 
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Figure 6.33 CK1 binding to ZIP6  
 
Pooled samples of the adherent and the non−adherent MCF−7 cells were immunoprecipitated 
with the ZIP6 E−20 antibody and rabbit IgG (control). Immunoblotting was performed using 
ZIP6 E−20 and CK1 antibodies. Protein bands of ZIP6 at 103 kDa and CK1 at 38 kDa are 
shown. The images of both the samples were taken from the same blot.  
 
 
 
To identify a specific site to which CK1 bound, immunoprecipitation using 
the V5 antibody was performed in the cells transfected with the ZIP6 mutants. 
The probing for CK1 demonstrated a CK1 band at 38 kDa (Fig. 6.34). When 
normalised to V5, the binding was decreased in the cells transfected with the 
ZIP6 mutants (Fig. 6.34). However, due to the high variability of the data, no 
significant decrease in intensity could be statistically demonstrated (Fig. 6.34).  
PLK1 has been predicted to phosphorylate ZIP6 on residues S471, 
S475, S478, and T479, although with low prediction scores. Interestingly, PLK1 
is activated before and during the mitotic process (Lindqvist et al. 2009). To 
demonstrate the binding of PLK1 to ZIP6 during mitosis, immunoprecipitation 
was performed in nocodazole−treated cells using the ZIP6 E−20 antibody. The 
blot both for the nocodazole−treated cells and the control revealed the 103 kDa 
and 68 kDa bands of ZIP6 when probed with the ZIP6 E−20 antibody 
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(Fig. 6.35), suggesting the robustness of the immunoprecipitation. Interestingly, 
the 68 kDa band of PLK1 developed only on the blot of the nocodazole−treated 
cells, but not the control (Fig. 6.35), confirming the specific binding in the mitotic 
cells. The absence of any specific bands in the IgG immunoprecipitation control 
(Fig. 6.35) verified the binding of PLK1 to ZIP6 in the nocodazole−treated cells.  
 
Figure 6.34 CK1 binding to ZIP6 with no specific sites identified 
 
MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 mutants (S478A, T479A, S471A, 
and S475A) in the presence of butyrate for 16 hours. Pooled samples of the adherent and the 
non−adherent cells were immunoprecipitated with V5 antibody. Immunoblotting was performed 
using V5 and CK1 antibodies. Representative protein bands of V5 and CK1 are shown. 
Densitometric data of the CK1 bands (38 kDa) normalised to V5 (108 kDa) are presented in a 
bar graph as mean ± standard (n = 4). 
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Figure 6.35 PLK1 binding to ZIP6 in nocodazole−treated cells 
 
MCF−7 cells were treated with 100 nM nocodazole for 20 hours. Pooled samples of the 
adherent and the non−adherent cells with nocodazole treatment (nocodazole) and without 
nocodazole treatment (control) were immunoprecipitated with the ZIP6 E−20 antibody and 
rabbit IgG (control). Immunoblotting was performed using ZIP6 E−20 and PLK1 antibodies. 
Protein bands of ZIP6 at 103 kDa and PLK1 at 68 kDa are shown. The images of all the 
samples were taken from the same blot. 
 
 
 
To determine a specific binding residue of PLK1, V5 immunoprecipitation 
was performed in cells transfected with the ZIP6 mutants. The PLK1 bands at 
68 kDa were detected in all the immunoprecitated samples (Fig. 6.36), revealing 
the binding of PLK1 to all the ZIP6 mutants. However, the intensity of the PLK1 
bands normalised to V5 did not show a significant decrease in binding for any of 
these mutants (Fig. 6.36), suggesting that PLK1 might be able to bind to ZIP6 
on multiple sites. 
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Figure 6.36 PLK1 binding to ZIP6 with no specific sites identified 
 
MCF−7 cells were transfected with wild−type ZIP6 and ZIP6 mutants (S478A, T479A, S471A, 
and S475A) in the presence of butyrate for 16 hours. Pooled samples of the adherent and the 
non−adherent cells were immunoprecipitated with V5 antibody. Immunoblotting was performed 
using V5 and PLK1 antibodies. Representative protein bands of V5 and PLK1 are shown. 
Densitometric data of the PLK bands (68 kDa) normalised to V5 (108 kDa) are presented in a 
bar graph as mean ± standard (n = 2). 
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Noteworthy, the immunoprecipitation in the cells transfected with ZIP6 
mutants to determine specific residues to which individual kinases bound had 
limited implications due to the inability to demonstrate the 73 kDa bands of the 
recombinant ZIP6, which represent the active ZIP6 on the plasma membrane 
(Fig. 6.8). These 73 kDa bands were severely masked by the smearing pattern 
of the bands in the particular region. The bands of the kinases were therefore 
normalised to the 108 kDa bands of the recombinant ZIP6, which are equivalent 
to the ZIP6 pro−protein in the ER (Fig. 6.8). Alternatively, this might be implied 
that the kinases were able to bind to ZIP6 in its pro−protein form in the ER. 
To visualise the binding of CK2, GSK−3β, CK1, and PLK1 to ZIP6 
specifically in mitotic cells, PLA was performed in cells that had been treated 
with nocodazole for 20 hours, using the ZIP6 E−20 antibody with individual 
antibodies that target these kinases. PLA signals were observed predominantly 
in the mitotic cells when the ZIP6 antibody was used together with CK2, 
GSK−3β, CK1, or PLK1 antibody (Fig. 6.37). For CK2, the mitotic cells 
contained an average of 5.9 PLA signals/cell, compared to an average of 0.8 
PLA signals/cell in the non−mitotic cells (Fig. 6.37). For GSK−3, 8.8 
signals/cell were detected in the mitotic cells, whereas the adjacent non−mitotic 
cells contained 1.0 signal/cell (Fig. 6.37). For CK1, averagely 4.5 PLA 
signals/cell were detected in the mitotic cells, compared to the adjacent 
non−mitotic cells, which contained 1.1 signals per cell (Fig. 6.37). For PLK1, the 
mitotic cells had 7.5 PLA signals/cell, compared to the adjacent non−mitotic 
cells with 0.5 PLA signals/cell (Fig. 6.37). When the PLA signals were 
compared between the mitotic cells and the non−mitotic cells, statistical 
significance was demonstrated for the binding of all the investigated kinases to 
ZIP6 (Fig. 6.37), signifying that this binding of these kinases was substantially 
increased in mitosis.  
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Figure 6.37 Binding of CK2, GSK−3, CK1, and PLK1 to ZIP6 in mitosis 
 
MCF−7 cells on 8−well chamber slides were treated with 100 nM nocodazole for 20 hours. 
Proximity ligation assays using the ZIP6 E−20 antibody plus either CK2, GSK−3, CK1, or PLK1 
antibody was performed. Mitotic cells are indicated by white arrows. Quantitative measurements 
in at least 6 images of 25 stacks taken 0.3 μm apart from 3 independent experiments are 
demonstrated as mean ± standard error. Statistical significance is compared between the 
signals in the mitotic and the non−mitotic cells. 
*** p < 0.001. Scale bar, 25 μm. 
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To exclude the non−specific staining produced by PLA reagents or the 
antibodies, PLA was performed using individual ZIP6, CK2, GSK−3β, and CK1 
antibodies, or without an antibody. The average signals when a single antibody 
was added were 0.9, 2.0, 1.7, and 1.0 PLA signals/cell for the ZIP6, CK2, 
GSK−3β and CK1 antibodies, respectively (Fig. 6.38). These signal levels were 
comparable to the PLA without antibody, which showed 1.5 PLA signals/cell 
(Fig. 6.38), suggesting that the non−specific signals were not attributed to the 
antibodies used. The PLA signals produced in these negative controls were 
significantly lower than when each pair of the antibodies was added, thereby 
validating the binding of the kinases to ZIP6. 
The PLA signals detected in these experiments (Fig. 6.37) were relatively 
low, when compared to the PLA that determined the binding of pS727 STAT3 to 
ZIP6 (Fig. 6.16), pStathmin (Fig. 6.18) and ZIP10 (Fig. 6.21) and the binding of 
ZIP6 to ZIP10 (Fig. 6.20), which detected a range of 21 to 140 PLA signals/cell 
in mitotic cells. These low signals might suggest that CK2, GSK−3β, CK1, and 
PLK1 bound to ZIP6 to a lesser extent than pS727 STAT3 and ZIP10 did. Given 
that the STAT3−binding site is located in the same region as the 
phosphorylation sites (Fig. 6.1), the binding of pS727 STAT3 to ZIP6 could have 
interfered with the recognition of either ZIP6 or the kinases by the antibodies. 
Alternatively, the antibody recognition might also be masked by the complex 
formation of ZIP6 and ZIP10, which could hide the epitopes within the complex. 
The GSK−3β binding to ZIP6 was notable, given that the PLA signals 
were the highest compared to the other kinases (Fig. 6.37), suggesting the 
greatest extent of the binding. Furthermore, this binding added a complexity to 
the previous finding of ZIP6 being an upstream inhibitor of GSK−3β (Hogstrand 
et al. 2013). A possible explanation was that when GSK−3 function was 
increased, the phosphorylation of ZIP6 by this kinase might provide a negative 
feedback loop to control the function of this kinase. Given that GSK−3 was 
inhibited during EMT, but active in phosphorylating ZIP6 during mitosis, this 
might also provide a switch mechanism that predestines whether a rounded cell 
should migrate or divide. Additionally, this GSK−3−mediated ZIP6 
phosphorylation might be needed before phosphorylation on other sites could 
occur (Ayuso et al. 2010).   
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Figure 6.38 Negative controls for proximity ligation assays 
 
MCF−7 cells on 8−well chamber slides were treated with 100 nM nocodazole for 20 hours. 
Proximity ligation assays using individual ZIP6 E−20, CK2, GSK−3, and CK1 antibodies or 
without a primary antibody (No Ab) was performed. Quantitative measurements in at least 4 
images of 25 stacks taken 0.3 μm apart are demonstrated as mean ± standard error (n = 3).   
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Additionally, the binding of PLK1 to ZIP6 suggested that the mechanism 
of action of ZIP6 in mitosis might involve its association with PLK1 both before 
and during mitosis. In the light of the pivotal roles for PLK1 in successful 
mitosis, ZIP6 might help PLK1 facilitate cell entry into the mitotic phase, 
formation of the mitotic spindles, and division of the cytosol during cytokinesis at 
the end of the mitotic process (van Vugt and Medema 2005). Alternatively, it is 
also possible that ZIP6 might in fact be a downstream effector of PLK1, which 
facilitated the mitotic processes through zinc influx mediated by ZIP6, given that 
zinc is required for mitosis (Chesters and Petrie 1999).  
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6.4 Chapter summary 
Our group have established that ZIP6 is required for cell rounding in EMT 
(Hogstrand et al. 2013). In this chapter, some evidence of ZIP6 involvement in 
cell rounding prior to mitosis was provided. ZIP6−mediated zinc influx was 
enhanced during mitosis, resulting in an increase in cellular zinc levels 
(Fig. 6.7−6.14). This increase in zinc levels in mitotic cells explained the 
presence of a particular modification of STAT3, pS727 STAT3, throughout 
mitosis, which is directly promoted by zinc (Nimmanon et al., manuscript in 
preparation). A twofold binding of pS727 STAT3 was also detected. Firstly, it 
bound to ZIP6 during mitosis on the predicted STAT3 binding site with 
sequence YESQ (positions 473−476) (Fig. 6.15 and 6.16), probably 
participating with ZIP6 in driving the mitotic process. Secondly, it was shown to 
bind to pStathmin (Fig. 6.18), linking the possible function of pS727 STAT3 to 
the role for pStathmin in microtubule reorganisation (Rubin and Atweh 2004). 
Importantly, the heteromer formation of ZIP6 and ZIP10 (Fig. 6.19 and 6.20) as 
well as the binding of pS727 STAT3 to ZIP10 was also observed in mitotic cells 
(Fig. 6.21), suggesting the close association of pS727 STAT3, ZIP6, and ZIP10 
in mitosis. Additionally, N−terminal cleavage of ZIP6 was detected in early 
mitosis (Fig. 6.22). Potential proteases for this cleavage as suggested by the 
protease antibody arrays included ADAM9, MMP−7, presenilin, and proprotein 
convertase, with presenilin having the most potential due to the highest 
percentage increase in enzyme levels during mitosis (Fig. 6.23−6.25).  
Additionally, ZIP6 was proved for the first time to be 
serine−phosphorylated. Interestingly, ZIP6 phosphorylation was shown to be 
enhanced not only as a result of zinc treatment (Fig. 6.26), but also during 
mitosis (Fig. 6.28). The kinases that were shown to bind to ZIP6 during mitosis, 
which might be responsible for the serine phosphorylation of ZIP6, were CK2, 
GSK−3β, CK1, and PLK1 (Fig. 6.29−6.38). Importantly, residue S471 of ZIP6 
was shown to be the specific GSK−3β−binding site (Fig. 6.32), whereas the 
inability to indicate any specific residue that was phosphorylated by CK2, CK1, 
and PLK1 suggested the presence of more than one residue targeted by these 
kinases. These data provided a deeper insight into the post−translational 
mechanism of ZIP6 in mitosis. 
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7.1 Introduction 
In chapter 6, ZIP6 was shown to be actively involved in mitosis through 
its zinc−import function and its association with zinc−induced pS727 STAT3. 
Furthermore, it was shown to form a complex with its closest paralogue, ZIP10. 
To demonstrate whether ZIP6 and ZIP10 were needed for initiation of mitosis, 
we inhibited ZIP6 and ZIP10 function by treating cells with ZIP6 or ZIP10 
antibodies that bound to these zinc channels at an extracellular epitope on the 
N−terminus. Additionally, NMuMg mouse mammary glandular cells with ZIP6 
knockout using the clustered regularly interspaced short palindromic repeats 
(CRISPR) technique were received from Dr. Gerold Schmitt−Ulms, University of 
Toronto. The effects of this ZIP6 knockout on cell growth were therefore also 
investigated.  
7.2 Materials and methods 
Please refer to Chapter 2 for the details of the treatments (Section 2.1), 
immunofluorescence (Section 2.3), western blotting (Section 2.4), flow 
cytometry (Section 2.5), and zinc assays (Section 2.5). The ZIP6 and ZIP10 
antibodies used for the treatments with their epitopes are listed in Table 2.1, 
and the schematic of their epitopes is shown in Fig. 6.5. 
7.3 Results and discussion 
7.3.1 ZIP6 Y antibody inhibits mitosis in MCF−7 cells  
Two ZIP6 antibodies, ZIP6 M and ZIP6 Y, have been developed in our 
group and designed to recognise the N−terminus of ZIP6 at residues 93–107 
and residues 238–254, respectively (Hogstrand et al. 2013) (Table 2.1). 
Exploiting these two ZIP6 antibodies, we determined the importance of ZIP6 in 
mitosis by performing treatment with either of the antibodies in the presence of 
nocodazole, hypothesising that the antibody binding was able to prevent ZIP6 
function. This means of functional inhibition of a protein has been successfully 
employed for investigating Wnt−1 in different human cancer cell lines (He et al. 
2004). In this study, a monoclonal Wnt−1 antibody successfully inhibited Wnt−1 
signalling and triggered the apoptotic process, the same effects that were 
observed when Wnt−1 gene expression was silenced using Wnt−1 siRNA. 
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To determine whether treatment with the ZIP6 antibodies could inhibit 
mitosis, MCF−7 cells were treated with a 1:20 dilution of the ZIP6 Y or ZIP6 M 
antibody in the presence of nocodazole for 20 hours and stained with propidium 
iodide. Cell cycle analysis was then performed using flow cytometry. 
Noteworthy, the ZIP6 M epitope was shown to be cleaved off prior to relocation 
of ZIP6 to the plasma membrane (Hogstrand et al. 2013), whereas the ZIP6 Y 
epitope was shown to be cleaved off in early mitosis (Section 6.3.5). Based 
upon these findings of the ZIP6 proteolytic cleavage, only the epitope of ZIP6 Y, 
but not the epitope of ZIP6 M, should be present on cell surface in early mitosis. 
The ZIP6 M antibody treatment was therefore employed as a negative control. 
The histogram revealed that the treatment with the ZIP6 Y or ZIP6 M antibody 
resulted in an increase in the diploid (2n) cell population (the left peak of the 
histogram), which represents cells in the G0 or G1 phase, when compared to 
the nocodazole−treated cells without antibody treatment (Fig. 7.1A). In contrast, 
the tetraploid (4n) cell population (the right peak of the histogram), which 
represents cells in the G2 or M phase, was apparently decreased as a result of 
the antibody treatment when compared to the nocodazole−treated cells without 
antibody treatment (Fig. 7.1A). The increases in the G0/G1 population and the 
decreases in the G2/M population as a result of the antibody treatments were 
confirmed by the analysis using the Watson Pragmatic algorithm (Fig. 7.1B,C). 
This analysis revealed that the nocodazole treatment successfully increased the 
G2/M population from 22% to 41%, and the nocodazole−induced G2/M cells 
were significantly reduced by 12% as a result of the ZIP6 Y antibody treatment 
(Fig. 7.1B,C). A 9% decrease in the G2/M population was also observed as a 
result of the ZIP6 M antibody treatment when compared to the 
nocodazole−treated cells without antibody treatment, but with no statistical 
significance observed (Fig. 7.1B,C). The inability of the ZIP6 M antibody to 
suppress nocodazole−induced mitosis confirmed the N−terminal cleavage of 
ZIP6 at a PEST site distal to the ZIP6 M epitope prior to ZIP6 relocation to the 
plasma membrane (Hogstrand et al. 2013). Furthermore, this negative result for 
the ZIP6 M antibody treatment also validated that the decrease in the G2/M 
population as a result of the ZIP6 Y antibody treatment was due to the binding 
of the antibody to ZIP6 on the plasma membrane.  
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Figure 7.1 Decreased G2/M population by ZIP6 Y antibody 
 
MCF−7 cells were treated with 100 nM nocodazole and incubated with the ZIP6 Y or ZIP6 M 
antibody for 20 hours. The cells were stained with propidium iodide. DNA content was 
measured using FACS analysis. Overlapping histograms for the nocodazole−treated cells 
without antibody treatment (Noc) and the nocodazole−treated cells incubated with either the 
ZIP6 Y (Noc + ZIP6 Y) or ZIP6 M (Noc + ZIP6 M) antibody were generated using Flowing 
Software (A). Percentages of the cells in the G0/G1, S and G2/M phases determined using 
FlowJo Software are presented as a 100% stacked column chart (B). The percentages of the 
G2/M population are also presented in a bar graph as mean ± standard error (n = 3) (C). 
Statistical significance is compared to the nocodazole−treated cells without antibody treatment. 
* p < 0.05, ** p < 0.01. 
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The insignificant decrease in the G2/M population observed as a result of 
the ZIP6 M antibody treatment (Fig. 7.1) might be attributed to an off−target 
binding effect of the antibody. Using a BLAST analysis tool of the National 
Center for Biotechnology Information (NCBI) (Madden 2002), the epitope of the 
ZIP6 M antibody was detected in the Swissprot database to partially match the 
sequences of alpha−1G and alpha−1H subunits of the voltage-dependent 
T−type calcium channel. T−type calcium channels are highly expressed in 
tumour cells and involved in cell cycle progression (Taylor et al. 2008a). The 
partial affinity of the antibody to this calcium channel could therefore interfere 
with nocodazole−induced mitosis, explaining the insignificant yet observable 
decrease in mitosis as a result of the ZIP6 M antibody treatment. Alternatively, 
this decrease in the G2/M population could also be attributed to the ability of 
IgG to bind zinc (Yamanaka et al. 2016), which might result in cellular zinc 
deficiency and thereby mitosis inhibition. For these reasons, the ZIP6 M 
antibody would not be included in the following experiments. 
To determine percentages of cells specifically in the M phase, 
immunofluorescence was performed in MCF−7 cells using a pS10 histone H3 
antibody, a mitotic marker. Mitotic cells were counted in images taken from the 
immunofluorescence slides. In non−treated cells, 4% of the cells were mitotic 
(pS10 histone H3−positive) (Fig. 7.2). With nocodazole treatment, the mitotic 
cells were increased to 22% (Fig. 7.2). This nocodazole−induced mitosis was 
significantly reduced to 4% as a result of treatment with a 1:20 dilution of the 
ZIP6 Y antibody (Fig. 7.2). This decrease was demonstrated to be 
concentration−dependent (Fig. 7.2). These data confirmed that the treatment 
with the ZIP6 Y antibody successfully inhibited nocodazole−induced mitosis. 
Noteworthy, when compared to the percentages of the G2/M population as 
determined by FACS analysis (Fig. 7.1), the percentages of the mitotic cells that 
were stained positive for pS10 histone H3 (Fig. 7.2) were relatively small. In 
particular, when the cells were treated with a 1:20 dilution of the ZIP6 Y 
antibody in the presence of nocodazole, only 4% of the cells were positive for 
pS10 histone H3, accounting for 13% of the G2/M population as shown by 
FACS. According to these findings, it could be implied that 87% of the G2/M 
cells were in the G2 phase, consistent with a previous study that reported an 
increase in G2 cells as a result of cell cycle arrest (Luk et al. 2009). 
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Figure 7.2 Concentration−dependent mitosis inhibition by ZIP6 Y antibody 
 
MCF−7 cells were treated with 100 nM nocodazole (Noc) and incubated with the ZIP6 Y 
antibody for 20 hours. The cells were immunostained with a rabbit pS10 histone H3 antibody, 
which was conjugated to Alexa Fluor 594 (red). The nuclei were stained with DAPI (blue). A 
representative image of each sample is shown. Percentages of mitotic cells are presented in a 
bar graph as mean ± standard error (n = 3). Statistical significance is compared to the 
nocodazole−treated cells without antibody treatment. 
Scale bar, 25 μm. ** p < 0.01, *** p < 0.001. 
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To determine whether the effect of the antibody treatment could be 
observed for endogenous mitosis without any chemical induction, MCF−7 cells 
were synchronised using a serum deprivation technique. This technique limits 
exposure of the cells to mitogens or growth factors, thereby causing the cells to 
exit the cell cycle and enter the G0 phase (Rosner et al. 2013). Serum was 
withdrawn from the medium for 24 hours and added back to allow the cells to 
re−enter the G1 phase and progress through the following stages of the cell 
cycle. To determine the time when the serum−deprived cells reached the M 
phase following the serum repletion, the cells were harvested at different time 
points and immunofluorescence was performed using a pS10 histone H3 
antibody. Mitotic cells were counted in images taken from the 
immunofluorescence slides and the mitotic cell numbers were compared to the 
control that had not been serum−deprived, which showed a basal mitotic rate of 
3.8% (Fig. 7.3). Following serum replenishment, the mitotic rate in the cells 
previously deprived of serum started to increase at 27 hours, and a maximal 
increase was observed at 30 hours, with a mitotic rate of 7.2%, indicating this 
time point as the optimised time for cell entry into the mitotic phase (Fig. 7.3). 
After 30 hours, the mitotic rate reduced from the peak to 6.7% at 31 hours and 
5.3% at 32 hours, implying the cells re−entering the G1 phase (Fig. 7.3). To 
determine the effect of the ZIP6 Y antibody treatment on endogenous mitosis, 
the antibody was added at 24 hours and the cells were harvested for 
immunofluorescence using the pS10 histone H3 antibody at 30 hours after 
serum replenishment. The mitotic count revealed that the mitotic rate was 
reduced from 8.2% to 4.4% as a result of the ZIP6 Y antibody treatment 
(Fig. 7.4). These data therefore confirmed the ability of the ZIP6 Y antibody to 
prevent not only the nocodazole−induced mitosis, but also the physiological cell 
cycle progression into the mitotic phase.  
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Figure 7.3 Maximum mitosis at 30 hours after serum replenishment 
 
When MCF−7 cells were 50−70% confluent, they were grown in serum−free medium for 24 
hours and fixed at 27−32 hours after serum replenishment. The cells were immunostained with 
a rabbit pS10 histone H3 antibody, which was conjugated to Alexa Fluor 594 (red). The nuclei 
were stained with DAPI (blue). A representative image of each of the samples that were 
harvested at 27−30 hours is shown. Percentages of mitotic cells are presented in a bar graph as 
mean ± standard error (n = 3). Statistical significance is compared to the control without serum 
starvation (Con). 
Scale bar, 25 μm. * p < 0.05, *** p < 0.001.   
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Figure 7.4 Inhibition of endogenous mitosis by ZIP6 Y antibody  
 
When MCF−7 cells were 50−70% confluent, they were grown in serum−free medium for 24 
hours. They were incubated with a 1:20 dilution of the ZIP6 Y antibody at 24 hours and fixed in 
4% formaldehyde at 30 hours after serum replenishment. The cells were immunostained with a 
rabbit pS10 histone H3 antibody, which was conjugated to Alexa Fluor 594 (red). The nuclei 
were stained with DAPI (blue). A representative image of each sample is shown. Percentages of 
mitotic cells are presented in a bar graph as mean ± standard error (n = 3). Statistical 
significance is compared between the samples with and without antibody treatment. 
Scale bar, 25 μm. ** p < 0.01.  
 
To observe the long−term effect of the ZIP6 Y antibody treatment on cell 
growth, MCF−7 cells were grown in a 24−well plate and allowed to attach to the 
surface for 24 hours, prior to the antibody treatment for 96 hours. Cell counting 
was performed every 24 hours to determine growth of the cells treated with the 
ZIP6 antibody compared to the control without antibody treatment. The medium 
with the antibody was refreshed on day 2 after the treatment, to ensure that the 
cells were not deprived of necessary nutrients and that the antibody was not 
degraded. MCF−7 cells demonstrated a typical exponential growth pattern, with 
cell numbers increasing 1.2−fold, 2.3−fold, 5.3−fold, and 7.8−fold at days 1, 2, 
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3, and 4 when compared to day 0, respectively (Fig. 7.5). With the ZIP6 Y 
antibody treatment at a 1:20 dilution, no change in cell number was observed at 
day 1, but a gradual increase in cell number could be observed at days 2, 3, 
and 4 (Fig. 7.5). A significant decrease in cell growth was seen at days 2, 3, and 
4, with cell numbers reduced by 33.0%, 57.4%, and 69.36% when compared to 
the control, respectively (Fig. 7.5). These data suggested prolonged mitotic 
inhibition as a result of the ZIP6 Y antibody treatment. Noteworthy, a small 
degree of cell growth was still noticed, signifying that the inhibitory effect was 
not complete. This might be associated with a milder side effect of the antibody 
if used for cancer treatment, since normal cells in the body would be allowed to 
grow to some extent. Furthermore, in the light of the concentration−dependent 
manner of the ZIP6 antibody−induced mitosis inhibition (Fig. 7.2), this 
incomplete mitosis blockade could be an antibody concentration effect, and 
complete mitosis inhibition might therefore be clinically achieved when a higher 
concentration of the antibody was applied. 
 
Figure 7.5 Long−term cell growth suppression by ZIP6 Y antibody  
 
MCF−7 cells were seeded in a 24−well plate, and were treated with a 1:20 dilution of the ZIP6 Y 
antibody at 24 hours (day 0). The cells were counted every 24 hours for 4 days. The medium 
with the antibody was refreshed on day 2. The number of the cells from each counting is 
presented in a line graph as mean ± standard error (n = 3). Statistical significance is compared 
to the cells without antibody treatment (Control). 
** p < 0.01, *** p < 0.001.  
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7.3.2 ZIP10 antibodies inhibit mitosis in MCF−7 cells  
Hypothetically, in so far as ZIP6 and ZIP10 heteromer formation was 
required for their zinc transport function, inhibiting ZIP10 should also have the 
same mitosis inhibition effect as inhibiting ZIP6. The experiments that were 
performed using the ZIP6 Y antibody were therefore repeated, but using ZIP10 
antibodies that specifically target the N−terminus of ZIP10 (Table 2.1). Using 
FACS in cells stained with propidium iodide, treatment with a 1:50 dilution of a 
ZIP10 antibody (Sigma−Aldrich, SAB2102209) (Table 2.1) was shown in an 
overlapping histogram to increase the 2n diploid cell population, but decrease 
the 4n tetraploid cell population (Fig. 7.6A). These changes in the cell cycle 
profile were confirmed by the analysis using the Watson Pragmatic algorithm 
(Fig. 7.6B,C). This analysis demonstrated an increase in the G2/M population 
from 22% in the control to 58% in the nocodazole−treated cells with a 
significantly decrease in the nocodazole−induced G2/M cells by 11% as a result 
of the antibody treatment (Fig. 7.6B,C).  
To confirm the changes detected by FACS, immunofluorescence was 
performed using a pS10 histone H3 antibody. Nocodazole treatment 
significantly increased the mitotic cell population by 18% (Fig. 7.7). A significant 
reduction in the percentage of the mitotic cells by 15.5% was observed as a 
result of treatment with a 1:50 dilution of the ZIP10 antibody in the presence of 
nocodazole (Fig. 7.7). This inhibitory effect of the antibody on mitosis was 
shown to be concentration−dependent (Fig. 7.7). When using the same 
dilutions of the antibodies, the ZIP10 antibody was able to show a greater 
extent of mitosis inhibition than the ZIP6 Y antibody. For example, at a 1:50 
dilution of the antibodies, the ZIP10 antibody was able to reduce the mitotic 
cells to 6.2% (Fig. 7.7), whereas the ZIP6 Y antibody decreased the mitotic cells 
to 8.8% (Fig. 7.2). The more potent cytostatic effect of the ZIP10 antibody 
suggested that ZIP10 might be more crucial in the mitotic process than ZIP6. 
Nevertheless, these two antibodies were made from different companies. The 
ZIP6 Y antibody was made in house and was not purified, whereas the ZIP10 
antibody was commercially available and purified. The difference in cytostatic 
efficiency between these two antibodies could therefore be due to the difference 
in antibody concentrations.  
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Figure 7.6 Decreased G2/M population by ZIP10 antibody 
 
MCF−7 cells were treated with 100 nM nocodazole and incubated with a ZIP10 antibody 
(Sigma−Aldrich, SAB2102209) for 20 hours. The cells were stained with propidium iodide. DNA 
content was measured using FACS analysis. An overlapping histogram for the 
nocodazole−treated cells without antibody treatment (Noc) and the nocodazole−treated cells 
incubated with the ZIP10 antibody (Noc + ZIP10) was generated using Flowing Software (A). 
Percentages of the cells in the G0/G1, S and G2/M phases determined using FlowJo Software 
are presented as a 100% stacked column chart (B). The percentages of the G2/M population 
are also presented in a bar graph as mean ± standard error (n = 3) (C). Statistical significance is 
compared to the nocodazole−treated cells without antibody treatment. 
* p < 0.05, ** p < 0.01. 
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Figure 7.7 Concentration−dependent mitosis inhibition by ZIP10 antibody 
 
MCF−7 cells were treated with 100 nM nocodazole (Noc) and incubated with a ZIP10 antibody 
(Sigma−Aldrich, SAB2102209) for 20 hours. The cells were immunostained with a rabbit 
pS10 histone H3 antibody, which was conjugated to Alexa Fluor 594 (red). The nuclei were 
stained with DAPI (blue). A representative image of each sample is shown. Percentages of the 
mitotic cells are presented in a bar graph as mean ± standard error (n = 3). Statistical 
significance is compared to the nocodazole−treated cells without antibody treatment. 
Scale bar, 25 μm. * p < 0.05, *** p < 0.001.   
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To validate the ZIP10 antibody treatment results (Fig. 7.6 and 7.7), FACS 
cell cycle analysis in cells stained with propidium iodide was performed again 
using the in−house made ZIP10 R antibody, which targets the N−terminus of 
ZIP10 similarly to the commercial ZIP10 antibody (Sigma−Aldrich, 
SAB2102209) (Table 2.1, Fig. 6.5). The overlapping histogram demonstrated a 
decrease in the 4n tetraploid peak as a result of the ZIP10 R antibody treatment 
when compared to the nocodazole−treated cells without antibody treatment, 
with no change in the 2n diploid peak observed (Fig. 7.8A). The G2/M cells 
were shown using the Watson Pragmatic algorithm to be significantly increased 
by 19% following the nocodazole treatment, and the ZIP10 R antibody 
treatment significantly reduced the percentage of the nocodazole−induced 
G2/M cell population by 12.5% (Fig. 7.8B), confirming that ZIP10 was required 
for initiation of nocodazole−induced mitosis.  
To investigate the long−term effect of the ZIP10 R antibody treatment, a 
growth assay was performed for 96 hours. Exponential growth of MCF−7 cells 
was demonstrated and used as a control (Fig. 7.9). In contrast, the number of 
cells treated with the ZIP10 R antibody remained steady throughout the 
experiment, with a small decrease at day 1, a small increase at day 2, and 
inconspicuous decreases at day 3 and day 4 (Fig. 7.9). The difference between 
the numbers of the ZIP10 R antibody−treated cells and the control started to be 
significant at day 1 (Fig. 7.9). These data revealed a prolonged potent 
growth−inhibitory effect of the ZIP10 R antibody in MCF−7 cells. Noteworthy, 
both the FACS analysis and the growth assay agreeably demonstrated a 
stronger cytostatic effect of the ZIP10 R antibody than the ZIP6 Y antibody. For 
example, a greater percentage decrease in the G2/M population compared to 
the nocodazole−treated cells was observed when the cells were incubated with 
the ZIP10 R antibody (Fig. 7.8) than when they were incubated with the ZIP6 Y 
antibody at the same dilution of 1:20 (Fig. 7.1). Furthermore, the ZIP10 R 
antibody treatment could significantly suppress cell growth as early as day 1 
(Fig. 7.9), whereas the ZIP6 Y antibody treatment still allowed the cells to slowly 
proliferate up to day 4 and did not show significant growth suppression until 
day 2 (Fig. 7.5). Both the ZIP10 R and ZIP6 Y antibodies were made in house 
and manufactured by the same company, with the same type of preservative 
added. However, exact concentrations of these antibodies were not known. The 
7. Mitosis inhibitory effects of ZIP6 and ZIP10 antibody treatment 
 
 
227 
comparison of the cytostatic effect between these two antibodies was therefore 
limited. The difference in their mitosis inhibition potency might be attributed to 
either the more important role of ZIP10 in zinc transport function of the 
ZIP6/ZIP10 heteromer or only the difference in antibody concentrations. 
 
Figure 7.8 Decreased G2/M population by ZIP10 R antibody 
 
MCF−7 cells were treated with 100 nM nocodazole and incubated with ZIP10 R antibody for 20 
hours. The cells were stained with propidium iodide. DNA content was measured using FACS 
analysis. An overlapping histogram for the nocodazole−treated cells without antibody treatment 
(Noc) and the nocodazole−treated cells incubated with ZIP10 R antibody (Noc + ZIP10 R) was 
generated using Flowing Software (A). Percentages of the cells in the G0/G1, S and G2/M 
phases determined using FlowJo Software are presented as a 100% stacked column chart (B). 
The percentages of the G2/M population are also presented in a bar graph as mean ± standard 
error (n = 3) (C). Statistical significance is compared to the nocodazole−treated cells without 
antibody treatment. 
* p < 0.05, ** p < 0.01. 
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Figure 7.9 Long−term cell growth suppression by ZIP10 R antibody  
 
MCF−7 cells were seeded in a 24−well plate, and were treated with a 1:20 dilution of the 
ZIP10 R antibody at 24 hours (day 0). The cells were counted every 24 hours for 4 days. The 
medium with the antibody was refreshed on day 2. The number of the cells from each counting 
is presented in a line graph as mean ± standard error (n = 3). Statistical significance is 
compared to the cells without antibody treatment (control). 
* p < 0.05, ** p < 0.01, *** p < 0.001. 
 
The ZIP10 R antibody without a preservative added was also made and 
used to investigate the growth suppression effect of sodium azide, which was 
added to all the antibodies made in−house, including the ZIP6 Y and ZIP10 R 
antibodies. The cytostatic effect of sodium azide has been reported in various 
cell types (Slamenova and Gabelova 1980), but this effect on MCF−7 cells has 
not been reported. To exclude the cytostatic effect of sodium azide, MCF−7 
cells were treated with the ZIP10 R antibody without any preservative added 
and compared to those treated with the ZIP10 R antibody with sodium azide 
added. Mitotic cells were identified by immunofluorescence using a 
pS10 histone H3 antibody. The mitotic cell count demonstrated that the 
nocodazole−induced mitotic cells were significantly reduced from 21% to 3% as 
a result of the treatment with the ZIP10 R antibody with sodium azide added, 
and to 4.5% as a result of the treatment with the ZIP10 R antibody without any 
preservative added (Fig. 7.10). No statistical significance was detected between 
the treatment with the ZIP10 R antibody with and without sodium azide added 
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(Fig. 7.10). These data proved that the inhibitory effect of the ZIP10 R antibody 
on mitosis was genuinely attributed to the binding of the antibody to ZIP10 and 
not due to cell toxicity of sodium azide. 
 
Figure 7.10 Exclusion of preservative−induced cytotoxic effects  
 
MCF−7 cells were treated with 100 nM nocodazole (Noc) and incubated with either the ZIP10 R 
antibody with 0.02% sodium azide or the ZIP10 R antibody without sodium azide for 20 hours. 
The cells were immunostained with a rabbit pS10 histone H3 antibody, which was conjugated to 
Alexa Fluor 594 (red). The nuclei were stained with DAPI (blue). A representative image for 
each sample is shown. Percentages of the mitotic cells are presented in a bar graph as mean ± 
standard error (n = 3). Statistical significance is compared to the nocodazole−treated cells 
without antibody treatment. 
Scale bar, 25 μm. *** p < 0.001.  
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7.3.3 ZIP6/10 antibodies inhibit mitosis in other breast cancer cell lines 
Mitosis in the hormone−responsive MCF−7 cells was successfully 
suppressed by the treatment with the antibodies that bind to the N−terminus of 
ZIP6 or ZIP10. To investigate the inhibitory effect of the antibodies on mitosis in 
other hormone−irresponsive breast cancer cells, we performed experiments in 
three additional cell lines: MDA−231 cells, MDA−436 cells, and TAMR cells. 
MDA−231 cells and MDA−436 cells are triple negative (ER−negative, 
PR−negative, and HER2−negative) breast cancer cell lines. TAMR cells are 
tamoxifen−resistant breast cancer cells that are derived from MCF−7 cells and 
known to have acquired a more aggressive phenotype than its 
endocrine−responsive parental cells (Knowlden et al. 2003).  
Immunofluorescence using a pS10 histone H3 antibody was performed 
in MDA−231 cells (Fig. 7.11) and MDA−436 cells (Fig. 7.12) that had been 
treated with the ZIP6 Y or ZIP10 (Sigma−Aldrich, SAB2102209) antibody in the 
presence of nocodazole. The nocodazole treatment successfully increased the 
mitotic cell population in both the cell lines (Fig. 7.11 and 7.12). 
Concentration−dependent mitosis inhibition as a result of the treatment with the 
ZIP6 Y or ZIP10 (Sigma−Aldrich, SAB2102209) antibody was observed in both 
MDA−231 and MDA−436 cells (Fig. 7.11 and 7.12) in the same manner as that 
seen for MCF−7 cells. Using the same concentrations of these antibodies, the 
nocodazole−induced mitosis was inhibited in MDA−231 cells to a greater extent 
than MDA−436 cells (Fig. 7.11 and 7.12). These results revealed that the 
ZIP6 Y and ZIP10 antibodies were able to inhibit nocodazole−induced mitosis in 
these two triple negative breast cancer cells as well as the hormone 
receptor−positive MCF−7 cells. Triple negative breast cancer is highly 
aggressive and does not respond to either hormonal or HER2−targeted therapy. 
A study in mice with severe combined immunodeficiency revealed that 100% 
and 90% of the mice that were injected with MDA−231 and MDA−436 cells 
developed lung macro−metastases 53 and 43 days after injection, respectively 
(Iorns et al. 2012). In contrast, the same study revealed that only 25% of the 
mice injected with MCF−7 cells developed lung macro−metastases 184 days 
after injection. The ZIP6 Y or ZIP10 antibody treatment could therefore become 
a potential therapeutic means to control growth of triple−negative breast cancer, 
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both at the primary site and at distant organs, thereby improving clinical 
outcomes in patients with this highly aggressive disease. 
Our group have demonstrated that TAMR cells have reduced mRNA 
expression of both ZIP6 and ZIP10 when compared to its parental MCF−7 cells, 
even though the decrease was not statistically significant (Taylor et al. 2007). It 
was therefore interesting to determine whether the treatment with the ZIP6 Y or 
ZIP10 R antibody could supress growth of TAMR cells as well as the parental 
MCF−7 cells. A growth assay was performed in TAMR cells that were treated 
with either the ZIP6 Y or the ZIP10 R antibody for 72 hours to determine the 
long−term effect of the treatment on growth of TAMR cells. To prevent nutrient 
starvation of the cells or degradation of the antibodies, the medium with the 
antibodies were replaced on day 2. TAMR cells without antibody treatment were 
increased 2−fold and 3−fold at day 1 and day 2, respectively, with no further 
increase observed at day 3 (Fig. 7.13). In the presence of a 1:20 dilution of the 
ZIP6 Y antibody, no increase was observed until day 3 when a 1.5−fold rise 
was detected (Fig. 7.13), suggesting that the antibody partially inhibited the 
growth of this cell line, and with enough time, the cells might grow again. On the 
contrary, in the presence of a 1:20 dilution of the ZIP10 R antibody, declines in 
cell numbers were observed at day 2 and day 3 (Fig. 7.13), suggesting that the 
antibody might also induce cell death in this cell line. The difference in cell 
numbers between the cells treated with either of the antibodies and the 
non−treated TAMR cells became statistically significant at day 1 (Fig. 7.13), 
suggesting a potent cytostatic effect of these antibodies in TAMR cells. 
Interestingly, this result also demonstrated a superior cytostatic effect of the 
ZIP10 R antibody treatment to the ZIP6 Y antibody treatment, as seen for 
MCF−7 cells, again suggesting either a more crucial role for ZIP10 in the mitotic 
process than ZIP6 or a higher concentration of the ZIP10R antibody than the 
ZIP6 Y antibody.  
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Figure 7.11 Mitosis inhibition by ZIP6 and ZIP10 antibodies in MDA−231  
 
MDA−231 cells were treated with 100 nM nocodazole (Noc) and incubated with either the 
ZIP6 Y antibody or the ZIP10 antibody (Sigma−Aldrich, SAB2102209) for 20 hours. The cells 
were immunostained with a rabbit pS10 histone H3 antibody, which was conjugated to Alexa 
Fluor 594 (red). The nuclei were stained with DAPI (blue). A representative image for each 
sample is shown. Percentages of the mitotic cells are presented in a bar graph as mean ± 
standard error (n = 3). Statistical significance is compared to the nocodazole−treated cells 
without antibody treatment. 
Scale bar, 25 μm. *** p < 0.001.   
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Figure 7.12 Mitosis inhibition by ZIP6 and ZIP10 antibodies in MDA−436 
 
MDA−436 cells were treated with 100 nM nocodazole (Noc) and incubated with either the 
ZIP6 Y antibody or the ZIP10 antibody (Sigma−Aldrich, SAB2102209) for 20 hours. The cells 
were immunostained with a rabbit pS10 histone H3 antibody, which was conjugated to Alexa 
Fluor 594 (red). The nuclei were stained with DAPI (blue). A representative image for each 
sample is shown. Percentages of the mitotic cells are presented in a bar graph as mean ± 
standard error (n = 3). Statistical significance is compared to the nocodazole−treated cells 
without antibody treatment. 
Scale bar, 25 μm. *** p < 0.001.  
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Figure 7.13 TAMR cell growth suppression by ZIP6 and ZIP10 antibodies 
  
Tamoxifen−resistant MCF−7 cells (TAMR cells) were seeded in a 24−well plate, and were 
treated with a 1:20 dilution of either the ZIP6 Y or ZIP10 R antibody at 24 hours (day 0). The 
cells were counted every 24 hours for 3 days. The number of the cells from each counting is 
presented in a line graph as mean ± standard error. Statistical significance is compared to the 
cells without antibody treatment (control). 
* p < 0.05, ** p < 0.01. 
 
7.3.4 ZIP6 knockout decreases mitosis in NMuMg cells 
ZIP6 knockout using clustered regularly−interspaced short palindromic 
repeats (CRISPR) technology was performed in NMuMg (mouse mammary 
glandular) cells by Dr. Gerold Schmitt−Ulms, University of Toronto. To 
determine the need for ZIP6 in the mitotic process, experiments were performed 
in this cell model. To characterise this cell line, zinc assays were performed 
using Fluozin−3. Imaging demonstrated that the green fluorescence of 
Fluozin−3 was decreased in the ZIP6−knockout NMuMg cells when compared 
to the wild−type NMuMg cells (Fig. 7.14). The calculation of the corrected total 
cell fluorescence in the representative fluorescence images revealed a 22% 
decrease in fluorescence intensity in the ZIP6−knockout cells when compared 
to the wild−type cells (Fig. 7.14). Furthermore, FACS analysis in cells loaded 
with the zinc−sensitive dye demonstrated a 35% decrease in the 
ZIP6−knockout cells compared to the wild−type cells (Fig. 7.15). These findings 
were consistent with the absence of ZIP6 in the ZIP6−knockout cells. 
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Nevertheless, a considerable amount of zinc was also present in the 
ZIP6−knockout cells, suggesting that zinc−import function of ZIP6 could be 
compensated for by other plasma membrane−located ZIP channels. 
 
Figure 7.14 Decreased zinc levels in ZIP6−knockout cells 
 
Wild−type (WT) and ZIP6−knockout (ZIP6 KO) NMuMg cells were stained with Fluozin−3 
(green), and fixed in 4% formaldehyde. The nuclei were stain with DAPI. A representative 
microscopic view captured with 63x magnification lens is shown. The total cell fluorescence was 
calculated from the images taken from the Fluozin−3−stained slides using ImageJ software 
(Schneider et al. 2012), and is presented in a bar graph as mean ± standard error. Statistical 
significance is compared between the wild−type and the ZIP6−knockout cells. 
Scale bar, 25 μm. * p < 0.05.  
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Figure 7.15 Decreased zinc levels in ZIP6−knockout cells 
 
Wild−type (WT) and ZIP6−knockout (ZIP6 KO) NMuMg cells were stained with Fluozin−3 
(green). FACS analysis was performed. The data are shown in an overlay histogram. The mean 
fluorescence is demonstrated in a bar graph as mean ± standard error (n = 3). Statistical 
significance is compared between the wild−type and the ZIP6−knockout cells. 
*** p < 0.001. 
 
To determine the effect of ZIP6 knockout on mitosis, FACS was 
performed in wild−type and ZIP6−knockout NMuMg cells stained with propidium 
iodide. The overlapping histogram revealed a decrease in the 4n peak, which 
represents cells in the G2/M phase, and the area between the two peaks, which 
represents cells in the S phase, with no change in the 2n peak, which 
represents cells in the G0/G1 phase (Fig. 7.16A). Further analysis in the 
ZIP6−knockout cells using the Watson Pragmatic algorithm revealed a 1.9% 
decrease in the percentage of the G2/M cells and a 16.6% decrease in the 
percentage of the S−phase cells when compared to the wild−type cells 
(Fig. 7.16B). Even though the decrease in the G2/M cells was relatively small, 
the decrease was statistically significant for both the G2/M cells (Fig. 7.16C) 
and the S−phase cells (Fig. 7.16D). The decrease in the S−phase fraction in the 
ZIP6−knockout cells suggested that ZIP6 might play a role in cell cycle 
progression even prior to cell entry into the mitotic phase. This early blockade of 
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the cell cycle was not detected in the ZIP6 antibody treatment experiment 
(Fig. 7.1), possibly because of the intracellular location of ZIP6 in the interphase 
cells and thereby lack of approachability of ZIP6 to the ZIP6 antibody. Given 
that the S−phase fraction has long been known as a biomarker of clinically 
aggressive tumours (Johnson 1994), this effect of the ZIP6 knockout supported 
ZIP6 as a potential target for cancer treatment. 
 
Figure 7.16 Decreased S and G2/M population in ZIP6−knockout cells 
 
Wild−type (WT) and ZIP6−knockout (ZIP6 KO) NMuMg cells were stained with propidium 
iodide. DNA content was measured using FACS analysis. An overlapping histogram was 
generated using Flowing Software (A). Percentages of the cells in the G0/G1, S and G2/M 
phases determined using FlowJo Software are presented as a 100% stacked column chart (B). 
The percentages of the cells in the G2M phase (C) and S phase (D) are individually presented 
in bar graphs as mean ± standard error (n = 3). Statistical significance is compared between the 
wild−type and the ZIP6−knockout cells. 
** p < 0.01, *** p < 0.001. 
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A 96−hour growth assay was performed to determine long−term growth 
of the ZIP6−knockout cells. Rapid proliferation was observed for the wild−type 
cells until day 4, whereas a slower increase in cell number was observed in the 
ZIP6−knockout cells until day 3, with statistical significance observed from day 
1 to day 3 when compared to the wild−type cells (Fig. 7.17). Unexpectedly, the 
growth of the ZIP6−knockout cells accelerated at day 4, when the cell numbers 
reached the levels comparable to the wild−type cells (Fig. 7.17). These data 
suggested that ZIP6 played important roles in mitosis, since the absence of 
ZIP6 resulted in the decrease in cell growth. Nevertheless, the ability of the 
ZIP6−knockout cells to grow with rapid acceleration at day 4 suggested that the 
role of ZIP6 in mitosis was dispensable, and ZIP6 might be compensated for by 
other ZIP channels, especially in long−term absence of ZIP6. The dispensability 
of the role for ZIP6 in cell proliferation was consistent with a recent report that 
shRNA−mediated suppression of ZIP6 gene expression by 80% did not have 
any effect on cell proliferation in pancreatic cancer cells (Unno et al. 2014). 
 
Figure 7.17 Cell growth suppression in ZIP6−knockout cells 
  
Wild−type (WT) and ZIP6−knockout (ZIP6 KO) NMuMg cells were seeded in a 24−well plate. 
The cells were counted every 24 hours for 4 days. The number of the cells from each counting 
is presented in a line graph as mean ± standard error (n = 3). Statistical significance is 
compared between the wild−type and the ZIP6−knockout cells. 
* p < 0.05, *** p < 0.001.  
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7.4 Chapter summary 
In this chapter, inhibition of ZIP6 and ZIP10 by treating cells with the 
antibodies that target the ectodomain of ZIP6 and ZIP10 was demonstrated to 
result in a decrease in mitosis and cell growth. These antibodies were shown to 
suppress both nocodazole−induced mitosis and endogenous mitosis in MCF−7 
cells, with a concentration−dependent manner demonstrated for the inhibition of 
nocodazole−induced mitosis (Fig. 7.1−7.9). Furthermore, inhibitory effects of 
the antibodies on mitosis were also seen in endocrine−resistant breast cancer 
cell lines, consisting of MDA−231 (Fig. 7.11), MDA−436 (Fig. 7.12), and TAMR 
cells (Fig. 7.13), as well as hormone−sensitive MCF−7 cells. Additionally, 
crucial involvement of ZIP6 in mitosis was supported by a decrease in cell 
proliferation in ZIP6−knockout NMuMg cells when compared to wild−type 
NMuMg cells (Fig. 7.16 and 7.17). These findings collectively confirmed the 
important role of ZIP6 and ZIP10 in the mitotic process and introduced ZIP6 and 
ZIP10 antibody treatment as a novel modality for cancer treatment. 
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An increasing number of human diseases, which include cancer, have 
been attributed to increases or decreases in zinc transport function of ZIP 
channels (Taylor et al. 2011). It is therefore crucial to comprehend functional 
control of ZIP channels in order to discover a novel therapeutic strategy for 
diseases that are associated with ZIP channel dysfunctions. To obtain some 
basic understanding about the predicted structure of ZIP channels, amino acid 
sequences were analysed, and potential phosphorylation sites in the cytosolic 
loop between TM3 and TM4 were explored in all members of the ZIP family of 
zinc transport proteins (Chapter 3). Post−translational mechanisms of ZIP7 
were further deciphered by determining usefulness of the pZIP7 antibody in 
indicating the modification and function of ZIP7 (Chapter 4) and exploring 
cellular kinases phosphorylated as a result of ZIP7−mediated zinc release from 
cellular stores (Chapter 5). To expand the insight into the ZIP channel functional 
control, the investigation was extended to post−translational mechanisms of 
ZIP6, another member of the LIV−1 subfamily in which a STAT3−binding site 
and multiple phosphorylation sites were detected (Chapter 6). Following the 
discovery of ZIP6 and ZIP10 mechanisms during mitosis in Chapter 6, the 
essentiality of these ZIP channels for the mitotic process was proved by 
inhibiting their function using specific ZIP6 and ZIP10 antibodies (Chapter 7). 
The most prominent discovery in this project was the post−translational 
mechanisms of ZIP6 and ZIP10 in mitosis with the application of ZIP6 and 
ZIP10 antibodies to inhibit mitosis. These two topics will therefore be discussed 
first in this chapter, followed by a separate discussion on the investigation of 
ZIP6 phosphorylation in mitosis. The discussion will then be focused on ZIP7, 
starting from an analysis of the kinases that were detected as downstream 
effectors of ZIP7−mediated zinc release from cellular stores. Finally, the 
potential usefulness of the pZIP7 antibody and the essential role of ZIP7 in 
human immunity will be discussed.  
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8.1 ZIP6 and ZIP10 play important roles in mitosis 
It has been recognised for decades that zinc is essential for cell division, 
and the absence of zinc in the medium results in cell proliferation arrest 
(Falchuk et al. 1975). The importance of zinc homeostasis in cell division is 
underlined by the demonstration of transient fluctuations of intracellular zinc 
levels during the mitotic cell cycle (Li and Maret 2009) as well as the meiotic cell 
cycle (Kim et al. 2010). However, little is known about the direct role of zinc in 
mitosis. It has been proposed that zinc is involved in mitosis because of its 
major involvement in DNA synthesis through its association with various 
metalloenzymes and zinc−finger proteins and how zinc affects the G1/S phase 
transition by an undefined mechanism (MacDonald 2000). Furthermore, zinc 
signalling has been linked to cell growth in prostatic cancer in a recent study 
(Zhang et al. 2010). In this study, ZIP4 overexpression was seen to activate 
CREB by phosphorylation, resulting in increases in IL−6 transcription, STAT3 
activation, cyclin D1 expression, and cell proliferation. However, these effects of 
ZIP4 overexpression might be attributed solely to the increase in cytosolic zinc, 
since no molecular association of ZIP4 with other molecules was indicated. 
According to the data in Chapter 6, the mechanism of how ZIP6 is 
involved in mitosis can be summarised in a schematic shown in Fig. 8.1. ZIP6 is 
transcriptionally activated by STAT3 (Yamashita et al. 2004; Hogstrand et al. 
2013) in its active tyrosine−phosphorylated form, pY705 STAT3 (Abroun et al. 
2015). ZIP6 is produced as a pro−protein, which is stored in the ER and 
represented by a 103 kDa band on a Western blot (Hogstrand et al. 2013) 
(Fig. 6.8). A recent study in our group detected that ZIP6 forms a heterodimer 
with ZIP10 in the ER (Taylor et al. 2016). When the cell is triggered by a 
mitosis−promoting factor, the ZIP6 pro−protein is N−terminally cleaved at a 
strong PEST site (Fig. 3.7) and relocated to the plasma membrane. This active 
form of ZIP6 on the plasma membrane is represented by a 68 kDa band on a 
Western blot (Hogstrand et al. 2013) (Fig. 6.8). At this stage, ZIP6 might be 
regulated by phosphorylation on the predicted sites in the cytosolic loop 
between TM3 and TM4, which could possibly be mediated by CK2, GSK−3β, 
CK1, or PLK1 (Fig. 6.29−6.38). Noteworthy, it is still not known whether ZIP10 
is also post−translationally regulated by phosphorylation.  
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Figure 8.1 ZIP6 and ZIP10 involvement in mitosis 
 
This schematic demonstrates a model of ZIP6 and ZIP10 involvement in mitosis based on the 
findings in this project.  
1. ZIP6 forms a heteromer with ZIP10 in the ER (Taylor et al. 2016), and the heteromer 
relocates to the plasma membrane in mitosis. 
2. The ZIP6/ZIP10 heterodimer mediates zinc influx into the cytosol, resulting in 
phosphorylation of STAT3 on residue S727. 
3. The serine−phosphorylated STAT3 (pS727 STAT3) binds to ZIP6 on residue Y473, 
which is in the intracytosolic loop between TM3 and TM4. pS727 STAT3 also binds to 
ZIP10 on an unidentified site. 
4. pS727 STAT3 binds to pS38 Stathmin, which is required for microtubule reorganisation 
during mitosis (Rubin and Atweh 2004).  
5. ZIP6 undergoes an additional N−terminal cleavage during early mitosis. 
 
 
When ZIP6 or ZIP10 on the plasma membrane is activated, the 
ZIP6/ZIP10 heteromer mobilises zinc into the cell (Fig. 8.1, step 1), resulting in 
conversion of pY705 STAT3 to pS727 STAT3 (Fig. 8.1, step 2), the form of 
STAT3 which is present in all mitotic cells (Nimmanon et al., manuscript in 
preparation). During mitosis, pS727 STAT3 binds to the ZIP6/ZIP10 
heterodimer on the plasma membrane (Fig. 8.1, step 3). This binding was 
shown to be at the predicted STAT3−binding motif in ZIP6 (sequence YESQ, 
positions 473−476) (Fig. 6.15−6.17) and at an unknown site in ZIP10 
(Fig. 6.21). Additionally, pS727 STAT3 also binds to pStathmin (Fig. 6.18; 
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Fig. 8.1, step 4), which is required for microtubule reorganisation, an essential 
process for mitotic progression (Rubin and Atweh 2004). During early mitosis, 
before the transition from prophase to metaphase, the extracellular N−terminus 
of ZIP6 is cleaved again just upstream of TM1 (Fig. 6.22; Fig. 8.1, step 5). The 
role of this second cleavage still needs to be investigated. Altogether, the 
findings in this project have introduced at least five molecules that are actively 
involved in the mitotic process according to this model: zinc, ZIP6, ZIP10, 
pS727 STAT3, and pStathmin. These molecules might therefore become 
interesting targets for treatment of proliferative diseases such as cancer. 
Tyrosine phosphorylation on a C−terminal tyrosine residue, Y705, is a 
crucial step for the formation of a STAT3 dimer (Rawlings et al. 2004). As a 
result, most studies on STAT3 have been focussed on pY705 STAT3, which is 
generally regarded as the transcriptionally−active form of STAT3 (Abroun et al. 
2015). However, phosphorylation on an evolutionarily−conserved serine 
residue, S727, which is located in the C−terminal tail distal to residue Y705, has 
also been reported (Decker and Kovarik 2000). In response to interferon−alpha, 
a luciferase assay in cells transfected with the interferon regulatory factor−1 
promoter demonstrated a 50% decrease in transcriptional activity when 
co−transfected with a STAT3 S727A mutant, compared to the wild type, even 
though a gel mobility shift assay could not show a decrease in DNA binding 
(Wen et al. 1995). Consistent with this finding, transfection with the 
STAT3 S727A mutant was shown to reduce transcription of the interleukin−6 
response element of the ICAM−1 promoter upon interleukin−6 induction by 
50%, compared to wild−type STAT3 (Schuringa et al. 2000). Importantly, the 
relevance of this S727 phosphorylation in physiology has been underlined by an 
in vivo study, showing that SA/− mice (one allele having the STAT3 S727A 
mutation and the other having no STAT3 gene) had a significant reduction in 
birth weight with 75% mortality rate soon after birth (Shen et al. 2004). Both the 
reduced birth weight and the mortality seen in these SA/− mice were correlated 
with a reduction in serum levels of IGF−1. Given the transcription−stimulating 
role of pS727 STAT3, this modification has been implicated in carcinogenesis. 
For example, in prostate cancer cells, when residue S727 of STAT3 is mutated 
to glutamate, which is a phosphomimetic amino acid, the cells were shown to 
have increased growth, tumorigenic potential, and invasion (Qin et al. 2008). 
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These aggressive characteristics were attributed to pS727 STAT3−mediated 
transcriptional activation of proto−oncogenes, such as mcl−1, surviving, and 
c−myc, independently of Y705 phosphorylation. In addition, the 
constitutively−present pS727 STAT3 was shown in chronic lymphoid leukaemia 
cells to bind to DNA and thereby activate transcription, suggesting 
pS727 STAT3 as a salient feature and a potential therapeutic target for this 
lymphoid neoplasm (Hazan-Halevy et al. 2010).  
Nevertheless, there are a few pieces of evidence contradicting these 
positive effects of pS727 STAT3 on transcriptional activity (Decker and Kovarik 
2000). In HepG2 hepatoma cells, investigations using a STAT3 S727A mutant 
as well as a STAT3 mutant with the distal 55 amino acids removed from the 
C−terminus proved a requirement of the C−terminus, but not residue S727, in 
transcription−activating function of STAT3 (Kim and Baumann 1997). 
Furthermore, a decrease in transcriptional activity has been demonstrated when 
residue S727 was phosphorylated by ERKs (Jain et al. 1998; Sengupta et al. 
1998), protein kinase C delta (Jain et al. 1999), or c−Jun N−terminal kinase 1 
(JNK1) (Lim and Cao 1999). Indirectly supporting this negative role of 
pS727 STAT3 in transcriptional activity, the phosphorylation on residue S727 of 
STAT3 in nocodazole−treated cells was shown to suppress gene expression of 
p21CIP1/WAF1 and p27Kip1, which are negative regulators of the cell cycle (Shi et 
al. 2006). The suppression of these cell cycle regulators therefore resulted in 
unopposed activation of cyclin−dependent kinase 1, which is required for mitotic 
progression. This study also demonstrated an inverse relationship between 
pY725 STAT3 and pS705 STAT3 in mitotic cells, and introduced pS727 STAT3 
as a positive regulator of the mitotic process. Collectively, these controversial 
data suggest that pS727 STAT3 can either activate or suppress gene 
expression, depending on cell types and circumstances.  
Importantly, zinc was shown to bind to STAT3, resulting in inhibition of 
STAT3 transcriptional function, as suggested by a decrease in the 
pY705 STAT3 levels (Kitabayashi et al. 2010). Furthermore, a recent 
investigation in our group confirmed this and further demonstrated in the context 
of mitosis that ZIP6−mediated zinc influx resulted in not only a decrease in 
pY705 STAT3, but also an increase in pS727 STAT3 (Nimmanon et al., 
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manuscript in preparation). Noteworthy, these effects of zinc on the two STAT3 
modifications were consistent with the inverse relationship between 
pY725 STAT3 and pS705 STAT3, which was seen in nocodazole−induced 
mitotic cells (Shi et al. 2006) and cells overexpressing ZIP6 (Hogstrand et al. 
2013). As previously mentioned, the binding of pS727 STAT3 to pStathmin 
provided a clear link between ZIP6−mediated zinc signalling and mitosis 
through the crucial role of pStathmin in facilitating microtubule reorganisation 
during mitosis (Rubin and Atweh 2004). In contrast to this binding of 
pS727 STAT3 to pStathmin, the role of the ZIP6/pS727 STAT3 complex 
formation was rather inconclusive. Interestingly, ZIP6 has been reported to 
associate with histone demethylase Jarid1B (Zhou et al. 2009a), which was 
previously demonstrated by our group to bind to histone H3, but not ZIP6, in 
mitotic cells (Nimmanon et al., manuscript in preparation). It is interesting to 
speculate that the ZIP6/pS727 STAT3 complex formation resulted in dislodging 
of Jarid1B from ZIP6, and the freed Jarid1B would then bind and activate 
histone H3, which is responsible for chromosome condensation (Wei et al. 
1999). Additionally, given that the cytosolic loop between TM3 and TM4 
contains histidine−rich regions that are required for zinc transport across the 
plasma membrane (Milon et al. 2006), the binding of pS727 STAT3 at this loop 
might in fact prevent excessive zinc influx, which could be toxic to the cell. This 
hypothesis is partly supported by the constant zinc levels observed throughout 
different mitotic stages (Fig. 6.14). Altogether, the unique presence of 
pS727 STAT3 and its binding to ZIP6 and pStathmin provided a mechanistic 
link between zinc signalling and mitotic control and suggested the importance of 
these proteins and their potential to become cancer therapeutic targets. 
The speculated involvement of Jarid1B in the ZIP6/pS727 STAT3 
complex−driven mitotic progression is intriguing. Jarid1B, previously known as 
PLU−1, is a histone demethylase that is specific for histone H3 with tri− and 
di−methylation on residue lysine 4 (Christensen et al. 2007). Using Northern 
blotting, the Jarid1B gene was highly expressed in different breast cancer cells 
when compared to non−malignant mammary glandular cells, with restricted 
expression in various non−cancerous adult tissues (Lu et al. 1999). Consistent 
with this gene expression profile, protein expression of Jarid1B was also shown 
using Western blotting to be increased in both breast cancer cells and breast 
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cancer tissue extracts, but not detectable in extracts from various normal adult 
tissues (Barrett et al. 2002). Through the demethylase activity of Jarid1B, which 
results in transcriptional repression of tumour suppressor genes such as 
BRCA1, this protein has been demonstrated to promote cell proliferation both in 
MCF−7 cells and in a mouse breast tumour model (Yamane et al. 2007). The 
speculation that the ZIP6/pS727 STAT3 complex formation resulted in binding 
of the freed Jarid1B to histone H3 during mitosis (Nimmanon et al., manuscript 
in preparation) therefore suggests another possible post−translational 
mechanism for Jarid1B in promoting cell proliferation independently of its 
demethylase activity. Interestingly, in contrast to the role of Jarid1B in 
enhancing cell proliferation, this protein has been reported to be a biomarker of 
the slow−growing subpopulation of melanoma cells, which is relatively small in 
number when compared to the rapidly growing population of melanoma cells 
(Roesch et al. 2010). Regardless of the apparently low proliferation rate of this 
subpopulation, these Jarid1B−positive melanoma cells were shown to be 
capable of continuously growing and highly tumorigenic, fulfilling a major 
criterion for cancer stem cells (Bruttel and Wischhusen 2014). Similar to 
Jarid1B, ZIP6 has also been revealed responsible for the stem cell properties in 
pancreatic cancer cells (Unno et al. 2014). In this study, ZIP6 knockdown in 
Panc-1 human pancreatic cancer cells was shown to result in decreased 
expression of stemness−related genes, spheroid−forming ability, invasiveness, 
and tumorigenicity in nude mice, thereby introducing ZIP6 as a regulator of 
pancreatic cancer cell stemness. Given the molecular link between Jarid1B and 
ZIP6 (Nimmanon et al., manuscript in preparation), it is plausible that both these 
molecules might work together to promote stemness of both melanoma cells 
and pancreatic cancer cells.  
ZIP6 and ZIP10 are grouped into the same sub−branch of the 
phylogenetic tree of the ZIP family of zinc transport proteins (Fig. 3.1), and 
share many common characteristics in terms of both gene sequences and 
biological roles. Both the ZIP6 and ZIP10 genes have been shown to contain a 
prion−like ectodomain (Schmitt-Ulms et al. 2009) and proteolytic cleavage sites 
(Fig. 3.7) with a STAT3−binding motif (Shao et al. 2004; Keshava Prasad et al. 
2009). Furthermore, both ZIP6 and ZIP10 are associated with cell migration in 
breast cancer (Kagara et al. 2007; Hogstrand et al. 2013). Interestingly, both 
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ZIP6 and ZIP10 are enriched in the cortex of mammalian oocytes, and 
disruption of their functions has been shown to result in meiotic cell cycle arrest 
during oogenesis (Kong et al. 2014). Importantly, ZIP6 was demonstrated to 
form a heteromer with ZIP10 (Taylor et al. 2016) (Fig. 6.19 and 6.20), the 
phenomenon previously reported for zinc exporters ZnT5 and ZnT6 (Fukunaka 
et al. 2009). This ZIP6/ZIP10 heteromer formation is contrary to ZIP5 
(Pocanschi et al. 2013) and ZIP13 (Bin et al. 2011), which were shown to form a 
homodimer. These data suggested that both ZIP6 and ZIP10 might be needed 
for mitotic progression, and blocking only one of the two would therefore not be 
sufficient to stop mitosis.  
8.2 ZIP6 and ZIP10 antibodies successfully inhibit mitosis 
To prove that ZIP6 and ZIP10 were required for initiation of mitosis, we 
employed different antibodies that target the N−terminus of either ZIP6 or 
ZIP10, expecting that the binding of the antibodies could inhibit the function of 
these ZIP channels. We were able to exhibit in Chapter 7 that treatment with 
either the ZIP6 or the ZIP10 antibody successfully inhibited mitosis in a 
concentration−dependent manner. This inhibition was observed in different 
breast cancer cell lines and seen for both endogenous mitosis and 
nocodazole−induced mitosis (Fig. 7.1−7.13). Incubation with a monoclonal 
antibody to inhibit its target protein has previously been performed in an 
investigation of the Wnt−1 pathway, showing that treatment with an antibody 
against the Wnt−1 protein successfully induced apoptosis and had the same 
effect as when Wnt−1 siRNA was used (He et al. 2004). The mitosis inhibition 
by the ZIP6 and ZIP10 antibodies supported that both these channels were 
essential for initiation of the mitotic process. However, it could be questioned 
that the reduction in mitotic cells might have been confounded by toxicity of 
chemicals added to the antibodies, such as the highly−toxic sodium azide. 
Sodium azide has differential cytostatic effects on various types of cells 
(Slamenova and Gabelova 1980), even though these effects have not been 
specifically reported for MCF−7 cells. This could be argued that the 
concentration of azide in the treatment solution was very low. Importantly, it was 
demonstrated using the ZIP10 R antibody with and without sodium azide that 
this preservative did not significantly influence the mitosis−inhibitory effect of 
the antibody (Fig. 7.10). The confounding effect of sodium azide could therefore 
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be excluded. An alternative potential mechanism of the mitotic cell reduction 
observed as a result of the antibody treatment is prolonged mitotic arrest, 
resulting in activation of caspase-dependent apoptosis (Hain et al. 2016). 
However, a follow−up investigation in our group using an apoptosis Western 
blot cocktail disproved this hypothesis by exhibiting no change in the apoptotic 
rate as a result of the antibody treatment (Nimmanon et al., manuscript in 
preparation). Noteworthy, IgG negative controls also produced some inhibition 
of mitosis (data not shown), the mechanism of which is currently unexplained. 
Comparison between the antibody−treated samples and the IgG control was 
also limited, because the exact ZIP6/10 antibody concentrations were not 
known. Nevertheless, a recent publication demonstrated the ability of IgG to 
bind zinc (Yamanaka et al. 2016), providing an explanation for the observed 
mitosis inhibition effect of IgG. Further investigation is now needed to explore 
the manipulation of zinc to confirm this effect. 
If ZIP6 is indispensably needed for mitosis, one point to consider is why 
some cells were able to escape the blockade by the ZIP6 antibody, since the 
antibodies did not completely inhibit mitosis. This question is confirmed to be 
legitimate by the finding that the ZIP6−knockout cells were able to proliferate, 
even though they did not grow as quickly as the wild type (Fig. 7.17). We might 
reasonably speculate that its function could be compensated for by other ZIP 
channels, such as ZIP10. It is therefore interesting to investigate whether the 
cells could still proliferate when both ZIP6 and ZIP10 are deleted. Nevertheless, 
we could exploit this imperfect mitosis inhibition of the ZIP6 antibody treatment. 
When using the antibody for treating a patient with a proliferative disease such 
as cancer, the antibody might cause less adverse effects related to its toxicity to 
normal cells, given that a small extent of mitosis would still be allowed in normal 
tissues. Additionally, given that ZIP6 was increased and present on the plasma 
membrane only in mitotic cells (Fig. 6.7, 6.9 and 6.10) and migrating cells 
(Hogstrand et al. 2013), this antibody would specifically target the highly 
aggressive cancer cell population that are actively dividing, invading, circulating, 
and metastasising. Hence, it is highly probable that this antibody could 
effectively prevent cancer progression with fewer side effects.  
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Importantly, exploiting the increased ZIP6 protein expression in the 
majority of breast cancer, prostate cancer, and melanoma cases detected using 
immunohistochemistry in tissue sections, an antibody–drug conjugate that 
targets ZIP6, SGN−LIV1A, has been developed (Sussman et al. 2014). 
Noteworthy, antibody−drug conjugates are a novel class of cancer 
chemotherapeutic drugs. Each antibody−drug conjugate has 3 components: a 
cancer−specific monoclonal antibody, a cytotoxic agent covalently attached to 
the antibody, and a linker (Peters and Brown 2015). Mechanistically, when an 
antibody−drug conjugate binds to its target, it is endocytosed, trafficked, and 
degraded, resulting in release of the active cytotoxic component into the cytosol 
where its intracellular target is located (Bouchard et al. 2014). Compared to 
treatments with naked antibodies, antibody−drug conjugates are believed to 
have higher clinical efficacy, because they have both high selectivity of the 
monoclonal antibodies and high potency of the cytotoxic drugs (Sassoon and 
Blanc 2013). The SGN−LIV1A antibody−drug conjugate is composed of a ZIP6 
monoclonal antibody conjugated to monomethyl auristatin E, an anti−cancer 
drug that inhibits mitosis by blocking tubulin polymerisation (Sussman et al. 
2014). In contrast to the results in Chapter 7 using the ZIP6 antibody that was 
developed in our group, this study on SGN−LIV1A demonstrated using a growth 
assay that MCF−7 cells were insensitive to the naked antibody used in the 
investigation, but were highly sensitive to SGN−LIV1A. The same study also 
revealed in immunodeficient mice with breast cancer xenografts that 
SGN−LIV1A was effective and well−tolerated at the dosage used with no 
serious side effect reported. Noteworthy, SGN−LIV1A is currently evaluated in a 
phase 1 clinical trial for its safety and anti−tumour activity in patients with 
ZIP6−positive metastatic breast cancer (Forero et al. 2014). Collectively, not 
only does the ZIP6 Y antibody, either in its naked or conjugated form, have high 
potential to be used as an anti−cancer agent, but these data on SGN−LIV1A 
(Sassoon and Blanc 2013) have also suggested good tolerability of this 
antibody. 
8.3 ZIP6 is phosphorylated in mitosis 
Given the importance of ZIP7 phosphorylation on residues S275 and 
S276 in ZIP7 activation (Taylor et al. 2012), other potential phosphorylation 
sites in ZIP7 and other ZIP channels were explored, using data from whole 
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genome phosphoscreens and online predictive software. Potential 
phosphorylation sites were detected in multiple ZIP channels besides ZIP7, 
including ZIP3, ZIP4, ZIP6, and ZIP10, suggesting the potential role of 
phosphorylation in their post−translational functional control (Table 3.2; 
Fig. 3.11). Interestingly, sites predicted to be phosphorylated by CK2 were also 
present in ZIP3 at S129, ZIP6 at S478, and ZIP10 at T573 and S583 (Table 3.2; 
Fig. 3.11). The sequences of these sites match the consensus sequence motif 
for CK2 phosphorylation (Pinna 1990; Meggio and Pinna 2003). Given that CK2 
plays important roles in cell growth and proliferation, oncogenesis, and 
pathobiological features of cancer (Tawfic et al. 2001), either ZIP7 alone or 
together with these other ZIP channels might be among the substrates of this 
kinase that are responsible for the CK2−associated cancer−promoting effects.  
In ZIP6, residue S478 was expected to be a key CK2−phosphorylated 
site for ZIP6, given that this kinase was ranked top as the potential kinase that 
phosphorylates this site (Hornbeck et al. 2012). Furthermore, this residue was 
shown to be highly−conserved across all mammalian species (Fig. 3.15), 
suggesting its potential importance in ZIP6 functional control. ZIP6 
phosphorylation was further investigated in Chapter 6, in which ZIP6 was 
demonstrated for the first time to be serine−phosphorylated as a result of zinc 
treatment (Fig. 6.26), the same activation method that has been proved to 
trigger the CK2−mediated ZIP7 phosphorylation (Taylor et al. 2012). This serine 
phosphorylation of ZIP6 was detected at 2 minutes after zinc treatment, which 
was as early as the phosphorylation of ZIP7 (Fig. 4.9). Importantly, residue 
S478 of ZIP6 was confirmed to be an important site that was phosphorylated by 
zinc treatment, since the S478A mutant successfully prevented this serine 
phosphorylation of ZIP6 (Fig. 6.27). According to these findings, it is interesting 
to speculate that CK2 might simultaneously stimulate ZIP7, which releases zinc 
from the stores, and other plasma membrane−located ZIP channels, especially 
ZIP6, which import zinc into the cell.  
In a previous investigation, ZIP6−mediated zinc influx into the 
subsynaptic compartment of the cytosol of T cells was detected within 1 minute 
after T−cell receptor stimulation by exposure of the cells to superantigen, which 
was presented by myeloid dendritic cells (Yu et al. 2011). Noteworthy, 
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according to the concept of immunological synaptic communication between a T 
cell and an antigen−presenting cell, this subsynaptic compartment was defined 
as the area in the cytosol of a T cell underneath the synapse with a dendritic 
cell (Huppa and Davis 2003). This ZIP6−mediated zinc influx was shown to 
result in increased ZAP70 phosphorylation, sustained calcium influx, and 
inhibition of Src homology region 2 domain−containing phosphatase−1 
recruitment (Yu et al. 2011). Based on this report of early ZIP6 activation in T 
cells, serine phosphorylation of ZIP6 could also occur within 1 minute after zinc 
treatment in MCF−7 cells, even though the different cell types and treatment 
methods also needed to be considered. This further raised the question whether 
ZIP6 or ZIP7 was activated first and whether ZIP6 was necessary for zinc influx 
into the cytosol prior to ZIP7−mediated zinc release from the stores. If ZIP6 
phosphorylation preceded ZIP7 phosphorylation, ZIP6−mediated zinc influx 
might act as an upstream signalling event that led to ZIP7 activation as well as 
a means of zinc supply to the stores. This zinc uptake might result in immediate 
activation of ERK1/2, which is required for zinc wave production (Yamasaki et 
al. 2007; Ho et al. 2008). Alternatively, zinc itself might be a trigger of zinc 
release from cellular stores, mimicking the well−known mechanism of calcium 
release from its stores called “calcium−induced calcium release” (Endo 2009).  
Calcium−induced calcium release was first described in skeletal muscle 
as a physiological mechanism by which a small amount of free calcium that was 
initially released from the sarcoplasmic reticulum triggered further calcium 
release from the stores (Ford and Podolsky 1970). This mechanism has been 
observed not only in skeletal muscle, but also in smooth muscle (Kotlikoff 
2003), cardiac muscle (Zahradníková and Zahradník 1999), and pyramidal 
neurons (Sandler and Barbara 1999). Supporting this mechanism in cardiac 
myocytes, it was demonstrated using computer simulations that in response to 
calcium influx via L-type voltage-dependent calcium channels, ryanodine 
receptors on the sarcoplasmic reticulum were rapidly activated, resulting in 
calcium release from the sarcoplasmic reticulum within 0.4 milliseconds after 
calcium influx (Cannell and Soeller 1997). In the light of this calcium−induced 
calcium release, there might also be a similar mechanism for zinc, which could 
be called zinc−induced zinc release. In parallel with the calcium−induced 
calcium release in cardiac myocytes, in response to zinc influx via a ZIP 
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channel on the plasma membrane such as ZIP6, ZIP7 was triggered, resulting 
zinc release from intracellular stores such as the ER. Noteworthy, cytosolic zinc, 
even at a physiological level, has been shown in cardiac myocytes to be able to 
activate the ryanodine receptor 2 and thereby induce calcium release in the 
absence of activating levels of calcium in the cytosol (Woodier et al. 2015). Zinc 
influx into cells might therefore trigger not only zinc release, but also calcium 
release from intracellular stores. Additionally, given the presence of potential 
tyrosine phosphorylation sites in ZIP3, ZIP6, and ZIP10 (Table 3.2; Fig. 3.11) 
and the known potent inhibitory effect of zinc on protein tyrosine phosphatases 
(Wilson et al. 2012), zinc release from cellular stores might also result in 
tyrosine phosphorylation of these ZIP channels. This phenomenon could 
therefore provide a positive−feedback mechanism by which zinc itself 
potentiated zinc signalling. 
According to the cellular homeostatic mechanisms of zinc that have 
previously been reported, the proposed mechanism of zinc−induced zinc 
release can still be challenged. The effects of ZIP7 activation as a result of 
CK2−mediated phosphorylation were shown to be independent of the activity of 
other ZIP channels that are located on the plasma membrane (Taylor et al. 
2012). This fact was proved in this study by demonstrating using a Fluozin−3 
assay that no apparent cytosolic free zinc was detected following zinc treatment 
until zinc was released from the ER. Furthermore, stimulation with EGF plus 
ionomycin produced cellular effects similar to those observed as a result of 
treatment with zinc plus pyrithione, proving that the rise in cytosolic free zinc 
levels resulted from the release of endogenous zinc from the ER, not from the 
influx of exogenous zinc added to the cells. These previous findings are 
consistent with the muffler model, which highlights the effectiveness of 
zinc−binding proteins such as the metallothioneins in controlling cytosolic free 
zinc levels within a narrow physiological range (Colvin et al. 2010). According to 
these data, the proposed simultaneous activation of ZIP6 at 2 minutes after the 
stimulation might not be important for the early effects of ZIP7 activation. 
However, ZIP6 might instead be necessary for the prolonged effects of ZIP7 
activation, since ZIP6 could provide zinc supply to cellular stores and prevent 
the stores from being depleted of zinc. Given that carcinogenesis is a chronic 
process, it is plausible that ZIP6 as well as other plasma membrane−located 
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ZIP channels could synergistically work with ZIP7 in sustaining the activation of 
ZIP7 downstream effectors and thereby promoting cancer phenotype. 
Regardless of the potential importance of residue S478 in ZIP6 serine 
phosphorylation, this residue showed no preference to other sites in binding to 
CK2 (Fig. 6.30). The specific binding residues in ZIP6 for the binding of CK1 
(Fig. 6.34) and PLK1 (Fig. 6.36) were also not detected. This might be because 
the sites that were investigated did not serve as major binding sites for these 
kinases. Alternatively, these sites might be notably activated only in mitotic 
cells, which were the minority of the cells in the samples tested, since the 
experiment was performed in the absence of a mitosis inducer such as 
nocodazole. Noteworthy, the combination of ZIP6 transfection and nocodazole 
treatment was not performed in the investigation due to our concern that the 
presence of nocodazole might adversely affect the transfection efficiency. 
Another possible explanation that a specific binding site was not detected for 
CK2, CK1, and PLK1 is that these three kinases bound to more than one 
residue in ZIP6, in as much as there are multiple potential sites on ZIP6 for 
which these kinases were predicted to be the responsible kinases. Additionally, 
multiple tyrosine residues have recently been reported as potential 
phosphorylation sites on ZIP6, consisting of residues Y493, Y528, and Y531 
(Palacios-Moreno et al. 2015). In consideration of the theory of hierarchical 
phosphorylation (Ayuso et al. 2010), another possibility is that these tyrosine 
residues needed to be phosphorylated first, and phosphorylation of the 
investigated sites would then follow.  
Importantly, residue S471 was the only residue in ZIP6 detected to be a 
specific phosphorylation site for a kinase, GSK−3 (Fig. 6.32). GSK−3 is a 
negative regulator of Snail (Zhou et al. 2004), which functions as a transcription 
repressor of E−cadherin (Peinado et al. 2007), thereby playing a major role in 
EMT control. Recently, our group have demonstrated that the ZIP6−mediated 
zinc signalling pathway in EMT involves inhibitory phosphorylation of GSK−3 
(Hogstrand et al. 2013), which is driven by either zinc itself (Ilouz et al. 2002) or 
zinc−activated AKT (Lee et al. 2009). It is therefore interesting to discover that 
this kinase bound to ZIP6 on residue S471 during mitosis (Fig. 6.32). In the light 
of the discovery in this project, GSK−3 could be either an upstream activator of 
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ZIP6 or a downstream effector of ZIP6−mediated cellular zinc influx. In so far as 
ZIP6 function could be regulated by GSK−3−mediated phosphorylation, a 
threefold implication could be drawn. Firstly, since ZIP6−mediated zinc influx 
results in inhibitory phosphorylation of GSK−3 (Hogstrand et al. 2013), this 
might be the mechanism whereby GSK−3 negatively controlled its own 
function. Secondly, because ZIP6 causes cell rounding prior to EMT (Hogstrand 
et al. 2013) or mitosis (Chapters 6), phosphorylation of GSK−3 might provide a 
switch mechanism by which the cell was predestined whether to migrate (when 
the phosphorylated form of GSK−3 predominated) or divide (when the active 
non−phosphorylated form of GSK−3 predominated). Thirdly, given that ZIP6 
might also be phosphorylated by other protein kinases, particularly CK2, this 
could also suggest a possibility of hierarchical phosphorylation for ZIP6, in 
which not until residue S471 had been phosphorylated could the other residues 
such as S478 be post−translationally modified, or vice versa (Ayuso et al. 
2010). Nevertheless, more investigations are needed to confirm this reciprocal 
interaction between GSK−3 and ZIP6 and its role in ZIP6 regulation.  
8.4 ZIP7 signalling is involved in diverse kinase pathways 
In order to investigate downstream effectors of ZIP7−mediated zinc 
release from cellular stores, three types of antibody arrays were employed, 
namely the phospho−receptor tyrosine kinase (RTK) arrays (Fig. 5.1−5.4, 
Table 5.1), the phospho−kinase arrays (Fig. 5.5−5.8, Table 5.2), and the 
phospho−mitogen−activated protein kinase array (MAPK) arrays (Fig. 5.9−5.12, 
Table 5.3). Two methods of increasing ZIP7 function were employed: 
transfection with wild−type ZIP7 and zinc treatment for 10 minutes, which 
activates ZIP7 by CK2−mediated phosphorylation on residues S275 and S276 
(Taylor et al. 2012). Only the kinases that were phosphorylated by both of these 
two ZIP7−activating methods were further analysed for potential downstream 
cascades triggered by ZIP7−mediated zinc release from cellular stores. A list of 
all these kinases is shown in Table 8.1. These kinases were linked together 
according to their common signalling pathways using different online platforms, 
including the Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) (Huang et al. 2009) and WikiPathways (Kutmon et al. 2016). 
Interestingly, 15 out of the 21 kinases that were phosphorylated as a result of 
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both ZIP7 transfection and zinc treatment regardless of their different isoforms 
were detected as signalling molecules involved in an integrated network of 
cancer signalling pathways (Fig. 8.2). 
According to the integrated network of the kinases phosphorylated as a 
result of ZIP7−mediated zinc release (Fig. 8.2), when different RTKs, including 
EGFR, ErbB2, IGF−1R, FGFR3, Flt−3, and RET, are activated by tyrosine 
phosphorylation, they can exert their effects on gene expression through 
activation of the RAS/RAF/MEK/ERK pathway (Fig. 8.2). The activation of this 
ERK pathway in turn regulates genes through transcription factors MYC, ELK, 
or CREB or through activation of the RAS/JNK pathway, which subsequently 
regulates genes through transcription factor JUN (Fig. 8.2). Alternatively, EGFR 
and ErbB2 are also able to trigger transcription factor STAT5, whereas IGF−1R, 
FGFR3, and Flt−3 are also known as upstream activators of the PI3K/AKT 
pathway (Fig. 8.2). The PI3K/AKT pathway can in turn either activate 
transcription factors −catenin and CREB through inhibitory phosphorylation of 
GSK−3 or regulate protein synthesis through activation of the MTOR pathway, 
which eventually triggers p70 S6 kinase (Fig. 8.2).  
Table 8.1 Downstream effectors of ZIP7−mediated zinc release 
Receptor−tyrosine kinases (RTK) 
   
c−Ret 
EGFR 
EphA7 
ErbB2 
FGFR3 
Flt−3  
IGF−1R 
Kinases including mitogen−activated protein kinases (MAPKs) 
  
AKT  
c−Jun 
CREB  
ERK1/2 
GSK−3α/β  
HSP27  
JNK  
p38α MAPK  
p70 S6  
PRAS40  
STAT2  
STAT5a  
STAT6  
WNK1 
   
 
MCF−7 cells were transfected with wild−type ZIP7 and treated with 20 μM zinc plus 10 μM 
sodium pyrithione for 10 minutes. Phosphorylation of selected kinases was determined using 
the human phospho−RTK, the human phospho−kinase and the human phospho−MAPK 
antibody arrays (R&D Systems). The kinases that were phosphorylated by both wild−type ZIP7 
transfection and zinc treatment are shown in this table. The kinases with more than one isoform 
or modification are merged together.  
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Figure 8.2 Potential downstream pathways of ZIP7−mediated zinc release from cellular stores 
 
This schematic reveals signalling pathways that include most of the kinases that were phosphorylated as a result of both ZIP7 overexpression and zinc treatment 
according to the phospho−receptor tyrosine kinase, phospho−kinase, and phospho−mitogen−activated protein kinase array data (grey boxes). The major pathways 
in which these kinases are involved include the MAPK pathway, the PI3K-AKT pathway and the MTOR pathway. 
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This network of the signalling pathways downstream of ZIP7−mediated 
zinc release from cellular stores (Fig. 8.2) has highlighted the diverse roles for 
ZIP7 in different cellular processes. All of these pathways have been reported to 
play pivotal roles in carcinogenesis. STAT5−regulated signalling, which can be 
triggered by the EGFR/ErbB pathway (Kloth et al. 2002), is important for both 
breast development and oncogenesis, in spite of its conflicting role in 
carcinogenesis as both a tumour suppressor and an oncogene (Ferbeyre and 
Moriggl 2011). The JNK pathway, with its crosstalk with p38α MAPK, 
orchestrates regulation of cell cycle progression, either dependently on or 
independently of gene transcription, and modulation of cell survival, 
differentiation, and migration (Wagner and Nebreda 2009). Uncontrolled 
activation of the Raf/MEK/ERK pathway (Friday and Adjei 2008), the PI3K/AKT 
pathway (Falasca 2010), and the MTOR pathway (Pópulo et al. 2012) has been 
implicated in various types of cancer and shown to participate in many 
carcinogenetic processes, such as cell proliferation, cell survival (through 
modulation of apoptosis), and cell migration (through inhibition of cell adhesion). 
Notably, many cancer−therapeutic drugs have been designed to target 
components of these cascades. Given that ZIP7 is capable of inducing 
phosphorylation of multiple signalling molecules in these cancer−related 
pathways through mobilisation of zinc from cellular stores, ZIP7−mediated zinc 
signalling has inevitably become an interesting target for cancer treatment.  
The additional kinases that were phosphorylated as a result of 
ZIP7−mediated zinc release from cellular stores but were not included in any of 
the cancer−related pathways in Fig. 8.2 consist of EphA7, HSP27, p38α MAPK, 
STAT2, STAT6, and WNK1. EphA7 signalling has been known for its significant 
roles in development of the central nervous system (Clifford et al. 2014). The 
p38α MAPK pathway, which has HSP27 as a downstream effector, is actively 
involved in cellular responses to various stimuli, such as inflammatory 
cytokines, environmental stressors, and growth factors (Cuadrado and Nebreda 
2010). The p38α MAPK pathway has a regulatory interplay with different MAPK 
pathways with, for example, p38α MAPK exerting its inhibitory action on EGFR 
and GSK−3 (Cuadrado and Nebreda 2010). In response to type 1 interferons, 
STAT2 and STAT6 form a heterodimer and mediate cytokine signalling in B 
cells (Delgoffe and Vignali 2013). WNK1 is phosphorylated upon cellular 
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exposure to EGF or different types of stress, resulting in activation of ERK5, 
which has significant roles in neuronal survival and cell proliferation (Xu et al. 
2005). Noteworthy, the activating phosphorylation on WNK1 also results in 
marginal activation of p38α MAPK (Xu et al. 2005). The link between ZIP7 and 
activation of these signalling pathways has therefore suggested potential 
involvement of ZIP7 in the non−carcinogenesis−related cellular processes that 
have not previously been associated with ZIP7 function, such as nervous 
system development, inflammation, stress response, and cell proliferation.  
Zinc is a competent inhibitor of protein tyrosine phosphatases, such as 
protein tyrosine phosphatase 1B (Haase and Maret 2005; Bellomo et al. 2014), 
and can effectively inhibit these enzymes even at the physiologically−relevant 
nanomolar levels (Wilson et al. 2012). Through this zinc inhibitory effect on 
protein tyrosine phosphatases, our group have experimentally demonstrated 
that ZIP7−mediated zinc release from cellular stores results in activation of 
various RTKs, such as EGFR (ErbB1), ErbB2, and IGF−1R, as well as 
non−RTKs, such as Src (Taylor et al. 2008b). EGFR, ErbB2, and IGF−1R were 
also confirmed to be phosphorylated as a result of ZIP7−mediated zinc release 
from cellular stores using the phospho−RTK arrays in this project (Fig. 5.1−5.4, 
Table 5.1). However, many other cellular kinases that were phosphorylated as a 
result of ZIP7−mediated zinc release from cellular stores are serine/threonine 
kinases, such as AKT or GSK−3. These serine/threonine kinases are not 
tyrosine−phosphorylated and are therefore not dephosphorylated by tyrosine 
phosphatases. Consequently, it is reasonable to question whether activation of 
these serine/threonine kinases was directly induced by zinc or indirectly induced 
by zinc−activated RTKs. In H9C2 rat myoblast cells, zinc ions were shown to 
activate AKT either directly through the zinc inhibitory effect on serine/threonine 
phosphatases or indirectly through activation of IGF−1R (Lee et al. 2009). The 
direct inhibition by zinc ions has also been reported in HEK293 human 
embryonic kidney cells for GSK−3 (Ilouz et al. 2002), a downstream effector of 
serine/threonine kinase AKT. Noteworthy, a recent investigation in our group 
revealed that GSK−3 was phosphorylated on residue S9 10 minutes after zinc 
treatment (Nimmanon et al., manuscript in preparation), compared to AKT 
which was phosphorylated on residue S473 5 minutes after zinc treatment 
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(Fig. 4.7). The activation of AKT in advance of the inhibitory phosphorylation of 
GSK−3 following zinc treatment suggested that in this context, GSK−3 was 
likely to be indirectly phosphorylated by zinc−activated AKT, rather than directly 
phosphorylated by zinc itself. Nevertheless, the exact activation mechanism of 
the cellular kinases other than AKT and GSK−3 is yet to be investigated.  
According to the antibody array data, zinc treatment was generally 
shown to result in activation of a greater variety of tyrosine kinases than 
wild−type ZIP7 transfection. This might be due to a relatively low transfection 
rate of ZIP7, which was approximately 20−30% (Fig. 4.3A and 4.4A). In spite of 
this low transfection rate, a 1.7−fold increase in pZIP7 levels as a result of 
wild−type ZIP7 transfection was seen on a Western blot (Fig. 5.13), which was 
compatible with a 50% increase in zinc levels observed in the transfected cells 
when compared to the non−transfected cells (Taylor et al. 2008b). Alternatively, 
zinc treatment might have activated kinases via an alternative 
ZIP7−independent signalling pathway that has not been reported. Nevertheless, 
this hypothesis of an alternative ZIP7−independent pathway is less possible, 
given the fact that the cellular effects of zinc treatment are mediated by the 
endogenous zinc that has been released from cellular stores via ZIP7 rather 
than the exogenous zinc that has been added to the cell (Taylor et al. 2012). 
Furthermore, according to the muffler model, zinc influx into the cell is 
immediately bound to the mufflers such as metallothioneins, so that the desired 
physiological levels of free zinc ions are well maintained (Colvin et al. 2008). 
Notwithstanding, there is a possibility that the intracellular kinases localised in 
the proximity of plasma−membrane−located zinc influx channels, such as ZIP6, 
are instantly activated by the imported zinc before zinc is muffled by the 
mufflers (Yu et al. 2011).  
Interestingly, some kinases, such as AMPK1, were phosphorylated 
specifically by zinc treatment without a detectable increase in phosphorylation 
following ZIP7 overexpression (Fig. 5.5−5.8, Table 5.2). AMPK functions as an 
energy sensor as well as a signal transducer, which can be activated by various 
forms of energetic stress (Inoki et al. 2012). Activation of AMPK results in 
phosphorylation of various substrates that are involved in energy metabolism, 
cell growth, and transcription regulation, suggesting its crucial roles in these 
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important cellular processes (Mihaylova and Shaw 2011). Importantly, 
consistent with our phospho−kinase array results, an exposure of mouse 
cortical neuronal cultures to 300 μM zinc in a serum−free solution for 10 
minutes resulted in delayed AMPK activation, which was detected 2 hours 
following the exposure (Eom et al. 2016). This zinc−induced AMPK activation 
was shown to induce the apoptotic pathway, explaining the role of zinc in 
neuronal cell death after an acute brain injury, such as ischemia, epilepsy, or 
trauma (Frederickson et al. 2005). This zinc−induced AMPK activation in 
neuronal cells was selectively mediated by activation of liver kinase B1 (Eom et 
al. 2016). Noteworthy, even though a much higher dose of zinc was used in this 
previous study in cortical neuronal cultures, the AMPK activation was 
apparently delayed compared to our phospho−kinase array results, which 
detected the AMPK activation as soon as 10 minutes after zinc treatment 
(Fig. 5.5−5.8, Table 5.2). The relatively delayed AMPK activation in this 
previous study might be due to the different types of cells in the study or the 
absence of an ionophore in the treatment solution (Huang et al. 2005). Given 
that the endogenous ZIP7 gene and protein expression has been demonstrated 
in mouse brain tissue using both Northern and Western blotting techniques, 
respectively (Huang et al. 2005), it is possible that ZIP7 might also play a role in 
this zinc−induced AMPK−mediated neuronal injury.  
In contrast to our findings of AMPK activation by zinc, a previous study in 
a mouse model demonstrated transient activation of hepatic AMPK that resulted 
from loss of function of intestinal ZIP4, which prevented zinc absorption by 
intestinal epithelial cells and caused a severe form of zinc deficiency called 
acrodermatitis enteropathica (Geiser et al. 2012). This discrepancy suggested 
that zinc signalling could be involved in regulation of AMPK in a tissue− or cell 
type−specific manner. Notwithstanding, no mechanistic link between the 
intestinal loss of ZIP4 and the increased hepatic AMPK activation was 
investigated in the study. This decrease in the hepatic AMPK activation might 
not be related to the decrease in hepatocellular zinc levels. Given that zinc 
deficiency is frequently associated with reduced food intake and thereby energy 
deficit (MacDonald 2000), the reduced AMPK activation might instead be 
induced by the hepatocellular increase in the AMP/ATP ratio, a condition which 
results in AMPK activation (Hardie 2015). 
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Another interesting observation is the phosphorylation of p53 as a result 
of ZIP7 overexpression, particularly the S46−phosphorylated form, which was 
clearly detected by both the phospho−kinase and the phospho−MAPK arrays, 
with no change observed following zinc treatment alone (Fig. 5.5−5.12, 
Table 5.2−5.3). This modification of p53 has been known to have a role in 
apoptosis (Smeenk et al. 2011). This finding might therefore be suggestive of 
activation of programmed cell death induced by either ZIP7 overexpression or 
the transfection procedure. Importantly, it has been established that differential 
post−translational modifications of EGFR at different sites in the molecule lead 
to activation of site−specific downstream signalling cascades (Tong et al. 2009). 
It has been established that ZIP7 is phosphorylated on residues S275 and S276 
as a result of zinc treatment (Taylor et al. 2012), whereas the role for other 
potential phosphorylation sites, such as residues S293 and T294, has not been 
fully investigated. Hypothetically, in so far as this modification of p53 resulted 
from the activation of ZIP7 independently of the phosphorylation on residues 
S275 and S276, our findings suggested that ZIP7 function might be regulated in 
the same way as EGFR, whereby ZIP7 post−translational modifications at 
different sites resulted in activation of different signalling pathways. 
It is noteworthy that many stress−related proteins, such as p38 MAPK 
(Coulthard et al. 2009) and HSP27 (Vidyasagar et al. 2012), were activated by 
both ZIP7 overexpression and zinc treatment (Fig. 5.5−5.8, Table 5.2). This 
could suggest that cell stress response was triggered by the increase in ZIP7 
function or the treatment with a supra−physiologic amount of zinc. Exposure of 
cells to a high amount of zinc could induce excessive production of reactive 
oxygen species, thereby causing oxidative stress (Morina et al. 2010). 
Nevertheless, these stress−related proteins are involved not only in stress 
responses, but also in other crucial cellular mechanisms. For example, 
p38 MAPK can also be activated by growth factors and cytokines, resulting in 
phosphorylation of a great variety of substrates that are involved in diverse 
cellular processes, such as nuclear transcription, chromatin remodelling, cell 
survival, cytoskeletal change, and cell migration (Cuadrado and Nebreda 2010). 
Not surprisingly, p38 MAPK has been shown to promote breast cancer 
metastasis (Hong et al. 2014). Moreover, HSP27 is also involved in cellular 
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cytoprotective functions and prevention of apoptosis (Wang et al. 2014) as well 
as promotion of breast cancer EMT (Wei et al. 2011). The activation of these 
proteins might therefore not necessarily be indicative of cell stress caused by 
the treatment, but it could again further support the involvement of 
ZIP7−mediated zinc signalling in various cellular processes and carcinogenesis. 
8.5 ZIP7 activity is accurately indicated by the pZIP7 antibody 
It has been established that ZIP7 is highly expressed in various 
anti−hormone−resistant breast cancer cell models (Taylor et al. 2007) and 
responsible for aggressive behaviours seen in these cell models (Taylor et al. 
2012). These aggressive behaviours have been attributed to ZIP7−mediated 
zinc release from the stores and consequential activation of multiple cellular 
signalling pathways (Taylor et al. 2008b). An antibody that recognises the 
non−phosphorylated form of ZIP7 is therefore potentially useful for evaluating 
ZIP7 expression in clinical samples, as it can provide helpful prognostic and 
predictive information for a clinician to make a therapeutic decision. 
Nevertheless, the usefulness of this antibody might be limited due to its inability 
to distinguish between the total levels of ZIP7 and the levels of the actively 
functioning ZIP7. Following the discovery of the ZIP7 activation mechanism by 
phosphorylation on residues S275 and S276 (Taylor et al. 2012), a monoclonal 
antibody recognising ZIP7 when phosphorylated on both these residues has 
been developed in our group and was characterised in Chapter 3. This antibody 
sensitively and specifically recognised the activated form of ZIP7 and accurately 
indicated the ZIP7 activity. It could therefore be implied that this pZIP7 antibody, 
either alone or together with the total ZIP7 antibody, would make a useful 
clinical biomarker, particularly for anti−hormone resistant breast cancer. 
Additionally, since there is currently no available reliable biomarker for 
assessing total body zinc status (Wieringa et al. 2015), this pZIP7 antibody also 
has potential to be used for this purpose, which might also benefit patients with 
subclinical zinc deficiency. 
8.6 ZIP7 is needed for human immunity 
An interesting fact about ZIP7 is that this zinc channel is encoded by a 
gene in the human leukocyte antigen (HLA) region on chromosome 6 (Ando et 
al. 1996). This chromosome region is a highly gene−dense area, which contains 
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at least 253 gene loci, with many these gene loci encoding proteins that are 
known to be involved in regulation of the immune system (Shiina et al. 2009). It 
is therefore possible that ZIP7 also participated in the immune system. 
Importantly, two ZIP7 mutants, P190A and E363K, have been detected in two 
young siblings by Doctor Sophie Hambleton at Newcastle University. These two 
siblings were shown to have immunodeficiency without clinically detectable zinc 
deficiency. In this project, these two mutant constructs were investigated for 
their ability to mobilise zinc from intracellular stores. Both the ZIP7 P190A and 
E363K mutants were shown to have impaired zinc−transport function, as 
suggested by their inability to significantly produce a zinc wave and the 
decrease in ZIP7 phosphorylation on residues S275 and S276 (Fig. 4.15−4.19; 
Table 4.2). The findings in this project therefore suggested that human immunity 
requires not only adequate zinc intake (Haase and Rink 2014a), but also proper 
cellular zinc homeostasis, which largely depends upon intact functions of zinc 
transport proteins, especially ZIP7.  
ZIP7 is known to be a gatekeeper of zinc release from intracellular stores 
(Hogstrand et al. 2009), which might be essential for an immune cell to function 
properly. Nevertheless, this zinc channel might also indirectly participate in the 
humoral immune system independently of its canonical role in cellular zinc 
transport. This speculation is based on a large−scale mass spectrometry−based 
investigation of protein−protein interactions in human embryonic kidney cells, 
showing an interaction between ZIP7 and CD40 (Ewing et al. 2007). In this 
proteomic study, CD40 (bait) tagged with a FLAG epitope was 
immunoprecipitated, and a high−throughput mass spectrometry analysis listed 
ZIP7 (prey) as a protein interacting with CD40 with an assigned confidence 
score of 0.309. Confirming this binding, we performed a preliminary proximity 
ligation assay using pZIP7 and CD40 antibodies, demonstrating 60 signals per 
cell, signifying strong binding between the two proteins (Fig. 8.3). CD40 is a 
member of the tumour necrosis factor receptor superfamily, which can be found 
on the surface of antigen−presenting cells including B lymphocytes (Elgueta et 
al. 2009). CD40 crucially engages in the adaptive immunity, both cell−mediated 
and humoral (Elgueta et al. 2009). In the humoral immune response, 
CD40/CD40L interactions are required for B−cell differentiation into 
plasmablasts upon induction by activated T helper cells as well as germinal 
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centre formation and progression (Elgueta et al. 2009). This preliminary finding 
of pZIP7 binding to CD40 (Fig. 8.3) therefore suggested that ZIP7 might be 
additionally involved in the regulation of the humoral response through its 
interaction with CD40, independently of its function as a zinc transport protein. 
 
 
Figure 8.3 Binding of pZIP7 to CD40  
 
A proximity ligation assay was performed in MCF−7 cells, using pZIP7 and CD40 antibodies 
(red fluorescent dots), with DAPI nuclear staining (blue). A preliminary result shows 60 signals 
per cells, signifying spatial proximity of the two proteins. 
 
 
The link between ZIP7 and the immune system has not been reported. 
However, ZIP10, another member of the LIV−1 subfamily of ZIP channels, has 
been shown to play an indispensable role in the immune system, particularly in 
humoral immunity. Ablation of the ZIP10 gene was shown to severely decrease 
survival of B cells in bone marrow through activation of apoptotic cascades, an 
effect similarly found as a result of zinc chelation (Miyai et al. 2014). In 
ZIP10−conditional knockout mice, B cells were not able to form a germinal 
centre, a defect also detected in zinc−deficient mice (Hojyo et al. 2014). 
Furthermore, B cells in these ZIP10−knockout mice also intrinsically failed to 
produce specific IgM and IgG1 in response to immunisation with 
4−hydroxy−3−nitrophenylacetyl chicken gamma globulin. Additionally, B−cell 
receptor signalling was demonstrated in the same study to be severely 
dysregulated in ZIP10−conditional knockout B cells. Collectively, these reports 
have suggested that ZIP10−mediated signalling is needed for B−cell survival, 
activation, immunoglobulin production, and receptor signalling. Even though no 
direct association of ZIP7 with immune function has been studied, it is plausible 
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that ZIP7 dysfunction could result in impaired immunity, since ZIP7 is the key 
zinc channel mobilising zinc from the stores (Taylor et al. 2012). In the light of 
the muffler model (Colvin et al. 2010), ZIP7 might even participate in the 
reported ZIP10−mediated signalling, given that zinc ions were likely to be 
muffled by zinc−binding proteins such as the metallothioneins immediately after 
the influx via ZIP10, and the action of zinc might require its release from cellular 
stores via ZIP7. Noteworthy, these two siblings with the ZIP7 mutants had a 
blood profile showing increased T−cell population and absent B−cell population, 
which was reminiscent of an X−linked genetic disorder called Bruton 
agammaglobulinemia (Ochs and Smith 1996). This blood profile was consistent 
with the decreased B−cell survival in ZIP10−conditional knockout B cells (Hojyo 
et al. 2014), further suggesting the involvement of ZIP7 in this ZIP10 axis. 
8.7 Conclusion 
In conclusion, the data in this project have advanced the insight into the 
post−translational mechanisms of ZIP channels, particularly ZIP7, ZIP6, and 
ZIP10. The knowledge of the signalling pathways that are triggered by zinc 
release mediated by ZIP7 has also been expanded, introducing ZIP7 as a prime 
potential target for modulating these oncogenesis−related signalling pathways 
and providing multiple research opportunities to decipher the individual 
pathways. Importantly, our pZIP7 antibody has been introduced as a potential 
predictive or prognostic biomarker various types of cancer. Furthermore, the 
N−terminal ZIP6 and ZIP10 antibodies have been proposed to be potential 
therapeutic agents for treatment of proliferative diseases such as cancer. It is 
therefore crucial to continue the investigation on these antibodies to determine 
their actual clinical usefulness when used in clinical samples or even in real 
clinical settings. If successful, these antibodies will inevitably benefit numerous 
patients worldwide who are suffering from cancer. 
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